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1 Introduction and objectives 
 
1.1 Resistance of bacteria to antibiotics 
 
The treatment of infectious diseases with antibiotics is becoming increasingly challenging [Levy 2004]. 
The rising resistance of bacteria to antibiotics is a direct result of the excessive and improper use of 
these drugs in conjunction with a not yet fully understanding of the role of natural antibiotics in natural 
bacterial communities. The effect of antibiotics is concentration dependent (hormesis) and there 
natural function is more of a signalling kind than that of a defensive weapon’s type [Davies 2006, 
Linares 2006, Couce 2009]. Antimicrobial resistance (AMR) is an increasingly serious threat to global 
public health. The problem is so serious that it threatens the achievements of modern medicine [WHO 
2014]. In Europe, 25.000 patients die annually from untreatable infections [Ackerman 2012, Verbeken 
2014a]. A good example in modern medicine, amongst others, could be the huge advances in burn 
wound medicine resulting in increased survival rate, as a consequence of resuscitation therapies and 
specific surgical interventions, but where the major reason of morbidity and mortality is still due to 
microbial infections, especially by increasingly untreatable bacterial infections [Pirnay 2003, Church 
2006]. Other examples can be found in the field of post-surgical orthopaedic surgery, as well as a 
variety of nosocomial infections due to multi-drug or pan-drug resistant bacterial infections. The actual 
estimate of deaths attributed to AMR worldwide for the year 2050 is 10 million (Figure 1) [O’Neill 
2014].  
 
 
 
 
 
Figure 1: Deaths attributable to antimicrobial resistance every year by 2050 © Review on Antimicrobial Resistance. 
Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. Review commissioned by UK Prime Minister, 
chaired by Jim O’Neill (December 2014) and supported by the Welcome Trust and the UK Government. 
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AMR also has a considerable economic impact: extra hospital costs and associated productivity 
losses amount to more than €1.5 billion per year in the European Union. In the USA, infections 
caused by multidrug resistant bacteria lead to US$20 billion in additional health-care costs and US$35 
billion societal costs annually [Roberts 2009]. The continued rise of resistance would cost the world 
US$100 trillion by 2050 [O’Neill 2014]. Those numbers were calculated on actual available data bases 
containing statistical data on AMR, patients’ infections rates and outcomes that where then 
extrapolated using two specific modelling systems in use by two multidisciplinary research teams, one 
from RAND Europe and another from KPMG. They looked for rising drug resistance and the 
consequent economic growth loss due to the labour force decline through morbidity and mortality 
developed
1
 [O’Neill 2014]. The situation is about to deteriorate even further, as there are only a few 
drugs left to treat multidrug-resistant bacterial strains and the first strains that are resistant to even 
these last-resort antibiotics have already emerged [Wang 2006, Magoriakos 2012]. Moreover, there is 
a dearth of genuinely novel antibiotics in the development pipeline [Bush 2011, Huys 2013a, 
Verbeken 2014a]. 
Various proposals have been made to address the problem. These range from the more prudent use 
of existing antibiotics or better sanitation, to the implementation of different potential antibacterial 
systems based on immune system related aspects (immuno-modulators, vaccines…), to the use of 
new insights in bacterial lifestyles. Here an example is the development of quorum sensing inhibitors 
[Brackman 2011]. Other helping tools are the systematic use and integration in the diagnostic 
workflow of rapid new diagnostics, improving the use of different existing antibiotics and the use of the 
CRISPR-Cas system as a specific tool to fight bacterial infections [Horvath 2010, Rath 2015]. All 
these approaches should be developed in parallel and implemented in an integrated way in order to 
face this multi-parametric AMR problem.  
However one approach seems to be promising and sustainable at the long term and implementable at 
the near future. That approach is “bacteriophage therapy”, the use of bacteriophages to kill bacteria. 
Indeed, the use of bacteriophages (bacterial viruses) to kill specific bacterial pathogens without 
harming the majority of the commensal bacteria has received increasing attention during the past 
decade. 
Since almost a century bacteriophages, independently discovered by Twort in UK and d’Herelle in 
France, are put forward and used as an antibacterial. Even before their formal discovery, the 
phenomenon seems to be observed by Hankin in India [Hankin 1896, Sulakvelidze 2001, Summers 
2012]. The principle, set forward by d’Herelle, is using the bacterium’s natural predator as weapon 
against a specific bacterium pathogenic for the human or animal being. Even against plant disease 
they could be set at work [Twort 1915, d’Herelle 1919, Thiel 2004, Sulakvelidze 2005, Bush 2011]. 
                                                          
1
 To model incidence rates for infections today, RAND used data on the likelihood of contracting a hospital-
acquired infection. They then used WHO data to calculate the average number of hospital stays in various 
countries and multiplied the two figures together to obtain an estimate for the number of hospital-acquired 
infections in each region. KPMG applied European in hospital and community infection rates to the whole 
world in the absence of better available data. As RAND did not include infections acquired outside of hospital 
and KPMG used European figures that are lower than the world average, both of these analyses are likely to 
systematically underestimate true infection rates. 
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Bacteriophage therapy could be complementary to the treatment with antibiotics or a potential 
alternative to this treatment [Comeau 2007, Verbeken 2007], but little has been done to capitalize on 
this interest and implement bacteriophage therapy in the clinic. The worldwide emergence of 
increasingly antibiotic resistant bacteria like the members of the so called ESKAPE group (Esherichia 
coli, Staphylococcus aureus, Klebsielle pneumoniae, Acinetobacter baumanni, Pseudomonas 
aeruginosa and Enterococcus spp.), the  “superbugs” and the dry-out of the antibiotic pipeline 
threaten modern society with a return to the pre-antibiotic era [Levy 2004, Bush 2011, Pirnay 2012, 
Blaser 2014]. 
 
1.2 Bacteriophages and bacteriophage therapy 
 
1.2.1 What are bacteriophages? 
 
Bacteriophages (“phages” in short) are the most abundant and ubiquitous biological entities on earth. 
Bacteriophages are the natural ‘enemies’ of bacteria. They are often ‘spider- like’ creatures (app. 40 
times smaller than a bacterium) with a transparent box-shaped head. The bacteriophages focused on 
in this study belong to the Caudovirales consisting of the Myoviridae, the Podoviridae and the 
Siphoviridae (Figure 1) [Harper 2011].  
 
 
Figure 1: The tailed bacteriophages (Caudovirales). 
 
Therapeutic lytic bacteriophages “take-over” the bacterium’s biochemical machinery in order to 
produce new viral particles, called virions, after amplification of its genome and associated proteins. In 
practice, the bacteriophage takes up the biosynthetic machinery of the host and genetic material 
expression occurs resulting in directed macromolecular biosynthesis. Once the newly produced 
bacteriophages are assembled, specific proteins (like holins) coded for by the bacteriophage genome 
induce the bacteria to lyse from inside and as such liberate the virions and kill the host bacterium. The 
released virions could again infect a new host bacterium and reiterate the cycle. Other 
bacteriophages (called temperate bacteriophages) integrate (temporarily) their DNA into the bacterial 
chromosomal genome. The resulting lysogenic cell can replicate indefinitely, but can be induced to 
switch into the lytic cycle with the excision of bacteriophage DNA from the chromosome (Figure 2) 
[Campbell 2003, Sulakvelidze 2005]. Lysis of the host cell by bacteriophages is a complex process 
consisting of a cascade of events involving several structural and reguatory genes. Moreover, not all 
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bacteriophages replicate in a similar way. Figure 2 illustrates the standard model of the two 
bacteriophage cycles, the lytic and the lysogenic. This PhD thesis focusses on the therapeutic use of 
natural lytic bacteriophages only. 
 
 
           Figure 2: Life cycle of bacteriophage coliphage-λ. 
 
Bacteriophages are bacterio-specific viruses that naturally cannot infect and replicate in a eukaryotic 
cell. This is due to biochemical differences such as the required polymerases that are different in 
eukaryotic and prokaryotic cells. To enter their bacterial host cell bacteriophages need specific outer 
membrane receptors beside the specific bacterial biochemical machinery for replication. 
Bacteriophages (derived from the Greek ‘bacterio-phagein’ or “bacteria eaters”) keep bacterial 
populations growth under control. Wherever bacteria are present, there are bacteriophages which are 
generally present in at least a ten times higher order of magnitude than the bacteria themselves and 
consequently constitute the most abundant biological lifelike constituents of the biosphere of this 
planet [Bergh 1989, Fuhrman 1999, Hendrix 2002]. This observation shows us that we actually live in 
an ocean of bacteriophages and have done so since the dawn of the human species and that natural 
bacteriophages are in principle harmless to us, eucaryotes. A recent paper showed that 
bacteriophages even form a natural protection on our mucosa against bacterial invasion [Barr 2013].  
Ecologically, bacteriophages are key as bacterial controllers and it is this ‘natural function’ of 
bacteriophages that bacteriophage therapy is exploiting. In combination with or as substitute for 
antibiotics, bacteriophages could be a therapeutic option in the eradication or control of bacterial 
colonisations/infections [Comeau 2007]. 
 
1.2.2 History of bacteriophage therapy  
 
Bacteriophages were discovered independently during World War I by the English microbiologist 
Frederick Twort and by the French-Canadian biologist Felix d’Herelle. d’Herelle announced that 
nature had provided humankind with a ‘living’, natural weapon against bacteria. In 1919, he used 
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bacteriophages to treat dysentery in Paris, in what was probably the first attempt to use 
bacteriophages therapeutically [Pirnay 2012]. d’Herelle eventually developed a commercial laboratory 
in Paris that produced bacteriophage preparations against various bacterial infections, which were 
marketed by what later became the large French company L’Oreal [Sulakvelidze 2001]. In the 1930s, 
therapeutic bacteriophages were also marketed in the United States by major pharmaceutical 
companies including Eli Lilly, Squibb & Sons (today Bristol-Meyers Squibb) and the Swan-Meyers 
division of Abbott Laboratories. However, scientific controversies due to technical reasons like product 
purity, mismatches between bacteria and specific bacteriophages, several studies or application 
outcomes were discordant. Also scientifical knowledge about bacteriophage biology and bacterial 
biology, especially the molecular aspects, were missing. It was the time where people like Belgian 
Noble Prize winner Jules Bordet were claiming that the observed phenomenon was not due to a 
bacteriophage eliminating a bacterium, but a consequence of a kind of immune interaction. Jules 
Bordet challenged both the conception of bacteriophage as a virus and the effect observed as an 
induced lytic enzyme.  
The advent of antibiotics relegated bacteriophage therapy to complete obscurity in most of the 
“Western World” [Summers 2012, Huys 2013a]. It was also the time that two negative reviews 
ordered by the Council on Pharmacy and Chemistry of the United States resulted in the cessation of 
commercial production of therapeutic bacteriophages [Eaton 1934, Krueger 1941, Sulakvelidze 2001, 
Summers 2012]. Interesting to know however is that therapeutic bacteriophage preparations could still 
be obtained at the Pasteur Institutes of Paris and of Lyon through the mid 1990’s [Dublanchet 2009, 
Kutter 2010]. There continued to be reports in the literature of bacteriophage therapy applied in 
France until about 1979 [Vieu 1975, Vieu 1979, Kutter 2010]. 
Nevertheless, bacteriophage therapy was further developed and extensively used in Eastern Europe 
and the former Soviet Union [Sulakvelidze 2005, Summers 2012] with activities centred at the Eliava 
Institute of Bacteriophage, Microbiology and Virology (EIBMV) in Tbilisi, Georgia, several institutes in 
Russia, and the Hirszfeld Institute of Immunology and Experimental Therapy in Wroclaw, Poland. 
Despite its long (Eastern European) history, bacteriophage therapy is not currently authorized for 
routine use on humans in the European Union.  
 
1.2.3 Bacterial resistance to bacteriophages 
 
Bacteria can evolve resistance to bacteriophages [Chanishvili 2012] through a variety of different 
mechanisms, including blocking bacteriophage adsorption, inhibiting the injection of bacteriophage 
genomes, restriction-modification systems, and abortive infection systems [Labrie 2010, Sander 2014, 
Rath 2015]. In in vitro monoculture studies, bacteriophage resistance can evolve in time frames of 
hours to days depending on mutation and growth rates. Whether the evolution of bacteriophage 
resistance in vitro is relevant to in vivo conditions where bacteria may be replicating more slowly and 
challenged with a greater set of environmental conditions can be questioned [Lu 2011]. 
Bacteriophage cocktails can delay the evolution of bacteriophage-resistance, bacteria and 
bacteriophages eventually reach co-existence [Kunisaki 2010, Tanji 2004]. Bacteriophage mutants 
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more active against the bacteriophage-resistant bacteria can be selected from the environment. 
Therapeutic bacteriophage banks, as they exist in Georgia and Poland, contain many different natural 
therapeutic bacteriophages and are regularly updated [Merabishvili 2012]. In 2015, the first modern 
“Western” European natural therapeutic bacteriophage bank was opened at the German Leibniz 
Institute - Deutsche Sammlung von Microorganism und Zellkulturen GmbH (DSMZ). Bacteriophages 
deposited in this special collection of the DSMZ could be of therapeutic interest if further propagated 
and prepared as new stocks under appropriately controlled conditions prior to their therapeutic 
application [DSMZ 2015]. From the environment isolated mutated bacteriophages, active against the 
bacteria that developed bacteriophage resistance, can be stored - for later use - in these banks. 
Sometimes patient-tailored bacteriophage preparations are developed [Merabishvili 2012]. This 
procedure is called the “Sur-Mesure” (“Tailor-Made”) approach [Pirnay 2011].  
The antibiotic crisis has triggered a renewed interest in the clinic, the agro-bio industry (the use of 
bacteriophages instead of antibiotics as growth promoters) and the food production sector [Pirnay 
2012]. This, combined with new scientific insights, has pushed bacteriophages to the forefront of the 
search for new approaches to fighting bacterial infections.      
 
The scope of this thesis is, seen the scientific meaningfulness and existing empiric evidence, to 
analyse why bacteriophage therapy is not yet a medical implementable tool in the European Union. 
The past years, we have realised that the main reason for its not yet routine implementation is of a 
regulatory kind. This thesis aims to propose a path for implementing bacteriophage therapy in the 
European Union, using natural bacteriophages as antibacterials in modern medicine. The 
bacteriophages at the centre of concern in our bacteriophage therapy concept are not bacteriophage 
derived products such as lysins, neither the potential use of genetically modified bacteriophages, 
neither products from the so called synthetic biology field. 
 
1.2.4 Co-evolutionary concept bacterium/bacteriophage 
 
Viruses, among which are bacteriophages, were involved in the origin of life itself and play a major 
role in biological evolution. Viruses played a critical role in major evolutionary transitions, such as the 
formation of the three domains of life (Archaea, Bacteria and Eukarya), or else, the origin of the 
eukaryotic nucleus [Forterre 2006, Raoult 2008]. Bacteriophage therapy, in view of our bacteriophage 
therapy concept, is the use of natural exclusively lytic bacterio-specific viruses as antibacterial agents. 
In fact, by setting up a screening system for the circulating noxious bacteria and their respective 
bacteriophages, it will be possible to obtain the right bacteriophage against any emerging pathogen. 
This way of working, taking into account the co-evolution of the couplet bacterium/bacteriophage, 
makes it just a fitting solution for a sustainable antibacterial bacteriophage therapy industry or a 
hospital-based use [De Vos 2012]. We must learn from the errors that contributed to the rise of 
antibiotic resistance. Any future sustainable bacteriophage therapy concept should, based on 
scientific grounds, fully acknowledge the potentialities of the co-evolutionary aspect of the couplet 
bacteriophage/bacterium in its ecological environment, in casum the human being. Only then the 
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inherent (positive) characteristics of bacteriophages as natural biological bacteria controllers can be 
put to use. Indeed, bacteria will inevitably become resistant to bacteriophages, but due to the 
continuously ongoing “arms race” between the two protagonists, specific bacteriophages able to infect 
the formerly resistant bacterial strains will quickly emerge. In fact bacteriophage therapy fits well in the 
new emerging field of Darwinian – evolutionary – medicine (in contrast to a classical mechanistic – 
man as a machine – view) where the insights of evolution are fully taken into account [Mayr 2004, 
Shanks 2007, Williams 2010, Pirnay 2011, Valenti 2012].  
 
1.2.5 Clinical practice of bacteriophage therapy 
 
While bacteriophage therapy can become a relevant medical option, including veterinary, agricultural, 
and food microbiology applications, it is for the treatment or prevention of human infections that 
bacteriophage therapy first caught the world's imagination and which today is the primary motivator of 
the field [Bruttin 2005, McVay 2007, Rhoads 2009, Harper 2010, Khawaldeh 2011, Morello 2011, 
Pires 2015]. Nonetheless, though the first bacteriophage therapy took place in the 1920s [d’Herelle 
1917, Bruynoghe 1921], by the 1940s the field was in steep decline despite early promise. The 
causes were at least four-fold: (1) insufficient understanding among researchers of basic 
bacteriophage and bacterial biology (2) lack of purified products (3) over exuberance which led, along 
with ignorance, to carelessness and two camps of “believers” versus “non-believers” in bacteriophage 
therapy [Summers 2012] and (4) the advent of antibiotics. The latter were directly chemically well 
controllable products that also where easier to handle (broad spectrum activity, not necessary to know 
the pathogen and developable in different galenic formulations). This time point was also the starting 
point for the development of “modern” pharmaceutical production environments and a pharmaceutical 
regulatory area in which we still live. Although the classic antibiotics have really pushed medicine into 
a very powerful period we have to admit that today its limits are reached and that we have to adapt 
our system which is still fundamentally based on an end 19
th
 century mechanical worldview, while 
todays (therapeutic) reality is much more dynamic. Evolution has to be integrated in medicine as a 
science on his own [Shanks 2007].    
The decline in bacteriophage therapy was neither uniform nor complete, especially in the former 
Soviet Republic of Georgia, where bacteriophage therapy traditions and practice continue to this day. 
The advent of antibiotics and further development was more a Western industrial development that 
relegated bacteriophage therapy in obscurity. In the former Soviet Union however the bacteriophage 
therapy path was just continued. Much of the detailed knowledge we have about the practice of 
bacteriophage therapy comes from two places: the Republic of Georgia, especially as associated with 
the Eliava Institute of Bacteriophages, Microbiology and Virology, and the Hirszfeld Institute of 
Immunology and Experimental Therapy located in Wroclaw, Poland. The Republic of Georgia is the 
only place in the world where bacteriophage therapy is a component of standard medical practice, 
routinely used in a number of hospitals and clinics for both prophylactic and treatment purposes. 
Much of the bacteriophage availability, both presently and historically, has been associated with the 
Eliava Institute. The Hirszfeld Institute has been supplying bacteriophages to local physicians dealing 
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with antibiotic-resistant infections and otherwise performing bacteriophage therapy-related work for 
many years. In 2005, the institute established its own bacteriophage therapy clinic. The clinicians 
involved in bacteriophage therapy at the Hirszfeld Institute are the group most experienced with 
bacteriophage therapy and studying bacteriophage physiological effects found outside of the former 
Soviet Union [Kutter 2010]. A small number of Western physicians have been making occasional 
therapeutic use of bacteriophages in recent years, in Australia, Canada, France, Germany, and the 
USA [Abedon 2011]. A major problem has often been the obtaining of suitable bacteriophage 
preparations. Most of the commercially available preparations in Georgia and Russia involve very 
complex mixtures of bacteriophages [McCallin 2013] targeting groups of relevant bacteria. An 
approach that has been found clinically very effective but, it is at least assumed, would probably not 
be well accepted by western regulators since only based on empirism and not on actual standardized 
evidence based studies. Although often similar bacteriophage preparations were commercially 
available at the Institut Pasteur in Paris until the end of the seventies/beginning of the eighties, 
acquiring appropriate bacteriophage preparations to support human bacteriophage therapy is 
challenging today [Dublanchet 2009]. The real re-introduction of clinical bacteriophage therapy in the 
European Union finally will depend on the funding private companies can find today to invest in the 
development of bacteriophage therapy under the actual pharmaceutical regulatory framework (e.g. 
Biocontrol - now AmpliPhi - , Néstle, Pherecydes, Technophage, Novolytics, Intralytics…) or on the 
definition of a regulatory exemption under which the non-profit stakeholders can (safe and 
qualitatively) operate (e.g. Queen Astrid Military Hospital, Brussels, Belgium) [Soothill 2004, Bruttin 
2005, Pherecydes 2013, Rose 2014, Clark 2015].  
Therefore, before bacteriophage therapy can be introduced into large-scale clinical practice in the 
European Union, several legislative challenges (including the definition of bacteriophage specific 
quality, safety and efficacy guidelines) must be overcome [Loc-Carrillo 2011, Verbeken 2014a, Kutter 
2015, Letkiewicz 2015]. The aim of this thesis is to propose an adapted regulatory frame for the re-
introduction of bacteriophage therapy into the European Union 
. 
1.3 European human medicinal products legislation  
 
For practitioners at hospitals seeking to use bacteriophages for treatment of antibiotic-resistant 
bacterial infections, Europe’s current regulatory framework for human medicinal products hinders 
more than it facilitates the introduction of bacteriophage therapy in the European Union [Huys 2013b]. 
Although many experts consider bacteriophage therapy to be a promising complementary (or 
alternative) treatment to antibiotic therapy, no bacteriophage- specific regulatory framework exists to 
date. Today, bacteriophage therapy is only approved in some former Soviet Republics like Russia and 
Georgia [Chanishvili 2009]. In Poland, a recent member of the European Union, bacteriophage 
therapy is considered an ‘Experimental Treatment’ covered by the Physician Practice Act (Polish Law 
Gazette N° 28 of 1997) and the Declaration of Helsinki, where other therapeutic options do not exist 
[Górski 2009]. In France, therapeutic made-to-order bacteriophage preparations from the Institut 
Pasteur (Paris and Lyon) were used until the beginning of the nineties. Historical clinical data on 
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bacteriophage therapy (from Eastern Europe, particularly Poland, and the former Soviet Republics, 
particularly Georgia and Russia, as well as from today’s 28 EU member states and the US) collected 
during the past decades are not taken into account by European regulators today [Pirnay 2010].  
The current pharmaceutical economic model, implying costly and time-consuming pathways for 
human medicinal product development and marketing, and requiring strong intellectual property 
protection, is not compatible with a (possible) smooth re-introduction of traditional sustainable 
bacteriophage therapy into the European Union. Another major obstacle for the clinical application of 
bacteriophages is a false perception of viruses as ‘enemies of life’ [Verbeken 2007]. Bacteriophages 
are not straightforward inanimate and stable substances, but they are evolvable and natural biological 
entities. Sustainable bacteriophage therapy legislative frameworks should fully acknowledge the 
potential of the co-evolutionary aspect of the bacteriophage–bacterium couplet. The existing 
pharmaceutical regulatory framework and business models are not compatible with a dynamic and 
sustainable bacteriophage therapy concept. A specific European regulatory frame with realistic 
production and documentation requirements, which allows a timely (rapid) supply of safe, tailor-made, 
natural bacteriophages to patients is a must [Huys 2013a]. Fundamental changes of mentality in the 
medical and pharmaceutical environment are essential for a successful re-introduction of 
bacteriophage therapy into modern Western medicine [Pirnay 2012].  
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1.4 Overview of the PhD project 
  
The clinical development of bacteriophage therapy faces major obstacles that hamper progress:  
 
• Lack of a specific regulatory framework for bacteriophage therapy inside or outside the actual 
human medicinal product legal framework 
• Difficulties to obtain IP-protection for bacteriophage-based products and, as a consequence, 
difficulties to find investors 
• Absence of well-defined, safe and targeted bacteriophage preparations  
• Societal misperception of viruses as ‘enemies of life’ 
 
This PhD project aims at contributing to the creation of a dedicated European regulatory framework 
that can support the smooth re-introduction of bacteriophage therapy into the European Union. The 
research hypothesis is that final reflections and proposals, specifically designed in relation to 
bacteriophage therapy, will offer new and usable insights to all stakeholders involved. 
 
The general objective is the assessment of the current regulatory situation in relation to the smooth 
implementation of bacteriophage therapy into the European Union and to formulate optimizing 
proposals.  
 
The specific objectives are:  
 
• to define the regulatory problems related to the use of therapeutic bacteriophages 
• to compare the concept of bacteriophage therapy with other human medicinal products 
• to discuss the bacteriophage therapy concept with stakeholders 
• to define the ethical and legal (IP) issues related to bacteriophage therapy 
• to formulate a proposal for a bacteriophage-specific regulatory framework for Europe 
 
The described research is based on the following information sources: 
 
• Literature reviews based on scientific databases (e.g. Pubmed), regulatory and legal 
databases (e.g. Eudralex), expert reports 
• Interviews with national and international stakeholders (scientists, clinicians, pharmacists, 
regulators, politicians) 
• Workshops (e.g. Viruses of Microbes, European Medicines Agency) 
• Focus group discussions (e.g. European Commission, European Medicines Agency, 
Innovation Task Force, Belgian Federal Agency for Medicines and Health Products) 
• Visits to bacteriophage therapy centres (e.g. Poland, Georgia) 
• Master thesis projects related to bacteriophage therapy supervision  
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 All thesis objectives are studied and discussed in detail in following chapters of this manuscript: 
 
• Problem setting: Regulatory conundrum of bacteriophage therapy (Chapter 2) 
• Development of a bacteriophage therapy concept (Chapter 3) 
• Comparison of the bacteriophage therapy concept with other medicinal products and 
assessing the implementation of the bacteriophage therapy concept with regulatory agencies 
(Chapter 4) 
• Defining a dedicated frame for bacteriophage therapy (Chapter 5) 
• Stakeholders moral responsibility in relation to bacteriophage therapy (Chapter 6) 
 
These 5 chapters are preceded by a general introduction (“Introduction and objectives”, Chapter 1) 
and followed by a general concluding discussion (“Concluding discussion”, Chapter 7). 
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12Reintroducing Phage Therapy in Modern Medicine: The Regulatory 
and Intellectual Property Hurdles
Daniel De Vos, Gilbert Verbeken, Carl Ceulemans, Isabelle Huys and 
Jean-Paul Pirnay
Abstract
Antibiotic resistance is a life-threatening problem 
worldwide and the industrial pipeline is dry. Other 
therapeutic options are needed and one of them is 
‘phage therapy’. Bacteriophages, phages in short, 
have proven to be effective in combating (mul-
tidrug-resistant) bacterial infections. However, 
legal obstacles and intellectual property rights are 
impeding the implementation of phage therapy in 
modern medicine and triggering ethical discus-
sions. Worldwide, medicinal product regulations 
are directed towards standardized marketing 
authorization for ‘classical’ medicinal products. 
But phage are of a different nature than antibiot-
ics on which most of our current regulation is 
based. Phage therapy is not covered by a specific 
regulatory pathway. Exceptions defined under the 
medicinal products legislation do not include the 
idea of phage therapy. Another hurdle is the Intel-
lectual Property issue. Owning patents is essential 
in our current industrial economic model. But 
natural phages are evolving biological lifelike enti-
ties and thus difficult to cover by patents. In the 
future the adapted legal framework should allow 
the coexistence of a ‘sur-mesure’ pathway beside 
a ‘prêt-à-porter’ road. Taking into account the 
sustainability concept, all relevant safety measures 
and quality production controls, the ‘sur-mesure’ 
pathway should enable the use of the most fruitful 
and efficiency based phage therapeutic approach 
at regional or hospital level.
Introduction
Bacteria increasingly evolve to outsmart the 
available antibiotics. Yet the antibiotic pipeline 
is running dry while new life threatening bacte-
rial strains are emerging continuously at an ever 
increasing rate (Levy and Marshal, 2004; Kumar-
asamy et al., 2010; Brzuskiewicz et al., 2011; Bush 
et al., 2011; Cooper and Shlaes, 2011). Bacteria 
that are resistant to all commercially available 
antibiotics, so-called superbugs, are emerging 
worldwide. The emergence and evolution of anti-
biotic resistance is complex and multifactorial 
requiring a challenging and multidisciplinary 
approach if we want to control it. Indeed, this 
still not yet fully understood, biological phe-
nomenon of drug resistance is a typical emergent 
characteristic of a dynamic, highly complex, and 
self-organizing system that evolves at the edge of 
chaos (Martinez and Baquero, 2002; Baquero et 
al., 2003). In this setting, some laboratories and a 
handful of small pharmaceutical companies are 
(re)turning to (bacterio)phage therapy (Thiel, 
2004). Phage are natural viruses that specifically 
infect bacteria. They are considered to be the 
most abundant and ubiquitous lifelike entities on 
Earth and co-evolve with their hosts, the bacteria 
(Bergh et al., 1989; Fuhrman, 1999; Hendrix, 
2002; Bamford, 2003). Up to 50% of bacterial 
mortality is thought to be due to bacteriophage 
predation (Wommack and Colwell, 2000). Lytic 
phage bind to receptors on the bacterial cell 
surface, inject their genetic material, use the bac-
terium’s biochemical reproductive machinery 
to replicate and subsequently destroy (lyse) the 
bacterium, irrespective of its resistance to antibi-
otics, releasing the newly formed phages (virons) 
to seek out new hosts. It really is an evolving self 
amplifying antibacterial drug obviously differ-
ent than a classic static chemical drug.
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In 1919, d’Hérelle used phage to treat dysen-
tery in Paris, in what was probably the first attempt 
to use phage therapeutically. D’Hérelle eventually 
developed a commercial laboratory in Paris that 
produced phage preparations against various 
bacterial infections, which were marketed by what 
later became the large French company L’Oreal 
(Sulakvelidze, 2001). In the 1930s, therapeutic 
phages were also marketed in the United States 
by major pharmaceutical companies including 
Eli Lilly, Squibb & Sons (today Bristol-Meyers 
Squibb) and the Swan-Meyers division of Abbott 
Laboratories. Scientific controversies and the 
advent of antibiotics, however, relegated phage 
therapy to complete obscurity in most of the 
Western world. Therefore, the current ‘knowledge’ 
of the therapeutic effect of phage is mainly based 
on theoretical grounds, basic laboratory observa-
tions, animal models and decades of empirical 
medical experience, accumulated mainly in East-
ern Europe and the former Soviet Union with 
activities centered at the Eliava Institute of Bacte-
riophages, Microbiology, and Virology (EIBMV) 
in Tbilisi, Georgia, several institutes in Russia, and 
the Ludwik Hirszfeld Institute of Immunology 
and Experimental Therapy in Wrocław, Poland 
(d’Hérelle, 1917, 1919; Sulakvelidze et al., 2001; 
Biswas et al., 2002; Wills et al., 2005; Brüssow, 
2005; McVay et al., 2007; Chanishvili, 2009, 2012; 
Gorski et al., 2009; Kutateladze and Adamia, 2010; 
Kutter et al., 2010; Maura and Debarbieux, 2011). 
According to most supporters, phage therapy has 
been proven safe through the massive applica-
tion of lytic bacteriophages in humans, mostly in 
former USSR states and Poland (Dabrowska et al., 
2003; Brüssow, 2005; Chanishvili, 2009), and in 
the Western world in animal studies (re-)initiated 
by UK researchers in the 1980s and reboosted by 
others two decades later (Smith et al., 1982. Biswas 
et al., 2002; Chibani-Chennoufi et al., 2004; Wills 
et al., 2005; Marza et al., 2006; McVay et al., 2007; 
Debarbieux et al., 2010) and safety trials in healthy 
volunteers and patients (Brüttin and Brüssow, 
2005; Rhoads et al., 2009; Sarker et al., 2012; 
McCallin et al., 2013).
This chapter discusses the problems encoun-
tered when trying to reintroduce ‘old school’ 
phage therapy in our modern liberal and precau-
tionary society.
Bacteriophage: a sustainable, 
evolving and self-amplifying 
drug
A virus is a natural biological entity, consisting 
of a molecular assemblage of nucleic acids (the 
genome) surrounded by proteins, that behaves as 
a genetic replicative parasite and co-evolves with 
its host. However, this co-evolutionary aspect, 
essential for sustainable phage therapy, has been 
practically under-estimated and consequently 
underutilized. Indeed, the dynamic bacteria–
phage interactions (co-evolution) give rise, in 
vitro and in vivo, to an ‘arms race’, consisting of the 
repeated origin and fixation of new phage viru-
lence and bacterial host defence traits (Buckling 
and Rainey, 2002; Faruque et al., 2005a,b).
Are these natural biological ‘lifelike’ entities 
living? At first sight, viruses are ‘not alive’ since 
they are acellular and lack metabolism. On the 
other hand, they replicate and evolve, in a Darwin-
ian sense, which is a typical trait of living systems. 
These characteristics, however, only emerge once 
the virion (the extra cellular viral particle or 
phage) has transferred its genome to an organis-
mal cellular environment, in casu a bacterial cell. 
Research has shown that viruses, including phage, 
play a fundamental role in the emergence and 
evolution of cellular (organismal) life.
New ideas on the definition of life and the tree 
of life are emerging with strong debate among 
scientists (Ward, 2005; Cleland, 2007; Raoult 
and Forterre, 2008; Brüssow, 2009; Benner, 
2010; Tirard et al., 2010). Viruses are more and 
more seen as essential elements in the origin 
and organization of life itself (Villarreal, 2005; 
Villarreal and Witzany, 2010). The fundamental 
transition of the RNA world into the DNA world, 
as well as the emergence of placental organisms, 
was probably mediated by viruses (Mi et al., 2000; 
Forterre, 2001). Mimivirus research brought 
Raoult and Forterre (2008) to conceive a new tree 
of life model including viruses as ‘capsid encoding 
organisms’ versus ‘ribosomal encoding organisms’.
In view of these fundamental scientific devel-
opments on the nature of phage and the empirical 
evidence of their therapeutic usefulness, it is clear 
that therapeutic phage are very different from 
classical (chemical molecular) drugs such as 
antibiotics (Chanishvili, 2009; Kutateladze and 
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Adamia, 2010). And this challenges our actual 
regulatory frame which is not well adapted for 
phage documentation in order to setup clear and 
well designed standard clinical trials which are 
required to prove phage therapeutic effective-
ness in different clinical settings as well as for the 
clinical optimization of this therapeutic approach 
(Verbeken et al., 2007, 2012; Gilmore, 2012; Par-
racho et al., 2012; Brüssow, 2012).
In fact, natural lytic phages are biological 
entities playing an important role in maintaining 
equilibrium in bacterial populations of ecological 
environments including man. Hence, we should 
not see them as a conventional chemically stable 
drug, but more as an interactive and evolving 
phage/bacterium couplet.
A phage is in fact a nucleic acid and protein 
based, self-amplifying and evolving medicine, 
exhibiting particular pharmacokinetics (Payne et 
al., 2000; Payne and Jansen, 2003; Levin and Bull, 
2004). Their action depends mainly on the sus-
ceptibility and the concentration of the targeted 
bacteria, the emergence of phage resistance as well 
as the physicochemical and immunological condi-
tions present at the site of infection, while also the 
route of phage delivery, the galenic formulation 
and phage concentration beside the frequency 
and time of administration will be of importance 
for a successful phage therapy (Payne et al., 2000; 
Debarbieux et al., 2010; Ryan et al., 2011, Morello 
et al., 2011; Hall et al., 2012).
This interactive and evolving phage/bacterium 
couplet, seen as a medicine, requires a new way 
of thinking that fits well in the emerging field 
of Darwinian medicine. But exactly this is less 
compatible with current drug development and 
marketing models. Indeed more than 150 years 
after Darwin’s first publication of ‘The Origin of 
Species’ in 1859, our society as a whole, and not 
even the biomedical sciences as a whole, have still 
not well grasped and surely not yet fully integrated 
the idea and consequences of evolution, the 
cornerstone of biology, which is a basic science 
on its own for medicine (Darwin, 1968; Ewald, 
1994; Corbellini, 2008; Williams, 2010). We 
agree with Shanks and Pyles that ‘it is important 
for the public, as consumers of medical services, 
and for medical practitioners themselves to have 
a greater appreciation of the medical implications 
of evolutionary biology’ as well as of the science 
of biology itself (Mayr, 2004; Shanks and Pyles, 
2007). A worldview that is too deterministic and 
mechanistic hampers the development of the 
evolutionary medicine’s approach as well as the 
consequently required adaptations of our regu-
latory setting and our current non-sustainable 
biopharmaceutical industry model. The cur-
rent focus on the ‘how’ questions (mechanistic 
explanations) with immediate effects should be 
equilibrated with the ‘why’ questions (evolution-
ary explanations) that typically are resulting in 
longer term views, based on evolutionary insights 
(Mayr, 2004; Shanks and Pyles, 2007; Williams, 
2010; Valenti, 2012).
Ethical considerations
It might be a good idea to consider some ethical 
issues.
Does a patient have a moral right of access to 
an unapproved medical treatment? Reflecting 
on such a question requires us to identify some 
of the ethical principles that seem to underlie 
such discussions. One of the basic principles 
in the realm of biomedical ethics is that of non-
maleficence (Beauchamp and Childress, 2009): 
a minimal moral duty of any health care profes-
sional is to abstain from inflicting harm on his or 
her patients. There exists a general moral and legal 
consensus that no patient should be subjected to 
experimental – and therefore unapproved – medi-
cal treatments, based on this fundamental moral 
principle. It is necessary to conduct rigorous test-
ing, followed by the approval by official public 
health agencies, in order to make sure that a pro-
posed treatment has the beneficial health effects 
claimed; while at the same time it is demonstrated 
not to cause unacceptable health risks.
Yet is a patient’s right absolute? Can they be 
subjected to a not (yet) approved treatment 
under certain conditions? If we assume that this 
is the case, then we need to find out under what 
conditions this right can justifiably be overridden. 
First of all, there has to be a very good reason for 
putting aside a patient’s moral protection against 
being subjected to possible hazardous medical 
treatments. The moral weight of whatever it is 
we want to achieve with this therapy has to be 
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sufficiently important – for example, saving the 
life of a patient may constitute a viable ethical 
motive. Secondly, we need to make sure that all 
the moral agents involved are motivated by ethi-
cally proper intentions. If indeed a patient’s life 
is at stake, our intention for using an unlicensed 
treatment has to be about improving the patient’s 
health condition, and not about commercial, 
research or cost-reducing benefits. Based on the 
results of ongoing experimental trials, we must 
also have sufficient reason to believe that the treat-
ment under investigation will indeed produce the 
beneficial health effects it claims to have. What 
is more, there must be a good prospect that the 
probable health benefits will outweigh the risks of 
subjecting the patient to the treatment.
Another criterion is that the unapproved 
treatment needs to be a last resort. All existing 
treatments must have been tried with little or no 
success. Finally, a decision to subject a patient to 
a not yet approved treatment needs to be made 
in respect with the patient’s right to autonomy 
(informed consent). Notice here, however, 
that a patient giving his informed consent to be 
subjected to an unapproved treatment does not 
automatically lead to the waiving of his right not 
to be subjected to that therapy. A patient’s moral 
protection against being subjected to unapproved 
treatment does not simply disappear because he 
wants it too and gives his consent as there may be 
ethical issues above the level of the patient that 
have to be considered by medical practitioners 
and others. Besides a patient’s informed consent, 
all the other criteria just cited (good reason, moral 
intention, reasonable chance of success, pro-
portionality, and last resort) need to be satisfied 
before that patient’s right not to be subjected to an 
unapproved treatment, may justifiably be set aside.
But what if all these conditions are satisfied? 
Does it automatically follow from this that a 
patient has a right to access to an unapproved 
treatment? Well, not necessarily. If it can be shown 
that all these safeguards have been met, it becomes 
morally permissible to subject a patient to that 
therapy. It does not follow, however, that there 
exists a duty to provide a patient with that therapy. 
It might be said that the right not to be subjected 
to an unapproved treatment corresponds with 
a negative duty (duty not to harm), whereas the 
right to have access to an unapproved treatment 
corresponds with a positive duty (duty not to 
allow a harm to happen). Do those responsible 
for the development of a new treatment have such 
a positive duty, once it has been established that 
they are no longer constrained by the negative 
duty not to harm? Given the fact that most of those 
involved in developing new treatments are private 
companies wanting to maximize their economic 
profits as much as they can, it is certainly not easy 
to see how one could argue that such positive duty 
exists. A possible defence for such a duty could be 
based on the principle that anyone engaged in 
the realm of public health – and this includes the 
pharmaceutical companies – implicitly accepts 
some moral responsibilities towards society, such 
as making available experimental treatments in 
sufficiently large quantities when called for. Such a 
‘public responsibility’-argument is of course only 
one example of a possible defence, and would 
require a lot more development than we can pro-
vide here, but that the problem of ethical conflicts 
in public health research and practice exists is well 
known. Specifically in the area of drug resistance, 
as well as in the research for new antibacterial 
products and/or treatment approaches, ethical 
issues emerge at the global public health policy 
level, in relation with the industry, and at the indi-
vidual (patient/doctor) treatment level (Aiello et 
al., 2006; Selgelid, 2007; Leibovici et al., 2012).
The Declaration of Helsinki
In 1964, the World Medical Association (WMA) 
elaborated a set of ethical principles for the 
medical community regarding human experimen-
tation, the Declaration of Helsinki. Today, it is 
widely regarded as the cornerstone document of 
human research ethics (Bošnjak, 2001; Tyebkhan, 
2003). Although it is not a legally binding instru-
ment in international law, it draws its authority 
from the degree to which it has been codified in, 
or influenced, national or regional legislation and 
regulations (Human and Fluss, 2001).
In paragraph 35 of the Declaration of Helsinki 
([35] of Declaration of Helsinki (2008: Sixth 
revision, 59th Meeting, Seoul) specifically states:
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In the treatment of a patient, where proven 
interventions do not exist or have been inef-
fective, the physician, after seeking expert 
advice, with informed consent from the 
patient or a legally authorized representative, 
may use an unproven intervention if in the 
physician’s judgement it offers hope of saving 
life, re-establishing health or alleviating suffer-
ing. Where possible, this intervention should 
be made the object of research, designed to 
evaluate its safety and efficacy. In all cases, 
new information should be recorded and, 
where appropriate, made publicly available.
During the latter part of the 20th.century, 
phage therapy was largely used in Poland and the 
former Soviet Union. One of the major centres 
of phage therapy is the L. Hirszfeld Institute of 
Immunology and Experimental Therapy, where 
since the 1970s specific phages have been used 
for the treatment of patients with suppurative 
bacterial infections, in whom a routine antibiotic 
therapy failed. The results obtained so far show 
that phage therapy is safe and highly effective 
(the majority of patients were cured) as reported 
by Slopek and Weber-Dabrowska (Slopek et al., 
1987; Weber-Dabrowska et al., 2000).
Today, Poland is a European Union (EU) 
Member State in which this therapy is still possi-
ble. Phage therapy is considered an ‘experimental 
treatment’ under the Declaration of Helsinki and 
the national adapted Act of 5 December 1996 on 
the Medical Profession (Polish Law Gazette, 2011, 
No. 277 item 1634). On this basis the L. Hirszfeld 
Institute of Immunology and Experimental 
Therapy (an institute of the Polish Academy of 
Sciences) offers phage therapy to treat patients 
infected with drug-resistant bacteria (Miedzy-
brodzki et al., 2012).
More recently in June 2005, the Ethical Com-
mittee of the Medical Academy in Wroclaw 
authorized a study entitled Experimental Phage 
Therapy in Antibiotic-Resistant Bacterial Infection, 
Including MRSA Infection. The results of experi-
mental phage therapy (conducted at the Phage 
Therapy Unit at the Hirszfeld Institute) were 
discussed in a recent publication (Miedzybrodzki 
et al., 2012).
Routine therapeutic application 
and marketing
The paragraph 35 of the Declaration of Helsinki 
is only applicable when therapeutic methods 
do not exist or have been ineffective. So, strictly 
speaking, the Declaration of Helsinki can only 
justify the application of phage in critical patients 
with untreatable MDR bacterial infections. For-
tunately, today this is only the case for a small 
number of patients. As a consequence we feel that 
the Declaration of Helsinki is not the appropriate 
tool to – once and for all – evaluate the efficacy 
of phage therapy, which requires (according to 
modern medicine) prospective, double blind, 
placebo-controlled clinical trials, in order to even-
tually use phage therapy as a routine antibacterial 
treatment.
Medicinal product regulation
A medicinal product is defined by the European 
regulation as ‘any substance presented for treating 
or preventing disease in human beings’ (European 
Parliament, 2003). With ‘substance’ is meant ‘any 
matter, irrespective of origin or intrinsic nature of 
that matter’. The current definition of a medicinal 
product is so broad that it covers a wide array 
of products, including foods, herbs, nutrients, 
micro-organisms, whole animals and even water. 
Consequently, leeches and fly larvae (maggots) 
are today indeed classified as medicinal products. 
Although, as previously mentioned, phage are 
included in the tree of life, they are definitely of 
a different nature than the above-mentioned 
‘organisms’. Nevertheless, if we strictly follow the 
medicinal product definition, therapeutic natural 
phage are undeniably medicinal products.
Based on the medicinal product regulation, 
they would in all probability be considered 
biological medicinal products, in analogy with 
leeches and maggots. According to some (com-
mercial) players in the field this positioning of 
phage as biologicals was adopted for a transitional 
period of a few years. But we were not able to 
find any official document or report attesting this 
transitional phage status. At the European level, a 
2008 EMEA/ECDC Technical Report ‘Bacterial 
Challenge: Time to React’ mentions phage as 
‘therapeutic agents’, no more.
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In our experience it is difficult to document 
phage as if they were classical medicinal products. 
In addition, given the specific nature of phage (i.e. 
natural bacterial co-evolving biological entities), 
we feel that it is irrational to develop and market 
them as if they were classical medicines (i.e. static 
chemical substances). In practice it is possible to 
produce (ad hoc) effective phage against current 
problematic bacterial infections (e.g. EHEC, 
NDM-1 carrying Gram-negatives, MRSA etc.) 
within days to weeks (Merabishvili et al., 2012). If 
the classical medicinal product development and 
licensing pathways were being followed, selected 
organism-specific phages would only become 
available several years later. As a consequence, the 
flexibility of phage therapy would be lost (Pirnay 
et al., 2010, 2012). Eventually, rapid updating 
and licensing procedures could be adopted (e.g. 
as in the case of influenza vaccines), but these 
would only reduce the postponement of use to, at 
best, several months. Recently Merabishvili and 
colleagues showed that it is possible to respond 
quickly on an emergent outbreak of for example 
the epidemic enteroaggregative Shiga toxin/
verotoxin-producing Escherichia coli (EAggEC 
STEC/VTEC) strain O104:H4 since the isola-
tion, selection and characterization of a candidate 
therapeutic bacteriophage could be done in the 
timeframe of days (Merabishvili et al., 2012). 
Therefore, a specific regulatory framework for 
phage therapy should be considered (Verbeken et 
al., 2007, 2012).
In the advanced therapy medicinal product 
(ATMP) regulation there is a gene therapy section 
that allows the use of genetically modified viruses 
targeting eukaryotic cells. This section, however, 
is not applicable to natural phage, which are not 
genetically modified and do not target eukary-
otic cells. Indeed, no phage-related nucleic acid 
sequence could be found in our genome, in con-
trast with the huge amount of retroviral remnants 
present in our human core genome. Up to 8–10% 
of the human genome consists of human endog-
enous retroviral sequences (HERV’s) (Lander et 
al., 2001).
Furthermore, it is impossible for a phage to 
interfere or multiply in an eukaryotic cell system 
since it requires the specific prokaryotic cell wall 
receptors and biochemical machinery for its 
attachment and replication (e.g. prokaryotic poly-
merases). Some phage-related polymerase gene 
sequences were, however, identified in human 
mitochondrial DNA. It is common knowledge 
that mitochondria originated from Rickettsia-like 
ancestor bacteria that started a symbiotic rela-
tionship with prototype eukaryotic cells. A 
similar event occurred in plants and gave rise to 
the chloroplast. This evolutionary process dates 
back from the endosymbiotic era, the time when 
the evolutionary split occurred between the pro-
and eukaryotes. This remnant of phage DNA was 
likely introduced in the eukaryotic cell during the 
bacterial phase of the mitochondrion, the actual 
energy production unit of our cells. Recent work 
also suggests that even the eukaryotic nucleus is 
a viral import (Bell et al., 2001). Very recently 
Jeremy Barr and colleagues published a paper 
showing a new kind of an, until now, unrecognized 
active mucosal protection system based on a sym-
biotic relationship between phage and metazoan 
hosts, including humans. The study showed the 
permanent and host-mucus dependent presence 
of an increased lytic phage density in the epithelial 
mucus layers protecting the host against invading 
bacteria (Barr et al., 2013). All this taking into con-
sideration shows that phage, and phage therapy, is 
intrinsically safe for us, human beings constituted 
of eukaryotic cells with whom the phage will not 
be able to interact.
Notwithstanding the unadapted regulatory 
status of phage therapy in the Western world 
(Verbeken et al., 2007, 2012) some studies were 
recently conducted or are ongoing beside some 
sporadic therapeutic applications (Kutter et al., 
2010). These recent studies in conjunction with 
earlier empiric experiences show at least signifi-
cant potentialities and basic patients safety.
As in burn centres all over the world, also the 
clinicians of the burn centre of the Queen Astrid 
Military Hospital in Brussels are increasingly con-
fronted with multi-drug resistant (MDR) bacteria 
causing virtually untreatable infections (Pirnay 
et al., 2003a). A leading Belgian Ethical Com-
mittee authorized a pilot clinical trial in which a 
Good Manufacturing Production (GMP)-like 
produced phage cocktail (Merabishvili et al., 
2009) was applied on burn wounds infected with 
MRSA and/or MDR Pseudomonas aeruginosa. In 
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the preparation phase of this pilot clinical trial 
researchers of the Brussels burn wound centre 
were confronted with the false perception of 
viruses as ‘enemies of life’, an observation that was 
previously expressed by Villarreal (2005). This 
‘fear’, for example, resulted in a ten times too high 
study insurance fee and an unwarranted request 
to notify the National Bio-safety Council, which 
normally is only entitled to rule on the release of 
genetically modified organisms and pathogenic 
micro-organisms in the environment. In addition, 
this cocktail was also used to successfully treat a 
critical patient, amongst others, suffering since 
months from a pelvic osteomyelitis infection 
accompanied with frequent septic episodes, after 
a car crash and subsequent surgical intervention, 
with MRSA and MDR P. aeruginosa under the 
umbrella of the Declaration of Helsinki.
In the UK a small phage therapy company 
conducted a phase I/II clinical trial in chronic 
otitis approved, on a national level, by the UK 
Medicines and Healthcare products Regulatory 
Agency (MHRA) and the Central Office for 
Research Ethics Committees (COREC). A pre-
liminary report of efficacy was published (Wright 
et al., 2009).
In France therapeutic made-to-order phage 
preparations from the Institut Pasteur of Paris and 
Lyon were available for medical use till the begin-
ning of the nineties (Dublanchet, 2009; Kutter 
et al., 2010). Although phage therapy was not 
retained in the current French Medicinal Product 
Regulation, a French MD, Alain Dublanchet, still 
applies phage therapy to treat patients infected 
with MDR bacterial infections. He obtains his 
phage products from pharmacies in Russia and/
or Georgia where they are legally and com-
mercially available (Personal communication of 
Dublanchet).
In the United States a Food and Drug Admin-
istration (FDA)-approved phase I clinical trial 
was performed (Rhoads et al., 2009). A recent 
publication from an international group describes 
in a case report the application of therapeutic 
bacteriophages for refractory P. aeruginosa urinary 
tract infection in a 67-year-old woman that under-
went extensive intra-abdominal resections and 
irradiation for adenocarcinoma. This treatment 
was approved by the Western Sydney Human 
Research Ethics Committee on a compassionate 
use basis and after patient’s informed consent was 
obtained (Khawaldeh et al., 2011).
Other potential paths
Several alternative application paths for phage can 
be taken into consideration.
Magistral or extemporaneous 
preparations
At first sight, phage preparations could be 
produced and dispensed as Magistral or Extempo-
raneous preparations by a (hospital) pharmacist. 
The dispenser (pharmacist) stands between the 
prescriber and the patient and only a very intimate 
acquaintance with the characters and doses of 
medicines will enable him to successfully perform 
his duty to each. The successful performance of 
this medication has to be preceded by knowledge 
of the physical and chemical characters of its 
(active) components and it is debatable whether 
this is currently the case for phage. Furthermore, 
in most countries the raw materials of Magistral or 
Extemporaneous preparations need to be licensed 
in/or accompanied by an adequate certificate of 
analysis. Also the traceability has to be guaranteed 
in a way which conforms to current regulations.
Compassionate use
‘Compassionate use’ is a method of providing 
experimental therapeutics (investigational drugs) 
prior to final approval for use in humans. This pro-
cedure is used with seriously ill individuals who 
have no other treatment options. This rule only 
applies to non-registered drugs that are already in 
a clinical-study phase and have proven potential. 
Phage preparations that are currently tested in 
approved clinical trials and have shown efficacy 
could thus theoretically, and under certain condi-
tions, be used to treat patients with life threatening 
MDR bacterial infections. Recently, an official 
question regarding the compassionate use, even-
tually under or in combination with the French 
‘statut d’Authorisation Temporaire d’Utilisation’ 
(ATU), of therapeutic bacteriophages against 
life threatening resistant bacterial infections in 
patients with functional or vital bad prognosis 
was asked by two French MDs, Larché and Lenoir 
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from the non-profit organization PhagEspoirs to 
the French competent authorities. The answer 
is still pending. In Australia however phage was 
recently successfully applied under a compassion-
ate use basis (Khawaldeh et al., 2011).
GRAS and QPS
Antibiotics and other antibacterial (preserva-
tion) products play an important role in the food 
and agro-biological industry. More than half of 
the antibiotic consumption worldwide is for 
non-human medical use, often as animal growth 
promoter/enhancer. The routine and widespread 
(over) use of antibiotics in the agro-biological 
industry, which are also used in human medicine, 
is no longer generally accepted since it was shown 
to accelerate the development of antibiotic-resist-
ant strains of bacteria. Several studies showed 
the presence of antibiotic-resistant strains and 
molecular antibiotic gene cassettes in the inani-
mate environment (Kümmerer and Henninger, 
2003; Pirnay et al., 2005; Allen et al., 2010). 
Although recent surveys and specific studies show 
the widespread presence of antibiotic resistance 
genes in the environment, even in remote pristine 
environments, we do not agree to quickly change 
the paradigm that ‘the overuse and misuse of 
antibiotics (OMUAB) is at the origin of the emer-
gence of the increased antibiotic resistant bacteria’ 
(Selgelid, 2007; Bertoloni et al., 2009; Allen et al., 
2010; D’Costa et al., 2011; Rolain et al., 2012). 
The effect of OMUAB might indeed not be spe-
cifically at the origin of the resistance genes as such, 
but it is apparently clearly related to their mobili-
zation from the so-called resistome (D’Costa et al., 
2006). This phenomenon is currently enhanced 
as a consequence of the worldwide massive use of 
antibiotics especially in the agrobio industry. We 
actually have to realize that in fact our knowledge 
of the natural role of antibiotics, as secondary 
metabolites, is incomplete or too low. They can 
have a signalling function(s), similar to cytokines 
in eukaryotes, in their natural ecological setting. 
Clearly, a better use of antibiotics requires more 
integrated and fundamental research. Research 
results through metagenomic studies will surely 
help and bring new useful insights (Schmieder 
and Edwards, 2012). Realizing this, it is not 
surprising, and even a good initiative of the food 
and agro-biological industry, to also try to exploit 
phage–host interactions for biotechnological 
applications (Shapiro and Kushmaro, 2011; 
Mahony et al., 2011) in order to avoid the use of 
antibiotics or at least to minimize it or use it more 
appropriately.
Some companies decided to penetrate the 
food market first in order to accustom the public 
and the regulatory authorities to bacteriophages, 
which should facilitate future clinical trials whilst 
already generating revenues. In the USA, the Food 
and Drug Administration (FDA) approved the 
use of the first phage preparation for food safety 
applications in April 2006. Since then, three other 
preparations have been approved. FDA classified 
two of these preparations under the Generally 
Recognized As Safe (GRAS) product regulation, 
one was cleared as a food additive, and another 
one as a food contact substance (Burdock and 
Carabin, 2004; FDA, 2006; Sulakvelidze, 2013).
In 2009, the European Food Safety Agency 
(EFSA) issued a product regulation similar to 
GRAS, the Qualified Presumption of Safety (QPS) 
regulation. In addition, the EFSA maintains a list 
of QPS micro-organisms that can be intentionally 
added to food or feed. Phage are not included 
on the list, but similar to the GRAS regulation, 
they can be authorized as antimicrobial agents in 
the industrial food production after assessment 
on a case-by-case basis. The review process pays 
specific attention to the characterization of the 
phage at the genomic and proteomic level, which 
should ascertain that the phage are exclusively 
lytic and are not carrying potential toxins and/or 
virulence factors that are potentially transmissible 
in the natural ecological environment. As such 
two different cocktails of phages active against L. 
monocytogenes were approved and are commer-
cially in use and available, Intralytix’s ListShield 
and Micreos’Listex.
Phage probiotics?
Phage are extremely abundant and ubiquitous. 
They are present in environments as diverse as 
seawater, drinking water, activated sludge, food 
and cosmetics, and inhabit our bodies, especially 
the digestive tract, outnumbering our own bodies 
eukaryotic cell number. In the food industry phage 
play an important role not only in ‘starter culture 
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mixes’ but also as ‘in-process agents of concern’, 
especially in all kind of fermentation products 
where they can have huge negative impact on bac-
terial fermentation based production processes 
(Shapiro and Kushmaro, 2011). Unknowingly 
we constantly consume phage with our drinking 
water and food (e.g. yoghurt, cheese, salami).
An equilibrated food intake is the basis for 
health. Yoghurts containing probiotics such as 
bifidobacteria, also available on the European 
market, are claimed to have a positive influence 
on our health through the restoration of the 
intestinal flora. This means, in fact, that there is 
a commercial claim that these yoghurts generate 
positive therapeutic effects. However, at the regu-
latory level, the therapeutic effects for this type of 
product are not perceived, since otherwise such 
yoghurts would be considered medicinal products 
according to European regulation. Fermented-
milk drinks containing living Lactobacillus spp. 
such as Lactobacillus casei shirota or Lactobacillus 
casei immunitas, but also their respective phage, 
are also present on the European market.
According to the Japanese Foods for Specified 
Health Use (FOSHU) regulation, the following 
therapeutic effects of probiotics can be claimed: 
‘regulation of the gastrointestinal condition’, 
‘reduction of harmful bacteria’ and ‘suitable for 
therapeutic use against acute diarrhoea’ (Sanders 
and Huis in’t Veld, 1999; Berman et al., 2006). 
These products did not receive the medicinal 
product status, either.
In The Netherlands, some milk drinks are 
claimed to ‘improve bowel habits’ in subjects 
who are susceptible to constipation and to ‘sup-
port a well-balanced gut microbiome’ through 
an increase in the number of Lactobacilli. These 
claims were validated by a committee of inde-
pendent scientists on specific request of The 
Netherlands Nutrition Centre and a major milk-
drink manufacturer. Despite these valorized 
claims, these products were not classified as a 
medicinal product, either (Agarwal et al., 2002).
Apparently, for food products, therapeutic 
claims did not have to be backed up by clinical 
(safety) trials or, in fact, by any study whatsoever. 
And what to think about other, more ‘classical’ 
nutritional supplements such as various vitamins 
or minerals like calcium, iron or magnesium 
amongst others, who in fact are considered as 
medicinal products. This shows that although a 
medicinal product was defined there are several 
exceptions that enable to use the ‘same substance’ 
as medicinal product or non-medicinal product. 
However, questions have increasingly been raised 
regarding the status of these ‘grey-zone’ prod-
ucts. New health claim regulations in Europe, 
and a tightening regulatory environment in the 
US make it harder to make therapeutic claims. 
Several claims are unfavourably assessed because 
they were not supported by any relevant studies 
in humans. Today, such studies are central to the 
establishment of a cause and effect relationship 
between the food and/or substance concerned 
and the beneficial health effect claimed. But even 
with some good scientific evidence ‘probiotics as 
therapeutics’ are actually facing approval prob-
lems as described by Reid (2011).
Phage could eventually be considered as 
food additives with therapeutic claims based for 
example on the restoration of the commensal 
flora of the gastrointestinal tract, by eliminating 
pathogens which could promote the growth of 
commensals, but the health claim regulation and 
licensing pathways for food-additives are, again, 
not compatible with the flexibility and sustain-
ability we pursue for phage therapy.
Intellectual property rights
As mentioned earlier the rise of multi-resistant 
bacterial infections shows the current limits of 
common antibiotics. In the bio-medical commu-
nity, there is currently a renewed interest in phage 
therapy, but (bio)pharmaceutical companies 
seem generally not interested to push it forward. 
The main reason for this is that, apart from the 
lack of an appropriate regulatory framework, it is 
hard to get patents for phage and their therapeu-
tic applications, hence no way to secure a return 
on investment costs (Thiel, 2004). The fact that 
intellectual property (IP) rights or patents give 
problems in the biomedical field is increasingly 
recognized (Aiello, 2006; Selgelid, 2007, Taub-
man, 2008; Gold et al., 2009; Kapczynski, 2009; 
Van Overwalle, 2009, 2010; Kesselheim, 2010).
In Europe, the four essential pre-conditions 
governing the patentability of inventions under 
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the European Patent Convention (EPC) are laid 
down in Art. 52(1) EPC, which reads: ‘European 
patents shall be granted for any inventions, in all 
fields of technology, provided that they are new, 
involve an inventive step and are susceptible of 
industrial application’. Thus, in a first step, in order 
to be patentable, there needs to be an invention. 
Thereafter, that invention has to fulfil the patent-
ability requirements of novelty, inventive step and 
industrial applicability. The concept of ‘invention’ 
as such is not defined in the EPC, but the Imple-
menting Regulations to the EPC do specify that 
the invention must have a technical character 
(Rule 29(1)), that is related to a technical field 
(Rule 27(1)(a)) and concerned with a technical 
problem (Rule 27(1)(c)). It is clear from these 
rules that ‘technicality’ is a key precondition for 
qualification as a patentable invention in Europe.
Article 52(2) EPC lists exclusions which 
should not be regarded as inventions, if claimed 
‘as such’ (Article 52(3) EPC), because they are 
abstract in nature (discoveries) or non-technical 
in nature (scientific theories or methods for per-
forming mental acts).
Thus in Europe, whether natural phage and 
cocktails of natural phage are to be regarded 
as inventions eligible for patent protection, or 
whether they are discoveries or principles of nature 
and thus excluded from patentability, depends 
on the technical character related to the claimed 
subject matter. There must be something more 
than mere disclosure of a natural phenomenon. 
Statutory, any ‘biological material isolated from 
its natural environment or produced by means 
of a technical process, may be the subject of an 
invention even if it previously occurred in nature’ 
(Art. 3 Biotechnology Directive 98/44/EC). 
Thus, in principle, a naturally occurring phage 
might become patentable as soon as some human 
intervention is needed to isolate the phage from 
its natural environment by any technical means as 
long as the phage can be properly characterized by 
either the process by which it is obtained (prod-
uct-by-process claim), by its structure or by other 
means. Even so, cocktails of naturally occurring 
phage might be patentable as a result of a technical 
contribution.
In the US patent law Code (U. C), general 
requirements for patentability are listed in the 35 
USC §101. That article defines that subject matter 
may be patentable, provided it or its improvement 
(1) belongs to one of four distinct classes, namely a 
process, machine, manufacture, or composition of 
matter, that is (2) new and (3) useful and (4) non-
obvious (§103). A precondition for patentability 
as to its ‘technical character’ does not seem to be 
explicitly present in US patent law. Even though 
the US does not have a statutory counterpart to 
Article 52(2) EPC, exceptions to patentability are 
established by case law and certain categories are 
also excluded from patentability, such as products 
of nature, laws of nature and/or natural phenom-
ena, and abstract ideas or basic human knowledge 
or thought. But what exactly means ‘abstract ideas 
or basic human knowledge or thought’?
The US case law is clear on the aspect of non-
naturally occurring organisms.
Most notably, the Supreme Court addressed 
the question in the 1980 landmark case Diamond 
v. Chakrabarty, 447 U.S. 303 considering a live, 
human-made genetically modified bacterium 
as patentable subject matter, because the newly 
formed bacterium had markedly different char-
acteristics from any found in nature. According to 
the Court, ‘a mere purification of known materials 
does not result in a patentable product, unless the 
product obtained has properties and character-
istics which were different in kind from those of 
the known product rather than in degree’. The 
Chakrabarty case has been viewed as mandating 
the patentability of non-naturally occurring, non-
human multicellular organisms such as transgenic 
animals, genetic materials, and purified biologi-
cally produced compounds such as enzymes.
For naturally occurring organisms, the US case 
law has also been developed in a specific way.
In 1948 the Supreme Court of the US consid-
ered a patent case known and recorded as Funk 
Brothers Seed Co. V. Kalo Inoculant Co. 333 
U.S. 127 related to a mixture of several naturally 
occurring species of nitrogen-fixing bacteria. The 
Court held that the qualities of these bacteria are 
the work of nature and hence these qualities are 
not patentable.
However, other cases in the US Court of 
Customs and Patent Appeals (CCPA, which was 
renamed in 1982 as the Court of Appeals for the 
Federal Circuits) such as the 1977 In re Application 
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of Bergy, 563 F.2d 1031 (CCPA) and the 1979 In 
re Kratz,592 F.2d 1169 (CCPA) have provided 
some support for the patentability of various 
biological materials, including cells, proteins, and 
organisms if isolated or purified from their natural 
environment or pre-existing material. On the 
other hand, recently, the ruling in the US Court 
for the Southern District of New York by Judge 
Robert Sweet in a case between the Association 
of Molecular Pathology (AMP) and the US Patent 
and Trademark Office (USPTO) invalidated seven 
patents claiming genes and genetic diagnostic 
methods held by Myriad Genetics (Huys et al., 
2009; Akst, 2010; Cho, 2010; Huys et al., 2011). 
Very recently however a new US court decision 
reversed Myriad gene patent ruling for BRCA1 
and BRCA2 (Brower, 2011).
Thus the discussion is still ongoing and shows 
that the topic is hotly debated and not yet set.
Although related to naturally occurring genes, 
this decision restarted the discussion about the 
patentability for genes, but also for other types of 
naturally occurring biological (lifelike) entities, 
such as phage, and organisms. A similar situation 
is found in another medical therapeutic situation, 
namely the Faecal Microbiota Transplantation 
(FMT) intervention for diseases such as pseu-
domembranous colitis due to Clostridium difficile 
and inflammatory bowel disease (IBD) including 
Crohn’s syndrome. Indeed bacterio-transplan-
tation therapy faces analogous hurdles of IP and 
regulatory classification as phage therapy before 
being recognized and introduced in routine medi-
cal practices (McKenna, 2011; Landy et al., 2011).
It is a very thin line that separates inventions 
from discoveries under both US law and European 
law. Therefore, it is very useful to investigate the 
second very important patentability requirement, 
namely novelty, which is of high relevance for 
naturally occurring phage. An invention can be 
patented only if it is new. An invention is con-
sidered to be new if it does not form part of the 
state of the art. European case law established that 
a natural substance which has been isolated for 
the first time and which had no previously recog-
nised existence, does not lack novelty because it 
has always been present in nature as was the case 
for the Howard Florey Institute’s Application on 
Relaxin OJEPO 1995, 388 (V 0008/94). In other 
words, this means that for a phage or the cocktail 
of phages as claimed in a patent, it should never 
have been isolated or produced before. Scientific 
literature with respect to phage as natural source 
to treat human bacterial infections exists and 
is increasing as mentioned in the introduction. 
In addition some clinical studies and reports on 
humans, using phage and performed in the East-
ern part of Europe, have recently been translated 
into English (Chanishvili, 2009). Therefore, many 
phage and their uses have been disclosed over the 
past decades to almost a century. European law 
allows the patentability of known substances (as 
phage might be) if claimed for use in a medical 
method, provided that such use is new, meaning 
that such use may not be comprised in the state 
of the art (first medical use claim). We have to 
keep in mind that for novelty, the US applies a 
different ‘state of the art’ as the EU. In the US, the 
invention is considered as being part of the state of 
the art (hence not patentable) if it was known or 
used by others only in the US itself, or if it is pat-
ented or described in a printed publication in the 
US or outside the US. Thus in case such isolated 
phage are known in another country, it can still be 
patentable in the US.
In the past, patents on purified natural 
products of many kinds have been granted. For 
instance, in 1873, Louis Pasteur was granted 
US141072 patent for ‘Yeast, free from organic 
germs of disease, as an article of manufacture’. 
And in 1903 Takamine obtained US730176 
patent for adrenaline purified from gland tissue. 
More recently, in the field of phage applications, 
several patents for phage used in the food sector 
were granted, such as US7507571 (food additive) 
owned by Intralytix, Inc., claiming ‘an isolated 
phage of a phage strain selected from a [specific] 
group, [somewhere] deposited under a [specific] 
accession number, together with variants thereof, 
wherein said variants retain the phenotypic char-
acteristics of said deposited phage and wherein 
said phage, and variants thereof, have lytic activ-
ity against Listeria monocytogenes strains’. More 
important for therapeutic use is the US patent 
7459272 of Intralytix, Inc., claiming ‘a method 
for reducing the risk of bacterial infection or 
sepsis in a person colonized with pathogenic 
bacteria comprising treating the colonized person 
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with a pharmaceutical composition containing 
phage of one or more strains which produce lytic 
infections in said pathogenic bacteria’. In 2001, a 
European patent application (EP1250143 A2) 
was filed claiming ‘a method for reducing the 
risk of bacterial infection or sepsis in a suscep-
tible patient by treating the susceptible patient 
with a pharmaceutical composition containing 
phage of one or more strains which produce lytic 
infections in pathogenic bacteria’. Such claim was 
considered not to be novel. The applicant tried to 
rescue the claim by using a second medical use 
wording, however, in 2004, this application was 
deemed to be withdrawn. Only recently ‘a method 
for production of compositions of phage with a 
specific titre and total yield’ was claimed in the 
US by Phage Biopharm LLC (US7588929). No 
European counterpart has been published yet. 
Two other interesting patents are the US patent 
7758856 and US patent 7807149, both of Bio-
control Limited and granted in 2010. They claim 
‘a composition for treating a bacterial biofilm’, 
as well as ‘a method for treating a biofilm infec-
tion’ and ‘a bacteriophage containing therapeutic 
agents’. Those ‘patents’ however, when analysed 
in depth do not patent phage as such, but a whole 
process from which phage is a part. They also are 
very broad in definition. One might ask what the 
real value of such a patent is in practical terms? A 
similar patent, covering also the use of phage for 
the treatment of biofilms, has been granted in 
Europe under the EPI code EP1587520 B1 and 
is owned by the Health Protection Agency (GB).
In summary, diverging views across Europe 
and the US exist on patenting biological material. 
Aside from the requirements of novelty, inventive 
step and industrial applicability (that are the same 
for Europe and the US), in order to be patentable 
in Europe, some technical intervention is needed 
to isolate the phage from its natural environment 
and the phage needs to be properly characterized. 
But this ‘technical intervention’ has been basically 
known since d’Hérelle while the fact that the phage 
‘needs to be well characterized’ seems obvious 
and technically not a big problem (Merabishvili 
et al., 2009). In the US, the phage, as claimed in 
a patent, needs to have markedly different char-
acteristics from any found in nature. However, 
if we talk about naturally occurring, exclusively 
lytic phage, which are our object of concern here, 
then they remain as they are found in nature. It 
is only when working with genetically modified 
phage that we can agree with the US statement. 
The use of ‘manipulated or engineered phage’ has 
certainly applications, which could be patented, 
but, considering the current concerns about 
potential risks for public health and the environ-
ment which may arise from genetically modified 
organisms (GMOs), they are not likely to be given 
more easily a market licensing approval in the 
near future even if a smoother regulatory pathway 
was constructed. Phage-derived products (e.g. 
cell wall-degrading enzymes such as endolysins) 
can and probably will be licensed and marketed 
within a few years. They may also select resistance, 
but presumably at a lower rate than antibiotics. 
Of course, these phage-derived products lack the 
capacity of self-replication and adaptation in the 
infectious site.
In this chapter we focus on natural lytic phage 
just because of their natural intrinsic bacterial 
co-evolutionary aspect allowing a sustainable 
antibacterial treatment approach that is suitable 
for quick, flexible, and potentially cheaper thera-
peutic applications.
Patents claiming genes or natural entities like 
plants and, for instance, phage seem difficult or 
even (and perhaps correctly) ‘impossible’. Even 
‘inventing around’ as Van Overwalle (2010) 
writes is not easy and therefore Taubman (2009) 
thinks that ‘technology specific interventions’ are 
required. From an industrial point of view this is 
difficult to accept, but this is mainly because we 
are still fixed on the classical thinking paths. As 
biologists we should know that nothing is stable 
and as a consequence our ‘laws’ and ‘attitudes’ 
should adapt and co-evolve.
At a concrete level, however, research groups 
are trying to propose constructive solutions such 
as the establishment of ‘genetic pools’, ‘clear-
ing houses’, ‘patent pool’, ‘alternative licensing 
models’ amongst others (Taubman, 2009; Van 
Overwalle, 2009). They are trying to work out 
the organization of several types of interface 
institutions such as clearing houses in order to 
facilitate the access to patents and technologies by 
research exemptions, the creation of patent pools 
or ‘collaborative patent systems’ for affordable 
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redistribution among interested developers. This 
matter was recently well reviewed by Van Zimme-
ren et al. (2011).
The renewed interest in natural phage as 
therapeutic agents might trigger scientists and 
entrepreneurs’ creativity in defining the contours 
of appropriate patent claims for phage. Such new 
ideas on patentability should not be based on the 
existing classical model but on a broader ‘new’ 
philosophy in relation to sustainable economic 
and industrial development. Thinkers such as 
Ricardo Petrella (and his colleagues from the 
Group of Lisbon) and Jeffrey D. Sachs are lead-
ing this potential paradigm shift (The Group 
of Lisbon, 1995; Sachs, 2008). Petrella claims 
that today ‘being competitive’ is no longer a tool 
for increased development but an aim on itself. 
This increasingly implies, that the possession of 
patents, often as a strategic weapon, is thought 
to be more important (in a short-term perspec-
tive) than owning a truly functional innovative 
technology. This kind of attitude tends to block 
the development of new biomedical approaches. 
The patent tragedy is indeed exemplified by the 
millions of AIDS victims that die while treat-
ment drugs exist and raises deep questions about 
global intellectual property rights and Western 
Ethics. How can the benefits of a global patent 
system that provides incentives for innovation 
and continuous development be combined with 
an assurance that the targeted people (rich and 
poor) gain access to the medical care that they 
need and have right to? As mentioned earlier 
the patentability of phage or phage-related pro-
cedures is key, but thorny, for the development 
of the potential of this rediscovered tool, which 
is urgently needed in an increasingly antibiotic 
resistant world (Levy and Marshal, 2004; Thiel, 
2004; Kümmerer and Henninger, 2003; Küm-
merer, 2004; Pirnay et al., 2005; Kumarasamy, 
2010; Abraham, 2011; Cooper and Shlaes, 
2011). In our opinion, changes to the patents, 
patentability and restrictive licensing, common 
in the current pharmaceutical environment are 
essential for our global medical future. This need 
for change, after an analysis of the multifactorial 
aspects of antibacterial resistance, with a focus on 
our current Western societal profitable attitudes 
brings us to a ‘medicineTM’ situation which we, 
amongst others, discussed already previously 
(Pirnay et al., 2003b). This ‘medicineTM’ situation 
is the consequence of the current industrializa-
tion of medicine, the ‘medical industry’, which 
neglects the fact that biological systems do not 
behave and consequently do not respond to mar-
kets as expected for typical mechanical behaving 
systems. Medicine, basically an applied biological 
science, based on biology a fundamental science 
on its own, is governed by inherent different rules 
than classic mechanics, and consequently should 
be considered as a common public good.
Along this line of thinking, the Group of 
Lisbon, led by Ricardo Petrella, proposes an 
evolution to world cooperative governance, 
which is based on a global contract that requires 
that each decision must be linked to the fact that 
each person should have access to all basic liveli-
hoods, including health access, which actually is 
often blocked by our out-dated economic model. 
This is also the result of the analysis of Selgelid 
in his well documented article ‘Ethics and drug 
resistance’ who concludes that ‘public goods 
warrant special treatment among which govern-
mental intervention/funding will play a key role’ 
(Selgelid, 2007). In this context, a ‘tailor-made’ 
approach as proposed and discussed by Pirnay 
and colleagues for phage therapy could eventu-
ally be developed under the umbrella of, for 
example, the WHO (Pirnay et al., 2010; Pirnay et 
al., 2012). The WHO recognizes the importance 
of the worldwide antibiotic resistance issues and 
is discussing new incentives to push the pharma-
ceutical industry in alliance with governments 
to launch new antimicrobial drug research and 
development projects (http://www.who.int/
drugresistance/en/). Specific working groups 
were created such as the WHO Advisory Group 
on Integrated Surveillance of Antimicrobial 
Resistance (AGISAR) and the Intergovern-
mental Task Force on Antimicrobial Resistance 
(ITFAR). The 2011 World Health Day (7 April 
2011) was specifically dedicated to the antimi-
crobial resistance issue. The strong eye catching 
slogan was as follows: ‘Antimicrobial resistance: 
no action today, no cure tomorrow’ (http://www.
who.int/world-health-day/2011/en/). We are 
therefore surprised that, although an awareness 
of the problem exists, ‘phage therapy’ is, as far as 
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we are aware, still not mentioned by this organi-
zation as one of the potential options in the fight 
against bacterial infections.
Conclusions
Having analysed several major aspects (nega-
tively) influencing the reintroduction of phage 
therapy as a potential antibacterial treatment we 
have to realise that Ethics, Science/Technology 
and Economy are intertwined and form a field of 
tension which can result in conflicting, although 
eventually constructive, situations.
Medicinal product regulation and marketing 
models evolved to predominantly accommodate 
stable, precautionary and profitable drugs with 
sufficient IP protection. Unfortunately, sustain-
able phage therapy seems to lack strong IP 
protection, which hampers its re-introduction 
in practical medicine today and justifiably raises 
ethical discussions.
In this respect we can ask ourselves ‘is our cur-
rent drug development and marketing model still 
the best suited and ethically consistent?’ We live 
in a globalizing society with a growing awareness 
of evolution and sustainability. This should also 
trickle down into the field of drug development. 
Are the current overregulation and IP issues ethi-
cally tolerable in a time when increasing numbers 
of patients die as a consequence of antibiotic 
resistant infections?
The current (European) regulatory setting 
allows for eventual sporadic clinical trials under 
the responsibility and supervision of leading 
Medical Ethical Committees and/or borderline 
applications under the umbrella of the Declara-
tion of Helsinki. Some strategies, for example the 
strategy adopted in Poland are possible but they 
will not enable the further optimal development 
of phage therapy in clinical practice at large. This 
is due to the difficulty of setting up well designed 
large scale and/or multi-centric (European) stud-
ies in order to prove the efficacy of this approach. 
Also will there be a need for studies which could 
optimize this therapeutic antibacterial approach in 
the different medical application fields (especially 
for such aspects as for example the most appropri-
ate galenic formulation, the application frequency, 
the optimal phage concentration amongst other 
essential clinical parameters). There is a clear need 
for an adapted European regulation tailored to 
phage therapy, allowing the justified and broad 
therapeutic use of phage as an alternative or com-
plement to antibiotics. In order to make full and 
safe use of phage therapy the frame has to allow, 
beside a ‘prêt-à-porter’ development a real flex-
ible near the patient ‘sur-mesure’ approach, the 
latter being intrinsically the better suited of both 
models.
We support a long-term solution, such as 
the creation of a specific section for phage 
therapy under the actual Advanced Therapy 
Medicinal Product (ATMP) Regulation (EC) 
No 1394/2007, amending Directive 2001/83/
EC and Regulation (EC) No 726/2004. This 
Regulation presently includes products for Gene 
Therapy, and for Somatic Cell Therapy and Tissue 
Engineered Products. We propose the creation of 
a fourth section, named Bacteriophage Therapy 
Preparations, which could be divided into two 
distinct sections: ‘tailor-made use in a hospital 
environment’ (via a specific hospital exemption 
regulation) versus ‘industrially produced for 
market placement’ (Verbeken et al., 2007; Pirnay 
et al., 2010). Amending Commission Directive 
2003/63/EC could also be considered. Placing 
Bacteriophage Therapy Preparations under or 
next to the current sections foreseen for Biologi-
cal Medicinal Products or Particular Medicinal 
Products could also be a possible approach.
A major hurdle is the lack of societal realization 
that the classic economic, ethical, medical and sci-
entific ways of thinking have to be adapted to our 
natural environment, which is a world in constant 
movement and evolution. Patent related issues 
should be seen from a more societal impact per-
spective and not only from the pure straight-line 
economic point of view, currently at the forefront. 
Our ethical views also have to be re-evaluated 
if we prevent patients’ access to therapy, which 
has at least empirically proven to be efficacious, 
under the umbrella of ‘patient’s safety’. The role of 
fundamental scientists and medical practitioners 
is also to show new insights and to advocate for 
some change, especially when the current societal 
views, often too reductionist and based upon 
short term considerations, are blocking a further 
promising development.
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This view of the future of ‘Phage Therapy’ was 
described in a primary opinion paper by Pirnay 
and colleagues (Pirnay et al., 2010) and further 
discussed in two recent review articles (Pirnay 
et al., 2012; Verbeken et al., 2012). During a 
recent EMBO sponsored meeting on ‘Viruses 
of microbes’ organized in Brussels at the Royal 
Military Academy a whole workshop and debate 
session was dedicated to the issue (Brüssow, 
2012). Phage therapy and antibiotic therapy, as 
well as the two proposed developmental models, 
should not be mutually exclusive as also dis-
cussed by Maura and Debarbieux (Maura and 
Debarbieux, 2011). At the contrary some studies 
even argue for a synergistic effect of phages and 
antibiotics as well as a limitation of the emergence 
of antibiotic resistance as a result of using phages 
(Comeau et al., 2007; Zhang and Buckling, 2011; 
Ryan et al., 2012; Kirby, 2012).
On 14 February 2011 the question ‘What is the 
European View on the status of Phage as antibac-
terial agent,’ was officially asked by the Belgian 
Christian Democrat Ivo Belet and his French par-
liamentarian colleague from the Socialist fraction 
Catherine Trautmann to the European Commis-
sion (http://www.europarl.europa.eu/sides/get 
D o c . d o? p u bR e f = -// E P// T E X T+WQ +E -
2 011- 0 0114 4 + 0 +D O C+X M L +V 0// E N& 
language=CS). This shows that reflections on 
the idea of reintroducing phage therapy diffuses 
out of the world of biomedical science and the 
pharmaceutical industry to the political arena as 
a topic for public discussion in a time of antibi-
otic shortages. The official answer, received on 
29 March 2011 was formulated as follows: ‘The 
Commission considers that the existing regula-
tory framework is adequate for bacteriophage 
therapy without the need for an extra set of docu-
mentation for bacteriophage therapy’ (http://
www.europarl.europa.eu/sides/getAllAnswers.
do?reference=E-2011–001144&language=CS). 
Thus the official answer was, as expected, that 
phage is covered by the actual European medici-
nal product regulation. This official statement 
was our starting point for opening discus-
sions, as described, at the level of the European 
Medicines Agency and its specifically dedicated 
Innovation Task Force (ITF) unit. Those discus-
sions are still going on and will hopefully result 
in an adequate change enabling the implementa-
tion of phage therapy in clinical practice.
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The treatment of infectious diseases with antibiotics is becoming increasingly challenging. 
Very few new antimicrobials are in the pharmaceutical industry pipeline. One of the 
potential alternatives for antibiotics is phage therapy. Major obstacles for the clinical 
application of bacteriophages are a false perception of viruses as ‘enemies of life’ and the 
lack of a specific frame for phage therapy in the current Medicinal Product Regulation. 
Short-term borderline solutions under the responsibility of a Medical Ethical Committee 
and/or under the umbrella of the Declaration of Helsinki are emerging. As a long-term 
solution, however, we suggest the creation of a specific section for phage therapy under the 
Advanced Therapy Medicinal Product Regulation.
The treatment of infectious diseases with anti-
biotics is becoming increasingly challenging. It
often brings the clinician back in time to the pre-
antibiotic era. Antibiotic resistance is a signifi-
cant medical problem worldwide and alter-
natives are urgently needed [1–3]. The reasons are
multiple and find their origin in disparate fields
ranging from socioeconomics and cultural atti-
tudes, to a lack of scientific and technological
knowledge or inappropriate application of
existing knowledge [4].
Very few new antimicrobials are in the pipeline
of the pharmaceutical industry, which apparently
focuses on other (more profitable) aspects of
healthcare, such as impotence, and chronic
diseases, such as hypertension and diabetes.
One of the potential alternatives for anti-
biotics is ‘phage therapy’. Bacteriophages are
among the most abundant and ubiquitous bio-
logical entities on earth. Lytic bacteriophages are
the natural ‘enemies’ of bacteria. They are tiny
(40-times smaller than a bacterium) often ‘spi-
der-like’ creatures with a transparent box-shaped
head (Figure 1). They attach to the walls of bac-
terial cells and subsequently inject their genetic
material that is stored in the head. They take
over the bacteria’s genetic machinery, thereby
forcing the bacteria to produce numerous copies
of the bacteriophage inside itself causing it to
explode (lyze), thus liberating vast numbers of
new bacteriophages. Bacteriophages were discov-
ered independently during World War I by the
English microbiologist Frederick Twort and by
the French–Canadian biologist Felix d’Herelle.
D’Herelle announced that nature had provided
humankind with a ‘living’, natural weapon
against bacteria. However, bacteriophages
proved to be a rather capricious therapy. The
reason for this being that there are numerous
types of bacteriophages, each killing only one
specific variety (sometimes only one or a few
strains) of bacteria. Since mixtures of bacteri-
ophages were often used empirically – without
efficient purification and without matching bac-
teriophages and bacteria – it is easy to under-
stand why on some occasions the treatment was
unsuccessful. This difficulty, and the advent of
antibiotics, forced bacteriophages to the margins
of Western medicine. Antibiotics are chemically
well-defined and controllable substances, which
exhibit an activity against a wide range of dis-
ease-causing bacteria (broad spectrum) and were
thus more user-friendly and commercially more
profitable than bacteriophages. 
Today there is a renewed interest in the West-
ern world for phage therapy. Modern molecular
biology tools (e.g., rapid diagnostics, DNA-
sequencing and fingerprinting) and purification
techniques allow the development of pyrogen-
free and well-characterized and targeted
bacteriophage cocktails. However, there are a few
economical and psychological obstacles that will
have to be surmounted: 
• The use of a virus to treat infectious diseases 
• The use of a treatment coming from the
former Soviet Union 
• Patent issues
The increasing number of papers and books
appearing on the subject, as well as the emer-
gence of specifically dedicated companies, show
that there is a real interest in the subject
worldwide [5–6].
Another major problem is the regulatory
conundrum. This paper will focus on the regu-
latory vacuum surrounding phage therapy in
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Europe. The current European Medicinal Prod-
ucts for Human Use regulation was established
with classical drug products in mind. Today, this
procedural pathway works as a ‘resistance
mechanism’ for an eventual breakthrough of
phage therapy in Europe. Indeed, in the actual
regulatory setting, it is hard, if not impossible, to
launch the clinical studies that are required to
generate the data demonstrating safety and
efficacy of phage therapy.
Figure 1. Electron micrographs of the bacteriophages present in the bacteriophage cocktail that will be used 
in our Burn Wound Center.
 
(A) Pseudomonas aeruginosa bacteriophage PNM (a member of the Podoviridae family). (B) Member of the Myoviridae family with 
contracted tail. (C) Member of the Myoviridae family with normal tail. (D) Member of the Myoviridae family. (E) Three PNM 
bacteriophages attached to P. aeruginosa (two of them have injected their DNA, the heads are empty). (F) P. aeruginosa under the 
attack of bacteriophages. (G) P. aeruginosa under the attack of bacteriophage 14/1, a member of the Myoviridae family (the 
bacteriophages breached the cell wall, causing leakage of cell content and subsequent death of the bacterium). (H) Cluster of newly 
formed 14/1 bacteriophages. (I) Staphylococcus aureus intravenous Staphylococcus phage bacteriophages (members of the Myoviridae 
family) attached to a dividing S. aureus bacterium. 
The electronmicrographs were made by Dr Jan Mast of the Veterinary Agrochemical Research Center in Brussels.
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Basic problem
A fundamental aspect in the discussion
surrounding the clinical application of bacterio-
phages is the biological status and definition of
viruses in general, and, more specifically,
bacteriophages.
A virus is a natural biological entity, a molecu-
lar, genetic, replicative parasite. But, is it living?
From one perspective, we cannot say viruses are
living organisms since they are acellular and have
no metabolism, however, they can self-replicate
and evolve, two typical aspects of life. Viruses,
however, only exhibit these life characteristics
when they are immersed in a specific cellular
environment. Viruses are the most abundant
biological lifelike entities on earth according to
the latest scientific insights, and as such are
major players in the evolution of living systems.
Furthermore, they seem to have played an essen-
tial role in the emergence of cellular (organismal)
life [7–8]. Today, some scientists put forward the
idea of an extended definition of life and a revi-
sion of the tree of life. This provocative idea was
recently discussed and exposed by Peter Ward in
his book Life As We Do Not Know It [9].
Regulatory conundrum
European regulation defines a medicinal product
as ‘any substance presented for treating or pre-
venting disease in human beings’ [10–11]. A ‘sub-
stance’ is defined as any matter, irrespective of
origin. As such, even microorganisms or whole
animals fall under this regulation. Today leeches
and fly larvae, for example, are classified as
medicinal products. 
According to this definition, therapeutically
used bacteriophages are medicinal products. In
today’s practice, however, it is impossible to
document bacteriophages as if they were
medicinal products. 
The Gene Therapy section of the Advanced
Therapy Medicinal Product Regulation describes,
amongst others, the use of genetically modified
viruses as vectors targeting eukaryotic cells for
gene therapy. However, this does not apply to
bacteriophages since they are not genetically mod-
ified and have no affinity for eukaryotic cells. No
bacteriophage DNA was found in our genetic
makeup, in contrast to the high number of retro-
viral remnants present in our core genome. Some
bacteriophage-related polymerase gene sequences
were identified in mitochondrial DNA. Mito-
chondria originated from ancestral Rickettsia-like
bacteria that began a symbiotic relationship with
prototype eukaryotic cells (similar to chloroplasts
in plants). This ancient process dates back from
the endosymbiotic era at the time of the evolu-
tionary split between pro- and eukaryotes. The
phage DNA was most probably introduced
during the bacterial phase of the mitochondrion.
Starting a clinical trial, based on the submis-
sion of an incomplete file in the official medicinal
product pathway (national notification, Eudract
number, production license etc.) could put the
investigators and the study at risk. In fact, we are
faced with a vicious circle in which we are
prevented from beginning the clinical studies
necessary to achieve an adequate regulation.
Probiotics
Bacteriophages are extremely abundant, ubiqui-
tous and present in environments as diverse as sea
water, drinking water, activated sludge, food and
cosmetics, and inhabit our bodies in at least as
large numbers as bacteria. Unknowingly we con-
stantly consume bacteriophages with our drinking
water and food (e.g., yogurt, cheese, salami etc.).
An equilibrated food intake is the basis for health. 
Probiotics such as active-bifidus containing
yoghurts, also available on the European market,
are claiming to have a positive effect on our
health through the restoration of the intestinal
flora. This means, in fact, that there is a com-
mercial claim that these yoghurts generate posi-
tive therapeutic effects. However, at the
regulatory level, the therapeutic effects for this
type of product are not claimed, since otherwise
such yoghurts would be considered medicinal
products according to European regulation.
Fermented-milk drinks containing living Lacto-
bacillus spp. such as Lactobacillus casei shirota or
Lactobacillus casei immunitas, but also their respec-
tive bacteriophages, are also present on the Euro-
pean market. Based on the Japanese Foods for
Specified Health Use (FOSHU) Regulation, the
following therapeutic effects are claimed: regula-
tion of the gastrointestinal condition, reduction of
harmful bacteria and suitable for therapeutic use
against acute diarrhea [12–13]. These products did
not receive the medicinal product status either.
In The Netherlands, these milk drinks claim to
improve bowel habits in subjects who are suscep-
tible to constipation and to support a well-bal-
anced gut microbiome through an increase in the
number of Lactobacilli. These claims were vali-
dated by a committee of independent scientists
on specific request of The Netherlands Nutrition
Center and a major milk-drink manufacturer.
Despite these valorized claims, the product was
not classified as a medicinal product [14,101]. 
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Apparently, for food products, therapeutic
claims do not have to be backed up by clinical
(safety) trials or, in fact, by any study whatsoever. 
‘Generally recognized as safe’
product regulation
Some companies decided to penetrate the food
market in order to accustom the public and the
regulatory authorities to bacteriophages, which
should facilitate future clinical trials whilst
already generating certain revenues. The applica-
tion of phages in the agrobio industry is also a
good alternative to antibiotics and represents a
considerable market.
Therefore, in the USA, the FDA recently
(April 2006) approved the use of bacteriophage-
cocktails against Listeria monocytogenes in ready-
to-eat meat and poultry. The FDA classified these
bacteriophages under the generally recognized as
safe (GRAS) product regulation [15–16].
Declaration of Helsinki
In Poland, a recent member of the European
Union, bacteriophages are already therapeutically
used. The Polish Academy of Sciences and
L. Hirszfeld Institute of Immunology and Experi-
mental Therapy offers phage-therapy to treat
patients infected with drug-resistant bacteria [102]. 
The regulatory basis for this therapeutic use of
bacteriophages on patients is the Declaration of
Helsinki. Paragraph 32 of this Declaration states: 
“In the treatment of a patient, where proven 
prophylactic, diagnostic and therapeutic methods do 
not exist or have been ineffective, the physician, with 
informed consent from the patient, must be free to use 
unproven or new prophylactic, diagnostic and 
therapeutic measures, if in the physician’s judgment it 
offers hope of saving life, re-establishing health or 
alleviating suffering. Where possible, these measures 
should be made the object of research, designed to 
evaluate their safety and efficacy. In all cases, new 
information should be recorded and, where 
appropriate, published”.
The other relevant guidelines of this Declaration
should be followed.
In June 2005, the Ethical Committee of the
Medical Academy in Wroclaw authorized a study
named Experimental Phage Therapy in Antibiotic-
Resistant Bacterial Infection, Including MRSA
Infection. Neither the European Medicinal Prod-
uct Regulation nor the Polish National trans-
lation of this regulation was applied and Europe
did not oppose to this. 
Brussels Burn Wound Center
The Burn Wound Center of the Queen Astrid
Military Hospital cares for 1350 patients
(10,000 consultations) yearly and, as in most
hospitals, clinicians are increasingly confronted
with multidrug resistant (MDR) bacteria
causing virtually untreatable infections [17]. 
In our function as biomedical researchers,
independent from the pharmaceutical industry,
we suggested to our clinicians the application of
bacteriophages as an alternative for antibiotics in
the treatment of MDR bacteria, such as methi-
cillin-resistant Staphylococcus aureus (MRSA),
MDR Pseudomonas aeruginosa and MDR
Acinetobacter baumannii.
An immediate application of phages covered by
the Declaration of Helsinki was out of the ques-
tion in our center. We wanted to set up a proof-of-
concept clinical trial in a well-specified burn-
wound patient population with well-defined
bacteriophages targeted against specific bacterial
species/strains. Furthermore, the Declaration of
Helsinki is only applicable when therapeutic meth-
ods do not exist or have been ineffective. When
applied correctly, the Declaration of Helsinki can
only justify the application of bacteriophages in
patients with untreatable infections caused by
MDR bacteria. This is only the case for a few
patients/year in our center. As a consequence we
feel this is not a durable solution for phage therapy. 
Alternatives
Several alternatives were taken into considera-
tion. First, we considered asking our hospital
pharmacist to prepare the phage cocktails as if
they were magistral preparations. Magistral prep-
arations, however, are normally prepared using
EU-registered product components, of which
phages are not.
Second, we considered using bacteriophages
under the compassionate use umbrella. This was
abandoned because this rule only applies to non-
registered drugs that are already in a clinical-study
phase and have proven a certain potential. 
We also considered going for the ‘orphan-
drugs’ approach. The use of phages on a limited
population of patients (e.g., third-degree burn
wound or cystic fibrosis patients) could justify
this option. But, this does not solve the docu-
mentation problem either, since in this setting
the bacteriophage cocktail remains to be
documented as a medicinal product. 
Finally, we decided to try to conduct a limited
clinical trial with the authorization of, and under
the supervision of, a Belgian leading Medical
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Ethical Committee that was provided with the
standard required detailed documentation
(product information, study protocol, ‘no fault’
insurance, informed consent etc.). The submit-
ted clinical trial consists of the application of a
characterized (fingerprint and electron micro-
scopy), targeted (against the bacteria in the Burn
Wound Center), safe (sterility and apyrogenicity
certified by accredited organizations), truly lytic
and noncytotoxic bacteriophage cocktail in ther-
mally injured patients with specific infections
caused by MRSA and/or MDR P. aeruginosa
strains. All the questions of the Medical Ethical
Committee were answered satisfactorily. On the
20th June 2007, we obtained the approval of a
Belgian leading Medical Ethical Committee to
conduct a limited clinical trial. A well-defined
bacteriophage cocktail targeted against the
P. aeruginosa and S. aureus strains present in our
Burn Wound Center will be applied on infected
or colonized burn wounds in 20 patients.
In the evaluation process of the study we were
confronted with the false perception of viruses
as ‘enemies of life’, an observation that was pre-
viously expressed by Luis Villareal [18]. This,
amongst others, resulted in a tenfold increase of
the study insurance fee and an unwarranted
request to notify the National Bio-safety
Council, which technically only rules on the
release of genetically modified organisms and
pathogenic microorganisms in the environment.
This was a false perception, since phage therapy
has been proven safe through the massive appli-
cation of lytic bacteriophages in humans, mostly
in former USSR states [19–21] and in animal
studies [22–26] and safety studies in healthy
humans [27] in the Western world. To our
knowledge, no specific or lethal product-related
adverse events were reported. 
Ultimately, we would like to support a long-
term solution, such as the creation of a specific
section for phage therapy under the Advanced
Therapy Medicinal Product Regulation included
in the European Directive 2003/63/EC, which
was translated into Belgian Law by the Royal
Decree of March 4, 2004 and presently includes
Gene Therapy and Somatic Cell Therapy. A
third section, Tissue Engineered Products, is in
preparation. We propose the creation of a fourth
section named Bacteriophage Therapy Prepar-
ations, which could be divided into two distinct
sections: ‘tailor made use in a hospital environ-
ment’ versus ‘industrially produced for market
placement’. This specific regulation should
allow nonprofit organizations such as hospitals
to apply in-house phage therapy without ham-
pering pharmaceutical companies in the
development of commercial phage preparations.
Conclusion
The current European regulatory setting only
allows for eventual sporadic clinical trials under
the responsibility and supervision of the Medical
Ethical Committees and/or border-line applica-
tions under the umbrella of the Declaration of
Helsinki. There is a clear need for an adapted
European regulation tailored to phage therapy,
allowing the justified and broad therapeutic use
of bacteriophages as an alternative or comple-
ment to antibiotics. The absence of a rational
regulation will leave a sterile discussion between
phage skeptics, who claim scientific evidence,
and phage enthusiasts, willing to test phage ther-
apy objectively but prevented to do so by high
administrative and regulatory hurdles.
Future perspective
The concept of selecting a mixture of various
phages would enable one to effectively target var-
ious bacteria. This can be applied to hard-to-
treat infected wounds or, with an appropriate
preparation, even against some systemic infec-
tions. Furthermore, as phages can be lyophilized
and stored for quite a long time, ready-to-use
cocktails could be used to fight outbreaks or
other public health emergencies, even in the con-
text of ‘bio-defense’. But, we are not there…yet.
In the future, regulation should be adapted in
order to give phage therapy a chance. We cannot
leave any opportunity to solve the antibiotic-
resistance problem unexplored. From an
economical point of view, phage therapy could
be a hidden fortune.
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Executive summary
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 2.2 Development of a selection and production scheme for 
bacteriophages used in a clinical setting (Study 2) 
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Abstract
We describe the small-scale, laboratory-based, production and quality control of a cocktail, consisting of exclusively lytic
bacteriophages, designed for the treatment of Pseudomonas aeruginosa and Staphylococcus aureus infections in burn
wound patients. Based on succesive selection rounds three bacteriophages were retained from an initial pool of 82 P.
aeruginosa and 8 S. aureus bacteriophages, specific for prevalent P. aeruginosa and S. aureus strains in the Burn Centre of the
Queen Astrid Military Hospital in Brussels, Belgium. This cocktail, consisting of P. aeruginosa phages 14/1 (Myoviridae) and
PNM (Podoviridae) and S. aureus phage ISP (Myoviridae) was produced and purified of endotoxin. Quality control included
Stability (shelf life), determination of pyrogenicity, sterility and cytotoxicity, confirmation of the absence of temperate
bacteriophages and transmission electron microscopy-based confirmation of the presence of the expected virion
morphologic particles as well as of their specific interaction with the target bacteria. Bacteriophage genome and proteome
analysis confirmed the lytic nature of the bacteriophages, the absence of toxin-coding genes and showed that the selected
phages 14/1, PNM and ISP are close relatives of respectively F8, wKMV and phage G1. The bacteriophage cocktail is currently
being evaluated in a pilot clinical study cleared by a leading Medical Ethical Committee.
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Introduction
In burn wound care, bacterial infection remains a major
therapeutic problem and renders large numbers of thermal injuries
virtually untreatable. Whereas Staphylococcus aureus remains a
common cause of early burn wound infection, Pseudomonas
aeruginosa is known as the most common and lethal infectious
agent in burn centres, essentially due to its intrinsic and acquired
resistance to antibiotics [1–3].
To improve burn wound patient care, research at the
Laboratory for Molecular and Cellular Technology (LabMCT)
of the Burn Centre of the Queen Astrid Military Hospital in
Neder-over-Heembeek (Brussels), Belgium is investigating alterna-
tives for the treatment of infections with multidrug resistant
(MDR) infectious agents, like (bacterio)phage therapy. The use of
bacteriophages against bacterial pathogens was first proposed by
d’He´relle in 1917 [4] and has a long and convoluted history.
Currently, phage therapy is the subject of renewed interest, as a
consequence of the continuing increase in antibiotic resistance
worldwide [5], illustrated by the growing number of scientific
papers and text books [6–12].
However, major obstacles for the clinical application of
bacteriophages are the perception of viruses as ‘enemies of life’
[13], the lack of a specific frame for phage therapy in the current
Medicinal Product Regulation [14] and the absence of well-
defined and safe bacteriophage preparations.
To evaluate the safety and efficacy of bacteriophages in the
treatment of burn wound infections in a controlled clinical trial, we
prepared a highly purified and fully defined bacteriophage cocktail
(BFC-1), active against the P. aeruginosa and the S. aureus strains
actually circulating in the Burn Centre of the Queen Astrid
Military.
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To our knowledge the present paper describes for the first time,
in detail - from the initial bacteriophage isolation to the final
composition - a laboratory-based production of a well-defined
bacteriophage cocktail.
Methods
A flow chart of the entire BFC-1 production process and quality
control tests is depicted in Figure 1.
Titration of bacteriophage suspensions using the agar
overlay method
The bacteriophage titre was determined by assaying decinormal
serial dilutions (log(0) to log(212)) of the bacteriophage suspen-
sions with the agar overlay method [27,28]. One ml of each
dilution was mixed with 2.5 ml molten (45uC) Luria Bertani (LB)
(Becton Dickinson, Erembodegem, Belgium), containing 0.7% top
agar (Bacto agar, Becton Dickinson), and a suspension of
bacteriophage sensitive bacteria (end concentration of 108 cfu/
Figure 1. Flow chart of the BFC-1 production and final quality control.
doi:10.1371/journal.pone.0004944.g001
Bacteriophage Cocktail
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ml) in sterile 14 ml tubes (Falcon, Becton Dickinson). This mixture
was plated in triplicate onto 90 mm diameter Petri dishes
(Plastiques Gosselin, Menen, Belgium) filled with a bottom layer
of 1.5% LB agar and incubated for 18–24 h at 37uC. To estimate
the original bacteriophage concentration, plates with one to 100
distinguishable homogenous plaques were counted depending on
the phage plaque size. The mean was then calculated for the
triplicate plates.
Initial isolation, separation and purification of P.
aeruginosa and S. aureus lytic bacteriophages
The bacteriophage sensitive strains used during the production
and quality control of BFC-1 are P. aeruginosa strain ‘573’, were
isolated at the Eliava Institute of Bacteriophage, Microbiology and
Virology (EIBMV) in the 1970s from bone marrow interstitial
fluid, and S. aureus strain ’13 S44 S9, isolated at the Brussels Burn
Centre in 2006 from a burn wound. Initially, S. aureus strain Wood
60 (EIBMV collection) was used for propagation of phage ISP, but
for the production of this cocktail the phage was propagated on S.
aureus 13 S44 S. The absence of temperate phages from the host
strains was tested as described in a separate section of this paper.
For bacteriophage isolation from natural samples such as
sewage and river water, one millilitre of 106concentrated LB
Broth (Becton Dickinson), 1 ml ‘host bacteria’ suspension,
containing 108 cfu in LB broth and 9 ml sewage or river water
were mixed in a 14 ml sterile tube. This tube was incubated at
37uC for 1.5–2 h. Subsequently, 200 ml of chloroform (Sigma-
Aldrich, Bornem, Belgium) was added and the tube was further
incubated at 4uC for 1 h. The lysate was aspirated with a sterile
5 ml syringe and passed through a 0.45 mm membrane filter
(Minisart, Sartorius, Vilvoorde, Belgium). Bacteriophages were
titrated using the agar overlay method, as described above. All
plaques with different morphology were touched with a sterile
pipette tip, inoculated into 2 ml of sterile LB broth in 14 ml sterile
tubes and incubated at 37uC for 2 h. Subsequently, 50 ml of
chloroform was added and the tube(s) were incubated at 4uC for
1 h. For each tube, a dilution series (log(0)2log(24)) was made in
sterile 14 ml tubes filled with LB broth. Each dilution was titrated
using the agar overlay method. Plates showing 1–10 plaques were
analysed in detail. Again, all plaques with different morphology
were touched with a sterile pipette tip, inoculated into 2 ml of
sterile LB broth in 14 ml sterile tubes and incubated at 37uC for
2 h. This complete cycle was repeated until one plaque
morphotype was obtained (homogeneous plaques).
In the case of bacteriophage ISP, which was isolated in the
1920s, porcelain, rather than membrane filters were employed.
Production of bacteriophage stocks
Bacteriophage stocks were prepared using the double-agar
overlay method with minor modifications. One millilitre of lysate
(see above) containing 103–105 plaque forming units (pfu) of
bacteriophages was mixed with 2.5 ml molten (45uC) Select
Alternative Protein Source (APS) LB (Becton Dickinson, Erembo-
degem, Belgium) top agar (0.7%) and a bacteriophage sensitive
bacterial suspension (end concentration of 108 cfu/ml) in a sterile
14 ml tube. This mixture was plated onto ten 90 mm diameter
Petri dishes filled with a bottom layer of 1.5% APS LB agar and
incubated at 37uC for 16–18 h. Subsequently, 200 ml of
chloroform was added to the lids of the Petri dishes and further
incubated at 4uC for 1 h. The top agar layer was scraped off using
a sterile Drigalski spatula (L-shaped rod) and transferred to a
sterile 14 ml tube. The mixture was centrifuged for 20 min at
6 000 g. The supernatant was aspirated using a sterile 10 ml
syringe (BD Plastipak, Becton Dickinson) with a 30 G sterile
needle (BD microlance 3, Becton Dickinson) and passed through a
0.45 mm membrane filter.
Selection of therapeutic bacteriophages
Large 24.5 cm square Petri dishes (Nunc, Wiesbaden, Ger-
many) with 2% LB agar were inoculated with the target bacteria
(108 cfu/ml LB broth). Each target bacterium was applied in one
horizontal strip. As a consequence, the dish contained multiple
parallel inoculation strips. Each strip was air-dried and spotted
with 5 ml of 107 pfu/ml of each of the bacteriophage suspensions
under consideration. The dish was incubated for 16–18 h at 37uC.
The obtained lysis zones were evaluated and scored as cl
(confluent lysis), ol (opaque lysis), scl (semi-confluent lysis), sp
(several plaques) and – (negative reaction).
Composition and endotoxin purification of the
bacteriophage cocktail
Each of the three bacteriophage stock suspensions (PNM, 14/1
and ISP) of the final cocktail was diluted into 100 ml of a sterile
0.9% NaCl solution (B. Braun, Diegem, Belgium) to a final
concentration of 3.109 pfu/ml. Subsequently, the three bacterio-
phage suspensions were mixed in a sterile 500 ml PETG NalgeneH
bottle (Nalge Europe, Neerijse, Belgium) to obtain a 300 ml
volume of the bacteriophage cocktail (named BFC-1), which
contained each bacteriophage at a concentration of 109 pfu/ml.
BFC-1 was subsequently purified from endotoxins using a
commercially available kit (EndoTrapH Blue, Cambrex BioSci-
ence, Verviers, Belgium), according to the instructions of the
manufacturer. One column was utilised per 50 ml of BFC-1.
Endotoxin purified BFC-1 was collected into a sterile 500 ml
PETG NalgeneH bottle and aliquoted into 3 ml doses in sterile
4 ml vials (Brand, We¨rtheim, Germany). The final titre of each
phage was approximately 1.109 pfu/ml.
Final quality control
pH. The pH of BFC-1 was determined by an accredited
laboratory (SGS Lab Simon AS, Brussels, Belgium) in accordance
to the European Pharmacopoeia standards (EP6).
Pyrogenicity
Pyrogenicity was tested by an accredited laboratory (SGS Lab
Simon SA) in accordance with the European Pharmacopoeia
standards (EP6). A sample of 1.2 ml BFC-1 was intravenously
injected in three rabbits. The calculation of the rabbit injection
volume in order to achieve the maximum safety level was done
according to the following equation: rabbit injection volume=hu-
man injection volume x safety factor x rabbit weight/70, with human
injection volume=3 ml - whereby 3 ml is the maximal volume
topically applied in the clinical trial and immediate and complete
resorption is assumed, to achieve maximal safety; with safety
factor=8 (i.e. maximum safety level) and with rabbit weight=3.5 kg.
Sterility
Ten percent of the BFC-1 production was tested for sterility by
an accredited laboratory (Laboratoire de Controˆle et d’Analyses,
Brussels, Belgium) using the membrane filtration method followed
by two weeks of incubation at 37uC, in accordance to the
European Pharmacopoeia (EP6).
Transmission electron microscopy
Bacteriophage particles, with and without target bacteria were
analysed by transmission electron microscopy as described by
Imberechts et al. [29]. Briefly, suspensions were brought on
Bacteriophage Cocktail
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carbon and pioloform-coated grids (Agar Scientific, Stansted, UK),
washed with water and negatively stained with 2% uranyl acetate
(Agar Scientific) in water and analyzed using a Technai Spirit
transmission electron microscope (FEI, Eindhoven, The Nether-
lands) operating at 120 kV. Micrographs were recorded using a
bottom-mounted digital camera (Eagle, 4X4K, FEI).
Exclusion of temperate bacteriophages from the host
strains
To confirm the absence of temperate bacteriophages, originat-
ing from the bacterial hosts used to grow the three lytic
bacteriophages, a standard technique for bacteriophage induction
using the DNA-damaging antimicrobial agent mitomycin C was
carried out, as described by Miller [30].
The host strains used in BFC-1 production (P. aeruginosa strain
573 and S. aureus strain 13 S44 S, as well as the P. aeruginosa
reference strain ‘PAO1’) were grown in APS LB broth at 37uC
until the early exponential growth phase. Bacterial cultures were
aliquoted in 1 ml volumes in sterile eppendorf tubes, covered with
aluminium foil thus protecting the bacteria from photoreactivation
of drug-induced DNA damage. Mitomycin C (Sigma-Aldrich) was
added to final concentrations of 1 or 5 mg/ml [30]. A control tube
without mitomycin C was added to evaluate the presence of ‘non-
drug-induced’ bacteriophages. The tubes were incubated for 3 h at
37uC. Subsequently, twenty ml of chloroform was added to the
control tubes to lyse the bacteria. The lysates were centrifuged in
order to separate the intact bacterial cells from the supernatant. The
final titre of bacteriophages in the supernatant was determined using
the double agar overlay method, as described above.
Genome sequencing and proteomic analysis
DNA from bacteriophages was isolated using a commercially
available kit (Lambda Mini Kit, Qiagen, Hilden, Germany).
Purified DNA from bacteriophages 14/1, PNM and ISP was
sonicated for 1 s at 20% intensity using a Sonics Vibracell and
separated on a 1% agarose gel (Eurogentec, Seraing, Belgium).
Fragments between 1000 and 2000 bp were excised from the gel
(Qiagen, Venlo, The Netherlands), end repaired using Klenow -
T4 polymerase mixture (Fermentas, St.-Leon-Rot, Germany) and
phosphorylated using T4 polynucleotide kinase (Roche, Vilvoorde,
Belgium). Subsequently, fragments were ligated using T4 ligase
(Fermentas) into SmaI-linearised pUC19 plasmids and transformed
to Escherichia coli XL1 blue MRF. This resulted in over 10 000
positive clones after blue white screening for each bacteriophage,
of which more than 90% contained inserts between 1 and 2 kb.
Plasmids from individual clones were isolated and sequenced using
the standard M13f vector primer. After standard ethanol
precipitation, samples were separated and analyzed on an ABI
3130 capillary sequencing device (Applied Biosystems, Lennik,
Belgium). To complete the genomes (sequenced from each strand
for each position), standard primer walking was used. Sequence
assembly into contigs was performed using Sequencher 4.1
software (Gene Codes Corporation, Ann Arbor, USA). ORF
predictions were made using comparative genomics approaches
(tBLASTx), searching for conserved gene products between closely
related phages (14-1 vs F8, PNM vs phiKMV and ISP vs G1). To
scan the genomes for known toxins/lysogeny-related genes,
sequence similarity searches were performed against the non-
redundant nr NCBI database.
Cytotoxicity towards keratinocytes
The effect of BFC-1 on the proliferation of primary neonatal
human foreskin keratinocytes was evaluated in triplicate, using the
trypan blue dye exclusion test. Keratinocytes (nFS02-006, passage
8) were seeded at a concentration of 2500 keratinocytes per cm2 in
24 ml EpilifeTM basal growth medium (Cascade Biologics,
Invitrogen, Merelbeke, Belgium) in six 75 cm2 cell culture flasks
(Falcon, Becton Dickinson). One ml of BFC-1 was added to three
flasks and 1 ml of sterile physiologic water was added to the three
remaining flasks as a control. Flasks were incubated at 37uC, 5%
CO2 and a relative humidity (RH) of 95% for 5 days without
medium change. Three ml of 0.025% trypsin in 0.01% EDTA
solution (Lonza, Verviers, Belgium) was added to the flasks. After
incubation at 37uC in 5% CO2 and 95% RH for 4 min, three
millilitres of 0.025% trypsin inhibitor (Sigma-Aldrich) was added
and mixed by pipetting. The keratinocyte suspension was collected
in a 15 ml tube (Falcon, Becton Dickinson) and centrifuged at
170 g for 10 min. The pellet was resuspended in 5 ml EpilifeTM
basal growth medium. Subsequently, 100 ml of cell suspension was
mixed with 100 ml of a trypan blue staining solution (Biochrom
AG, Berlin, Germany) and the living (colourless) and dead (blue)
cells were counted using a Bu¨rker cell counting chamber and an
inverted microscope (TMS-F, Nikon, Belgium). The mean ratio of
dead keratinocytes versus the total number of keratinocytes,
expressed in %, compared to the control group, was taken as a
measure for the cytotoxicity of BFC-1.
Stability at 4uC
The stability of a dedicated batch of BFC-1 was monitored on a
monthly basis, by determining the titre of each of the three
bacteriophages after storage at 4uC. Taking into account test result
deviations, inherent to bacteriological methods, titres within a
range of 1.108 to 1.1010 pfu/ml confer retention of activity and
thus stability.
Stability after spraying
One ml of BFC-1 was aspired in a 2 ml syringe. A spraying
head with pore size of 300 mm was fixed onto the syringe and the
total volume of cocktail in the syringe was sprayed into a 50-ml
tube. Phage titres were determined prior to and after spraying by
the double agar overlay method.
Batch record file
A batch record file was compiled and checked for conformity to
the product information file by an industrial pharmacist. Principal
aspects contained in the batch record file include:
– the positive advice of the leading ethical committee that
approved the BFC-1 clinical study;
– the BFC-1 product information file, which describes, in detail,
the production process and the characteristics of BFC-1;
– the material transfer and confidentiality disclosure agreement
signed by all partners;
– the filled out working instructions describing all BFC-1
production steps;
– the quality and analysis certificates of all products, materials
and equipment (e.g. bench flow), used in the production of
BFC-1;
– the results and analysis certificates of all final quality control
tests; and
– the labels of the BFC-1 vials.
Clinical application
Prior to patient application, 3 ml of BFC-1 was aspirated
from a ‘single use only’ vial (Figure 2) using a sterile 5 ml
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syringe (B. Braun) with a sterile 20 G620 needle (Terumo
Europe, Leuven, Belgium). The needle was replaced by a sterile
spray nozzle (actuator V04.1313 BC/NR with micromist insert
V06.203, Robertpack Engineering B.V., Zwolle, The Nether-
lands). BFC-1 was sprayed on the infected burn wound
(Figure 3).
Results
Selection and host range activity of therapeutic
bacteriophages
The activity of 82 P. aeruginosa and 8 S. aureus bacteriophages
from the collections of the Eliava Institute for Bacteriophage,
Figure 2. The final product, a defined bacteriophage cocktail.
doi:10.1371/journal.pone.0004944.g002
Figure 3. Application of BFC-1 on an infected burn wound using a syringe spray.
doi:10.1371/journal.pone.0004944.g003
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Microbiology and Virology (EIBMV), Tbilisi, Georgia and the
State Institute of Genetics and Selection of Industrial Micro-
organisms (SIGSIM), Moscow, Russia was determined against a
total of 113 P. aeruginosa and 99 S. aureus strains, isolated from
different clinical and environmental habitats across the world. The
complete data on used strains and phages is shown in Table S1.
Eight bacteriophages (PT6, PT8, PNM, 14/1, 9/3, F77, PL and
ISP) were selected for further matching against 23 P. aeruginosa and
17 S. aureus strains, recently isolated from patients at the Burn
Centre of the Queen Astrid Military Hospital in Brussels. The data
on strains and phages tested are shown in Table S2. This resulted
in the selection of three bacteriophages that exhibited a large host
range activity, specific for the burn wound isolates: PNM, 14/1
and ISP (Table 1).
P. aeruginosa bacteriophage PNM, a member of the Podoviridae
family, was isolated in 1999 from the Mtkvari river in Tbilisi, P.
aeruginosa bacteriophage 14/1, a member of the Myoviridae family,
was isolated by Victor Krylov in 2000 from sewage water in
Regensburg, Germany and S. aureus bacteriophage ISP, also a
member of the Myoviridae, was isolated from the Intravenous
Staphylococcal Phage (ISP) preparation produced by the EIBMV
in the 1970s. ISP was initially isolated in the 1920s from an
unknown source in Tbilisi, Georgia.
Quality control parameters verified for this cocktail included
sterility, pyrogenicity and pH stability, evaluated as described in
the materials and methods section and further specified in
Table 2.
Transmission electron microscopy
Microscopy confirmed that BFC-1 only contained bacterio-
phage particles with the expected morphology (Figure 4) and the
expected target strain activity.
Different types of particles were observed consisting of a non-
enveloped head with icosahedral symmetry and a tail with helical
Table 1. Characteristics of the three lytic bacteriophages present in BFC-1.
Phage 14/1 PNM ISP
Host species P. aeruginosa P. aeruginosa S. aureus
Initial source Sewage water Mtkvari River Unknown
Initial place of isolation Regensburg, Germany Tbilisi, Georgia Tbilisi, Georgia
Initial date of isolation 2000 1999 1920–1930
Isolated by V. Krylov (SIGSIM) N. Lashki & M. Tediashvili (EIBMV) from ISPa
Serogroup E PT5, PNC101 ISP
Genome size (kb) 66.1 42.4 120
Family of Caudovirales Myoviridae A1 Podoviridae C1 Myoviridae A1
Host range activity (%)
All strains 37 44 91
BWC strains 83 96 100
aISP: Intravenous Staphylococcal Phage (ISP) preparation produced by Eliava IBMV. Phage ISP was isolated from this preparation in the 1970s.
doi:10.1371/journal.pone.0004944.t001
Table 2. Summary of the quality control test results.
Test Specifications Method BFC-1 test result
pH 6.0–8.0 pH test (EP6) 7.0 (conform)
Pyrogenicity #1.15uC temperature rise Intravenous injection in 3 rabbits (EP6) 0.5uC (conform)
Sterility Sterile Membrane filtration method (EP6) Sterile (conform)
Cytotoxicity No cytotoxicity, no growth inhibition,
no morphology changes
Co-culture with human keratinocytes No cytotoxicity (conform), no growth
inhibition (conform), no morphology
changes (conform)
Activity (titre) log(8)–log(10) pfu/ml Bacteriophage titration 8 log(8)–log(9) pfu/ml (conform)
Morphology of the bacteriophages 2 Myoviridae and 1 Podoviridae Transmission electron microscopy 2 Myoviridae and 1 Podoviridae (conform)
Recognition of targeted bacteria Specific recognition Transmission electron microscopy One Myo- and one Podoviridae member
recognize and kill P. aeruginosa. The other
Myoviridae member recognizes and kills S.
aureus (conform)
Phage intactness Absence of
cellular debris
Intact, pure Transmission electron microscopy Pure (conform)
Temperate bacteriophages in host
strains
Total absence Mitomycin C induction of temperate
bacteriophages
Total absence (conform)
Lytic nature Lytic DNA sequence and proteome analysis Lytic (conform)
Presence of toxic proteins No toxic proteins DNA sequence and proteome analysis No predicted toxic proteins (conform)
doi:10.1371/journal.pone.0004944.t002
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symmetry. These characteristics are consistent with the attributes
of the bacteriophage order Caudovirales.
One type of particles had an isometric hexagonal head with a
diameter of 60 nm and a straight, short, thick, non-contractile tail
built of stacked non-banded rings. The tail had a length of 10 nm
and a width of approximately 8 nm. Subterminal fibers were short
and difficult to visualize. These characteristics attribute this type of
bacteriophages to the Podoviridae family.
Two morphotypes of Myoviridae could be distinguished, based on
the respective sizes of the head and the length of the (non-
contracted) tail. One population had a head diameter of
approximately 78 nm and a tail length of 100 nm, whereas a
second morphotype had a head diameter of approximately 90 nm
and a tail length of approximately 175 nm.
When BFC-1 was combined with cultured S. aureus and P.
aeruginosa bacteria, bacteriophages from the Podoviridae and the
Myoviridae adsorbed to (and killed) their respective host.
The material observed in BFC-1 was pure, consisting almost
entirely of (exculsively lytic) bacteriophages, or bacteriophage-
derived material (isolated tails, heads, etc). No other etiological
agents or residual bacteria were observed.
DNA sequencing and in silico proteomic analysis
The complete genome sequences of the two P. Aeruginosa
infecting phages 14/1 and PNM were determined by a
combination of shotgun sequencing and primer walking as
described in Experimental Procedures. The genome of 14/1
comprises 66.2 kb and has a G+C content of 55.6%, which is
significantly lower than that of its host (66.6%).
Sequence analysis showed that bacteriophage 14/1 is a close
relative of bacteriophage F8 (66 kb) [31], having an overall DNA
identity of 87% (total average), spread throughout the genome.
Bacteriophage F8 is one of the original Lindberg Pseudomonas
typing phages. Among the 90 predicted gene products of 14/1 (or
corresponding homologsin F8 or F8-like bacteriophages like
BcepF1 or BcepB1A) no toxic proteins are present and the
genome does not contain a recognizable integrase gene, corrobo-
rating the lytic nature of these bacteriophages. Indeed, an initial
screen revealed a single, potentially toxic gene (VirE) within the
genome of phage 14/1 (NC_011703). However, the BCep1 VirE
homologue was recently connected to the prim-pol primase
superfamily of DNA polymerases, implying a role in phage DNA
replication for VirE, rather than promoting host pathogenicity.
Figure 4. BFC-1 transmission electron micrographs. a) S. aureus bacteriophage ISP, a member of the Myoviridae family. Bar: 100 nm. b) PNM
bacteriophages (Podoviridae) freed from a burst P. aeruginosa bacterium. Bar: 500 nm. c) Bacteriophage 14/1 attaching to the P. aeruginosa cell wall.
Bar: 200 nm. d) ISP bacteriophages (Myoviridae) attached to S. aureus. Bar: 500 nm.
doi:10.1371/journal.pone.0004944.g004
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The genome of PNM is 42.7 kb and with its 62.3% it
approximates the host G+C content.
The bacteriophage PNM genome shows close homology to
wKMV, with only minor (single nucleotide) differences between
PNM and wKMV, located in the DNA replication and structural
region (average homology .95%). Differences are most obvious in
the early region (80–90% DNA homology), which is consistent
with the known genomic variations between the members of the
wKMV-like bacteriophages [32]. To date, proteomic character-
ization of wKMV-like viruses has not revealed any toxic gene
products present in these bacteriophages [32,33], indicating their
absence in PNM.
For bacteriophage ISP, the 816 sequencing runs on shotgun
clones yielded a total of 120 kb of unique sequences, 100 kb of
which is contained within contigs. This represents about 86% of
the predicted genome length of about 140 kb. Preliminary analysis
of the ISP genome data suggests that this bacteriophage is almost
identical to S. aureus bacteriophage G1 (over 99% DNA
homology). The homology of bacteriophage ISP to bacteriophages
G1 and K is interesting from a therapeutic perspective, since these
bacteriophages have been used in several clinical settings and
animal studies [34,35].
Physicochemical properties of BFC-1
The pH of BFC-1 was 7.0, which is within specifications (6.0–
8.0 pH).
Since ten percent of the BFC-1 production was found to be
sterile as assessed by the membrane filtration method, the product
was considered to conform to the European Pharmacopoeia
standards (EP6).
The monthly titration of the separate bacteriophages in BFC-1
showed a conservation of 100% of the initial activity (1.109 pfu/
ml) for at least 12 months and further testing is ongoing.
Toxicity and pyrogenicity of BFC-1
No cytotoxicity towards human neonatal foreskin keratinocytes
was observed. The addition of BFC-1 to the culture medium had
no impact on the viability of the keratinocytes (Table 3). The
proliferation rate of the keratinocytes, represented by the mean
cell number after 5 days of culture (Table 3), was not inhibited,
and the morphology of the keratinocytes was not altered by the
bacteriophages. Keratinocyte cultures, with and without BFC-1,
reached 80–90% confluence after 5 days of culture whilst
maintaining a normal morphology.
Since the sum of the increase of body temperature after
injection of 1.2 ml of BFC-1 in the three rabbits was 0.5uC, which
is much lower than the allowed increase of 1.15uC, the product
was found to conform to the European Pharmacopoeia standards
(EP6).
Table 2 summarizes the tests, specifications, methods and
results of the final quality control.
Discussion
Phage therapy has the potential to be one of the promising
alternatives/complements to antibiotics. In the past, this approach
was often not as effective as hoped. Reasons for this included the
empirical use of poorly characterised crude bacteriophage
preparations. In addition, the clinical application of bacteriophag-
es for treatment of infections of humans in modern western
medicine is stuck in a vicious regulatory circle [14]. Under the
current regulatory framework, bacteriophages do not exist because
of the lack of clinical trials - yet to perform these trials one needs a
regulatory existence. As such, the development of a well-
characterized bacteriophage preparation using GMP (Good
Manufacturing Practices)-like procedures was warranted for
scientific and medico-legal reasons.
All products used in the production of BFC-1, were certified or
accompanied by an adequate certificate of analysis and were fully
compatible with the topical application on burn wound patients.
In addition, all equipment (e.g. pipettes, bench flow and
incubators) used in the production of BFC-1 was calibrated and
certified. Apart from the bacteriophages (PNM, 14/1 and ISP),
BFC-1 is composed of sterile and apyrogenic water (aqua ad
injectabilia as required by the European Pharmacopoeia) as solvent,
supplemented with 0.9% w/w NaCl for adaptation to physiologic
osmotic strength.
The minimal bacteriophage titres required for the intended
clinical applications are unknown. Bacterial loads of 105 bacteria
per g wound tissue were shown to confer a septicaemic risk [36].
Our choice of 109 pfu/ml of each bacteriophage, applied in doses
of 1 ml per 50 cm2 wound bed, should result in concentrations of
at least 100 bacteriophages for each target bacterium.
Since it cannot be excluded that BFC-1 also contains traces of
the initial bacterial growth medium and since traditional growth
media for bacteria contain animal extracts (implying a risk of
transmission of infectious agents such as BSE), it was decided to
use a bacterial growth medium certified to be free of animal
proteins. The most important medium remnants in BFC-1 are soy
hydrolysate and yeast extract, inherent components of the Select
APS LB Broth Base used for bacterial growth and bacteriophage
production. The theoretical final concentrations of these rem-
nants, before endotoxin removal, are 25 and 125 mg/ml of BFC-1
respectively.
Phage therapy faced several problems often due to an
inadequate preparation methodology. Purification, removal of
endotoxins and pyrogenic substances, stability and pH control of
the preparation were rather problematic in the past [6].
Endotoxins possess a high degree of toxicity, and their removal
is essential for safety in antibacterial bacteriophage therapy [37].
BFC-1 was easily and successfully purified from endotoxins using
a commercially available, column endotoxin purification kit,
which is based on the principles of affinity chromatography. The
high endotoxin affinity ligand of the EndoTrapH Blue affinity
matrix is proteinaceous and derived from a bacteriophage. It is
Table 3. Results of cytotoxicity testing.
Without BFC-1
Culture flask Cell number (log6) Viability (%)
1 2.00 90.9
2 2.23 89.3
3 2.10 85.1
Mean: 2.11 88.5
Standard deviation: 1.17 3.0
With BFC-1
4 1.90 93.4
5 2.30 90.8
6 2.33 89.7
Mean: 2.18 91.3
Standard deviation: 2.41 1.9
doi:10.1371/journal.pone.0004944.t003
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not an antibody, and is covalently immobilized on agarose beads
in order to ensure negligible leakage.
Accredited laboratories, able to deliver certified results,
performed the final quality control tests such as determination
of pH, pyrogenicity and sterility, classically required in clinical
studies. An in-house cytotoxicity test was performed. For
endotoxin testing, the Limulus Amoebocyte Lysate (LAL) assay
is the regulatory first line test (EP6, chapter 2.6.14/11.2). The
reference laboratory to which the cocktail was sent for
pyrogenicity testing first attempted to apply the LAL assay, but
the phages appeared to interfere with this test. The rabbit
pyrogenicity test can be used only when there is interference with
the endotoxin test, which was the case here. In fact the
pyrogenicity test encompasses all pyrogens and not only
endotoxins. We applied the real volumes that were to be applied
on patients and took the largest safety factor for acceptability of
the phage cocktail.
In theory, there is no need to ascertain the absence of pyrogens
from products, which are not intravenously/parenterally admin-
istered. However, we worked with a product that during its
production process was in close contact with bacteria and that by
application to a burn wound could diffuse partially into the blood
stream.
The pH is a homeostasis and stability indicator and thus an
important parameter of a therapeutic product. A pH between 6.0
and 8.0 guarantees the stability of infectivity of the bacteriophages
[38] and is compatible with the wound bed physiology [39]. The
pH 7.0 of BFC-1 (ideal for stable storage) is suitable for topical use
on burn wounds.
According to guideline Q5C (Quality of Biotechnological
Products: Stability Testing of Biotechnological/Biological Prod-
ucts), published by the International Conference on Harmonisa-
tion of Technical Requirements for Registration of Pharmaceu-
ticals for Human Use (ICH), the manufacturer should propose a
stability indicating profile to ensure that changes in the identity,
purity and potency of the product will be detected. Since BFC-1
consists of three bacteriophages suspended in a physiological
solution and is stored at 2–8uC in 3 ml ‘single use only’ vials,
identity and purity are not considered likely to alter. In this
particular case, the parameter that is thus proposed to profile the
stability characteristics of BFC-1 is the activity or potency of the
sole active components of BFC-1, the bacteriophages PNM, 14/1
and ISP. The slightest deterioration of one or all of the
bacteriophages will immediately result in a decrease of the
capacity to achieve its intended effect ( = activity or potency) of
BFC-1. This capacity was measured through titration of the
bacteriophages against the host strains that were used to propagate
the phages. BFC-1 was shown to maintain 100% of its initial
activity after storage at 4uC for at least one year. Further follow-up
of stability testing is ongoing.
Since temperate bacteriophages are known to transfer
antibiotic resistance and virulence genes from one bacterium
to another, a process known as lysogenic conversion, the absence
of temperate bacteriophages from the host bacteria used in the
production of BFC-1 had to be confirmed. The chemical
induction test suggested an absence of temperate bacteriophages
and the DNA sequence and proteomic analysis confirmed the
lytic character of the bacteriophages and the absence of toxin
genes. Transmission electron microscopy confirmed the phage
particle intactness and expected morphology as well as the
absence of cellular debris.
The host specificity of the phages could be established by means
of electron microscopy as well.
Data documenting the BFC-1 production process and the
certified quality control tests on the final product were compiled
into a batch record file. An industrial pharmacist certified the
conformity of this file to the product information file.
BFC-1 is currently evaluated in a clinical trial, which was
approved by the Ethical Committee of the ‘‘Universitair
Ziekenhuis’’ of the ‘‘Vrije Universiteit Brussel’’ and started in
October 2007. To date, BFC-1 has been applied topically
(Figure 3) on the infected burn wounds of eight patients. No
adverse events were observed.
This is, to our knowledge, the first detailed description of a
quality-controlled small-scale production of a bacteriophage
preparation, leading to a safety trial in burn wound patients,
which was approved by a leading Belgian ethical committee. The
aim of this manuscript was therefore not to produce a commercial
product, or to assess regulatory aspects of phage therapy, but
merely implementing a small step in the further evaluation of
phage therapy in Western medicine.
Together with European experts, we are currently in the process
of creating a discussion platform that could act as one of the
interlocutors with the regulatory authorities (e.g. EMEA) for the
creation of a specific regulatory framework and appropriate
production standards for phage therapy. Another, equally
important objective is to help provide the necessary studies to
enable a coherent use of phage therapy.
Supporting Information
Table S1 Activity of phages against 113 P. aeruginosa and 99 S.
aureus strains, isolated from different clinical and environmental
habitats across the world.
Found at: doi:10.1371/journal.pone.0004944.s001 (0.25 MB
XLS)
Table S2 Activity of phages against 23 P. aeruginosa and 17 S.
aureus strains, recently isolated from patients at the Burn Centre of
the Queen Astrid Military Hospital in Brussels.
Found at: doi:10.1371/journal.pone.0004944.s002 (0.03 MB
XLS)
Acknowledgments
The authors wish to thank Mr. William Anderson for reviewing this
manuscript.
Author Contributions
Conceived and designed the experiments: MM JPP GV NC MT VK RL
GVMZ DDVMV. Performed the experiments: MM NL TG JMWMGV
PDC TR. Analyzed the data: MM JPP GV NC MT NL TG VK JM LVP
RL GV WM GV PDC TR SJ MZ DDV MV. Contributed reagents/
materials/analysis tools: MM JPP GV NC MT VK JM RL SJ DDV MV.
Wrote the paper: MM JPP GV NC MT VK JM LVP RL MZ DDV MV.
References
1. Altoparlak U, Erol S, Ackay MN, Celebi F, Kadanali A (2004) The time-
related changes of antimicrobial resistance patterns and predominant
bacterial profiles of burn wounds and body flora of burned patients. Burns
30: 660–664.
2. Church D, Elsayed S, Reid O, Winston B, Lindsay R (2006) Burn wound
infections. Clin Microbiol Rev 19: 403–434.
3. Pirnay J-P, De Vos D, Cochez C, Bilocq F, Pirson J, et al. (2003) Molecular
epidemiology of Pseudomonas aeruginosa colonization in a burn unit: persistence of
a multidrug-resistant clone and a silver sulfadiazine-resistant clone. J Clin
Microbiol 41: 1192–1202.
4. d’He´relle F (1917) Sur un microbe invisible antagoniste des bacilles
dysente´riques. Acad Sci Ser D: 165, 373.
Bacteriophage Cocktail
PLoS ONE | www.plosone.org 9 March 2009 | Volume 4 | Issue 3 | e4944
PhD Dissertation - Gilbert Verbeken - Page 87
5. Levy SB, Marschal B (2004) Antibacterial resistance worldwide: causes,
challenges and responses. Nat Med 10: S112–S129.
6. Bru¨ssow H (2007) Phage therapy: the Western perspective. In: McGrath S, van
Sinderen D, eds. Bacteriophage Genetics and Molecular Biology. Norfolk: Caister
Academic Press. pp 159–192.
7. Chanishvili N, Chanishvili T, Tediashvili M, Barrow PA (2001) Phages and their
application against drug-resistant bacteria. J Chem Technol Biotechnol 76:
689–699.
8. Go´rski A, Borysowski J, Miedzybrodzki R, Weber-Dabrowska B (2007)
Bacteriophages in medicine. In: Mc Grath S, van Sinderen D, eds. Bacteriophage
Genetics and Molecular Biology. Norfolk: Caister Academic Press. pp 126–158.
9. Krylov VN (2001) Phage therapy in terms of bacteriophage genetics: hopes,
prospects, safety, limitations. Russian J Genetics 37: 869–887.
10. Merril CR, Scholl D, Adhya SL (2003) The prospect for bacteriophage therapy
in Western medicine. Nat Rev Drug Discov 2: 489–497.
11. Sulakvelidze A, Kutter E (2005) Bacteriophage therapy in humans. In: Kutter E,
Sulakvelidze A, eds. Bacteriophages: Biology and Applications. Boca Raton: CRC
Press. pp 381–436.
12. Calendar R, Abedon S, eds (2006) The bacteriophages. Oxford: Oxford Univ
Press. 746p.
13. Villareal LP (2005) Overall issues of virus and host evolution. In: Villareal LP, ed.
Viruses and the Evolution of Life. Washington: ASM Press. pp 1–28.
14. Verbeken G, De Vos D, Vaneechoutte M, Merabishvili M, Zizi M, et al. (2007)
European regulatory conundrum of phage therapy. Future Microbiol 2:
485–491.
15. Babalova EG, Katsitadze KT, Sakvarelidze LA, Imniashvili NS,
Sharashidze TG, et al. (1968) Preventive value of dried dysentery bacteriophage.
Zh Mikrobiol Epidemiol Immunobiol 2: 143–145.
16. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, et al. (2002) Bacteriophage
therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant
Enterococcus faecium. Infect Immun 70: 204–210.
17. Bruttin A, Bru¨ssow H (2005) Human volunteers receiving Escherichia coli phage
T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 49:
2874–2878.
18. Capparelli R, Ventimiglia I, Roperto S, Fenizia D, Iannelli D (2005) Selection of
an Escherichia coli O157:H7 bacteriophage for persistence in the circulatory
system of mice infected experimentally. Clin Microbiol Infection 12: 248–253.
19. Chibani-Chennoufi S, Sidoti J, Bru¨ttin A, Kutter E, Sarket, et al. (2004) In vitro
and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage
therapy. Antimicrob Agents Chemother 48: 2558–2569.
20. McVay CS, Velasquez M, Fralick JA (2007) Phage therapy of Pseudomonas
aeruginosa infections in a mouse burn wound model. Antimicrob Agents
Chemother 51: 1934–1938.
21. Smith HW, Huggins MB (1982) Successful treatment of experimental Escherichia
coli infections in mice using phage: its general superiority over antibiotics. J Gen
Microbiol 128: 307–318.
22. Smith HW, Huggins MB (1983) Effectiveness of phage treatment in
experimental Escherichia coli diarrhoea in calves, piglets and lambs. J Gen
Microbiol 129: 2659–2675.
23. Smith HW, Huggins MB, Shaw KM (1987) The control of experimental
Escherichia coli diarrhoea in calves by means of bacteriophages. J Gen Microbiol
133: 1111–1126.
24. Soothill JS (1992) Treatment of experimental infection of mice with
bacteriophages. J Med Microbiol 37: 258–261.
25. Watanabe R, Matsumoto T, Sano G, Ishii Y, Tateda K, et al. (2007) Efficacy of
bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa
in mice. Antimicrob Agents Chemother 51: 446–452.
26. Wills QF, Kerrigan C, Soothill JS (2005) Experimental bacteriophage protection
against Staphylococcus aureus abscess in a rabbit model. Antimicrob Agents
Chemother 49: 1220–1221.
27. Adams MH (1959) Assay of phages by the agar layer method. In: Adams MH, ed.
Bacteriophages. New York: Interscience Publishers. pp 450–451.
28. Carlson K (2005) Methodological Approaches. In: Kutter E, Sulakvelidze A,
eds. Bacteriophages: Biology and Applications. Boca Raton: CRC Press. pp
437–490.
29. Imberechts H, Wild P, Charlier G, De Greve H, Lintermans P, et al. (1996)
Characterization of F18 fimbrial genes fedE and fedF involved in adhesion and
length of enterotoxemic Escherichia coli strain 107/86. Microb Pathog 21:
183–192.
30. Miller RV (1998) Methods for enumeration and characterization of bacterio-
phages from environmental samples. In: Burlage RS, Atlas R, Stahl D, Geesey G,
Sayer GS, eds. Techniques in Microbial Ecology. New York: Oxford University
Press. pp 218–235.
31. Kwan T, Liu J, DuBow M, Gros P, Pelletier J (2006) Comparative genomic
analysis of 18 Pseudomonas aeruginosa bacteriophages. J Bacteriol 188: 1184–1187.
32. Ceyssens PJ, Lavigne R, Mattheus W, Chibeu A, Hertveldt K, et al. (2006)
Genomic analysis of Pseudomonas aeruginosa phages LKD16 and LKA1:
establishment of the phiKMV subgroup within the T7 supergroup. J Bacteriol
188: 6924–6931.
33. Lavigne R, Burkal’tseva MV, Robben J, Sykilinda NN, Kurochkina LP, et al.
(2003) The genome of bacteriophage phiKMV, a T7-like virus infecting
Pseudomonas aeruginosa. Virology 312: 49–59.
34. O’Flaherty S, Coffey A, Edwards R, Meaney W, Fitzgerald GF, et al. (2004)
Genome of staphylococcal phage K: a new lineage of Myoviridae infecting gram-
positive bacteria with a low G+C content. J Bacteriol 186: 2862–2871.
35. Gill JJ, Pacour JC, Carson ME, Leslie KE, Griffiths MW, et al. (2006) Efficacy
and pharmacokinetics of bacteriophage therapy in treatment of subclinical
Staphylococcus aureus mastitis in lactating dairy cattle. Antimicrob Agents
Chemother 50: 2912–2918.
36. Perez-Cappelano R, Manelli JC, Palayret D, Carlin G, Echinard C, et al. (1976)
Evaluation of the septicaemic risk by a quantitative study of the cutaneous flora
in patients with burns. Burns 3: 42–45.
37. Boratynski JD, Syper D, Weber-Dabrowska B, Kusiak-Szelachowska M,
Pozniak G, et al. (2004) Preparation of endotoxin-free bacteriophages. Cell
Mol Biol Lett 9: 253–259.
38. Kerby GP, Gowdy RA, Dillon ES, Dillon ML, Csaˆky TZ, et al. (1949)
Purification, pH stability and sedimentation properties of the T7 bacteriophage
of Escherichia coli. J Immunol 63: 93–107.
39. Schneider LA, Korber A, Grabbe S, Dissemond J (2007) Influence of pH on
wound-healing: a new perspective for wound-therapy. Arch Dermatol Res 298:
413–420.
40. Merabishvili M, Verhelst R, Glonti T, Chanishvili N, Krylov V, et al. (2007)
Digitized fluorescent RFLP analysis (fRFLP) as a universal method for
comparing genomes of culturable dsDNA viruses: application to bacteriophages.
Res Microbiol 158: 572–581.
Bacteriophage Cocktail
PLoS ONE | www.plosone.org 10 March 2009 | Volume 4 | Issue 3 | e4944
PhD Dissertation - Gilbert Verbeken - Page 88
PhD Dissertation - Gilbert Verbeken - Page 89
PhD Dissertation - Gilbert Verbeken - Page 90
 2.3 The launch of a bacteriophage therapy safety trial 
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Abstract: Antibiotic resistance has become a major public health problem and the antibiotics pipeline is running 
dry. Bacteriophages (phages) may offer an ‘innovative’ means of infection treatment, which can be combined or 
alternated with antibiotic therapy and may enhance our abilities to treat bacterial infections successfully. Today, in 
the Queen Astrid Military Hospital, phage therapy is increasingly considered as part of a salvage therapy for patients 
in therapeutic dead end, particularly those with multidrug resistant infections. We describe the application of a well-
defined and quality controlled phage cocktail, active against Pseudomonas aeruginosa and Staphylococcus aureus, 
on colonized burn wounds within a modest clinical trial (nine patients, 10 applications), which was approved by a 
leading Belgian Medical Ethical Committee. No adverse events, clinical abnormalities or changes in laboratory test 
results that could be related to the application of phages were observed. Unfortunately, this very prudent ‘clinical 
trial’ did not allow for an adequate evaluation of the efficacy of the phage cocktail. Nevertheless, this first ‘baby step’ 
revealed several pitfalls and lessons for future experimental phage therapy and helped overcome the psychological 
hurdles that existed to the use of viruses in the treatment of patients in our burn unit.
Keywords: Phage therapy, burn wound, infection, Pseudomonas aeruginosa, Staphylococcus aureus, antibiotic 
resistance 
Introduction
Multidrug resistance, first reported in the 
1970s, has become a major threat to the prog-
ress made in infection control worldwide. Each 
year in the EU, an estimated 25,000 patients 
die from infections with multidrug-resistant 
(MDR) bacteria [1]. Also in burn units, a large 
number of infections are virtually untreatable. 
Whereas Staphylococcus aureus remains a 
common early colonizer of burn wounds, 
Pseudomonas aeruginosa is known as the 
most common cause of life-threatening infec-
tion in burn patients [2, 3]. Both bacteria, but 
especially P. aeruginosa, are known for their 
intrinsic and acquired resistance to many anti-
biotics. Persistent multidrug-resistant P. aeru-
ginosa strains have frequently been reported to 
cause nosocomial outbreaks of infection in 
burn units [4, 5]. 
Bacteriophages (phages) are (among) the most 
abundant and ubiquitous organisms on Earth 
and are the natural controllers of bacteria. They 
are the ‘viruses’ of the bacteria and are able to 
lyse, among others, strains of S. aureus or P. 
aeruginosa, irrespective of the antibiotic sus-
ceptibility of these strains. As such, they may 
offer an independent means of infection treat-
ment, which can be combined or alternated 
with antibiotic therapy and may enhance our 
abilities to treat bacterial infections success-
fully [6]. Since the 1920s, phages have been 
used to treat all sorts of bacterial infections in 
Eastern Europe and the former USSR States, 
with the Eliava Institute in Tbilisi (Georgia) as 
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one of the key centers [7]. The advent of antibi-
otics, which exhibited a broader spectrum of 
activity and which could be produced easier in 
large quantities (i.e. in a commercially more 
profitable manner), forced phage therapy to the 
margins of Western medicine. With the world-
wide spreading of MDR bacteria, however, the 
therapeutic use of phages is going through a 
renaissance in the Western world [8]. 
The few burn wound related phage therapy 
papers in the scientific literature [9-17] suggest 
that phages could have the potential to control 
bacterial burn wound infection. 
Phages were shown to be able to rescue burned 
mice from infection caused by P. aeruginosa 
and Klebsiella pneumonia [9, 10]. In 1990, in 
Egypt, 30 patients with burn wounds were 
treated during 5-17 days with between 15 and 
45 phage-saturated dressings [11]. The clinical 
success ratio was difficult to assess because 
of the lack of validated controls, but the mere 
fact that not-endotoxin-purified phages had 
been applied massively to burn wounds, with-
out reporting adverse effects, could be indica-
tive for their intrinsic harmlessness. Soothill 
and colleagues showed that in a test popula-
tion of 14 guinea pigs with excised burn wounds 
to which 6 x 105 cfu/ml of P. aeruginosa and 
1.2 x 107 P. aeruginosa BS24 phages were 
applied simultaneously and upon which the 
excised tissue was replaced, 6 out of 7 phage 
treated grafts were not rejected, whereas all 7 
of non phage treated grafts failed [12]. Weber-
Dabrowska et al. reported the treatment of 49 
burn wounds in human patients, infected with 
P. aeruginosa, S. aureus, Escherichia coli, 
Klebsiella and/or Proteus. Forty-two patients 
fully recovered and the condition of the remain-
ing 7 patients improved markedly [13]. A 2005 
publication addressed the treatment of local 
radiation injuries in two individuals, using a 
novel biodegradable preparation capable of 
sustained release of phages and ciprofloxacin 
[14]. The same product was applied in Georgia 
on 22 patients with infected venous static 
ulcers and other poorly healing wounds, after 
standard therapy had failed [15]. Seventy per-
cent of the patients showed full recovery after a 
period ranging from 6 days to 15 months. In the 
UK, the group of Soothill reported the case of a 
27-year-old male with 50% TBSA burned and 
excised burn wounds covered with skin grafts, 
which became infected with P. aeruginosa after 
several months [16]. Grafted areas broke down 
rapidly despite appropriate antibiotic treat-
ment. Therefore, treatment with ‘purified’ phag-
es was started. Phages multiplied in the wound 
and a 43 to 1200-fold increase of phages was 
observed. Three days after phage application, 
P. aeruginosa could not be isolated from swabs 
and subsequent extensive grafting was succ- 
essful. 
There are, however, some major obstacles 
hampering the clinical application of phages in 
Western medicine [18-22]. In the EU, discus-
sions between small and medium-sized enter-
prises (SMEs) and competent authorities led to 
the classification of bacteriophages as human 
medicinal products (biologicals) regulated 
under the European Human Code for Medicines 
(Directive 2001/83/EC). A handful of compa-
nies are now struggling to take large-scale and 
uniform phage cocktails through the elaborate 
and expensive medicinal product licensing 
pathway. Funding for the development of phag-
es as medicinal products is difficult to obtain, 
since intellectual property (IP) protection for 
phages (products of nature) is very fragile. In 
addition, we feel that in hospital settings phage 
therapy would better be served by small-scale 
productions and distributions of tailor made 
phage preparations [21, 22]. Finally, but not 
less important, the reluctance to embrace 
phage therapy is also linked to the false percep-
tion of viruses, with which phages are identified 
– often without nuance –, as ‘enemies of life’ 
[23]. As a result, in the Western world, phages 
for controlling microbial contamination in food 
and the food-processing environment are read-
ily used, while no phage medicinal products are 
currently authorized for human use [24].
In 2007, we developed a well-defined phage 
cocktail, BFC-1, which was active against the P. 
aeruginosa and S. aureus strains that populat-
ed the burn wound center of the Queen Astrid 
Military Hospital.  The quality controlled pro-
duction process of BFC-1 was mainly based on 
our experience in producing cell and tissue 
autografts and allografts for human transplan-
tation (regulated under Directive 2004/23/EC 
of the European Parliament and of the Council) 
and was published in 2009 [25].
This paper gives an account of the first applica-
tion, in 2007, of BFC-1 on colonized burn 
wounds in the burn wound center of the Queen 
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Astrid Military Hospital. Since in 2007 phages 
were not yet classified as medicinal products, 
these phage applications were performed with-
in a small (9 patients, 10 single dose applica-
tions) investigator driven clinical trial (no spon-
sor) under the responsibility and supervision of 
a leading Medical Ethical Committee. The study 
was not designed according to one of the com-
mon phases (I, II or III) of the classical medici-
nal product approval process and we did not 
solicit for approval by any regulatory authority 
for future use in the general population (mar-
keting authorization). The study was notified (by 
the ethical committee) to the national compe-
tent authorities and informed consent was 
obtained from the patients. The parties involved 
in this study had no commercial interests. 
Materials and methods
Phage cocktail
The phage cocktail BFC-1, which was evaluated 
in this study, consisted of three exclusively lytic 
phages, designed for the treatment of P. aeru-
ginosa and S. aureus infections in burn wound 
patients [25]. Based on successive selection 
rounds three phages were retained from an ini-
tial pool of 82 P. aeruginosa and 8 S. aureus 
phages, specific for the P. aeruginosa and S. 
aureus strains that were the most prevalent in 
the burn wound center of the Queen Astrid 
Military Hospital. This cocktail, consisting of P. 
aeruginosa phages 14/1 (Myoviridae) and PNM 
(Podoviridae) and S. aureus phage ISP 
(Myoviridae), at a concentration of 109 plaque 
forming units (pfu)/ml of each phage, was pro-
duced and purified of endotoxin according to 
Merabishvili et al. [25]. Quality controls includ-
ed stability (shelf life), determination of pyroge-
nicity, sterility and cytotoxicity, confirmation of 
the absence of temperate phages and trans-
mission electron microscopy-based confirma-
tion of the presence of the expected virion mor-
phologic particles as well as of their specific 
interaction with the target bacteria. Phage 
genome and proteome analysis confirmed the 
lytic nature of the phages and the absence of 
toxin-coding genes.
Patients’ inclusion criteria
Nine acute burn wound patients with MDR P. 
aeruginosa and/or S. aureus burn wound colo-
nization, as determined by classical bacterial 
culture and species identification and antibiotic 
susceptibility testing using the VITEK 2 system 
(bioMérieux) of routine burn wound swabs, 
were included in this study. Pregnant women 
and patients in critical condition (APACHE II 
score > 20) were not included. Only patients 
with burn wounds that allowed for punch biopsy 
sampling were included. Patients or their legal 
representatives were provided with relevant 
and understandable information regarding the 
study and the need to give informed consent 
Figure 1. A vial of bacteriophage cocktail BFC-1.
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before they participated in the study. A no-fault 
(regardless of liability) compensation insurance 
was provided to the patients.
General trial set up
We compared the standard treatment for P. 
aeruginosa and S. aureus burn wound coloni-
zation with a phage treatment. Since an objec-
tive evaluation and classification of burn 
wounds is impossible and colonization and 
infection levels can vary significantly, we com-
pared both treatments on the same colonized 
burn wound. 
Just before the application of BFC-1, the colo-
nized burn wound was divided into two halves. 
One half received the standard treatment, the 
other half the phage treatment with BFC-1. Two 
biopsies were taken by the MD in charge of the 
patient using a 4 mm punch biopsy needle 
(Labo Stiefel); one in the centre of the zone 
where BFC-1 was to be applied, the other in the 
centre of the zone where the standard treat-
ment was to be applied. Tissue biopsies were 
preceded by local anesthesia (xylocaine 2%, 
Asta Zeneca). It was shown that infiltration with 
additive-free lidocaine 1% into a ring block 
shortly before the biopsy procedure did not 
affect the result of bacterial culture provided 
that culture was started within 2 hours [26]. 
Biopsy sites were sutured with green ethilon 
4/0 (standard treatment site) or with blue 
prolene 4/0 (BFC-1 site). The MD in charge of 
the patient applied a single-dose of approxi-
mately 1 ml of sterile and endotoxin-purified 
BFC-1 per 50 cm2 on one half of the burn 
wound, using a 5 ml syringe with a spray adapt-
er (Coster®) (Figure 1). The other half of the 
burn wound was treated with antimicrobial sub-
stances according to the standard treatment 
protocols. Patients with suspected P. aerugi-
nosa burn wound infection were administered 
amikacin (single initial dose of 25 mg/kg body 
weight) in combination with ceftazidime (single 
initial dose of 1 g) or meropenem (2 g/8 h) sys-
temically. Patients with suspected S. aureus 
burn wound infection were treated with system-
ic vancomycin (single initial dose of 1 g) or line-
zolid (2 x 600 mg/d).
A digital photograph was taken of the burn 
wound. The entire burn wound was then cov-
ered with dressings, gauze and bandages 
according to the standard treatment protocols. 
Two to five hours later, the burn wound was 
uncovered. Immediately, two biopsies were 
taken next to (within 2 cm) the previous ones. A 
digital photograph was taken of the burn 
wound. The entire burn wound was further 
treated according to standard protocols. The 
wound biopsies were immediately weighed and 
collected into separate, sterile and adequately 
labeled microtubes (Eppendorf AG) containing 
0.5 ml of sterile phosphate buffered saline 
(PBS) and transported to the laboratory for bac-
terial load determination. 
The main objective of this study was to explore 
the hurdles that early Western phage therapy 
clinical trials would inevitably face. The second-
ary objective was to document eventual 
adverse events and therapeutic effects.  
Determination of bacterial load
The biopsies were immediately homogenized, 
on ice, for 1 min at 30000 rpm, using a tissue 
tearer (Biospec Products, Inc.). Serial tenfold 
dilutions of the homogenized wound biopsy 
samples were spread, in triplicate, on blood 
agar, Manitol Salt Agar (MSA) and cetrimide 
agar plates (media were purchased from 
Becton Dickinson). Colony counts were per-
formed after overnight incubation at 37°C. The 
bacterial load, expressed as colony forming 
units (cfu) per g tissue, was calculated for each 
biopsy.
Monitoring of eventual adverse events
Patient medical files were screened for adverse 
events, clinical abnormalities and changes in 
laboratory test results that could be related to 
the application of phages. Clinical abnormali-
ties that were screened for included cardiovas-
cular, renal, and respiratory complications and 
pain. Clinical laboratory tests included the 
blood formula and standard haemostasis, bio-
chemical, pharmacological and toxicological 
parameters.
Informed consent and approval of a leading 
Medical Ethical Committee
This clinical trial was conducted with the under-
standing and the consent of the human sub-
jects. The study protocol was cleared by the 
Medical Ethical Committee of the Vrije 
Universiteit Brussel (VUB), which also notified 
the competent authorities.
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Results
Ten BFC-1 applications were performed on 9 
patients (4 males, 5 females; mean age 61 
years; age range, 27 to 88 years; mean TBSA 
burned, 30%; TBSA burned range, 6-45%). The 
surface of the burn wounds to which BFC-1 was 
administered averaged 95 cm² (range 25-150 
cm²) and on average 0.03 ml of BFC-1 (equat-
ing 107 phages) per cm² were applied in a sin-
gle dose. The second biopsies were obtained 
181 min (range 120-240 min) after BFC-1 appli-
cation. Standard treatment consisted of 
Isobetadine® gel (Meda Pharma) (n = 4) and 
Mepilex® Ag (Mölnlycke) (n = 1). Five applica-
tions occurred within the time frame of a surgi-
cal procedure, prior to which the burn wounds 
had been washed with Hibitane (5%) and fil-
tered tab water. 
The 10 burn wounds to which BFC-1 was admin-
istered were colonized or infected with MDR 
(resistance to a representative of at least 3 
classes of antibiotics) strains of P. aeruginosa 
(n = 7), S. aureus (n = 1) or both P. aeruginosa 
and S. aureus (n = 2). This distinction was 
based on the results of the most recent routine 
bacteriological screening of the burn wounds, 
associated to relevant clinical signs and bio-
logical markers. Despite the initial indications 
of colonization or infection, bacterial cultures of 
the homogenised biopsies taken before and 
after BFC-1 application showed only a very 
small bacterial load (a few colonies) in 8 of the 
10 applications. In the two remaining applica-
tions bacterial loads before BFC-1 application 
were 103 and 108 cfu per g tissue. In all cases, 
the bacterial load remained unchanged, after 
BFC-1 application as well as after standard 
treatment.
No adverse events were reported and no clini-
cal or laboratory test abnormalities related to 
the application of phages were observed.
Discussion
Hurdles 
It was far from easy to get this small pilot study 
on the rail. We had to disarm a lot of resistance. 
This reluctance towards phage therapy was 
expected and was largely due to pre- and mis-
conceptions about phage therapy. For example, 
we were asked to submit our phage cocktail to 
the National approval system for Genetically 
Modified Organisms (GMO), in which the safety 
for humans, animals and the environment is 
thoroughly assessed. Then, the experts of the 
insurance company that was asked to provide 
the no-fault compensation insurance assimi-
lated phages with viruses and consequently 
assigned our modest experiment to risk class 5 
(on a scale from 1 to 7), which resulted in a 
relatively high premium. Some editors and 
reviewers, who evaluated a former paper 
describing the quality controlled production of 
our phage cocktail, asked for conventional 
pharmaceutical tests and clinical trials, which 
take many years and cost millions of euros. 
They reckoned phages should be considered as 
classical drugs. Although phages are therapeu-
tic agents, we disagree on the fact they have to 
be considered as classical drugs. Phages are 
evolving natural controllers of bacteria. If one 
were to consider them as a stable ‘drug’, and 
apply the whole regulatory framework thereof, 
their composition and characteristics are not 
meant to vary. Unfortunately, bacteria are 
expected to escape such ‘stable’ phage prepa-
rations and the real power of the use of phages 
would be lost. The real added value of phages 
as antimicrobials relies on the possibility to 
generate certified phage preparations on faster 
time scales than those common for classical 
medicinal products. Then and only then will we 
have a ‘new’ powerful and sustainable tool in 
the fight against bacterial diseases. Hence, if 
they are to be successful, phages cannot be 
considered as classical molecules and will thus 
need a dedicated regulatory framework with 
adequate and realistic production and quality 
control requirements [20].
Pitfalls
During this study, we were confronted with 
some significant technical and logistic prob-
lems. We opted for biopsy samples to monitor 
the bacterial load of the burn wounds because 
they are still considered to be the gold standard 
by the majority of researchers [2, 27, 28]. On 
reflection, we found this technique to be very 
elaborate (e.g. necessitated local anesthesia 
and complex sample processing) and at some 
occasions we were confronted with patient 
and/or nursing aversion to biopsies. All in all, 
biopsy sampling turned out to impede the clini-
cal trial in our burn wound center. In the future, 
we will likely opt for semi-quantitative swab cul-
tures instead of quantitative biopsy cultures for 
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the monitoring of burn wound colonization, 
even if this is bound to result in less accurate 
quantification of burn wound colonization or 
infection.
The disappointing bacterial load of wound tis-
sue at the moment of BFC-1 application was 
probably due to the long period (up to 7 days) 
between initial detection of a potential candi-
date with MDR P. aeruginosa and/or S. aureus 
burn wound colonization and the actual enroll-
ment of this patient in the study. Major reasons 
for this were the delays in receiving antibio-
grams and obtaining informed consent. 
Meanwhile patients were treated with potent 
topical antimicrobials, dressings and systemic 
antibiotics. Some treatments were even applied 
minutes before the start of the trial. In the 
future, we will probably use clinical signs and 
biological markers of burn wound colonization 
or infection, instead of deferred bacteriological 
results, as inclusion criterion for this type of 
clinical trial. This would of course imply the 
inclusion of all P. aeruginosa and S. aureus 
burn wound infections, not only those with MDR 
strains. Finally, the sprayed BFC-1 cocktail had 
the tendency to run off the burn wound. The 
use of a suitable carrier, such as a gel or a 
dressing that is compatible with phage activity, 
seems more appropriate.
Notwithstanding these pitfalls, we were not 
expecting that a one-off application of 3 ml of 
BFC-1 on a small wound surface would gener-
ate conclusive proof of the efficacy of BFC-1.
Why publish (now)?
This study ran from the end of 2007 until 2008 
and we planned to publish a report in a peer-
reviewed scientific journal in the course of 
2008. However, we decided to abandon the 
idea of a widespread scientific report of this 
study because it did not go as expected. We 
would use the experience gained during this 
small pilot study to set up a larger double blind 
study. Unfortunately, we had to put our plans on 
hold because meanwhile phages were classi-
fied as medicinal products and the subsequent 
and unattainable obligation to comply with the 
classical pharmaco-economical framework. We 
had waived publication, but colleagues from 
like-minded research groups were interested in 
the fate of our study and encouraged us to pub-
lish our experiences, as they might be helpful in 
convincing their competent authorities and 
ethical committees in approving experimental 
phage applications and in designing future 
studies. In addition, the study is increasingly 
mentioned (obviously without citing a peer-
reviewed publication) in other scientific papers 
and this often without including relevant facts 
and details. Finally, we realized that this study 
had been an essential and necessary step 
towards the acceptance of phage therapy in our 
burn wound center. Since then the medical and 
nursing staff of our hospital has grown familiar 
with phages and deemed them safe for topical 
use on burn wounds. Today, phage therapy is 
increasingly part of the successful treatment of 
a handful of ‘abandoned’ patients with MDR 
infections, outside of a clinical trial and con-
form to the requirements of article 37 the 
Declaration of Helsinki (Unproven Interventions 
in Clinical Practice). Recently, the Belgian 
Ministry of Defense approved a feasibility study 
for the establishment of a dedicated phage 
therapy center in the Queen Astrid Military 
Hospital. On the first of June 2013, Phagoburn 
(www.phagoburn.eu), a project funded by the 
European Commission under the 7th Framework 
Programme for Research and Development 
was launched. It aims at evaluating phage ther-
apy for the treatment of burn wounds infected 
with Escherichia coli and P. aeruginosa. 
Conclusions
This small pilot study did identify some signifi-
cant pitfalls and hurdles associated with phage 
therapy related clinical trials and broke down 
the psychological barriers with the healthcare 
team. The local topical application of bacterio-
phage cocktail BFC-1 on 10 burn wounds in 9 
patients did not elicit any adverse events 
whatsoever.
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InTRoDucTIon
The worldwide emergence of “Superbugs” and 
a dry antibiotic pipeline threaten a return to the 
pre-antibiotic era, i.e. prior to the 1940s when 
millions of people died of bacterial infection1.
In hospitals in both high-income and low-
income countries, the majority of nosocomial 
outbreaks are caused by a small group of patho-
gens – Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumanni, 
Pseudomonas aeruginosa and Enterobacter species, 
hereafter referred to as “the ESKAPE bugs.” 
These ESKAPE bugs are increasingly prevalent 
in our hospitals and increasingly resistant to many 
of our antimicrobial agents threatening patients’ 
lives and confronting society with huge socio-
economic costs1. 
While extensively drug resistant Acinetobacter 
baumannii, often associated with military opera-
tions (Iraq, Afghanistan), NDM-1 containing En-
terobacteriaceae, pan-resistant Pseudomonas aerugi-
nosa clones and methicillin resistant Staphylococcus 
aureus (MRSA) are mainly prevalent in our hos-
pitals, it seems that the community as a whole is 
threatened by these worrisome pathogens. This 
was demonstrated by the EAHEC 0104:H4 epi-
demic in Germany in 20112-5. Some infectious 
agents are indeed not confined to human beings 
but actually deeply settled in our environment. 
Beside the overuse, and misuse of antibiotics in 
human medicine it seems also more and more evi-
dent that the animal food production sector serves 
as a major antibiotic consumer and consequently a 
reservoir for multi-drug resistant (MDR) bacteria. 
Our ever growing and crowded cities also seem 
to play a role in the emergence of these ESKAPE 
bugs6-8. Taking all this into account it is evident 
that the situation is alarming.
A reflection on the biological role of natural, as 
well as (semi-)synthetic antibiotics, in nature as 
secondary metabolites and their use as antimi-
crobial agents in human, veterinary and agro-bio 
industry reveals that we still have much to learn 
about these molecules. The lack of fundamental 
knowledge on the actual role of antibiotics (sec-
ondary metabolites often functioning as signalling 
molecules) in nature and their effect on living sys-
tems (bacteria) in relation with the whole ecologi-
cal setting means that we actually disequilibrate 
our natural environment as a consequence of the 
mis/over use of those molecules. This biological 
phenomenon of antibiotic resistance is typically 
an emergent characteristic of a dynamic, highly 
complex and self-organizing system that evolves 
at the edge of chaos9-10.
Antibiotics are typically studied and developed 
through models in which the bacteria are in a 
planktonic (free living and growing) life style, but 
most of the infections seem to be due to bacte-
rial infectious foci, which mainly harbour bacteria 
that exhibit a biofilm life style11. It was shown by 
gene expression analysis that planktonic and bio-
film lifestyle modes have distinct differential gene 
expression profiles. This affects, amongst other 
features, the bacterial sensitivity to antibiotics12-13. 
These bacterial biofilm-related findings imply 
that the mechanical barrier function of the biofilm 
is not the main reason why bacteria residing in a 
biofilm lifestyle mode do not respond as expected 
to antibiotics. Some antibiotics can diffuse into 
the biofilm complex and reach the bacteria, but 
as a consequence of the changed bacterial physi-
ology and biochemical pathways in the biofilm 
modus some antibiotics cannot interfere with the 
biofilm bacteria in the same way as they would 
do with free living and proliferating planktonic 
bacteria. In a biofilm the bacterial growth rate is 
dramatically slowed down while the mechanical 
barrier protects them essentially from the immune 
system. Antibiotics were developed only taking 
into account the bacterium’s planktonic lifestyle, 
but we know today that biofilms play a major role 
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in most infectious states11. New strategies, based on fun-
damental biofilm research to cope with this problem are 
under development. Recently, a review on bacterial bio-
films was published in this journal by Antonio Fonseca14. 
Apart from the overuse and misuse of antibiotics there 
are thus several additional reasons for the antibiotic crisis 
which is partly a consequence of our current socio eco-
nomic society15. The pharmaceutical industry is not eager 
to develop new antibiotics due to the long term resource-
intensive research and development costs while knowing 
that eventually resistance will emerge and the return on 
investment will decrease. As the industry antibiotic pipe-
line is virtually dry and infectious diseases steadily on the 
increase, experts struggle to find acceptable solutions 16-
18. The use of bacteriophages, bacterio specific viruses, is 
currently being (re)considered as a sensible option. Last 
year several reports of clinical applications in animals and 
humans were published 19-24. With our actual knowledge 
we can consider that bacteriophages are not harmful for 
eukaryotic organisms, such as humans. Eukaryotic or-
ganisms include fungi, plants and animals (including hu-
mans). They typically have a specific membrane-bound 
nucleus with its specific biochemical enzyme systems and 
organelles in contrast to the prokaryotic bacteria. Thus 
bacteriophages are bacterio-specific viruses that naturally 
cannot infect and replicate in a eukaryotic cell. In order 
to enter their host cell they need specific outer membrane 
receptors beside the specific bacterial biochemical machin-
ery for replication. Bacteriophages (meaning bacteria eat-
ers) are in fact the bacteria’s natural predators. As such 
they keep bacterial populations growth under control. 
Wherever bacteria are present there are bacteriophages 
(or phages in short) which are generally present in at least 
a ten times higher order of magnitude than the bacteria 
themselves and consequently constitute the most abun-
dant biological lifelike constituents of the biosphere of this 
planet25. This observation shows us that actually we live 
in an ocean of phages and have done since the dawn of 
the human species and that natural phages are in principle 
harmless to us. Ecologically they are key as bacterial con-
trollers and it is this ‘natural function’ of bacteriophages 
that phage therapy is exploiting. In combination with or 
as substitute for antibiotics they could be a therapeutic 
option in the eradication or control of bacterial colonisa-
tions/infections. Indeed applying a specific natural lytic 
bacteriophage, targeted against a specific pathogenic bacte-
rium, on for example an infected wound, should result in 
the lysis of the targeted bacterium after the amplification 
of the phage in the bacterial cell. As a result the wound 
would be cleared by the phage of its noxious bacteria. In 
fact the bacteriophage could be considered as a self am-
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plifying drug at the place of infection. Once the bacteria 
are eradicated (through lysis) or brought to a low enough 
density that the host’s immune system can take over the 
situation, the bacteriophages will also be eliminated by 
the host’s immune system.
However today there is a lack of standardized evidence-
based clinical research. This rediscovered antibacterial 
therapeutic approach, first proposed by d’Herelle almost 
a century ago, was only further developed, mostly empiri-
cally, in the former Soviet Empire 17-18, 26-29. Since the 
early beginning of phage therapy this approach was con-
tinuously used in medical practice and empirically adapted 
so that today in countries like Georgia, phage therapy is 
considered an established medical practice not requiring 
any further questioning. To reintroduce it however in our 
actual medical practice requires clinical studies in accord-
ance with current standards. But documenting a “lifelike” 
entity is not the same as documenting a chemical static 
substance, what an antibiotic in fact is. Also there is the 
aspect related to Intellectual Property Rights (IP) that after 
all looks to be the thorniest problem. Phage therapy could 
provide a sustainable solution for the multi-drug resistance 
crisis. Phage therapy is the use of natural exclusively lytic 
bacterio-specific viruses as antibacterial agent. In fact by 
setting up a screening system for the circulating noxious 
bacteria and their respective phages it will always be pos-
sible to obtain the right lytic phage against any emerging 
pathogen. This way of working, taking into account the 
co-evolution of the couplet bacterium/phage, makes it 
just a fitting solution for a sustainable antibacterial phage 
therapy industry. We think that phage therapy will surely 
have its (exclusive) application setting(s) and in addition 
could be used in combination (synergy) with antibiot-
ics30. Studies show that phages can enhance antibiotic’s 
activity by interaction with the bacterial biofilm modus. 
The search for a specific phage or phage cocktail against 
a specific bacterium will not take the time nor require the 
costs of searching and developing a new antibiotic. The 
search for a potent natural phage and the preparation of 
classic galenic preparation (physiological water, basic oint-
ment…) containing phages is practical and feasible in the 
time frame of days to weeks, in contrast to new antibiotics 
which require many years of research and development. 
If an infection is caused by a pan-resistant bacterium it 
is realistic to select a specific phage for clinical use, in 
contrast to the search of a new antibiotic. 
The clinical development of phage therapy however 
faces major obstacles, typical of the current medico-phar-
maceutical environment, that hamper progress18, 28-29, 31
n The lack of a specific adapted regulatory frame in the 
medicinal product regulations (mainly based on the 
classic static chemical drugs)
n It is difficult to obtain IP, and as a consequence 
 difficult to find investors
n The absence of well-defined, safe and targeted phage 
preparations (technically feasible, but due to the 
above mentioned reasons there are currently no 
dedicated therapeutic phage centres) 
n The societal false perception of viruses as ‘enemies 
of life’. 
AIm AnD mETHoD
It was our aim to evaluate the potential of phage therapy 
and to bring it eventually to the patient.
A multidisciplinary team of biologists, medical doctors 
and pharmacists was established and worked simultane-
ously, from the start, on different aspects, ranging from the 
regulatory to the in vitro and in vivo (clinical) experiments 
of this antibacterial treatment. 
n An exhaustive analysis of the current relevant drug or 
medicinal products regulatory frameworks was per-
formed to analyse whether they could cater for phage 
therapy. 
n A small-scale production process for the preparation 
of quality controlled and well-defined phage cock-
tails for clinical use was set-up. The elaboration of 
this project involved several research groups and a 
clinical team. Parts of the quality control tests would 
be outsourced. The final goal was to use this bacteri-
ophage cocktail as a topical treatment against MDR 
P. aeruginosa and MRSA infected wounds in a pilot 
trial in burn wound patients with the agreement of a 
Belgian Medical Ethical Committee. 
n To foster national and international interactions and 
to promote phage therapy in Europe, an interna-
tional organization ‘Phages for Human Applications 
Group – Europe’ (P.H.A.G.E.) was created. 
RESuLTS AnD DIScuSSIon
An analysis of the regulatory framework and multiple dis-
cussions with several experts as well as the relevant com-
petent authorities revealed that clinical phage therapy ap-
plications in the EU are possible, but that the regulatory 
frame is not well-adapted 28-29. 
Although the development of phages as classical 
medicinal products like an antibiotics, including Good 
Manufacturing Practices (GMP) production, pre-clinical 
and phase I, II and III clinical trial and marketing is pos-
sible, it is, in our opinion, not the most appropriate route 
Such a developmental path would cost millions of Euros 
and take many years (± 10 years for biologicals). These 
investments are not compatible with the apparent lack of 
Intellectual Property (IP) protection (at least for natural 
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phages). Phages, as natural entities, belong to mankind 
as a whole, and cannot be patented in the classical sense. 
Also the idea of phage therapy itself first put forward by 
Felix d’Herelle who coined the name of bacteriophages 
meaning ‘bacterium eating entities’, cannot, in principle, 
be patented since it belongs to the common knowledge 
and has done for almost a century. This situation does not 
stimulate the industry to invest, since the actual paradigm 
is “no IP, no investment”15 -18. 
To overcome this embarrassing situation, new views 
and consequent ways of (pharmaceutical) industrial mod-
els have to be developed29. 
Established pharmaceutical companies are not likely 
to invest substantial amounts of money and time in the 
development of potentially interesting products that will 
need to be adapted (evolve) even more quickly than flu 
vaccines, to be effective. This fast adaptation is needed to 
exploit the main advantage of phages over classical ‘static’ 
drugs such as antibiotics, namely their ability to rapidly (in 
a matter of days to weeks) evolve to target emerging patho-
genic strains. This is possible by continuously screening 
bacteria and their phages, as is also done in Georgia. This 
“Sur-mesure” or tailor-made pathway for the future im-
plementation of phage therapy is proposed and discussed 
by Pirnay et al 29. This view is also what was proposed to 
the Innovation Task Force (ITF) at EMA. The discussion 
is still ongoing. 
Non profit institutions like hospitals that would like 
to develop phage therapy are not necessarily disheartened 
by the IP issues and the uncertainty of large profits, but 
are generally unable to generate the necessary funding and 
are furthermore most likely better served by a tailor-made 
(e.g. to a patient or an outbreak) approach29. This means 
that in a timeframe of days to weeks a specific phage can 
always be found to target a specific emerging pathogen. 
It is this specific power of phage therapy, namely its co-
evolutionary aspect, which guarantees an efficient anti-
bacterial agent when needed. 
As a result of this conundrum, until now, only local 
and sporadic phage applications were performed in the 
Western World, often under the umbrella of the Declara-
tion of Helsinki. In Poland, an EU member state, a specific 
national adaptive regulation, based on the Declaration of 
Helsinki, was issued to regulate phage therapy. A medical 
doctor is allowed to apply phage therapy where proven 
therapeutic methods do not exist or have been ineffective 
(e.g. MDR infections) and provided that the patient or his 
legal representative signs an informed consent. 
In France, Dr. Alain Dublanchet, a veteran of phage 
therapy, occasionally applies phages in desperate osteo-
myelitis cases and with success 24, 29 In Australia, phage 
therapy was recently applied under the umbrella of “com-
passionate use” for the successful treatment of refractory 
P. aeruginosa urinary tract infection in a cancer patient24. 
In Belgium a basic clinical safety trial was performed with 
the approval of a leading Medical Ethical Committee. 
Clinical trials of course need safe and well-defined 
phages. Therefore a phage cocktail (BFC-1) that targeted 
the most prevalent MDR P. aeruginosa and MRSA bac-
teria was produced. The cocktail consisted of two phages 
against P. aeruginosa and one against S. aureus (Fig. 1). It 
was produced on a small scale and in accordance with basic 
clinical-pharmaceutical standards (sterility, apyrogenic-
ity, pH, cytotoxicity, adequate shelf life and stability). In 
addition, the phages in BFC-1 were proven to be exclu-
sively lytic and characterized at the genomic and proteomic 
level. This specific production process was published by 
Merabishvili et al.32 and is actually used as a basic discus-
sion document for future adaptations in the regulatory 
documentation process.
BFC-1 was applied, in a small pilot study, in the burn 
unit of the Queen Astrid Military Hospital (9 patients, 
10 applications) (Fig. 2). This was one of the first uncon-
cealed phage applications in modern Western medicine. 
As expected, no adverse events or side effects were observed 
based on clinical as well as laboratory-measurable param-
Figure 1. 
BFC-1 transmission electron micrographs (. 
a) P. aeruginosa bacteriophage 14/1, a member of the  
Myoviridae family. Bar: 100 nm. 
b) PNM bacteriophages (Podoviridae) freed from a burst  
P. aeruginosa bacterium. Bar: 500 nm.
c) Bacteriophage 14/1 attaching to the P. aeruginosa cell wall.  
Bar: 200 nm.
d) ISP bacteriophages (Myoviridae) attaching to S. aureus.  
Bar: 500 nm.
Ref. 26 Merabishvili et al 2009.
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eters. This small pilot safety trial, showing the innocuity 
of phages when applied to burns, was discussed in a review 
by Kutter and colleagues27. In addition, we successfully 
applied (systemically, through a wound drain) large quan-
tities of BFC-1 (300 ml of 105 phage particles), under the 
Declaration of Helsinki, in a critical pelvic trauma patient 
with MDR P. aeruginosa and MRSA osteomyelitis. 
Over the years, it has become clear that, in order to de-
velop phage therapy, an adapted regulatory framework 
and eventually even a change in (medical/pharmaceutical) 
mentality and developmental models needs to be achieved. 
Especially the natural evolutionary and sustainability as-
pects of the approach, not compatible with our current 
bio/pharmaceutical business models where IP issues are at 
the core, have to be taken into consideration when devel-
oping phage therapy. The P.H.A.G.E. network allowed 
us to discuss fundamental and practical issues such as the 
status of phages (e.g. are they (classical) drugs?), exchange 
information on applications and services and subsequently 
to efficiently interact with authorities like the European 
Medicines Agency (EMA). 
In February 2011 we officially interpellated the EU 
parliament: ‘what is the status of phage as antibacterial 
agent’ which brought the discussion to the European 
level. The question was put on the agenda by the Belgian 
Christian democrat Ivo Belet and his colleague Cather-
ine Trautmann from the Socialist faction in France. The 
Commission’s view was that the current regulatory frame-
work was sufficient for “phage therapy”, a standpoint we 
clearly don’t share. Indeed if we consider the phage as a 
static chemical substance we cannot develop phage therapy 
as it should be developed in a sustainable efficacious way 
and tailor made as discussed by Pirnay et al29.
Concerning the “false perception of viruses as enemies of 
life” obstacle, which we feared when starting our clinical 
trial, we found – to our surprise – that it was easily re-
solved through clear and scientific communication with 
the members of the ethical committee as well as the medi-
cal and nursing staff of the hospital. 
concLuSIon
Natural phages are not straightforward inanimate and sta-
ble substances, but rather lifelike evolvable natural biologi-
cal entities. The major obstacle hampering the further de-
velopment of phage therapy at large, in wound treatment 
as well as in other clinical settings (otitis, osteomyelitis, 
diabetic foot, diarrhoea, impetigo…) in our current medi-
cal/pharmaceutical environment is mainly related to the 
intellectual IP issues. 
The existing relevant regulatory frameworks and busi-
ness models are not compatible with a dynamic sustainable 
phage therapy concept. And this point of view is not com-
patible with the current economic models that reduce the 
pharmaceutical industry to ‘common button’ producers, 
when their main societal role should be ‘providing people 
with adequate products for a better health’. Therefore a 
suitable environment should be worked out 28-29. We need 
to radically redesign our (pharmaceutical) economic mod-
els to cater for more dynamic and sustainable approaches 
that fit an eventual future green economy. We are actually 
bouncing against our own ‘limits’ of growth 33-34.
Any future sustainable phage therapy concept should, 
based on scientific grounds, fully acknowledge the po-
tentialities of the co-evolutionary aspect of the couplet 
phage/bacterium in its ecological environment, in casu the 
human being29. Only then the inherent (positive) char-
acteristics of phages as natural biological bacterium con-
trollers can be put to use. Indeed, bacteria will inevitably 
Figure 2.b. 
Application of BFC-1 on an infected burn wound using a syringe 
spray. (Ref 26)
Actually phages could be applied by a spray or a galenic ointment 
formulation. Before application on wounds the wound bed should 
always be cleaned, debrided and rinsed with bicarbonated 
 physiological water in order to provide a neutral pH environment. 
This is to allow the phages to be stable. Too acidic or alkaline 
 environments cause phage degradation (protein denaturation). 
Studies are warranted in order to optimize applications and 
 frequency of application as well as the type of the most suited 
 galenic formulation in function for the site of use.
Figure 2.a. 
The final product, a bacteriophage cocktail ready for use
in a human clinical trial. (Ref 26)
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become resistant to phages, but due to the continuously 
ongoing arms race between the two protagonists, specific 
phages able to infect the formerly resistant bacterial strains 
will quickly emerge29. In fact phage therapy fits well in 
the new emerging field of Darwinian – evolutionary – 
medicine (in contrast to a classical mechanistic – man 
as a machine – view) where the insights of evolution are 
fully taken into account. Viruses, among which phages are 
included, were involved in the origin of life itself and play 
a major role in biological evolution 35-36. Hopefully they 
will play a role in the future control of bacterial disease. 
We feel that our plea for a more realistic approach, taking 
into account the co-evolutionary aspect of the bacterium 
and its phage is scientifically sound. Let’s hope that the 
political and economic factors will adapt.  m
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The present opinion is the result of discussions on the future of
phage therapy (personalized or large-scale uniform therapy?)
during the first International Congress on Viruses of Microbes,
held at the Institut Pasteur in Paris on June 21–25, 2010.
Antibiotics are becoming ineffective as important bacterial
pathogens evolve to outsmart them. Yet the antibiotic pipeline
is running dry with only a few new antibacterial drugs
expected to make it to the market in the foreseeable future.
Bacteria that are resistant to all available antibacterial drugs,
so-called superbugs, are emerging worldwide. Evolutionary
ecology might inform practical attempts to bring these
pathogens under stronger human control (1).
In this context, various laboratories worldwide and a
handful of small pharmaceutical companies are turning to
(bacterio)phages (2). Phages are natural viruses that
specifically infect bacteria. They are (among) the most
abundant and ubiquitous lifelike entities on Earth and
coevolve with their hosts, the bacteria. Lytic phages bind to
receptors on the bacterial cell surface, inject their genetic
material, use the bacterium’s reproductive machinery to
replicate and subsequently destroy (lyse) the bacterium,
irrespective of its resistance to antibiotics, releasing the
newly formed phages to seek out new hosts.
In 1919, d’Herelle used phages to treat dysentery in
Paris, in what was probably the first attempt to use phages
therapeutically. d’Herelle eventually developed a commercial
laboratory in Paris that produced phage preparations against
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various bacterial infections, which were marketed by what
later became the large French company L’Oréal (3). In the
1930s, therapeutic phages were also marketed in the United
States by major pharmaceutical companies including Eli
Lilly, Squibb & Sons (today Bristol-Meyers Squibb) and the
Swan-Meyers division of Abbott Laboratories. Scientific
controversies and the advent of antibiotics, however,
relegated phage therapy to complete obscurity in most of
the Western world. Nevertheless, phage therapy was further
developed and extensively used in Eastern Europe and the
former Soviet Union with activities centered at the Eliava
Institute of Bacteriophage, Microbiology, and Virology
(EIBMV) in Tbilisi, Georgia, several institutes in Russia,
and the Hirszfeld Institute of Immunology and Experimental
Therapy in Wroclaw, Poland.
Despite its long (Eastern European) history, phage therapy
is not currently authorized for routine use on humans in the
West. Today, it is only approved in some former Soviet
republics like Russia and Georgia, where commercial phage
preparations are sold in pharmacies (4). In Poland, a recent
member of the European Union, phage therapy is consid-
ered an ‘Experimental Treatment’ covered by the Physician
Practice Act (Polish Law Gazette N° 28 of 1997) and the
declaration of Helsinki, where other therapeutic options do
not exist (5). In France, therapeutic made-to-order phage
preparations from the Institut Pasteur (Paris and Lyon) were
used until the beginning of the nineties. Today, a French
practitioner, Alain Dublanchet, still uses commercial phage
preparations (purchased in Russia and Georgia) to treat
severe infections. Despite the absence of a specific framework
for phage therapy (6), a pilot clinical trial in burn wounds
was approved by a leading ethical committee in Belgium (7).
In the United States, a Food and Drug Administration
(FDA)-approved phase I clinical trial was conducted. No
safety concerns were found (7). Recently, a British phage
therapy company conducted a phase I/IIa clinical trial in
chronic otitis. This study was approved through the UK
Medicines and Healthcare products Regulatory Agency
(MHRA) and the Central Office for Research Ethics
Committees (COREC) ethical review process (7).
Phages are harmless to eukaryotic (e.g. animal or
plant) cells and are reported to elicit few, if any, side
effects in humans. In contrast to antibiotics, they target
specific bacterial species or even strains and can thus be
chosen to be harmless for the non-target beneficial
commensal flora (e.g. the gut flora) of the patient. This
specificity also means that the right match between the
phages and the targeted bacterial pathogen must be
found. To improve the chance of success, off-the-shelf
phage preparations should contain multiple phage strains
per targeted bacterial species. This phage mixture should
target the bacterial strains that are most commonly
present at the intended point of use.
As with antibiotics, bacteria can evolve resistance to
phages during the course of treatment (e.g. by alteration of
phage receptors), to survive the phage attacks. This might
result from mutations acquired during the course of
treatment, but it is also likely that resistant bacteria are
already present in the target population before phage
treatment. Indeed, it is not in phages’ best interest to kill all
the host bacteria in the infection site, but they can be
expected to (bio)control the bacterial pathogens and
significantly reduce their numbers and thus give the
patient’s immune system and/or antibiotics the chance to
eliminate the remaining bacteria. Moreover, in vitro, natural
selection drives the rapid emergence of new phages that can
destroy bacteria that have become resistant (9), and this
may also be important in clinical contexts.
Ninety years of phage therapy have shown that after a
while phage preparations become less effective and need to
be updated. The ineffective phages can either be “trained,”
a term used in the EIBMV to indicate the selection of
phage mutants more active against the phage-resistant
bacteria, or replaced by new active phages. New phages
are generally selected from the environment (e.g. sewage
water), but in some cases they can be isolated from clinical
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samples containing the problematic bacterium. In phage
therapy centers in Georgia and Poland, banks containing
many different phages are kept and regularly updated.
Sometimes custom phage preparations are developed for a
patient’s infection (autophage), a procedure that usually
takes a few days to weeks.
This sur-mesure approach is not compatible with the
current licensing processes. Recently, the European Med-
icines Agency (EMA) placed phages under the Medicinal
Product Regulation and more specifically under the
category of biologicals. Also, in the US, the amount of
research and testing required by the FDA is seriously
hampering the resurgence of phage therapy. Regulators
impose many years of research and clinical trials, which cost
millions of euros, to entrepreneurs to develop and distribute
phage preparations (Fig. 1).
Fig. 1 Phage therapy concepts: prêt-à-porter or sur-mesure? Both approaches should be possible and could even be complementary. The specificity of
phages, resistance and IP issues may thus hamstring pharmaceutical companies in the worldwide marketing of generic phage preparations. The long and
expensive regulatory pathways, on the other hand, form insurmountable obstacles for bonafide or non-profit phage therapy centers or hospitals, which opt
for a sur-mesure concept, and for institutions that would like to use inexpensive phages for commercially unattractive applications, in emerging countries,
for example. Of course, this sur-mesure approach should also adhere to certain standards of behavior, safety and quality control (8). These standards could
be defined in a new and specific section for phage therapy under the Advanced Therapy Medicinal Product Regulation (6).
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Notwithstanding these regulatory hurdles and the
empirical evidence suggesting that stable and widely
distributed phage preparations (prêt-à-porter) will only be
of (time-)limited use, a few companies have picked up the
gauntlet and are moving along the elaborate and
expensive licensing pathways. If nothing else, these efforts
will put phage therapy back on the map in the Western
world, and, once commonly accepted, EMA and FDA
might revise their rules the way they did for influenza
vaccines, which also require a rapid updating and
licensing procedure (10). However, are pharmaceutical
companies willing to commit to rapidly and regularly
adapting their phage preparations to very specific or
newly emerging demands? Take, for example, a hospital
unit confronted with an MDR bacterial strain that causes
untreatable infections in only one or two patients. Phage
therapy is probably best—but not exclusively—served by
small-scale productions and distributions of locally adapted or
personalized phage preparations (cottage industry) (Fig. 1).
To avoid the drug licensing pathway, some US-based
phage companies decided to first develop phage products
for the decontamination of food, plants, fields and livestock
(2). They hope to create revenue to fund research into
human therapeutics and to familiarize the authorities and
the general public with phages. Phages for decontaminating
food plants, ready-to-eat meat, poultry products, cheese
and live animals that will be slaughtered for human
consumption were approved by the FDA and are now in
use. Very little is known, however, about the impact of such
massive and widespread applications of phages on natural
microbial communities.
The lack of strong intellectual property (IP) protection
is another discouraging factor for pharmaceutical com-
panies. The principle of phage therapy has been
common knowledge since the 1920s, and many aspects
might thus be unpatentable. In addition, there are
indications that in the future, phages, which are natural
entities composed of genetic material and proteins, will
only be patentable if they have been engineered into
something distinctly different in character (11). Engi-
neered phages could be patented, but, considering the
current concerns about potential risks for public health
and the environment which may arise from genetic
engineering in genetically modified organisms (GMOs),
they are not likely to be given licensing approval in the
near future. Phage-derived products (e.g. cell wall-degrading
enzymes such as endolysins) can and probably will be
licensed and marketed within a few years. They may also
select resistance, but presumably at a lower rate than
antibiotics. Of course, these phage products lack the capacity
of self-replication and adaptation in the infectious site.
Phage therapy has great potential in some (niche) clinical
contexts, but as with antibiotic treatment, there are likely to be
important evolutionary consequences (12) if it is implemented
widely and without sufficient oversight. Some aspects of phage-
bacterium evolution ecology (e.g. emergence of resistance)
should first be analyzed in the light of future phage therapy.
Real-time experimental evolution studies could help determine
these evolutionary consequences and generate the analytical
knowledge in support of the empirical knowledge and clinical
experience that was accumulated in the Eastern world. More
importantly, they will hopefully enable the creation of a
rational phage therapy concept (Fig. 1), thus avoiding the
historical mistakes that occurred in the course of antibiotic
therapy development and which lead to the current massive
and widespread occurrence of antibiotic resistance in the
patient population as well as in the natural environment.
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Spreading antibiotic resistance: 
a universal threat
The worldwide emergence of ‘superbugs’ and 
a dry antibiotic pipeline threaten modern soci-
ety with a return to the preantibiotic era, when 
bacterial infections were the primary cause of 
morbidity and mortality [1]. A recent estimate 
indicates that 400,000 people in Europe were 
infected with multidrug-resistant (MDR) bacte-
ria during 2007, with 25,000 attributable deaths 
[2]. In hospitals in both the developed and the 
developing world, the majority of nosocomial 
outbreaks are caused by a small group of patho-
gens (i.e., Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter bau-
mannii, Pseudomonas aeruginosa and Enterobacter 
species, hereafter referred to as the ‘ESKAPE 
bugs’) [3]. These ESKAPE bugs are increasingly 
prevalent and resistant to most of our anti-
microbial agents, threatening patients’ lives and 
confronting society with huge socioeconomic 
costs. To date, MDR pathogens, such as highly 
drug-resistant A. baumannii (often associated 
with military operations in the Middle East [4]), 
NDM-1-producing Enterobacteriaceae [5], pan-
resistant P. aeruginosa clones [6] and methicillin-
resistant S. aureus (MRSA) [7], have been mostly 
associated with hospital outbreaks. 
In addition, community-associated MRSA 
infections and specific Escherichia coli out-
breaks demonstrate that the community as 
a whole is increasingly threatened by virulent 
anti biotic-resistant pathogens. Community-
associated MRSA infections arise in other-
wise healthy individuals and are more viru-
lent and transmissible than are traditional 
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The worldwide emergence of ‘superbugs’ and a dry antibiotic pipeline threaten 
modern society with a return to the preantibiotic era. Phages – the viruses of 
bacteria – could help fight antibiotic-resistant bacteria. Phage therapy was first 
attempted in 1919 by Felix d’Herelle and was commercially developed in the 
1930s before being replaced by antibiotics in most of the western world. The 
current antibiotic crisis fueled a worldwide renaissance of phage therapy. The 
inherent potential of phages as natural biological bacterium controllers can only 
be put to use if the potential of the coevolutionary aspect of the couplet 
phage–bacterium is fully acknowledged and understood, including potential 
negative consequences. We must learn from past mistakes and set up credible 
studies to gather the urgently required data with regard to the efficacy of phage 
therapy and the evolutionary consequences of its (unlimited) use. Unfortunately, 
our current pharmaceutical economic model, implying costly and time-consuming 
medicinal product development and marketing, and requiring strong intellectual 
property protection, is not compatible with traditional sustainable phage therapy. 
A specific framework with realistic production and documentation requirements, 
which allows a timely (rapid) supply of safe, tailor-made, natural bacteriophages 
to patients, should be developed. Ultimately, economic models should be 
radically reshaped to cater for more sustainable approaches such as phage 
therapy. This is one of the biggest challenges faced by modern medicine and 
society as a whole.
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hospital-associated MRSA strains [8], and the 
recent outbreak of enteroaggregative Shiga toxin/
verotoxin-producing E. coli strain O104:H4 in 
Germany [9] caused over 4000 cases of diarrhea 
– 3167 without hemolytic–uremic syndrome 
(16 deaths) and 908 with hemolytic–uremic syn-
drome (34 deaths) [10]. These cases demonstrate 
that infectious agents are not confined to hospi-
talized patients, but are actually deeply settled 
in our environment. 
For rapidly evolving, genetically versatile bac-
teria such as Pseudomonas, it has turned out to be 
quite easy to develop mechanisms to avoid the 
toxicity of antibiotics, which have remained more 
or less ‘static’ for the last decade. More reflection 
on the biological role of antibiotics in nature as 
secondary metabolites would have revealed that 
resistance evolution was inevitable. Also, in 
nature, bacteria are constantly outsmarting tox-
ins produced by competitors. However, the dif-
ference is that these natural competitors in turn 
react by selection towards adjusted toxins. The 
biological phenomenon of antibiotic resistance is 
typically an emergent characteristic of a dynamic, 
highly complex and self-organizing system that 
evolves at the edge of chaos [11,12]. Moreover, the 
rate of resistance evolution has been exacerbated 
by the overuse and misuse of antimicrobial agents 
in both clinical and agricultural contexts [13–15]. 
Due to the complexity of the antibiotic resis-
tance issue and the immense research and devel-
opment costs and time-frames of developing new 
antibiotics, for which resistance will inevitably 
occur, the pharmaceutical industry is not keen 
to continue with the development of new mol-
ecules. Moreover, even if pharmaceutical com-
panies succeed in developing and marketing 
highly active antibiotics, authorities, sensitized 
by past experiences concerning the rapid emer-
gence of resistance, are likely to withhold these 
new antibiotics as third-line last-rescue drugs, 
thereby limiting the market and consequently 
the commercial interest of the pharmaceutical 
companies. As the industry antibiotic pipeline 
is virtually dry and infectious diseases – major 
causes of morbidity and mortality – are steadily 
on the increase, new initiatives are urgently 
needed.
Phage therapy
Could (bacterio)phages, the viruses of bacteria, 
help fight antibiotic-resistant bacteria [16–18]? A 
virus is a natural biological entity, consisting 
in essence of a molecular assemblage of nucleic 
acids (the genome) surrounded by proteins, 
that behaves as a genetic replicative parasite. 
Lytic phages attach to receptors on the sur-
face of bacteria, inject their genetic material 
through the bacterial membrane and take over 
the bacterium’s transcription and translation 
machinery to synthesize new phages. Finally, 
the bacterial cell wall is destroyed (lysed), releas-
ing the newly assembled virions to the environ-
ment, where they can invade new bacteria. 
Importantly, phages are able to infect bacteria 
regardless of their susceptibility to antibiotics. 
Wherever bacteria are present, there are bound 
to be phages, generally in an order of magnitude 
higher than bacteria. With an estimated unit 
number of 1031, phages are the most abundant 
biological lifelike constituents of our biosphere 
[19–21]. In fact, one could say that we live in an 
ocean of phages. But this does not automati-
cally mean that all phages are safe at therapeutic 
concentrations. No phage-related nucleic acid 
sequence can be found in our genome, unlike 
the huge amount of human endogenous retro-
viral sequences, which make up 8–10% of the 
human genome [22,23]. Some phage-related poly-
merase gene sequences were identified in human 
mitochondrial DNA. It is common knowledge 
that mitochondria originated from Rickettsia-
like ancestor bacteria that started a symbiotic 
relationship with prototype eukaryotic cells [24]. 
Phage DNA was likely introduced in the bac-
terial phase of the mitochondrion, at the time 
when the evolutionary split occurred between 
the prokaryotes and eukaryotes (endosymbiotic 
era), and does not constitute evidence for recent 
DNA exchange. Moreover, recent work suggests 
that even the eukaryotic nucleus itself is a viral 
import [25]. It is possible that phage sequences 
did enter the human genome, but were lost over 
time. In addition, entry into our germline may 
be irrelevant to the potential for causing harm, 
and we do not know how often phage DNA 
integrated into human somatic cells. One must 
also consider that the potential adverse effects of 
phages might not be caused by them acting as 
viruses. Researchers from the Hirszfeld Institute 
of Immunology and Experimental Therapy in 
Poland found phages to be constantly present 
in human and animal bodies [26], where they 
were shown to modulate immune functions [27] 
and interact with cancer cells [28]. It is virtually 
impossible for a phage to enter directly into a 
eukaryotic cell system and subsequently mul-
tiply since it requires prokaryotic-specific cell 
wall receptors and biochemical machinery for 
its attachment and replication (e.g., prokary-
otic polymerases and tRNAs). However, we 
should also consider indirect ways for phages 
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to enter eukaryotes, no matter how far-fetched 
they may be. For example, theoretically, a phage 
could integrate into a plasmid, which could then 
transfer from a bacterium to a eukaryote. 
According to most supporters, however, phage 
therapy has been proven safe through the massive 
application of lytic bacteriophages in humans 
in the past. We conclude that, although there 
are indications that phages are not harmful for 
eukaryotic organisms, more research is needed.
Today, a few laboratories and small and 
medium enterprises are developing phage 
cocktails or phage-based products for the 
treatment of bacterial infection [29]. This anti-
bacterial therapeutic approach was first pro-
posed by Felix d’Herelle almost a century ago. 
The first therapeutic application of phages 
probably occurred as early as 1919 in Paris, 
where d’Herelle used phages to treat patients 
suffering from bacterial dysentery [30]. Later, 
he founded the Laboratoire du Bactériophage 
in Paris, which produced five phage prepara-
tions for commercial use. They were marketed 
by the French company Robert et Carrière, 
which later was acquired by L’Oréal [31]. In 
the USA in the 1930s, pharmaceutical giants 
like Eli Lilly, Squibb & Sons (today Bristol-
Myers Squibb) and the Swan–Myers division 
of Abbott Laboratories started marketing sev-
eral phage preparations. Scientific uncertainties 
and the discovery and widespread marketing of 
antibiotics, however, relegated phage therapy 
to the history books in the western world. As 
such, the current ‘knowledge’ of the therapeu-
tic effect of phages is mainly based on theo-
retical grounds, basic laboratory observations, 
animal models [32–37], safety studies in healthy 
humans [38,39] and decades of empirical medi-
cal experience [31,40–43]. These empirical data 
were mainly accumulated in the former Soviet 
Union and its eastern European satellite states, 
with an important role for the Eliava Institute 
of Bacteriophage, Microbiology and Virology 
in Tbilisi (Georgia), several institutes in 
Russia and the Hirszfeld Institute in Wroclaw 
(Poland). Phage therapy remained a valid ther-
apeutic component in France until the early 
1990s [44]. Unfortunately, the historical clini-
cal data are not taken into account by regula-
tors because it has not been validated accord-
ing to current western regulatory standards. 
The emergence of MDR bacteria has caused a 
renewed interest in phage therapy in western 
Europe and the USA, as illustrated by an expo-
nential increase in phage therapy-related papers 
in the medical literature (Figure 1). 
Phages: not your regular medicinal 
products
Phages can be seen as bacteria’s natural infec-
tious agents. Up to 50% of bacterial mortal-
ity is thought to be due to phage-induced lysis 
[45]; hence, phages impose strong selection for 
bacteria resistance. However, lytic phages can 
only propagate by infecting and lysing bacteria, 
hence there is strong selection to overcome this 
resistance. This interaction leads to antagonistic 
coevolution, consisting of the repeated emergence 
of new phage infectivity and bacterial defense 
mutations [46–50]. Typically, coevolution results 
in continual increases in bacteria resistance and 
phage infectivity ranges, although recent work, 
including a study following real-time coevolu-
tion in soil [51], suggests that high costs associ-
ated with resistance may instead result in differ-
ent, rather than greater, resistance mechanisms 
being selected through time [48,52]. In principle, 
coevolution between bacteria and phages could 
therefore allow the continual production of 
highly infectious phages that can overcome com-
mon bacterial defense mechanisms. However, it 
is important to emphasize that not all phages 
are lytic. Many integrate into bacterial genomes, 
and are propagated via bacterial reproduction 
[53]. Such lysogenic phages will themselves 
coevolve with each other [54], with bacteria and 
with other lytic phages, and the consequences 
of this for phage therapy are currently unclear. 
A recent study showed that in vitro coinfection 
of Pseudomonas fluorescens with multiple phages 
had no net effect of accelerating or slowing down 
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Figure 1. PubMed search results for ‘phage therapy’ or ‘bacteriophage 
therapy’ across time periods. 
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adaptation to the host through between-parasite 
conflict in the system [55]. It is thus tempting 
to speculate that phages act as ‘evolving anti-
biotics’ during real-time coevolution between 
therapeutic phages and infecting bacteria within 
patients. However, while real-time coevolution 
between bacteria and phages results in continual 
suppression of bacterial densities to some extent 
[51,56], the clinical significance of these relatively 
modest density directions is still unclear [57]. 
Phages do, however, play a major role in control-
ling bacterial densities in natural populations, 
and it is reasonable to assume that coevolution 
plays a role in this. For example, phages appear 
to be key players in ending cholera epidemics. 
Faruque et al. observed that seasonal epidemics 
of cholera inversely correlated with the preva-
lence of environmental cholera phages [58]. The 
removal of phages by conditions such as severe 
flooding might contribute to rendering water 
more conducive to human-to-human transfer 
of Vibrio cholerae. Phage amplification in chol-
era patients during a cholera epidemic likely 
contributed to increased environmental phage 
abundance, decreased load of environmental 
V. cholerae and, hence, the collapse of the epi-
demic. In vivo phage amplification in patients 
and subsequent phage infection in the environ-
ment could thus explain the self-limiting nature 
of seasonal cholera epidemics in Bangladesh [59].
It is clear that therapeutic phages are very dif-
ferent from classical (chemical, molecular) medic-
inal products such as antibiotics. Instead, they 
are natural biological entities that play an impor-
tant role in maintaining equilibrium in bacterial 
populations of ecological environments, includ-
ing humans. Hence, we should not see them as 
conventional stable medicinal products, but more 
as interactive and evolving antibacterial prod-
ucts, which could also be used in combination 
(synergy) with antibiotics [60]. The coevolutive 
aspect of the phage–bacterium couplet, which is 
essential for sustainable phage therapy, is often 
neglected.
However, there are potential negative conse-
quences of this coevolutionary potential. For 
example, coevolution has been shown to drive 
the evolution of bacterial mutation rates in labo-
ratory populations of the bacterium P. fluorescens. 
A quarter of the bacterial populations coevolving 
with phages had rapidly (i.e., in less than 200 
generations) acquired mutations that resulted 
in ten- to 100-fold increases in mutation rates, 
whereas no significant change in mutation rates 
was observed in the absence of phages [61]. Given 
the increase in evolvability of mutator bacteria 
(e.g., elevated rates of resistance evolution to anti-
biotics), evolvable phages may have unknown net 
consequences on disease severity. Phage therapy 
should not be implemented widely and without 
limitation, without first determining these con-
sequences through real-time experimental evolu-
tion studies. In the end, natural phages could 
prove useful, but maybe only in specific (niche) 
clinical contexts and under certain conditions 
(e.g., dosage). 
Phage therapy fits well in the emerging field 
of Darwinian medicine (in contrast to a clas-
sical mechanistic – man as a machine – view) 
[62,63], whereby the insights into evolution are 
fully taken into account, but it is less compatible 
with our actual western drug development and 
marketing model.
Hurdles in the current medicinal product 
development & marketing model
This section discusses the problems encountered 
when trying to reintroduce traditional phage 
therapy in modern medicine. 
An analysis of the current European regula-
tory framework [64] and multiple discussions with 
experts and the relevant competent authorities 
revealed that, although the development and 
marketing of phage medicinal products (includ-
ing good manufacturing practice production, 
preclinical and Phase I, II and III clinical trials 
and centralized marketing authorization) is tech-
nically possible, in practice it is not compatible 
with traditional (sustainable) phage therapy [65]. 
The cost of conventional medicinal 
product development & marketing 
(millions of Euros) necessitates strong 
intellectual property protection, but 
today, for natural phages, this protection 
is fragile
Recently, the ruling in a US court in a case 
between the Association of Molecular Pathology 
and the US Patent and Trademark Office invali-
dated seven patents claiming genes and genetic 
diagnostic methods held by Myriad Genetics [66]. 
Although related to genes, this decision opens the 
discussion about the ability to patent naturally 
occurring organisms such as phages. 
In patent law, an invention is considered to be 
new if it is not part of the state of the art. This 
means that a phage or a phage cocktail claimed 
in a patent should never have been isolated or 
produced before. The literature with respect 
to phages as natural entities to treat human 
bacterial infections is enormous. In addition, 
clinical studies using phages performed in 
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the eastern part of Europe have recently been 
translated into English (e.g., [40]). Therefore, 
many natural phages and their uses have been 
disclosed over the past century. European law 
allows the patenting of known substances, such 
as natural phages, for use in a medical method, 
provided that such use is new, meaning that 
such use may not be comprised in the state of 
the art. In the USA, several patents for phages 
used in the food sector were granted, such as 
US7507571 (food additive), claiming “an iso-
lated bacteriophage of a bacteriophage strain 
selected from a [specific] group, [somewhere] 
deposited under a [specific] accession number, 
together with variants thereof, wherein said 
variants retain the phenotypic characteristics of 
said deposited bacteriophages and wherein said 
bacteriophages, and variants thereof, have lytic 
activity against Listeria monocytogenes strains” 
[67]. More important for therapeutic use is the 
US patent 7459272 of Intralytix, Inc., claim-
ing “a method for reducing the risk of bacterial 
infection or sepsis in a person colonized with 
pathogenic bacteria comprising treating the 
colonized person with a pharmaceutical com-
position containing bacteriophage of one or 
more strains which produce lytic infections in 
said pathogenic bacteria.” In 2001, a European 
patent application (EP1250143 A2) was filed, 
claiming “a method for reducing the risk of bac-
terial infection or sepsis in a susceptible patient 
by treating the susceptible patient with a phar-
maceutical composition containing bacterio-
phages of one or more strains which produce 
lytic infections in pathogenic bacteria,” but 
this application was withdrawn in 2004. Only 
recently, “a method for production of compo-
sitions of bacteriophages” was claimed in the 
USA by Phage Biopharm, LLC (US7588929). 
No European counterpart has been published 
yet. Another interesting patent is the US patent 
7758856 (Biocontrol, Ltd) claiming “a compo-
sition for treating a bacterial biofilm,” as well 
as “a method for treating a biofilm infection.” 
A similar patent owned by the UK Health 
Protection Agency has been granted in Europe 
(EP1587520 B1). 
Diverging views between Europe and the USA 
exist on the patenting of biological material. 
Next to the requirements of novelty, inventive 
steps and industrial applicability (which are the 
same for Europe and the USA), in order to be 
patentable in Europe, a certain technical inter-
vention is needed to isolate the phage from its 
natural environment, and the isolated phage 
needs to be properly characterized. However, 
this ‘technical intervention’ has basically been 
known since the 1920s, and the requirement that 
the phage ‘needs to be well characterized’ seems 
obvious and is technically not particularly hard 
to meet [68]. In the USA, phages claimed in a 
patent need to have markedly different charac-
teristics from their counterparts found in nature. 
But, for natural exclusively lytic phages – our 
object of concern here – they simply are the ones 
found in nature. It seems as if only genetically 
modified phages can agree with the US state-
ment. While ‘manipulated’ or engineered phages 
certainly have potential applications (which are 
patentable), given the growing public concern 
and awareness over the potential health and 
environmental risks of genetically modified 
organisms, they are unlikely to obtain licensing 
approval in the near future.
Phage-encoded proteins such as cell wall-
degrading endolysins [69] will be marketed a 
few years from now in the food industry, the 
veterinary field and possibly in medicine. They 
will select resistance, but presumably and 
hopefully at a slower pace than antibiotics. Of 
course, these phage-derived products are not 
capable of self-replicating and evolving in the 
infectious site. 
In this paper, we focus on natural phages sim-
ply because of their natural intrinsic bacterial 
coevolutionary aspect making them suitable for 
flexible therapeutic applications. Patents claim-
ing natural phages are fragile, and ‘inventing 
around’ (making an invention that accomplishes 
the same thing as the original patented invention 
but does not infringe the patented invention) 
also seems to be very difficult [70].
These intellectual property (IP) issues do 
not stimulate investment (of venture capital), 
for the actual paradigm is ‘no IP protection, 
no investment’. However, the renewed interest 
in natural phages as therapeutic agents might 
trigger scientists’ and entrepreneurs’ creativity 
in defining the contours of appropriate patent 
claims for phages or, even better, because there 
are good reasons for not patenting certain natu-
ral substances, considering a new kind of IP 
instrument. New ideas on IP protection should 
not be based on the existing classical model, 
but on a broader ‘new’ philosophy in relation 
to sustainable economic and industrial develop-
ment, as advocated by Petrella and Sachs [71,72]. 
Petrella states that, today, “being competitive” is 
no longer a tool for increased development, but 
an aim in itself [71]. This increasingly implies 
that the possession of patents, often as strategic 
weapons, is more important (in the short term) 
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than owning a truly functional innovative tech-
nology. This kind of attitude tends to block the 
development of new approaches such as phage 
therapy. The patent tragedy is indeed exempli-
fied by the millions of AIDS victims who died 
while drug treatments existed and raises deep 
questions about global IP rights. How can the 
benefits of a global patent system that provides 
incentives for innovation and continuous devel-
opment be combined with an assurance that 
the targeted people (rich and poor) gain access 
to the medical care they need and have rights 
to [73]? 
Therefore, the Group of Lisbon, led by 
Petrella, proposed an evolution to world coop-
erative governance, which is based on a global 
contract that requires that each decision should 
be linked to the fact that each person should 
have access to basic livelihoods [71], including 
health access, which is actually often blocked 
by our outdated economic model. As such, 
phage therapy could be developed under the 
umbrella of, for example, the WHO. The 
WHO recognizes the importance of the world-
wide antibiotic resistance issues [101] and is dis-
cussing new incentives to push the pharma-
ceutical industry to launch new research and 
development projects. Could phage therapy be 
one of them?
The time frames for conventional 
medicinal product development  
& marketing (years) are not 
compatible with a flexible, 
tailor-made & sustainable phage 
therapy concept
Phage therapy depends upon safe and well-
defined phages, but is it really necessary to 
produce and market them in the same way as 
conventional medicinal products? 
In 2009, a phage cocktail, BFC-1, which tar-
geted the most prevalent MDR P. aeruginosa 
and MRSA bacteria in the burn wound cen-
ter of the Queen Astrid Military Hospital in 
Brussels (Belgium), was produced. The cocktail 
consisted of two phages against P. aeruginosa 
and one against S. aureus. It was produced on 
a small scale and in concordance with certain 
relevant quality and safety standards (e.g., ste-
rility, apyrogenicity, pH, adequate shelf life and 
stability). In addition, the phages were shown 
to be exclusively lytic and were characterized at 
the genomic and proteomic level. This specific 
production process was published in 2009 by 
Merabishvili et al. [68]. As the authors did not 
consider phages to be conventional medicinal 
products, the phage cocktail was not produced 
in concordance with the requirements of the EU 
medicinal product regulation. After approval 
by a leading Medical Ethical Committee (of 
the Free University of Brussels), phage cock-
tail BFC-1 was applied in a small pilot study 
in the burn unit of the Queen Astrid Military 
Hospital in Brussels. This small trial was dis-
cussed in a recent review by Kutter and col-
leagues [43]. No adverse events or side effects 
were observed. 
However, the European Commission stated 
recently that EU’s legislation on medicinal 
products does not define specific requirements 
related to bacteriophage therapy or medicines 
composed of bacteriophages because it consid-
ers that the existing regulatory framework is 
adequate for bacteriophage therapy. There is 
thus no need for a specific set of documentation 
for bacteriophage therapy [74]. We do not share 
this opinion for the reasons discussed below. 
To exploit the main advantage of phages 
over classical ‘static’ drugs such as antibiotics, 
and more specifically their capacity to rapidly 
(in a matter of days to weeks) evolve to target 
emerging (phage-resistant) pathogenic bacterial 
strains, phage cocktails should not be submit-
ted to the conventional long medicinal product 
development and licensing pathway. Even if the 
EMA would eventually adapt its rules in a simi-
lar manner to what they did for updated seasonal 
influenza vaccines, which are annually licensed 
[75], development times of many months are still 
much too long in view of the enormous chal-
lenges related to rapidly progressing bacterial 
resistance. The real power of phage therapy lies 
in the fact that the search for a potent natural 
phage and the preparation of a classic galenic 
preparation (e.g., physiological water or a basic 
ointment) containing phages is practically fea-
sible in the time frame of days to weeks. In tra-
ditional phage therapy, new therapeutic phages 
are usually selected from environmental sources 
such as raw sewage water or isolated from clini-
cal specimens from infected patients (Figure 2). 
Georgian and Polish phage therapy centers are 
keeping extensive therapeutic phage collections, 
which are regularly enriched with new phages, 
thus widening the host range of the collection. 
Ineffective phages can be ‘trained’, a term indi-
cating the in vitro selection of phage mutants 
that exhibit an increased infectivity range. As 
such, it is possible to obtain potent lytic phages 
against problematic enteroaggregative E. coli 
strains [76] in a matter of days, for example. 
Theoretically, they could thus have been used to 
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help control the O104:H4 outbreak that caused 
the death of 50 patients in Germany [9,10]. In 
this context, an O104:H4 phage preparation 
that takes months to years to develop, produce 
and register is ineffective. As phages are species- 
and often even strain-specific, it is very likely 
that current O104:H4-specific phage prepara-
tions will not be active against future epidemic 
enteroaggregative E. coli strains. Provided that 
future problematic bacteria are broadly known, 
some ‘broad-spectrum’ cocktails could be devel-
oped in advance and used as the first-line answer 
to acute healthcare problems (e.g., bioweapons). 
Some cocktails will inevitably fail due to the 
greater biodiversity outside of the laboratory, 
and the ones that initially work will need to 
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Figure 2. Two phage therapy concepts. IP issues may hamper pharmaceutical companies in the worldwide marketing of generic 
phage preparations. The long and expensive regulatory pathways form insurmountable obstacles for eventual nonprofit phage therapy 
centers or SMEs, which opt for a tailor-made concept, and for institutions that would like to use inexpensive phages for commercially 
unattractive applications (e.g., in developing countries) [65].
GMP: Good manufacturing practice; IP: Intellectual property; SME: Small and medium enterprise.
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be regularly updated due to the emergence of 
resistance. In a recent study, it was shown that 
P. aeruginosa challenged in vitro with a cocktail 
of four potent phages swiftly developed resis-
tance to all four phages [Hall AR, De Vos D, Friman 
VP, Pirnay JP, Buckling A. Effects of sequential and simul-
taneous application of bacteriophages on populations of 
Pseudomonas aeruginosa in vitro and in waxmoth larvae 
(2012), Submitted]. We are currently discussing our 
viewpoint with EMA’s Innovation Task Force 
(ITF). The ITF has the competence to facilitate 
the informal exchange of information and the 
provision of guidance early in the development 
process of medicinal products. Our objectives 
are to develop a specific framework (e.g., realistic 
production and documentation requirements) 
that allows a timely (rapid) supply of tailor-
made productions of natural bacteriophages to 
patients.
Responsible & sustainable phage 
therapy is not compatible with current 
pharmacoeconomic models 
Acceptable IP protection and development and 
licensing procedures were available for antibi-
otics. They did not prevent the overuses and 
misuses that gave rise to the current antibiotic 
resistance crisis. Solving the aforementioned IP 
and development issues will thus not necessarily 
lead to rational and sustainable phage therapy. 
The question is, how can responsible and lim-
ited use be promoted? It is very doubtful that 
this will be compatible with actual economic 
incentives. Even world cooperative governance 
will provide no guarantees, as the primary 
goal of organizations such as the WHO is to 
limit infections, not to support sustainable 
approaches. 
It is our opinion that, ultimately, economic 
models will need to be radically reshaped in 
order to cater for more sustainable approaches 
such as phage therapy. 
Current state
The tailor-made approach and sustainable 
nature of traditional phage therapy and IP 
issues may hamper pharmaceutical companies 
in the worldwide marketing of generic phage 
preparations. Nonprofit/public institutions 
such as (university) hospitals that would like 
to develop flexible and sustainable tailor-made 
(i.e., to an outbreak) phage therapy and are 
not necessarily disheartened by the IP issues 
and the subsequent uncertainty of large profits 
are generally unable to generate the necessary 
funding. In addition, the prescribed medicinal 
product development and licensing pathways 
cancel the advantages of phage therapy over 
antibiotics. It is thus difficult to reconcile a 
flexible and sustainable phage therapy concept 
with the current (western) medical and phar-
maceutical environment (Figure 2). As a result of 
this conundrum, only local and sporadic phage 
applications have been performed in the west-
ern world to date, often based on individual 
approval governed within the ‘Declaration of 
Helsinki’ framework [102]. In Poland, an EU 
member state, a specific national adaptive regu-
lation, based on the Declaration of Helsinki, 
was issued to regulate phage therapy. A medi-
cal doctor is allowed to apply phage therapy 
where proven therapeutic methods do not exist 
or have been ineffective (e.g., in MDR infec-
tions) and provided that the patient or their 
legal representative gives informed consent. In 
France, Alain Dublanchet, a veteran of phage 
therapy, occasionally applies phages in hope-
less osteomyelitis cases [65]. In Australia, phage 
therapy was recently applied under the umbrella 
of ‘compassionate use’ for the successful treat-
ment of refractory P. aeruginosa urinary tract 
infection in a cancer patient [77]. 
Conclusion
Phages are not straightforward inanimate and 
stable substances, but evolvable and natural 
biological entities. Future sustainable phage 
therapy concepts should fully acknowledge the 
potential of the coevolutionary aspect of the 
phage–bacterium couplet. Only then can the 
inherent potential of phages as natural biologi-
cal bacterium controllers be put to use. Indeed, 
bacteria will inevitably become resistant to 
phages, but due to the continuously ongoing 
arms race/competition between the two pro-
tagonists, specific phages that are able to infect 
the formerly resistant bacterial strains can be 
expected to quickly emerge. However, more 
experimental evolution studies are necessary to 
determine the potential negative evolutionary 
consequences of unlimited phage therapy. 
The existing pharmaceutical regulatory 
framework and business models are not com-
patible with a dynamic and sustainable phage 
therapy concept. The actual economic models 
reduce pharmaceutical companies to ‘com-
mon button’ producers neglecting their main 
societal role: providing people with adequate 
products for better health. Therefore, a suitable 
environment for phage therapy should be devel-
oped. Fundamental changes of mentality in the 
medical and pharmaceutical environment (e.g., 
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towards patentability and restrictive licensing) 
are essential for a successful introduction of 
phage therapy in modern (future) medicine. 
We need to radically reshape our (pharmaceuti-
cal) economic models to cater for more sustain-
able approaches that are beneficial for human 
survival. 
Phage therapy fits well in the new emerg-
ing field of Darwinian medicine, where the 
insights of evolution are fully taken into 
account. Viruses, among which are phages, 
were involved in the origin of life itself and 
play a major role in biological evolution [78–
82]. Hopefully, they will play a role in the 
future control of bacterial disease. We con-
sider our plea for a more realistic approach to 
phage therapy, which takes into account the 
coevolutionary aspect of the bacterium and 
its phage, to be scientifically sound. We must 
learn from the errors that contributed to the 
rise of antibiotic resistance. We hope to foster 
this vision in collaboration with the competent 
authorities and responsible economic actors, 
as only a common effort will make it a (direly 
needed) reality.
Future perspective
In the short term, we predict the setting up of 
credible studies to gather the required data with 
regard to the efficacy and evolutionary conse-
quences of phage therapy. These studies could 
be chaperoned by health protection agencies 
such as the European CDC. 
In the medium term, we predict the develop-
ment of a specific framework, in collaboration 
with the EMA’s ITF (or with the US FDA), 
with realistic production and documentation 
requirements that allow a timely supply of safe, 
tailor-made natural bacteriophages.
In the long term, we predict the radical 
reshaping of our (pharmaceutical) economic 
models to cater for more sustainable approaches. 
Phage therapy could be developed under the 
umbrella of the WHO.
Executive summary
Spreading antibiotic resistance: a universal threat
 n Overuse and misuse of antibiotics caused the emergence of organisms that are resistant to these medicinal products, leading to 
increased morbidity and mortality and increased healthcare costs. 
 n Because new antibiotics have become of limited use and are thus less profitable, pharmaceutical companies are reluctant to invest in 
the research and development of new antibiotics. 
Phage therapy
 n Phage therapy – the use of the viruses of bacteria to fight bacterial infection – was first advocated by Felix d’Herelle in 1919. 
 n Due to the advent of antibiotics and scientific controversies, phage therapy was abandoned in the western world. 
 n The current antibiotic resistance crisis has caused a renewed interest in phage therapy.
Phages: not your regular medicinal products
 n Phages are very different from classical (chemical molecular) medicinal products.
 n Phages are natural biological entities that coevolve with and control bacteria in the environment, including humans, which is the basis 
of sustainable phage therapy.
 n There might also be potential negative consequences of bacterial phage coevolution.
Hurdles in the current medicinal product development & marketing model
 n When trying to introduce traditional sustainable phage therapy in modern medicine, one is confronted with three issues:
– The cost of conventional medicinal product development and marketing (millions of Euros) necessitates strong intellectual property 
protection, but today, for natural phages, this protection is fragile;
– The time-frames for conventional medicinal product development and marketing (years) are not compatible with a flexible, 
tailor-made and sustainable phage therapy concept;
– Responsible and sustainable phage therapy is not compatible with current pharmacoeconomic models.
Current status 
 n Only local and sporadic phage applications are performed in the western world, often based on individual approval governed within 
the ‘Declaration of Helsinki’ framework.
Conclusion
 n Future sustainable phage therapy concepts should fully acknowledge the potential of the coevolutionary aspect of the phage–bacterium 
couplet.
 n More research is needed to determine the potential negative coevolutionary consequences of unlimited phage therapy. 
 n Our (pharmaceutical) economic models need to be radically reshaped to cater for more sustainable approaches that are beneficial for 
human survival.
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The increasing resistance of bacteria to antibiotics is a significant threat to human health and is a direct result 
of the excessive and improper use of these 
drugs. In 2007, multidrug-resistant bact erial 
strains infected more than 400,000 people 
in Europe and 25,000 patients died from 
the infections [1]. ‘Superbugs’ also have 
considerable economic impact: extra hos-
pital costs and related productivity losses 
amount to more than €1.5 billion per year 
in the European Union. In the USA, infec-
tions caused by multidrug resistant bac-
teria lead to US$20 billion in additional 
health-care costs and US$35 billion soci-
etal costs annually [2]. The situation is 
about to get worse, as there are only a few 
drugs left to treat multidrug-resistant bac-
terial strains, and the first strains that are 
resistant to even these last-resort antibiotics 
have already emerged. Moreover, there is a 
dearth of genuinely novel antibiotics in the 
development pipeline.
Various proposals have been made to 
address the problem. These range from the 
more-prudent use of existing antibiotics or 
better hygiene, to providing incentives to the 
pharmaceutical industry to develop novel 
drugs. In addition, the use of bacteriophages, 
or phage therapies, to kill specific pathogens 
without harming the majority of harmless, 
commensal bacteria has received increas-
ing attention during the past decade, but little 
has been done to capitalize on this interest 
and implement phage therapies in the clinic.
The application of bacteriophages to 
treat infection dates back to around the 
1920s. Today, phage therapies are routinely 
used in countries such as Georgia and 
Poland, but countries in western Europe 
abandoned such therapy after the introduc-
tion of antibiotics. Only a handful of clinical 
trials are on going and some are taking place 
in countries where European regulatory 
standards do not apply. Elsewhere, phage 
therapies are only applied sporadically in 
specialized medical centres for the ad hoc 
treatment of patients with severe infections. 
At this time, the greatest hurdle to the medi-
cal use of bacteriophages in Europe is the 
lack of an appropriate regulatory framework 
that appreciates the concept and specif-
ics of this approach to support its applica-
tion in the clinic. Part of the problem is that 
whether phage therapies are medicinal 
products or something completely different 
is unclear under current European legisla-
tion. Implementation and regulation of their 
use is therefore challenging.
The current legal framework for the use of medicines in Europe is mainly dictated by European directive 
2001/83/EG, which outlines the European 
Community code relating to medicinal 
products for human use. This directive was 
passed into law more than 10 years ago. It 
defines any substance or combination of 
substances used to treat or prevent disease 
in humans as human medicinal products 
and, therefore, makes them subject to spe-
cific requirements relating to safety, quality 
and efficacy. How phage therapies should 
be defined remains in question.
Bacteriophages are viruses that spe-
cifically attack bacteria and can be used to 
control, treat or prevent infectious diseases 
(Sidebar A). By controlling bacterial over-
growth, bacteriophages can re-equilibrate 
the host–bacteria balance and consequently 
they can indirectly restore physiological 
functions and boost the immune system. 
According to the definitions in the direc-
tive and the national legislation based on 
it, bacteriophages could be considered to 
be human medicinal products. The con-
sequences of classifying them in this way 
would be far-reaching: phage therapies 
would require assessment in large clinical 
studies to demonstrate safety and efficacy. 
A strength of phage therapies is that they 
can be tailored to each patient and to each 
patient’s bacterial infection. This flexibility 
is not fully compatible with the approach of 
the directive. In fact, bacterio phages are not 
mentioned in the current legislation, and 
the technical assistance or documentation 
that could be used to prepare a regulatory 
dossier does not exist.
Paving a regulatory pathway for phage 
therapy
Europe should muster the resources to financially, technically and legally support the introduction  
of phage therapy
Isabelle Huys, Jean-Paul Pirnay, Rob Lavigne, Serge Jennes, Daniel De Vos, Minne Casteels & Gilbert Verbeken
“...there are only a few drugs 
left to treat multidrug-resistant 
bacterial strains, and the first 
strains that are resistant to even 
these last-resort antibiotics have 
already emerged”
“...the greatest hurdle to the 
medical use of bacteriophages 
in Europe is the lack of an 
appropriate regulatory 
framework that appreciates [its] 
concept and specifics...”
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Nevertheless, if we are to introduce phage therapy into clinical prac-tice, they must be regulated 
according to the directive. To address its 
limitations, therefore, and in order to draft 
(Sidebar A) appropriate regulatory protocols 
for use, it is first necessary to define under 
which categ ory of human medicinal prod-
ucts bacterio phages fall. The first category 
includes conventional small molecules or 
synthetic human medicinal drugs, such as 
aspirin, that can be described and 
researched in a standardized manner. From 
a functional point of view, such products are 
not comparable to bacterio phages because 
they operate in entirely different ways. 
Bacteriophages kill their specific bacterial 
host cells through bacterial lysis, which 
causes the release of new bacteriophage 
virions. When the targeted bacterial density 
drops below the detection threshold, the 
bacteriophages are removed by the reticulo-
endothelial system and the therapeutic 
intervention becomes self-terminating. 
Also unlike standard drugs, bacterio phages 
mutate and co-evolve with their host 
bacteria, an evolutionary ‘arms race’.
The second category of biological 
human medicinal products, which includes 
vaccines, seems more suitable, but it does 
not encapsulate all the features of phage 
therapies. From a general structural point of 
view, a bacteriophage is a protein-encapsu-
lated nucleic acid genome. Moreover, they 
might be collected from a biological 
source, for example released from bacteria 
or collected from a patient’s tissues or fluids 
(for instance from wounds) or from waste-
waters. Like vaccines, bacteriophage-based 
products used in humans need to be 
updated over time—especially when bac-
teria develop resistance—just as the flu-
vaccine cocktail is tailored anew each year. 
Bacteriophages, however, do not produce 
active immunity against a specific pathogen 
as ‘regular’ vaccines do. Rather, they are 
antimicrobials, with a secondary com-
petence of boosting the immune system. As 
such, they are perhaps better considered as 
similar to therapeutic vaccines.
Therapeutic vaccines fall under a third 
category of human medicinal products, 
the advanced-therapy medicinal products 
(ATMPs). ATMPs are defined in directive 
2001/83/EC as complex therapeutic prod-
ucts for gene therapy, cell therapy or tissue 
regeneration, and have their own regulatory 
framework. Obviously, though, natural bac-
teriophages are not somatic cells or tissue- 
engineered medicinal products and are not 
natural products used in gene therapy, since 
they are not genetically modified.
The conclusion from the arguments 
presented above is that phage therapies 
should probably be classified as biologi-
cal human medicinal products, despite 
the poor fit with this classification. Phage 
therapies do not fit into a single category 
perfectly, but this choice would be in 
accordance with the current UK practice 
of classifying bacteriophages. 
If bacteriophages are regarded as human biological medicinal products, they must adhere to the relevant legal framework: 
any therapy has to demonstrate safety and 
efficacy and conform to quality standards. 
Bacteriophages exist ubiquitously in the envi-
ronment, including in the human body. They 
specifically infect certain bacteria, but do not 
attack other bacterial strains or eukaryotic 
human cells. To assume that bacterio phages 
will be safe for therapeutic use and ought not 
to require extensive studies that would delay 
their clinical use, therefore, seems appropri-
ate. Even so, clinicians should prospectively 
collect and register data and clinical out-
comes of phage therapies to create a body 
of information for further research and on 
which applications can build.
In regard to efficacy and safety, only 
virulent, exclusively lytic phages are gen-
erally considered to be clinically useful 
because they kill their host cells and do not 
integrate into the bacterial host genome. 
Therefore, the presence of temperate 
bacterio phages must be strictly excluded. 
Detailed mol ecular characterization of the 
bacteriophage genome is also mandatory to 
exclude the presence of any toxin genes or 
antibiotic-resistance genes.
With respect to quality, a combination of 
physical, chemical and biological tests could 
be used to characterize bacteriophage- 
based products, together with standard 
quality control procedures applied to 
the production process. Bacteriophages 
should be produced in a non-pathogenic 
bacterial host and the final therapeu-
tic preparations must be pure (absent of 
residual contaminating bacteriophages 
and other host cells), sterile, apyrogenic and 
pH neutral [3]. Such a focused approach to 
guarantee safety, quality and efficacy could 
enable clinicians to quickly prepare phage 
therapeutics against severe infections with 
multi drug-resistant pathogens. 
The current regulatory regime for human biological medicinal prod-ucts, which implies the conduct of 
clinical trials and the submission of a full 
product dossier compliant with directive 
2001/83/EG, imposes expensive and time-
consuming overheads on the urgent develop-
ment of phage therapies. If we consider the 
example of a patient currently infected with 
a multidrug-resistant bacterial strain who 
needs immed iate treatment because anti-
biotics have failed, the need to conduct clini-
cal trials and compile dossiers is not feasible 
within the time frame required to develop a 
targeted ad hoc therapy, and would not allow 
timely treatment of the patient. Isolation of a 
bacterio phage to combat the infection, prep-
aration of a therapeutic dose and its adminis-
tration to the patient needs to be done within 
days. Under the human biological medici-
nal product framework, we would have to 
wait 8–10  years until clinical studies have 
demonstrated safety and efficacy.
“Isolating a bacteriophage 
to combat the infection, 
preparing a therapeutic dose and 
administering it to the patient 
needs to be done within days”
Sidebar A | Further reading
d’Herelle F (1917) C R Acad Sci 165: 373–375. 
In this historical paper, the first isolation 
of bacteriophages for use in treatment and 
prophylaxis of infectious diseases is described.
Kutateladze M, Adamia R (2010) Trends 
Biotechnol 28: 591–595.  
The authors report on the growing body of 
literature describing the validation of the use of 
bacteriophages for therapy and prophylaxis in 
the war against drug-resistant bacteria.
Pirnay JP et al (2011) Pharm Res 28: 934–937. 
The authors stress the importance of a sur-
mesure approach for phage therapy.
Merabishvili M et al (2009) PLoS ONE 4: 1–10. 
A quality-controlled small-scale production of 
a well-defined bacteriophage cocktail for use in 
human clinical trials is described. 
“...the full therapeutic potential 
of natural bacteriophages can 
only really be exploited through 
a patient-specific approach”
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Another problem is the massive cost 
of conducting clinical studies. Non-profit 
clinics and research institutes will not be 
able to shoulder the financial burden of 
a regulatory regime originally designed 
for drug development by pharmaceutical 
companies. Some companies, such as Eli 
Lilly, have invested in bacteriophage-based 
products or cocktails for human treatment, 
but the host-specificity of phage therapies 
excludes uniform production and clinical 
application. Large-scale production of natu-
ral bacteriophages might be helpful in some 
instances, such as in cases of epidemic 
outbreaks or in clinical programmes where 
phage cocktails are regularly updated, but 
the full therapeutic potential of natural 
bacterio phages can only really be exploited 
through a patient-specific approach.
The most likely places that patient-specific phage therapies would be administered are hospitals, in close 
collaboration with associated microbiologi-
cal laboratories that would select and iso-
late the most suitable bacteriophages. This 
approach would require a simplified regula-
tory framework, given that neither time nor 
money is available. From this perspective, 
bacteriophage therapy resembles the histori-
cal context of ATMPs, which were mainly 
developed at clinics and academic research 
institutions and were only recently brought 
under the human medicinal product legis-
lation (regulation 1394/2007). The legisla-
tion exempts hospitals from the regulatory 
framework if a cell therapy is applied under 
the direct supervision and prescription of a 
medical doctor for a specific patient (article 
28 of regulation [EC] No. 1394/2007), but 
for ATMPs, national rules apply instead.
As argued above, bacteriophages 
should probably be classified as human 
medicinal products. Unfortunately, direc-
tive 2001/83/EG does not provide a hos-
pital exemption for these. It does state, 
however, that it “shall not apply to any 
medicinal product prepared in a pharmacy 
in accordance with a medical prescrip-
tion for an individual patient (commonly 
known as the magi sterial formula)”. Even if 
this clause allowed hospitals to bypass the 
costly requirement to demonstrate safety 
and efficacy, hospital pharmacists can 
only use licensed products as components 
for magisterial preparations. Since natural 
bacteriophages are not licensed products, 
this regulatory bypass would be difficult 
to implement.
How then can the regulatory frame-work be adapted to allow hos-pitals to design and administer 
tailor-made phage therapies? Although 
regulators are responsible for applying 
regulations, a regulation itself can only be 
changed through legislative action. We 
suggest an adapted regulatory framework, 
inspired by the existing legislation govern-
ing ATMPs, which includes exemption for 
the hospital-based use of cell and gene 
products and therapies. Hospitals should 
be granted exemption for biological human 
medicinal products, accompanied by spe-
cific regulation for phage therapies devel-
oped from natural bacteriophages with 
regard to safety, potency, purity and toxi-
city. Pharmaceutical companies developing 
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products based on natural bacterio phages 
would still have to abide by the normal 
regulations that apply to biological medi-
cinal products. Thus, such a regulatory 
framework would distinguish between the 
hospital-based (tailor-made) use of natural 
bacteriophages in patients and the indus-
trial production and distribution of uniform 
phage products. Quality and safety criteria 
would be specified and efficacy documen-
tation required, but it would allow treating 
physicians to fully exploit the coevolution-
ary aspects of natural bacterio phages for the 
benefit of patients (Sidebar A).
It is necessary to start talking to regula-
tors and legislators and persuade them of 
the prudence of a dedicated legal frame-
work for bacteriophage therapy. Doing 
nothing to address the growing bac-
terial resistance to antibiotics is not an 
option. Considering that more than 20,000 
European citizens die annually from 
untreatable bacterial infections, Europe and 
its member states should find the courage 
and creativity to financially, technically and 
legally support the introduction of phage 
therapies throughout Europe.
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Bacteriophage Therapy in Human Medicine
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Abstract For practitioners at hospitals seeking to use
natural (not genetically modified, as appearing in nature)
bacteriophages for treatment of antibiotic-resistant bacte-
rial infections (bacteriophage therapy), Europe’s current
regulatory framework for medicinal products hinders more
than it facilitates. Although many experts consider bacte-
riophage therapy to be a promising complementary (or
alternative) treatment to antibiotic therapy, no bacterio-
phage-specific framework for documentation exists to date.
Decades worth of historical clinical data on bacteriophage
therapy (from Eastern Europe, particularly Poland, and the
former Soviet republics, particularly Georgia and Russia,
as well as from today’s 27 EU member states and the US)
have not been taken into account by European regulators
because these data have not been validated under current
Western regulatory standards. Consequently, applicants
carrying out standard clinical trials on bacteriophages in
Europe are obliged to initiate clinical work from scratch.
This paper argues for a reduced documentation threshold
for Phase 1 clinical trials of bacteriophages and maintains
that bacteriophages should not be categorized as classical
medicinal products for at least two reasons: (1) such a
categorization is scientifically inappropriate for this spe-
cific therapy and (2) such a categorization limits the
marketing authorization process to industry, the only
stakeholder with sufficient financial resources to prepare a
complete dossier for the competent authorities. This paper
reflects on the current regulatory framework for medicines
in Europe and assesses possible regulatory pathways for the
(re-)introduction of bacteriophage therapy in a way that
maintains its effectiveness and safety as well as its inherent
characteristics of sustainability and in situ self-amplifica-
tion and limitation.
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article (doi:10.1007/s00005-012-0175-0) contains supplementary
material, which is available to authorized users.
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Lack of an Adequate European Regulatory Framework
for (Natural) Bacteriophage Therapy
The European Directive 2001/83/EC1 is considered the
main code governing medicinal products for human use
within the European Union. This piece of legislation was
designed to specify the file requirements for the authori-
zation of classical medicinal products (e.g., small chemical
molecules). Specific regulatory aspects were included for
some types of medicinal products2 (see Table 1), such as
radiopharmaceuticals, herbal medicinal products, homeo-
pathic medicinal products, biologicals (vaccines, toxins
or serums) and advanced therapy medicinal products
(ATMPs). Historically, herbal medicinal products are at the
origin of a large number of commonly used pharmaceuti-
cals and cannot be documented as, for instance, small
chemical medicinal products. For ATMP, a separate reg-
ulation (No 1394/20073) was established with specific
scientific and procedural features adapted to these complex
medicinal products.
This paper deals strictly with bacteriophage therapy
based on the use of natural bacteriophages in human
therapy. Natural bacteriophage therapy uses bacteriophages
that are not genetically modified. Natural bacteriophages
have been known for decades to be anti-infectious agents
that can be used complementary to, or as an alternative
for, antibiotic treatment (Abedon et al. 2011; Caplin
2009; Go´rski et al. 2009a, b; Housby and Mann 2009;
Kutateladze and Adamia 2008; Kutter et al. 2010; Monk
et al. 2010; Skurnik and Strauch 2006; Sulakvelidze et al.
2001; Thiel 2004). Natural bacteriophages can be isolated
from the environment, identified, up-scaled, purified and
used as antimicrobial agents (Gill and Hyman 2010;
Merabishvili et al. 2009). In view of their potential thera-
peutic uses, it is imperative that natural bacteriophages be
processed according to the appropriate quality and safety
standards. However, no such framework detailing the file
requirements specific to (natural) bacteriophage therapy
products exists today (Shorthose et al. 2010). Therefore, a
specific and appropriate quality and safety documentation
framework is needed for the application of natural bacte-
riophages on humans.
In this paper, we investigate whether bacteriophage
therapy can be situated within existing European regulatory
frameworks. We then summarize possible regulatory
pathways at different policy levels. Finally, we reflect on
several alternative approaches.
Can Natural Bacteriophages Used in Anti-Microbial
Therapy on Humans be Situated Within One
of the Existing Particular or Specific European
Legislation Frameworks Governing Medicinal
Products?
Bacteriophages are not comparable to standardized chem-
ical medicinal products (Abedon and Thomas-Abedon
2010; Krylov 2011, Payne and Jansen 2003; Pirnay et al.
2011; Ryan et al. 2011). However, it is worthwhile to call
to attention a number of particular and specific regulatory
Table 1 Directive 2001/83/EC of the European Parliament and of
the Council of 6 NOV 2001 on the Community Code Relating to
Medicinal Products for Human Use (consolidated version)
Annex 1
Analytical, pharmaco-toxicological and clinical standards and
protocols in respect of the testing of medicinal products
Part I: Standardized Marketing Authorization Dossier Requirements
Part II: Specific Marketing Authorization Dossier Requirements
Well-established medicinal use
Essentially similar medicinal products
Additional data required in specific situations
Similar biological medicinal products
Fixed combination medicinal products
Documentation for applications in exceptional circumstances
Mixed marketing authorization applications
Part III: Particular medicinal products
Biological medicinal products
Plasma-derived medicinal products
Vaccines
Radio-pharmaceuticals and precursors
Radio-pharmaceuticals
Radio-pharmaceutical precursors for radio-labelling purposes
Homeopathic medicinal products
Herbal medicinal products
Orphan medicinal products
Part IV: Advanced therapy medicinal products
Gene therapy medicinal products
Somatic cell therapy medicinal products
Tissue engineered products
http://ec.europa.eu/health/files/eudralex/vol1/dir_2001_83_cons2009/
2001_83_cons2009_en.pdf
http://ec.europa.eu/health/files/eudralex/vol-1/dir_2003_63/dir_2003_
63_en.pdf
1 http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_83_cons
2009/2001_83_cons2009_en.pdf (consolidated version).
2 http://ec.europa.eu/health/files/eudralex/vol-1/dir_2003_63/dir_
2003_63_en.pdf.
3 http://ec.europa.eu/health/files/eudralex/vol-1/reg_2007_1394/reg_
2007_1394_en.pdf.
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frameworks in European legislation governing medicinal
products and analyze briefly where bacteriophages may or
may not fit in (see Table 1).
Biologicals
Biologicals are products whose active substance is bio-
logical. At first sight and in view of the nature of several
approved biologicals, the ‘‘biological medicinal product’’
chapter of the consolidated 2001/83 EC Directive could be
considered applicable to bacteriophages given the biolog-
ical nature of natural bacteriophage products. That is, the
active substance of bacteriophage therapy seems to have a
biological origin. However, only a few types of biological
medicinal products, such as plasma-derived medicinal
products and vaccines, have a dedicated specific docu-
mentation package defined under the current biological
medicinal products legislation. Bacteriophages, thus,
probably would not qualify as biologicals.
Homeopathic Products
Products based on homeopathy are also regulated through a
specific category under the European consolidated 2001/83
EC Directive. It may seem surprising that these homeopathic
‘‘products’’ can be documented as medicinal products given
the difficulty applicants have with proving their products’
(even limited) health claims to the competent authorities.
Bacteriophage-based therapeutic products are not compa-
rable to homeopathic products. Bacteriophages have the
potential to kill bacteria and have a clear, specific antibac-
terial effect (Bush et al. 2011; Fernebro 2011; Maura and
Debarbieux 2011).
Advanced Therapy Medicinal Products
ATMPs are characterized as complex high-tech thera-
peutic products with technical specificities that require
precise legal definitions. The ATMP section of the con-
solidated 2001/83 EC Directive only covers products for
gene therapy, somatic cell therapy and tissue engineered
products. In this sense, one could argue that natural bac-
teriophages are not ATMPs since their nature differs
significantly from that of the gene and cell-based thera-
peutics currently covered by this regulation. Isolation and
production technology used for natural therapeutic bacte-
riophages do not have the same technological complexity
as that used for ATMPs, although one could argue that it
is also a complex process (e.g., Matinkhoo et al. 2011;
Puapermpoonsiri et al. 2010). This fact does not, however,
mean that natural therapeutic bacteriophages are the same
as ATMPs.
Well-Established Medicinal Products
European legislation considers a medicinal product to be
‘‘well established’’ if data confirm that the product has been
used systematically within the European Community for
more than a decade. In addition, the available documen-
tation should assess safety and effectiveness and must
include an overview of relevant scientific literature. Based
on this criteria, one could potentially classify natural
therapeutic bacteriophages as ‘‘well-established medicinal
products’’ because they were in use long before the Euro-
pean Medicinal Product Regulation came into force and as
far back as the early 1920s (Abedon et al. 2011; Bruynoghe
and Maisin 1921; Go´rski et al. 2009a, b; Housby and Mann
2009; Kropinski 2006; Kutter et al. 2010). Regulators could
counter, however, that most (but not all) clinical evaluation
dealing with bacteriophage therapy was compiled outside
the current 27 EU member states (Fortuna et al. 2008;
Go´rski et al. 2009a, b; Khawaldeh et al. 2011; Kutateladze
and Adamia 2010; Rhoads et al. 2009; Wright et al. 2009)
and that the proven positive clinical effects were not doc-
umented by state-of-the-art, Western-standard-controlled
clinical trials.4 For these reasons, this ‘‘well-established
medicinal product’’ framework may not entirely apply to
bacteriophage therapy either.
Regulatory Pathways for Bacteriophage Therapy
as Discussed at Different Policy Levels
The lack of adequate regulatory guidance for documenting
safety, quality and effectiveness of natural bacteriophages
when used as therapeutics prompted a first attempt to
clarify the situation at the European level [European Par-
liament and European Medicines Agency (EMA)],
followed by discussions at the national level.
European Parliament
On 14 February 2011, a Parliamentary Question5 was sent
to the cabinets of two Members of the European Parliament
[Ivo Belet (Belgium/PPE) and Catherine Trautmann
(France/S&D)] who addressed the Question to the Euro-
pean Commission and Council. Belet and Trautmann began
by explaining to the Commission what ‘‘bacteriophage
therapy’’ was. Second, they explained what the existing
regulatory hurdles are when working with natural
4 http://www.eortc.be/services/doc/clinical-eu-directive-04-april-01.
pdf.
5 http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//
TEXT?WQ?E-2011-001144?0?DOC?XML?V0//EN&language
=CS.
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therapeutic bacteriophages in Europe (Pirnay et al. 2011;
Verbeken et al. 2007). Then they raised the question of
how bacteriophage therapy is currently regulated in Eur-
ope and whether the Commission would consider creating
an extra documentation box, ‘‘Bacteriophage Therapy’’,
under the ‘‘particular’’ European Medicinal Product
framework.
On 29 March 2011, Mr. Dalli, the European Commis-
sioner for Health and Consumer Policy, formulated his
written answer on behalf of the European Commission6:
‘‘The EU’s legislation on medicinal products does not
define specific requirements related to bacteriophage ther-
apy or medicines composed of bacteriophages’’. In addition,
his answer goes on to say, ‘‘the Commission considers that
the existing regulatory framework as explained above is
adequate for bacteriophage therapy without the need for an
extra set of documentation for bacteriophage therapy’’ (see
Supplementary Materials Online Resource 1).
European Medicines Agency Innovation Task Force
The European Commission’s, thus, did not clarify how the
existing regulatory framework (which it characterized as
‘‘adequate’’) should be interpreted in view of bacteriophage
therapy. Clarification was sought at the level of the EMAs
Innovation Task Force (ITF). The ITF is tasked with
facilitating the informal exchange of information and
providing guidance in the early stage of medicinal product
development (see Box 1 of Appendix). A request for a
Briefing Meeting was submitted to the ITF, supported by
specific briefing documents (Merabishvili et al. 2009;
Pirnay et al. 2011; Verbeken et al. 2007). The objectives of
the meeting were to clarify bacteriophage therapy’s clas-
sification, to identify the type of documentation needed to
launch clinical trials testing natural therapeutic bacterio-
phages and/or to get marketing authorization and, finally,
to discuss a two-way regulatory route for bacteriophage
therapy, as described by the author(s) (Pirnay et al. 2011).
In short, the ‘‘two-way regulatory approach’’ differentiates
between the industrial development of uniform bacterio-
phage products meant for uniform market placement7
and the tailor-made production of patient-specific natural
therapeutic bacteriophages.
On July 12, the authors’ delegation (6 experts, hereafter
called ‘‘the delegates’’) met with the ITF (13 experts) and
discussed the current situation and certain specific aspects.
Subsequently, the final opinion was published by the ITF in
the Briefing Meeting Report,8 reflecting the opinions of the
members of the ITF and of the contributing experts. These
opinions should be interpreted as a preliminary set of sci-
entific considerations related to the information presented.
Point of View of the Delegates
Working with natural bacteriophages in a non-profit hos-
pital environment contrasts with industrial approaches to
the preparation of bacteriophage-based products in that the
latter prioritizes regular market authorization while the
former does not. Bacteriophage therapy should be under-
stood as a ‘‘therapy concept’’. Bacteriophages and bacteria
co-evolve in a dynamic system. Taking this reality into
account is crucial if the full sustainable potential of bac-
teriophages in therapeutics is to be actualized. Industry
actors may pursue uniform market placement of bacterio-
phage cocktails for economic reasons, but this diverges
from the idea and practical aspects of bacteriophage ther-
apy itself, which is based first and foremost on a tailor-
made patient approach. Additionally, securing intellectual
property (IP) protection for tailor-made natural bacterio-
phages, while likely possible, is far from simple. Phages
are widespread and the therapy has existed for years. One
can thus anticipate broad patent claims covering production
processes, intended (new) uses and the phages themselves.
However, such broad patent claims are weak and easy to
circumvent. Weak IP protection makes the task of attract-
ing venture capitalists difficult, which means developers of
tailor-made natural bacteriophage therapies often lack the
financial resources necessary to pursue costly regulatory
pathways. The ‘‘reusing’’ or ‘‘refitting’’ of [non-good
manufacturing practices (GMP) but carefully developed
and delineated] production process developed in the
authors’ previous study (see Box 2 of Appendix) (Kutter
et al. 2010) raises an important regulatory question. Do
production processes approved for similar products satisfy
EMA regulators and adhere to the necessary safety and
quality standards (Merabishvili et al. 2009)?
Final Opinion of the ITF
Medicinal Products
Since the pathway for developing a medicinal product
is specific to each indication and each product, the ITF
advises applicants to submit, free of charge, a request to
have EMA scientific services investigate a specific pro-
posed bacteriophage product’s ‘‘eligibility’’ to be classified
6 http://www.europarl.europa.eu/sides/getAllAnswers.do?reference=
E-2011-001144&language=CS.
7 http://ec.europa.eu/health/files/eudralex/vol-1/reg_2004_726_cons/
reg_2004_726_cons_en.pdf.
8 ITF’s Opinion, Briefing Meeting Report, EMA/642573/2011, 22
July 2011, available on request to the author of correspondence.
Arch. Immunol. Ther. Exp.
123
PhD Dissertation - Gilbert Verbeken - Page 160
as a medicinal product.9 The EMA then evaluates whether
that product is a medicinal product based on the description
of the active substance, the manufacturing process, the
production process, the mechanism of action and the
intended clinical application. The European Commission is
consulted during that process. At the moment of submis-
sion, a product-specific website with a description of the
information to be submitted is created, the information is
then submitted by the applicant and the EMA consult its
experts.
Biologicals or ATMPs
If bacteriophage-based products are considered medicinal
products, they will likely be classified as biological
medicinal products. In general, a bacteriophage-based
product is not considered an ATMP in light of the current,
highly specialized ATMP Regulation. This holds unless the
Scientific Committee changes its opinion and the European
Commission interprets the legislation to include a partic-
ular bacteriophage-based product. The ITF does not
anticipate this, but this does not preempt the decision
(should there be one) made by the Commission and the
Scientific Committee.
Dossier Requirements
The specific regulatory requirements necessary for bacte-
riophage therapy approval are evaluated on a case-by-case
basis and are determined by the specific characteristics of
the product and its intended use and hence not on the
product as such. The quality and safety data presented in
the authors’ study (Merabishvili et al. 2009; Kutter et al.
2010) were considered to be basic. However, these data
could be part of an Investigational Medicinal Product
Dossier (IMPD) when launching clinical trials. Addition-
ally, an EMA’s Scientific Advise (SA) procedure could
also be requested to seek advice on medicinal product
development. All information related to SA requests is also
available on the EMA website.10
It is notable that the EMA explicitly acknowledges
efforts to develop tailor-made bacteriophage products. But
SA’s are still needed for each particular bacteriophage-
based product based on a review of the full package
submitted in a separate SA procedure. Each natural bac-
teriophage-based product must prove to be safe, with a
suitable dosage and with evidence of clinical significance.
European regulators currently emphasise ‘‘Quality by
Design’’, where one designs the critical parameters that
form the core of the product before moving forward with
development or marketing authorization. One can decide to
apply for a product classification (as described above) to
get an idea of how the product is positioned and based on
this information, can then consider various elements of the
product’s Marketing Authorization options. One element to
consider, for instance, is the production process. The EMA
has sufficient insight into what elements may be important
for a particular product. It has extensive experience with
the manufacturing process, disease frequency and condi-
tions to target (for example for an orphan drug
designation), and SA on the quality aspects relevant to
these defined elements is also available. The ‘‘quality by
design’’ approach could potentially be very useful, but
would require some modelling and simulation exercises
(especially in view of co-evolutionary aspects). It could
nonetheless be particularly critical to defining the key
parameters for production processes or manipulations,
which could then provide the basis for further
development.
Evolving Products
Bacteriophages are not considered unique as ‘‘evolving’’
products. The EMA has handled precedents in this respect,
for instance, living cell preparations and the flu vaccine.
Every 1–2 years, the recommended strains for the seasonal
flu vaccines are reviewed to investigate whether an adap-
tation is needed to accommodate for the flu strain(s) that
will likely appear in the next season. The launch of a new
vaccine needs to be supported by facts and data and an
appropriate risk management strategy for the product.
Likewise, bacteriophage product for a given indication and
produced according to a given manufacturing process
could also be updated every 1–2 years. While natural
bacteriophage therapy is an unprecedented particular case,
the EMA has dealt with similar products before, which
suggests that it would be able to handle natural bacterio-
phage therapy as well.
Procedure
Authorization of a medicinal product follows either a
centralized, decentralized, or mutual recognition proce-
dure, depending on the product’s categorization. For a
biological medicinal product, authorization processes are
not homogeneous between EU member states, as applicants
may opt for a national rather than European procedure and
national procedures can differ from country to country.
However, the product’s quality, safety and efficacy must be
9 http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/
general/general_content_000334.jsp&mid=WC0b01ac05800ba1d9&
jsenabled=true.
10 http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/
general/general_content_000334.jsp&murl=menus/regulations/
regulations.jsp&mid=WC0b01ac05800ba1d9.
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demonstrated in all procedures. ATMPs can only be
authorized via the centralized procedure.
Personalized Medicine
One possible method for using phages in patient treatment
could be to provide a first injection of natural bacterio-
phages geared toward attacking a broad bacterial infections
problem. This would then be followed by a treatment with
a specific (personalized) set of bacteriophages, selected and
applied to the patient to combat an emerging additional
problematic bacterial strain specific to that patient. Tests
should be performed before administering the second batch
of personalized bacteriophages. The best way to use bac-
teriophages—and this is where it becomes especially
personalized—would be to take the original bacteriophage
(to which resistance emerged) and let it evolve (in vitro), in
parallel with the patient’s infecting strain, that is, to use the
bacteria-phage dynamics to actually evolve a phage.
Although it complicates matters, it exemplifies the real
power of this approach. This approach is considered
comparable to some therapies using autologous cells that
are manipulated ex vivo and then returned to the patient.
There is a particular need for critical dialogue with EMA
Scientific Committees on this topic. However, in the case
of bacteriophage therapy, the target is not a human cell but
a bacterial cell. There are millions of bacteria and phages
living in and on the human body. The question thus arises
as to whether bacteriophages can be considered ‘‘human
body material’’. If so, bacteriophages would be covered by
the European Human Cells and Tissue Directive.11 How-
ever, no real answer has been provided on this question.
Although bacteriophages differ from conventional bio-
logical products and an adaptation of the current legislation
is urgently needed, regulators like the EMA stress that they
do not make new rules; they only apply existing regula-
tions. It is the view of the ITF that a new regulation cannot
be ‘‘invented’’ by regulators.
Actions Proposed by the ITF
First, a request could be submitted to the Committee for
Medicinal Products for Human Use to investigate the
eligibility of a particular phage-based product.12 If bacte-
riophage therapy could be used for an orphan indication, an
application for Orphan Designation could be considered,
making use of specific incentives in the law such as pro-
tocol assistance and fee reductions. Second, the option
remains to apply for EMA scientific advice to delineate a
clinical development strategy as well as specific protocols
and models of how to prepare the product and the precise
use of bacteriophages, for instance, whether to use a fixed
cocktail or a fixed cocktail complemented with personal-
ized bacteriophages. Overall, the clinical development of
bacteriophage therapy needs to show that phage products
are safe (Phase I), that the proposed dose will be the most
effective one (Phase II) and that in clinical trials (in which
bacteriophages are applied exactly as they will be used in
practice) the therapy shows efficiency, taking into account
the ‘‘appropriate indication’’ and ‘‘clinical end point’’
(Phase III).
National Competent Authority
Following the opinion of the ITF at EMA, a discussion
took place with the Belgian Competent Authority, the
Belgian Federal Agency for Medicines and Health Products
(FAMHP), which, though unofficially, expressed the fol-
lowing view:
Medicinal Products
In line with EMA, natural bacteriophages used as thera-
peutics are considered medicinal products, based on their
nature and intended use.
Biologicals or ATMPs
In addition, bacteriophages are seen as biological medici-
nal products that can be commercialized via a national
regulatory procedure. However, these natural bacterio-
phages are not considered as ATMPs. This was the
conclusion reached at a consultation by FAMHP of EMA’s
Committee for Advanced Therapies. This standpoint has
specific consequences for hospital-based therapies. The
ATMP Regulation as such is a lex specialis which intro-
duces additional provisions to those laid down in Directive
2001/83/EC. The scope of the ATMP Regulation is to
regulate the authorization of ATMPs intended to be placed
on the market in European Union member states, either
prepared industrially or manufactured by a method
involving an industrial process, in accordance with Direc-
tive 2001/83/EC. ATMPs are excluded from the scope of
the European ATMP Regulation if they are prepared on a
non-routine basis according to specific quality standards
and used within the same member state in a hospital under
the exclusive professional responsibility of a medical
practitioner and an individual medical prescription for a
custom-made product for an individual patient. This
11 Directive 2004/23/EC of the European parliament and of the
council of 31 March 2004 on setting standards of quality and safety
for the donation, procurement, testing, processing, preservation,
storage and distribution of human tissues and cells.
12 http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/
general/general_content_000334.jsp&mid=WC0b01ac05800ba1d9&
jsenabled=true.
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exclusion is called the hospital exemption. The precise
interpretation of the definition of hospital exemption is left
to the National Competent Authorities. For instance, the
(national) definition of ‘‘non-routine use’’ can be different
in each member state. However, the member states have to
ensure that relevant community rules related to quality and
safety are not undermined. This national procedural path-
way for hospital exemptions could be of interest to hospitals
working with their own tailor-made natural bacteriophage
therapies. However, since the ATMP framework is not
considered to be relevant by the EMA and Belgian regu-
lators when positioning natural bacteriophages, the hospital
exemption procedure cannot be applied to bacteriophage
therapy and therefore hospitals interested in bacteriophage
therapy cannot benefit from this hospital exemption.
File Requirements
At the national level (FAMHP), the possibility of obtaining
an ‘‘early phase’’ clinical trial status for bacteriophage
therapy could be considered. It should be pointed out that,
at present, obtaining an authorization to produce IMP’s
(Trouet et al. 2007) may be an impossible burden for
hospitals. It is even questionable as to whether a full
authorization is always needed for the limited IMP pro-
duction that is required for a phase I clinical trial, for
instance. At this level, as at the European level, there is a
need for a pragmatic approach.13
Actions Suggested by the National Competent Authority
A reduced IMPD could be submitted for evaluation, and
interactions with the National Competent Authority con-
cerning the content of the application could be initiated in a
constructive and open-minded way.
Reflection by the Authors
Theoretically, the proposal to opt for a full market autho-
rization via a simplified procedure at the National
Competent Authority appears feasible. However, this pro-
posed approach lacks an awareness of the specific ‘‘personal
medicinal character’’ of natural bacteriophages and reflects
only a (classical) medicinal product development approach.
Today, there is no legal definition for ‘‘Personalized Med-
icine’’ and most preparations intended for use as
‘‘personalized medicinal products’’ are not really ‘‘per-
sonal’’, meaning that they are produced for a very small
patient population and not for one patient as such.
Hospitals willing to use bacteriophage therapy in clini-
cal practice, working independently from industry in a non-
profit setting and using tailor-made phage products to treat
patients, are not necessarily interested in obtaining mar-
keting authorization and IP protection. Moreover, a
stringent marketing authorization approach, even with
simplified procedures, is nearly impossible for hospitals to
manage to date. In addition, in view of the enormous
challenges related to rapidly progressing bacterial resis-
tance, a product development process that takes many years
does not seem to be the best way forward.
Belgian and UK Notified Bodies
Given the opinions expressed by European and national
regulators and given that uncertainties remain regarding the
appropriate regulatory pathway for a natural bacterio-
phage-based product, it is worth considering whether such
a product could fall under the Medical Device framework.
To find out whether such an approach would work for
bacteriophages, a burn wound ointment that is actually on
the market as a medical device was supplemented with
natural bacteriophages. In fact, the antimicrobial compo-
nent of the burn wound ointment (in this case an enzyme)
was replaced with natural bacteriophages.
In May 2011, a request for opinion was submitted to a
Belgian Notified Body (SGS) authorized to certify medical
devices for market placement. SGS Belgium forwarded the
question to their London office, and this SGS London
office contacted the UK Competent Authority, the Medi-
cines and Healthcare Products Regulatory Agency.
Medical Devices Framework and Current Applications
Directive 2001/83/EC defines a medicinal product as ‘‘any
substance or combination of substances presented as
having properties for treating or preventing disease in human
beings or any substance or combination of substances which
may be used in or administered to human beings either with a
view to restoring, correcting or modifying physiological
functions by exerting a pharmacological, immunological or
metabolic action, or to making a medical diagnosis’’.
According to the Medical Devices Directive 93/42/EC,14
medical devices support the restoration, correction or
modification of physiological functions as described above,
rather than being the cause of it. Some medical device
manufacturers drop the primary therapeutic claim for the
proposed product so that this product can be covered by the
Medical Devices Directive 93/42/EC. In light of the above,
it seems useful to consider whether bacteriophage therapy
13 http://www.pharma.be/assets/files/2309/2309_1295209549827530
81.pdf?bcsi_scan_3c79e7817cdc4fd7=0&bcsi_scan_filename=2309_
129520954982753081.pdf.
14 Council directive 93/42/EEC of 14 June 1993 concerning medical
devices (consolidated version).
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can be covered by the Medical Device Directive. Under
current practice, for instance, as long as a burn wound
ointment only moistens and protects a wound bed (primary
claims), these ointments are considered to be medical
devices, even when they contain antimicrobials that keep
the ointment aseptic.
Opinion of the UK Notified Body
Adding natural bacteriophages to a burn wound ointment
would turn a medical device (such as the ointment
described above) into a medicinal product, based on the
fact that phages have a ‘‘targeted action’’.
Reflection by the Authors
It is true that phages have a targeted action when consid-
ering a tailor-made use of bacteriophages for treating
specific infections on defined patients. However, in theory,
uniform bacteriophage cocktails could be placed on the
market as medical devices, without claiming any primary
therapeutic effects, circumventing the current and usual
medicinal product regulation. This cannot be the intention
of regulators. Therefore, the preferred route is the creation
of an adequate regulatory framework for therapeutic nat-
ural bacteriophages.
Alternative Regulatory Approaches
During the consultations at different regulatory levels,
certain specific concepts and types of product status were
mentioned that are useful to investigate in greater detail.
Medicinal (Whole) ‘‘Animal’’ Product Status
It is worthwhile to consider whether bacteriophages can be
regarded as ‘‘whole animals’’ (as mentioned in Art. 1 of the
consolidated Directive 2001/83/EC), such as larvae
(medicinal maggots used, for instance, in debridement of
wounds) and leaches (medicinal leaches used, for instance,
in the stimulation of vascularization after amputation), all of
which are present on the European market for therapeutic
use. Some of these types of products are regulated via the
current European medicinal products regulation. Product
files have been compiled and licenses have been granted in
that area, and in some cases, such ‘‘animals’’ have even
been GMP produced. In practice, some manufacturers of
these ‘‘whole animal’’ products try to avoid the full GMP
requirement in a way similar to that described above in the
medical device section. For instance, manufacturers put
their animals in a dressing and call this dressing a ‘‘bio-
surgical wound dressing’’. The animals (e.g., maggots) are
‘‘aseptically cultivated/raised’’. Preparations are available
by prescription only and are individually produced for a
specific patient.15 Indeed, such a situation is preferable and
compatible with bacteriophage-based therapy. However,
defining a natural bacteriophage as a ‘‘whole animal’’ is
somewhat far-fetched.
Magisterial (Compounded) Preparations
During the GEEPhage 2011 meeting (March 2011),16 the
French Competent Authority explained that the pathway
that regulates magisterial hospital preparations could per-
haps provide a regulatory gateway for hospitals that have
the intention to use, in-house, home-made preparations of
natural bacteriophages on a non-routine basis and in a
patient-tailored manner.
Under Belgian legislation, certain specific consider-
ations need to be taken into account. First, if the
bacteriophage cocktail is not authorized to enter the
European market, a ‘‘product monograph’’ must be com-
piled. Specifically, this means that a documentation and
description of the identity, the purity and the properties of
the natural bacteriophage preparation must be provided.
This monograph must be submitted for evaluation to the
Belgian Pharmacopeia Commission. The bacteriophage
preparation as published by Merabishvili et al. (2009) is
considered as ‘‘crude material’’ by regulators. To be con-
sidered as a magisterial preparation, the preparation must
be produced under GMP. After a positive answer from the
Pharmacopeia Commission, the microbiological lab of the
particular hospital can be licensed by the necessary Belgian
Minister as a supplier of ‘‘crude materials’’. Only then may
a pharmacist at the respective hospital use that particular
bacteriophage cocktail as a component for magisterial
preparations. It is clear that this pathway is not adapted to
hospitals that do not have the ambition, intention, or
financial resources to place a product on the national or
European market.
Medicinal Products without Marketing Authorization:
‘‘Compassionate Use’’
Medicinal products that are not (yet) authorized to enter the
European market can be used on patients when this use is
covered by compassionate use programmes, regulated at
the national level. Compassionate use programmes are
meant for patients with chronically or seriously debilitating
diseases or for patients whose disease is not considered to
be treated satisfactorily with an authorized product (Dodds-
Smith and Valverde 2009). As tailored bacteriophage
15 http://www.biomonde.de/English/protected/bio_produkt.html.
16 http://geephage.org/bacteries/.
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cocktails (Merabishvili et al. 2009) are in fact not in the
pipeline to obtain European marketing authorization, the
compassionate use pathway seems untenable yet still pos-
sible. On the other hand, compassionate use programmes
would definitely be relevant to potential uniform bacte-
riophage preparations that are currently involved in
marketing authorization procedures.
The Declaration of Helsinki is particularly relevant for
medicinal products not intended for placement in the
European market under license. Paragraph 35 of the Dec-
laration of Helsinki17 states the following: ‘‘In the
treatment of a patient, where proven interventions do not
exist or have been ineffective, the physician, after seeking
expert advice, with informed consent from the patient or a
legally authorized representative, may use an unproven
intervention if in the physician’s judgment it offers hope of
saving life, re-establishing health, or alleviating suffering.
Where possible, this intervention should be made the object
of research, designed to evaluate its safety and efficacy. In
all cases, new information should be recorded and, where
appropriate, made publicly available’’.
Taking this paragraph into account, natural tailored
bacteriophages can be used on patients in need when the
Helsinki conditions are fulfilled. This is what is sporadi-
cally done in Europe at the moment, for instance, at the
Queen Astrid Military Hospital in Brussels, Belgium. Due
to its ‘‘exceptional’’ character, the Helsinki procedure is not
a regulatory procedure with the potential to introduce
bacteriophage therapy into modern medicine in any wide-
spread, sustainable sense.
National Legislation Defining Exemptions
Some countries have published national legislation to
regulate certain specific products or techniques made
available in the country in a non-profit setting. In Poland,
phage therapy is considered an experimental treatment.
Experimental treatment occurs when a physician intro-
duces new or only partially tested diagnostic, therapeutic,
or prophylactic methods for the direct benefit of the person
being treated. In contrast, an investigational experiment has
the primary purpose of broadening medical knowledge.
Two basic items are prerequisites for experimental therapy
in Poland: (a) the written informed consent of the patient
and (b) approval by an institutional review board (bioethics
commission). Furthermore, experimental therapy may only
be applied by a qualified doctor and when other available
treatment has failed.18 In Poland, this type of treatment is
also covered by the Helsinki Declaration (Kutter et al.
2010; Letkiewicz et al. 2010).
In the Czech Republic there is an (reimbursed) anti-
staphylococcal bacteriophage product (lysate) on the mar-
ket under the trade name Stafal.19 Stafal was approved for
market placement by the Czech National Competent
Authority, the State Institute for Drug Control. The product
is an anti-staphylococcal phage lysate intended for topical
use (registration number 59/0149/89-CS).
When considering clinical trials, the type of exemptions
listed above may favour small (to very small) investigator-
driven trials, allowing clinicians to conduct pilot studies
without the full burden of commercial regulation. How-
ever, it is uncertain as to whether bacteriophage therapy
would be covered by such exemptions, and even so, bac-
teriophage therapy would not be covered in a harmonized
manner across Europe. Again, there is a need for an
adapted framework for defining (natural) bacteriophage
therapy at the European level. Member states are forced to
try to find solutions at the national level because there is no
adequate European framework.
Grey Areas
Aside from bacteriophages, there are some other products
that could be called ‘‘grey area’’ products. This means that it
is not always clear whether a certain product has to be
classified as a medicinal product, as a food supplement (see
Box 3 of Appendix), as a cosmetic, as a biocide, as a nutrient,
or as a product for regular consumption. The regulatory
pathway for each of these categories differs considerably.
In a sense, a natural bacteriophage preparation could
also be considered a ‘‘grey area’’ product. As yet, it is
unclear whether a bacteriophage-based preparation is really
a medicinal product. Some member states have installed a
specific commission at their national regulatory authority
to tackle ‘‘grey area’’ products. For instance, in Belgium, a
‘‘Mixed Commission’’ is in place that decides on the
classification (or not) of a particular ‘‘grey area’’ product as
a medicinal product. When the commission decides that a
specific product is a medicinal product, the medicinal
product regulatory framework (Directive 2001/83/EC) has
to be applied. Thus, for ‘‘grey area’’ products, the national
competent authorities at the member state level decide
whether such a product is a medicinal product, after con-
sulting other relevant stakeholders. They can take
European precedents into account and they can, of course,
also consult the European Competent Authorities.
If this Mixed Commission were to decide that tailored
natural bacteriophages are indeed medicinal products,
the question arises as to how Directive 2001/83/EC
17 http://irb.sinica.edu.tw/declaration%20of%20helsinki%20(2008).
pdf.
18 arts. 29/1, 21/2, and 21/3 of the Polish law on the physician’s
profession. 19 http://www.sevapharma.cz/file/Stafal_EN.pdf.
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(Consolidated) would then be applied, taking into account
its scope. Indeed, Article 2 of the Directive explains that
the rules shall only apply to ‘‘medicinal products for human
use intended to be placed on the market in the European
Member States and are either prepared industrially or
manufactured by a method involving an industrial pro-
cess’’. ‘‘In cases of doubt’’, the Directive mentions,
‘‘where, taking into account all its characteristics, a product
may fall within the definition of a ‘‘medicinal product’’ and
the definition of a product covered by other Community
legislation, the provisions of Directive 2001/83/EC shall
apply’’. In addition, the Directive shall also apply to
medicinal products intended only for export and to inter-
mediate products. In view of these wordings, ‘‘home-
made’’ and ‘‘in-house-applied’’ natural bacteriophage
cocktails such as bacteriophage preparations do not seem to
be captured by the scope of the Medicinal Products
Directive, since such cocktails are not intended to be
placed on the market in the European member states.
Indeed, everything depends on what the legislator takes
‘‘placing on the market’’ to mean. Informal contacts with
EMA and the Belgian National Competent Authority
determined that even the in-house application on one
patient of an in-house-prepared product could be consid-
ered a market placement. However, to date no legal
argumentation for this position has been made available,
and no such interpretation seems likely to be implemented,
especially if this service is not publicly advertised. None-
theless, it is important that the issue be clarified.
Conclusions
The authors are convinced that products for bacteriophage
therapy deserve their own regulatory framework in Europe.
Various pharmaceutical products different from the classi-
cal chemical molecules already have a proper framework
designed under the Medicinal Products Directive 2001/83/
EC (see Table 1). Natural bacteriophages are products that
proved to have a well-established medicinal use in Eastern
Europe and the former Soviet republics. They could be
considered a type of Particular Medicinal Products, to be
defined under a separate (dedicated) chapter in Annex 1 of
the Directive. Alternatively, the optimal framework could
be one dedicated specifically to bacteriophage therapy,
alongside the present Medicinal Products Directive
2001/83/EC. As regulatory frameworks for other medicinal
products have been introduced via particular Directives in
the past, a new Directive for bacteriophage therapy could be
a suitable solution. This new Bacteriophage Directive could
then be called ‘‘Directive concerning the Therapeutic use of
Natural Bacteriophages’’. This ‘‘new’’ adapted regulatory
framework should certainly also include adequate
timeframes, since the actual timeline for a classical drug
approval is of the order of months/years/decades while the
development of a ‘‘new’’ natural bacteriophage product can
happen in a matter of days/weeks. Regulators at the com-
petent national or European authorities (like EMA or
FAMHP in Belgium) understand the potential of bacterio-
phage therapy. However, they cannot change or adapt any
legislation. A collective lobby at the European political
level could be an option for securing a vote of the European
Parliament to adapt the actual European medicinal product
regulatory framework. At the international level, dedicated
bacteriophage therapy symposia such as the recent Phage
2011 meeting20 are important at the scientific and technical-
industrial level, but additional encounters and meetings are
needed as platforms for increasing awareness at the political
as well as at the public opinion levels. Classical pharma-
symposia should start to integrate bacteriophage therapy
issues into their programmes. For this reason, initiatives led
by non-profit organizations like GEEPhage, P.H.A.G.E.21
and PHAGESPOIRS22 can play an active and primary role
for change, particularly because these organizations were
created to support bacteriophage research and therapy to the
benefit of all patients. As foci of patient support efforts,
these organizations play an important role in the creation of
greater awareness among competent authorities (regulatory
implementation) and policymakers (voting regulation).
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Appendix
Box 1 Innovation Task Force (ITF)
The ‘‘Innovation Task Force’’ of the European Medicines
Agency (EMA)23 is a multidisciplinary group of scientific,
regulatory and legal experts set up at the EMA to provide a
forum for early dialogue in the form of ‘‘briefing
20 http://www.libpubmedia.co.uk/Conferences/Phages2011/About.
htm.
21 http://www.p-h-a-g-e.org/Home.html.
22 http://translate.google.be/translate?hl=nl&sl=fr&tl=en&u=http%
3A%2F%2Fphagespoirs.unblog.fr%2F.
23 http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/
general/general_content_000334.jsp&mid=WC0b01ac05800ba1d9&
jsenabled=true
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meetings’’. The scope of the briefing meetings covers
regulatory, technical and scientific issues arising from
innovative medicines development, new technologies and
borderline products. Within 60 days of receipt of a valid
request, the ITF arranges free-of-charge briefing meetings
to facilitate the informal exchange of information and the
provision of guidance early in a development process. The
scientific discussions are led by experts from the European
Medicines Agency network, working parties and commit-
tees, where the best available scientific expertise is
represented. Briefing meetings are meant to complement
and reinforce existing formal regulatory procedures (e.g.,
ATMP classification, ATMP certification, designation of
orphan medicinal products, etc.).
Box 2 Quality and safety evaluation criteria
bacteriophage cocktail BFC1 (Merabishvili et al. 2009)
Characterization of the bacteriophages:
• Determination of the morphotype
• Complete DNA and proteome analysis (confirm
absence of lysogeny and toxin genes)
• Testing host bacteria used in production for absence of
(lysogenic) phage (mitomycin test)
QC tests performed by qualified accredited laboratories:
• Phage titer (agar overlay method)
• pH (according to EP)
• Cytotoxicity (ISO10993-5)
• Pyrogenicity (10 ml/kg rabbit, according to USP)
• Sterility (according to EP)
• Confirm morphology and activity towards targeted
bacteria (transmission electron microscopy)
Box 3 Bacteriophages introduced into the food chain:
some reflections
As a regulatory pathway, legislation for food supplements
was investigated. In the US, the Food and Drug Adminis-
tration (FDA) approved the use of Listex natural
bacteriophages for the decontamination of foods.24 Addi-
tionally, in the Netherlands and Switzerland anti listeria
bacteriophages are in use for food products.25 Current
practice in the US for bacteriophage-based products is that
such products are evaluated ‘case-by-case’ and finally
approved (or not) under the US GRAS regulation (Federal
Regulation of Substances Generally Recognized As Safe).
In the US, foods and drugs are administered by one
competent authority, the FDA, which is a federal structure
without an equivalent in Europe. In Europe, the European
Medicines Agency (EMA) and the European Food Safety
Authority (EFSA) are two separate structures, probably
explaining why it is a bigger step from food to medicinal
products in Europe than it is in the US. However, in 2008
the European Commission (DG Health and Consumers)
asked the EFSA to provide technical assistance in relation
to the use and mode of action of bacteriophages on food of
animal origin (Question No EFSA-Q-2008-40026). The
scientific opinion of the EFSA panel on biological hazards
was endorsed on 22 April 2009. The EFSA panel con-
cluded that some bacteriophages, under specific conditions,
have been demonstrated to be very effective in the targeted
elimination of specific pathogens present on meat, milk and
products thereof. The panel, however, could not conclu-
sively find that bacteriophages could protect such products
when re-contamination of the decontaminated products
occurs. The panel also proposed that a ‘‘case-by-case’’
evaluation of presented phage products is necessary. This
European approach is comparable to the US (GRAS)
approach, which is in fact a positive evolution.
Surprisingly, however, some (pro-biotic) food-products
define health claims in their dossier without being regis-
tered as medicinal products (for example, Actimel27 and
Yakult28). These types of products, by definition, also
contain natural bacteriophages. It is questionable whether
these health claims are evidence-based. In any case, the
issue is hot in Europe, especially because Europe recently
refused to accept some of the health claims related to
specific products based on lack of evidence.29 ,30 Recently,
an international workshop on the topic was organized in
Brussels31 entitled ‘‘how to design studies to prove the
claimed health effects of these food products’’. Obviously,
this field is moving quickly as well.
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 4.2 Comparison to the historical development of 
Advanced Therapy Medicinal Products (Study 7) 
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 Abstract Since 1987, the Burn Wound Centre of the Queen Astrid Military Hospital (Brussels, 
Belgium) has been generating cultures of human epithelial cells (keratinocytes) as an additional surgical tool 
to treat its critically burnt patients. Initially, the production environment of keratinocyte grafts at the Burn 
Wound Centre as well as other important aspects that guarantee the safe use of these products on patients 
(e.g. the donor- and release testing) were regulated solely by national legislation and national quality 
guidelines. Production units and cell banks were licensed and inspected only by the Belgian national health 
authorities. In 2004, the European Tissues and Cells Directive 2004/23/EC on setting standards of quality 
and safety for the donation, procurement, testing, processing, preservation, storage and distribution of 
human tissues and cells [1] was published and later transposed into Belgian Law. For the Burn Wound 
Centre, implementing this new law meant increased production costs and no significant increase in final 
quality and/or safety of the produced grafts. In 2007, Europe published Regulation (EC) No 1394/2007 on 
Advanced Therapy Medicinal Products [2], amending Directive 2004/23/EC. Overnight, the keratinocytes 
cultured at the Burn Wound Centre became (arguably) “Advanced” Therapy Medicinal Products (ATMPs) to 
be produced as medicinal products for human use. The practical impact of this amendment was (and still is) 
considerable. A similar development appears imminent in bacteriophage therapy. Bacteriophages are 
bacterial viruses that can be used for tackling the problem of bacterial resistance development to antibiotics. 
Therapeutic natural bacteriophages have been in clinical use (including in Europe) for almost 100 years. 
Regulators today are framing the (re-)introduction of (natural) bacteriophage therapy into “modern western” 
medicine as biological medicinal products, also subject to stringent regulatory medicinal products 
requirements. In this paper, we look back on a century of bacteriophage therapy to make the case that 
therapeutic natural bacteriophages should not be classified under the medicinal product regulatory frames 
as they exist today. 
 
Keywords  Bacteriophage; Bacteriophage Therapy; Keratinocytes; Fecal Transplants; Regulatory; 
Advanced Therapy Medicinal Products; ATMP; Biological Medicinal Products; Hospital 
Exemption. 
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 1. Introduction 
 
Regulation (EC) No 1394/2007 of the European Parliament and of the Council on Advanced Therapy 
Medicinal Products (hereafter referred to as “ATMP” Regulation) was adopted in 2007 and covers products 
that are based on gene therapy, somatic cell therapy or tissue engineering [2]. The ATMP Regulation 
entered into force in Europe on 30 December 2008. A transitional period was foreseen for ATMPs that were 
already on the EU market. Gene therapy products and somatic cell therapy products were required to 
comply with the Regulation by 30 December 2011. Tissue-engineered products were required to comply 
with the new requirements by 30 December 2012. The new ATMP Regulation gives EU member states the 
freedom to authorise the production and use of custom-made ATMPs in hospital settings at the member 
state level as an exemption to the general obligation to follow the central ATMP marketing authorisation 
procedure. This exemption is called the “hospital exemption”. A hospital exemption can be granted for 
ATMPs that are prepared on a non-routine basis and are prescribed for individual patients and are applied 
in a hospital setting and on patients that are treated under the professional responsibility of a medical 
practitioner. Under the hospital exemption, national requirements on quality, traceability and 
pharmacovigilance equivalent to those required for authorised medicinal products are applicable. Before the 
publication of the ATMP Regulation, dozens of human cell and tissue products were produced and used in 
European hospitals. In Belgium, for instance, patients had access to 22 cloaked ATMP products produced 
by 9 accredited and hospital-based (not-for-profit) human cell and tissue establishments [3]. The safe use of 
these products was guaranteed by national guidelines as well as by Belgium’s transposition of the European 
Cell and Tissue Directive 2004/23/EC [1]. Human-derived cell and tissue products were, at that time, not 
considered as medicinal products. Under the new ATMP regulatory framework, only 10 marketing 
authorisation applications for ATMPs have been submitted to the European Medicines Agency (as of 30 
June 2013) [4]. Out of these ten marketing authorisation applications, only four have successfully completed 
the procedure and have been granted a marketing authorisation by the Commission (ChondroCelect®, 
Glybera®, MACI®, and Provenge®). What happened to the high-quality “hospital-produced” products that 
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 were in use before the publication of the ATMP Regulation? Not-for-profit stakeholders were forced to stop 
using these products due to the financial strain linked to the production and market placement of medicinal 
products. Other stakeholders continue to use these ATMPs despite a legal grey zone and an uncertain 
future.   
In Europe, ATMPs have been extensively researched in a clinical context. Up to 250 distinct 
ATMPs were reported in the European Clinical Trial Database (EudraCT) during the period 2004-2010 [4]. 
The majority of research on ATMPs is conducted by Small and Medium Enterprises (SMEs) and entities that 
operate on a not-for-profit legal basis (70%). Big pharmaceutical companies account for less than 2% of all 
sponsorships [4]. Despite being financially well-equipped and accustomed to investing in pharmaceutical 
product development, big pharmaceutical companies do not appear to be interested in developing ATMPs.  
The Burn Wound Centre of the Queen Astrid Military Hospital (Brussels, Belgium) has been a 
European pioneer in the defined production of human epithelial skin cultures (keratinocytes) for use on 
acute and chronic skin wounds for nearly 30 years. Since 1987, the centre has successfully treated more 
than one thousand patients with keratinocyte-based grafts. As the Belgian definition of an ATMP hospital 
exemption has not yet been articulated, the centre continues its work within the framework of the European 
Tissues and Cells Directive 2004/23/EC [1]. Arguably, the hospital should stop producing keratinocytes for 
clinical use since it does not have a medicinal product production licence, it does not have a pharmaceutical 
production environment and it does not have a pharmaceutical marketing authorisation license for 
keratinocytes produced on its premises. Due to this situation, the centre is forced to continue its work in a 
legally grey zone at the mercy of the National Competent Authority. Important is that the European 
Commission has now advised the European Parliament to create a more favourable environment for ATMP 
developers working in an academic or non-for-profit setting [4]. However, it is unlikely that this advice will 
result in immediate action. 
Patients in the Burn Wound Centre of the Queen Astrid Military Hospital (Brussels, Belgium) are not 
only treated with cultured keratinocytes. They are, since 2007, also sporadically treated with natural 
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 bacteriophages, under the umbrella of Article 371 of the Helsinki Declaration [5]. Antimicrobial resistance in 
bacteria is, also in the Burn Wound Centre, an increasingly serious threat. New initiatives to tackle the 
problem of antibiotic resistance are urgently needed. One promising solution is the therapeutic use of 
natural bacteriophages – the viruses of bacteria – to treat bacterial infections. When discovered in the early 
twentieth century, bacteriophages were immediately applied in medicine (bacteriophage therapy) with 
variable success. After World War II, Western industry and policymakers preferred antibiotics, which at the 
time had obvious advantages in terms of breadth of coverage and ease of production and patentability, and 
bacteriophage therapy was pushed into the background. Today, bacteriophage therapy is again put forward 
as a potential way to address the current antibiotic crisis. Regulatory parallels can be seen between the 
regulation history for human keratinocyte-based grafts and that of natural therapeutic bacteriophages. 
Natural bacteriophages have been used for therapeutic purposes in humans for almost 100 years. Today, 
Europe classifies therapeutic bacteriophages as human medicinal products to be regulated through the 
classical human medicinal product frameworks [6]. We urge regulators not to repeat the regulatory mistakes 
of the past. To maximally exploit the advantages bacteriophages have over conventional drugs, it is 
important that sustainable bacteriophage products are not submitted to the conventional long medicinal 
product development and licensing pathway. There is a need for an adapted framework, including realistic 
production and quality and safety requirements, that allows a timely supplying of bacteriophage therapy 
products for ‘personalized therapy’ or for public health or medical emergencies [7]. All stakeholders should 
be aware that they have a moral duty to proceed fast within their respective domains of responsibility in 
countering bacterial antibiotic resistance [8,9]. We are convinced that opting for a local, patient-specific 
approach will allow us to strike the right balance between the obligation to protect the patient from 
unnecessary risks on the one hand and the obligation to offer the best possible medical attention to the 
patient on the other. Flexibility (at all levels) is a basic requirement for success in this endeavour.   
                                                          
1
 Art. 37.       In the treatment of an individual patient, where proven interventions do not exist or other known 
interventions have been ineffective, the physician, after seeking expert advice, with informed consent from 
the patient or a legally authorised representative, may use an unproven intervention if in the physician's 
judgement it offers hope of saving life, re-establishing health or alleviating suffering. This intervention should 
subsequently be made the object of research, designed to evaluate its safety and efficacy. In all cases, new 
information must be recorded and, where appropriate, made publicly available. 
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 2. The Belgian Ministry of Defence’s historical ATMP experience 
 
The Queen Astrid Military Hospital established a human keratinocyte production unit in the late 1980s. Its 
principal goal was to produce autologous keratinocyte sheets (see Figure 1) for immediate use on critically 
burnt patients (mostly civilians). The launch of this production unit (staffed primarily by biologists performing 
their obligatory military service at that time) was successful and the first patients were grafted in 1987. The 
technique for growing keratinocytes was referred to as the “Rheinwald and Green” technique [10]. Over 
time, the technique has been optimised. Keratinocytes can now be grown in totally defined and animal-
component-free culture media, without the additional use of animal fibroblasts feeder layers (see Figure 2). 
This defined production protocol was published open access (without patent protection) in 2012 [11]. Figure 
3 illustrates the timeline related to this project (see Figure 3). Alongside culturing autologous cells, donor 
keratinocytes for allogeneic use are also grown. The cultured keratinocytes can be cryopreserved for later 
use (see Figure 4). Keratinocytes can be applied under the form of a sheet or under the form of a spray (see 
Figure 5). It is also possible to generate cultures using adult skin or from neo-natal foreskin donations. The 
keratinocyte bank of the Queen Astrid Military Hospital became ISO 9001 certified in 2008. The hospital 
works in compliance with the European Tissues and Cells Directive 2004/23/EC [1] and the keratinocyte 
bank is compliant with specific Belgian regulation and guidelines as defined by the Belgian Health 
Authorities and advised by the Belgian Superior Health Council. In addition, the hospital’s keratinocyte bank 
is licenced by the Belgian Federal Public Service for Health, Food Chain Safety and Environment. Initially, 
the keratinocyte bank was inspected (in view of the prolongation of the licenses) by the Belgian hospital 
inspection authorities. Inspection duties later transferred to the pharmaceutical inspection authorities, the 
Belgian Federal Agency for Medicinal and Health Products (FAMHP). The use of keratinocytes for treating 
burn wounds or chronic skin wounds was (and still is) reimbursed by the Belgian social security system 
(after having documented the efficacy) at a (not-for-profit) production cost.  In 2012, the hospital received a 
letter from the Belgian National Competent Authority (FAMHP) that these cultured keratinocytes had been 
reclassified, effective immediately, as medicinal products for human use and were thus to be produced and 
PhD Dissertation - Gilbert Verbeken - Page 180
 placed on the market as if they were human medicinal products. Keratinocytes are cultured currently in a 
“controlled environment” (GMP air quality Class A in a minimum Class D background). Halting production at 
the centre meant ceasing all keratinocyte-based treatments, since no equivalent products for keratinocytes 
are currently available on the market. Faced with this situation, the Belgian Ministry of Defence had no other 
choice but to invest €5.3 million in a cleanroom facility for GMP (keratinocyte) production. The authors are 
convinced that this investment only increases production costs and, again, will not increase the quality and 
safety of the final products.  
 
3. Gleaning lessons on the (re-)introduction of natural bacteriophage therapy in Europe 
 
Parallels can be seen between the regulatory history of keratinocytes and current developments in the re-
introduction of (natural) bacteriophage therapy. Europe recently classified natural bacteriophages, used as 
therapeutics, as human medicinal products [6]. This classification will impact access for patients in a way 
similar to how the ATMP Regulation impacted patient access to cultured keratinocytes. Therapeutic use of 
natural bacteriophages (on humans) goes back for almost 100 years [12,13]. Since 2007, the Burn Wound 
Centre of the Queen Astrid Military Hospital sporadically applies bacteriophage therapy in patients infected 
with antibiotic-resistant bacteria. The first therapeutic use of bacteriophages in the centre was conducted in 
a small clinical trial [14] in which bacteriophages were sprayed on the patients’ wound bed (see Figure 6). 
Ten bacteriophage applications in total were performed on 9 patients. This trial was approved by the 
Leading Medical Ethical Committee of the University Hospital of the Free University of Brussels (UZ 
Brussel). After the trial, patients in the Burn Wound Centre continued to receive sporadic spray-based and 
drain-based treatments with natural therapeutic bacteriophages (see Figure 7). These treatments were 
performed under Article 37 of the 2013 Helsinki Declaration [5]. All patients (or their legal representative) 
signed an informed consent document. Protocols for the production of natural therapeutic bacteriophages 
have been increasingly optimised much as keratinocyte production protocols have been optimised over the 
years. The results of these efforts were published open access (without patent protection) in 2009 [15].  
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 In-house bacteriophage production activities at the hospital are actually not performed in a 
pharmaceutical GMP environment and the produced natural bacteriophage cocktails are not compliant with 
the Belgian Medicinal Product Legislation [16]. Bacteriophage cocktail BFC1 (see Figure 8) contains 2 
different bacteriophages against Pseudomonas aeruginosa (see Figure 9) and 1 phage against 
Staphylococcus aureus . 
Within the medicinal product frame, natural bacteriophages are classified as Biological Medicinal 
Products (BMPs). This classification is disadvantageous because the BMPs legal framework does not 
provide for a hospital exemption procedure, as it does for ATMPs. Big pharmaceutical companies are no 
longer interested in investing in the development of small-spectrum antibacterial products [17]. The Queen 
Astrid Military Hospital does not experience the Medicinal Product Legislation as an adequate tool for 
bringing natural therapeutic bacteriophages to patients in a sustainable and tailored way [9,18,19]. Hospitals 
working under a - yet-to-be-defined - BMP “hospital exemption” should have access to a specific European 
Bacteriophage Therapy Legislative Frame that guarantees quality and safety for also these therapeutic 
bacteriophage products.  
 
4. Fecal microbiota transplantation 
 
In May 2013, the US Food and Drug Administration (FDA) announced that it would begin regulating human 
feces for transplantation as a “drug” [20,21]. Where the FDA uses the term “drug”, Europe uses the 
equivalent term “medicinal product”. The FDA reasoned that this would make fecal microbiota 
transplantation (FMT) safer by providing oversight, standardising therapy and, eventually, encouraging 
development of commercial drug products. FMT has been effective in cases of treatment-resistant 
Clostridium difficile infection [22], a killer of 14.000 patients in the U.S. each year. 
At a public meeting that month organised by the FDA and the US National Institutes of Health (NIH), 
patients, physicians and representatives of the Centres for Disease Control and Prevention (CDC) and 
several professional medical societies voiced concern about restricting access to care. Six weeks later, the 
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 FDA revised its position. The agency decided, for the time being, not to enforce Investigational New Drug 
(IND) requirements for the treatment of recurrent Clostridium difficile infections. This compassionate 
exception is now enabling many patients to receive much-needed care. Whether and when the therapeutic 
potential of FMT is realised will depend on how FDA and other agencies regulate the future therapeutic use 
of stool. Treating stool as a drug imposes strict patient-protection requirements but it significantly limits 
access to care. Reclassifying stool as a tissue product or giving it its own classification, as the FDA does for 
blood, would keep patients safe, ensure broad access and facilitate research. We urge European regulators 
to do the same for natural bacteriophages. 
 
5. Discussion and Conclusion  
 
Today’s European Medicinal Product Legislation needs to be reworked to ensure the sustainable larger-
scale (re-) introduction of natural bacteriophage therapy in Europe. Defining a hospital exemption under the 
actual Biological Medicinal Product Legislation is crucial to this effort. This new hospital exemption needs to 
target the “in-hospital” use of natural bacteriophages, tailored to the patient’s needs and taking into account 
the co-evolutionary aspects of what natural bacteriophage therapy really stands for. Hospitals that have 
obtained the hospital exemption status should have access to tailored and bacteriophage-specific quality 
and safety guidelines. Efficacy and safety of the treatments needs to be documented [23] but not 
necessarily in the format of a clinical trial which exists for the testing and development of new medicinal 
products. Specific quality and safety requirements should be elaborated to guarantee patients’ safe access 
to efficient bacteriophage therapy products and to facilitate research.  
 
We sincerely hope the arguments put forth in this paper can contribute to effective regulation of 
bacteriophage therapy within existing regulatory frameworks. Should that fail, a final strategy could be to 
contend that the tailored use of natural bacteriophages produced in-hospital for use on its own hospitalised 
patients does not constitute a market placement of that product. Such an interpretation places production of 
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 bacteriophages outside of the scope2 of European Medicinal Product Directive 2001/83/EC [24] and would 
render European Medicinal Products Legislation irrelevant to the use of natural bacteriophages inside the 
hospital on its own patients. A specialised law firm studied this issue in detail and supported this position 
[25]. Meanwhile, it is possible to revise the actual medicinal product regulatory status of natural therapeutic 
bacteriophages, allowing compassionate use analogous to the US FMT issue [21]. 
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2
 EMPD 2001; Title II;  Scope;  Article 2; 1;  This Directive shall apply to medicinal products for human use 
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Figure 1 Keratinocyte sheet             Figure 2 Microscopic view (magnification      
            40x) of neonatal foreskin keratinocytes 
 
           
 
 
Figure 3 Timeline related to the keratinocyte productions in the Queen Astrid Military Hospital, Brussels, 
Belgium 
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Figure 4 Keratinocyte blister package              Figure 5 Keratinocyte spray                         
   
    
 
Figure 6 Bacteriophages sprayed on a burn Figure 7 Bacteriophages applied through a 
drain in a pelvic traumatic patient under the 
umbrella of Art. 37 of the Helsinki Declaration 
 
       
 
 Figure 8 Investigational Bacteriophage Cocktail   Figure 9 Transmission Electron Microscopy  
 BFC1       micrograph of Pseudomonas aeruginosa 
       bacteriophage PNM     
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Abstract The worldwide emergence of antibiotic resis-
tances and the drying up of the antibiotic pipeline have
spurred a search for alternative or complementary antibac-
terial therapies. Bacteriophages are bacterial viruses that
have been used for almost a century to combat bacterial
infections, particularly in Poland and the former Soviet
Union. The antibiotic crisis has triggered a renewed clinical
and agricultural interest in bacteriophages. This, combined
with new scientific insights, has pushed bacteriophages to
the forefront of the search for new approaches to fighting
bacterial infections. But before bacteriophage therapy can
be introduced into clinical practice in the European Union,
several challenges must be overcome. One of these is the
conceptualization and classification of bacteriophage ther-
apy itself and the extent to which it constitutes a human
medicinal product regulated under the European Human
Code for Medicines (Directive 2001/83/EC). Can thera-
peutic products containing natural bacteriophages be
categorized under the current European regulatory frame-
work, or should this framework be adapted? Various actors
in the field have discussed the need for an adapted (or
entirely new) regulatory framework for the reintroduction
of bacteriophage therapy in Europe. This led to the identi-
fication of several characteristics specific to natural
bacteriophages that should be taken into consideration by
regulators when evaluating bacteriophage therapy. One
important consideration is whether bacteriophage therapy
development occurs on an industrial scale or a hospital-
based, patient-specific scale. More suitable regulatory
standards may create opportunities to improve insights into
this promising therapeutic approach. In light of this, we
argue for the creation of a new, dedicated European regu-
latory framework for bacteriophage therapy.
Keywords Bacteriophage  Therapy  Human 
European  Regulatory  Legal  Legislation
Introduction
Antimicrobial resistance is a key twenty-first century global
health challenge (Cooper and Shlaes 2011; Kutateladze and
Adamia 2010). The potential of bacteriophages for treating
(multi-drug resistant) bacterial infections has been acknowl-
edged for decennia (Bru¨ssow 2005; Gill and Hyman 2010;
Go´rski et al. 2009a, b; Maura and Debarbieux 2011; Pirnay
et al. 2012) and bacteriophage research is being performed
intensively worldwide (Ackermann 2012). Bacteriophage
therapy was developed mainly in Eastern Europe (Poland)
and the former Soviet Republics (Georgia and Russia). A
handful of clinical trials have been performed in those
countries, as well as in the United States and India (Bruttin
and Bru¨ssow 2005; Monk et al. 2010); however, most of
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these studies were not carried out according to modern, evi-
dence-based standards of medical research (Parracho et al.
2012). Today, a small number of clinical trials have been
carried out and/or are ongoing and bacteriophage therapy is
being applied in clinical settings under the purview of specific
national regulatory frameworks and/or the Helsinki Declara-
tion (Go´rski et al. 2009a, b; Kutter et al. 2010).
The lack of a smooth (re-) introduction of bacteriophage
therapy in Europe is related to several obstacles within the
current European Regulatory Framework (Bru¨ssow 2012;
Pirnay et al. 2011; Verbeken et al. 2012; Wright et al. 2009).
Meanwhile, the UK’s Medicines and Healthcare Products
Regulatory Agency has approved a bacteriophage clinical trial
(Pirnay et al. 2011), which is now ongoing. In this context,
bacteriophages used as therapeutics are considered ‘‘biological
medicinal products’’ by European regulators. In the United
States, such bacteriophage-based products are handled by the
FDA division for vaccines and related product applications
(Parracho et al. 2012). This suggests that a non-specific, tech-
nical and stringent legislative pharmaceutical framework is
likely to be introduced into the field of natural bacteriophage
therapy in the near future. Hospitals using bacteriophage-based
products to treat hospitalized patients—many of which hospi-
tals have used these products for many years—must now meet
the stringent requirements pertaining to ‘‘true’’ human medic-
inal product development. This is likely to be destructive for the
non-profit (tailored) hospital-based use of therapeutic bacte-
riophages as well as for small and medium enterprises lacking
the necessary financial resources to fund the full product
development cycle for bacteriophage-based products (Pirnay
et al. 2012; Thiel 2004).
Currently, the regulatory aspect of bacteriophage ther-
apy is understudied. No technical, scientific arguments
currently exist addressing the question of whether and to
what extent bacteriophages fit within the actual definitions
and procedures of the existing regulatory framework for
human medicinal products in Europe.
This study investigates the scientific arguments related
to the classification of bacteriophages as human medicinal
products under the current European regulatory framework.
The core of the discussions was the European legislation
relevant to the therapeutic (anti-bacterial) use of natural
(not genetically modified) bacteriophages in humans.
The aim of the study was to evaluate whether the current
European regulatory framework for human medicinal products
needs to be adapted with regard to an eventual (re-) introduction
of bacteriophage therapy into the European Union.
Methodology
The research focuses on the application of natural bacte-
riophages in a therapeutic context. Other possible fields of
applications for bacteriophages (e.g., prevention of infec-
tions; use as vaccines; use as diagnostic tools; use as a tool
to influence cancer or to decontaminate skin grafts) were
excluded.
To investigate the extent to which the concept of bac-
teriophage therapy does or does not fit into the current
European regulatory framework for human medicinal
products, the existing biomedical-economic literature was
reviewed and in-depth interviews with 35 key informants
with knowledge and/or regulatory expertise of bacterio-
phages were carried out. Participants were selected using
purposive sampling. The experts represent different
stakeholder groups, including industry (11), academia (18),
hospitals (5) and competent authorities (1). The intervie-
wees were based in Belgium (15), France (8), United States
(3), United Kingdom (2), Georgia (2), Germany (1), Poland
(1), Portugal (1), Switzerland (1) and The Netherlands (1).
The interview was based on a standardized question-
naire. Three definitions from the existing European
regulatory framework were presented to the interviewees
(Boxes 1–3): the general definition of a medicinal product,
the definition of a biological medicinal product, and the
definition of an Advanced Therapy Medicinal Product
(ATMP). The interviewees were asked to comment on how
bacteriophages did or did not fit into the wordings of the
presented definitions (see Fig. 1). Beside these three main
definitions, the following topics where also discussed: the
definition of a bacteriophage, whether (or not) a bacterio-
phage is in fact a living entity, therapeutic quality and
safety issues, application methodologies, possible side
effects of bacteriophages, differences/similarities of bac-
teriophage therapy versus antibiotic therapy, marketing
authorization pathways, the hospital exemption issue and
intellectual property aspects. The interviewees were asked
to formulate conclusions about whether (or not) the current
European regulatory framework is sufficient, needs to be
adapted or whether there is a need for a new, dedicated
framework specifically for bacteriophages.
The interviews were qualitatively analyzed and consis-
tent themes and patterns were identified. Due to the
complexity of the interview data, results were processed
and analyzed using non-computational qualitative meth-
odology (Silverman 2010).
Results
This chapter summarizes the answers/the reflections of the
interviewees in relation to the questions asked. These
answers, reflections or statements do not necessary reflect
the position of the authors of this paper. Literature-refer-
ences are not included in this chapter since it is not known
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to the authors from what (publication) background the in-
terviewees were answering the questions.
Bacteriophages as Human Medicinal Products
under the European Regulatory Framework
Arguments Related to Bacteriophages and the Definition
of a Human Medicinal Product (see Box 1)
The definition of a human medicinal product (Art. 1 of
Directive 2001/83/EC) refers to a ‘‘substance’’ (or a
combination of substances) presented with particular
therapeutic properties and used in therapeutic contexts.
Such a substance is also defined in the Directive (Box 1)
and is perceived to be ‘‘any matter irrespective of ori-
gin’’, with some additional examples. The definition of
this referred substance is so broadly defined that it
includes natural bacteriophages used as antimicrobial
agents within human beings. The definition could even be
taken to cover a physician, since a physician is also
‘‘presented to patients as having properties for treating
disease’’.
In view of the particular examples of substances (Box
1), opinions differ on what a natural bacteriophage really
is. A bacteriophage can be considered a microorganism—
or not—and as living—or not. Differences at this concep-
tual level are important when considering a potential
classification of natural bacteriophages in the existing legal
framework for human medicinal products.
In the case that a bacteriophage is considered a
microorganism, we can refer to it as a bacterial virus, a
microbe or some other organism. According to classical
taxonomical terminology, a bacteriophage is indeed a
virus. A virus outside a bacterium is called a ‘‘virion’’ (an
‘‘intermediate phase’’). ‘‘Virions’’ can be compared to
spores or sperm cells. A spore is not a plant, and a sperm
cell is not a human being. Once the virion is inside the
bacterium, this bacterium is no longer the same cell. The
virion takes over the essential elements and processes
within the bacterium. The changed (infected) cell could
thus be called a ‘‘viral cell’’. It is the virus-cell combi-
nation that then produces the bacteriophages (virions). In
this view, the bacteriophage together with its bacterium
can be considered to be one microorganism, since a
bacteriophage has no existence without that bacterium.
The bacteriophage-bacterium combination could be
classified as a new taxonomic entity.
On the other hand, there are arguments supporting the
idea that a bacteriophage is not a microorganism since a
bacteriophage has no ‘‘organs’’ and requires a cell
machinery to be ‘‘alive’’. According to this logic, a bac-
teriophage can be considered as derived from a
microorganism.
With respect to its replicating nature, a bacteriophage is
perceived as a biological entity that, by interacting with its
(biological) environment, is capable of replicating and
evolving as an independent, self-replicative particle. But
others do not consider a bacteriophage self-replicative
Fig. 1 Overview of methodological approach of the interviews
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since a bacteriophage needs a host (a biological system) to
self-replicate.
Is a Bacteriophage Living? Some do not consider a
bacteriophage as a living entity since it lacks the most basic
component of a biological system, namely, a cell (the
biologic basic entity). A cell is an open thermo-dynamic
system with a constant material and energy flow. Being
alive implies a status with a ‘‘anti-entropic effect’’. This
contrasts with a bacteriophage as a (classically defined)
virus consisting only of (static) proteins and nucleic acids.
Others consider bacteriophages as living entities. Due to it
being a very small entity—a capsuled single-stranded
DNA—(the entire DNA of) a bacteriophage was one of the
first molecules to be synthesized in the laboratory.
Although very simple in design, this piece of DNA is not
functional when introduced as such into a bacterium.
Therefore, arguments can be found to qualify bacterio-
phages as ‘‘living’’. Viruses are, after all, part of the ‘‘tree
of life’’.
Therapeutic Action of Bacteriophages Bacteriophages
can ‘‘treat or prevent’’ a disease in human beings and they
‘‘restore, correct or modify physiological functions by
exerting pharmacological, immunological or metabolic
actions’’ as described in the Directive (Box 1). Different
aspects can be considered with respect to the exact mode of
action of a therapeutic bacteriophage. Bacteriophages can
restore physiological function and the original endemic
flora by controlling the pathogens present there. In this
way, they can restore balance to out-of-control systems. In
cases where different bacteria are involved, bacteriophages
can generate a competitive exclusion by specifically
attacking a particular bacterium, thus rebalancing the
ecosystem.
Another mode of action of bacteriophages relates to
their capacity to effectively modify human physiological
functions, be it in an indirect way, by destroying the bac-
teria. In this sense, they are comparable with antibiotics.
Immunological actions can be attributed to bacteriophages
by specifically boosting the human immune system. Even a
metabolic action of bacteriophages can be observed, since
bacteriophages interact with the microbial parts of the
human body, correcting or modifying physiological func-
tions by killing off pathogenic microorganisms. In
addition, bacteriophages take over the bacterial metabo-
lism. Bacteriophages can also generate a pharmacological
action since bacteriophages are not only antimicrobials but
can also suppress inflammation caused by infection.
Finally, bacteriophages can be used as a medical diag-
nostic tool (Box 1), as was the case when they were used in
salmonella testing during salmonella outbreaks and fast
plaque testing for tuberculosis.
Route of Administration of a Bacteriophage-Based Prod-
uct There is a lack of scientific evidence about the most
optimal application format and methodology for bacterio-
phage therapy. The external (topical) or oral use of
bacteriophages should pose no problems. The preferable
application method, however, is intra-peritoneal or intra-
muscular. Bacteriophages are then released into the
bloodstream very slowly, gradually and at low levels. In
this way, the immune system is stimulated much less than
it would be were the bacteriophages to be directly injected
intravenously. Once the bacteriophages are at the point of
action, they will auto-amplify as needed. Bacteriophages
have widely been used intravenously. For instance, the
intravenous anti-staphylococcal bacteriophages produced
at the Eliava Bacteriophage Institute’s industrial depart-
ment have been used across the whole Soviet Union from
the end of 1970s through the end of 1980s for treatment of
septic infections in humans (children and adults) caused by
multiple drug-resistant Staphylococcus aureus. However,
there is some sense in not administering bacteriophages
intravenously, particularly because bacteriophages are
likely to be filtered out by the immune system almost
immediately using this method. In an effort to prevent this,
one could try to cover the bacteriophages with molecules,
making them invisible to the immune system. However,
after this manipulation, the bacteriophages can no longer
be considered ‘‘natural’’ bacteriophages. Ultimately, while
promising as an avenue for further research, bacteriophages
may not be suited to treating kidney or liver infections
since maintaining adequate bacteriophage concentrations
to treat at these locations is probably infeasible.
Possible Side Effects of Bacteriophage Therapy Predicted
side effects are very few and mostly depend on the time of
administering the bacteriophages, the applied amount of
bacteriophages, the type of bacteriophages used, the format
of application, and whether the bacteriophages are
administered as cocktails.
With respect to genetic (carcinogenic) consequences
related to bacteriophage therapy, gene transfer cannot be
totally excluded, but will probably only happen at a very
low frequency.
Bacteriophages can cross the blood–brain barrier, but no
known specific side effects related to this have been
reported.
Immunological response at the moment of treatment and
immunization against the bacteriophages when used in the
long run could also be possible. This phenomenon is not
likely to appear when the treatment period is (very) short.
This is why repetitive treatment at intervals of several
weeks or months (with the same bacteriophages) should be
avoided. When using bacteriophage cocktails in a partic-
ular therapy, bacteriophages must be changed or updated
Arch. Immunol. Ther. Exp.
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frequently and broad-spectrum cocktails must be composed
of the least possible number of bacteriophages.
The use of therapeutic bacteriophages will lead to a quick
and in some cases quit massive destruction of the bacterial
cells involved. At worst, this massive and total lysis of
bacteria and the subsequent release of toxins could generate
potentially life-threatening reactions such as endotoxin
shock, mechanical osmotic effects or respiratory symptoms.
The use of small quantities of bacteriophages at once is
necessary in order to avoid the large-scale release of toxins.
In addition, a first, limited amount of bacteriophages prior to
a higher therapeutically relevant dose can prevent large-
scale toxin release because the initial bacteriophages destroy
the bacteria before they multiply massively.
A side effect of bacteriophage cocktails in particular is
the risk of recombination that can occur within a bacte-
riophage, ending all control over the process. Recombining
the genetic information within bacteriophages can modify
the original bacteriophages. This happens in nature and is
being studied in labs; however, more modeling studies are
necessary to fully explore this.
It is clear that the long-term consequences of bacterio-
phage therapy remain partly unknown, especially in view
of the resistance development. Although bacteriophages
can adapt and evolve along bacterial changes, research
related to the development of resistance in general and
research on bacteriophages more specifically is therefore
necessary. We must treat carefully and draw on lessons
learned in the past from the development cycle of antibi-
otics, which progressed without any profound, thorough
risk assessment. For bacteriophages, the (environmental)
risk assessment for (non-human) medical use is also
important due to problems that may arise from the massive
use of bacteriophages in, e.g., the veterinary, bio-agricul-
tural industry, as was and continues to be the case for
antibiotics use in that industry.
Views Related to Bacteriophages and the Definition
of a Biological Medicinal Product (see Box 2)
The definition of a Biological Medicinal Product refers to
the active substance as a biological substance produced or
extracted from a particular biological source. Active pro-
ducts used in natural bacteriophage therapy can be
classified under the definition of a Biological Medicinal
Product.
This is the case for several reasons. First, a natural
bacteriophage itself can be perceived as a biological sub-
stance. Such bacteriophages can be produced by or
extracted from a biological source, as proclaimed in the
Directive. The bacterium itself can be seen as the biolog-
ical source. Other possible biological sources are the initial
ecological combination ‘bacteriophage-bacterial host’, or
the bacteriophage itself, which enters a bacterial cell,
interacts with it and replicates. Even the wound fluid of the
patient or the wastewater out of which bacteriophages can
be extracted could be viewed as possible biological
sources.
It is also possible to view a bacteriophage as not
extracted from but made by the bacterial cell. The bacte-
riophage lyses the bacterial cell and releases itself from its
host. A bacteriophage has a self-replicating nature, but it
can only reproduce (or make) itself when present in a
bacterium, namely, a very bacterial-specific host or the
biological system to which it belongs.
One could also consider the endozymes produced by the
bacteriophage as active biological substances. Such endo-
zymes cause lysis of the bacterium and originate from the
bacteriophages as a biological source.
When bacteriophages are considered as human medici-
nal products, the starting material (as indicated in
Directive 2001/83/EC) for producing the therapeutic bac-
teriophage product must be a substance of biological origin
(Box 2). The exact meaning of that starting material can
differ. One can consider a microorganism as the starting
material for producing a therapeutic bacteriophage, or a
particular substance, produced by a microorganism.
Another view identifies two types of starting materials for
producing therapeutic bacteriophages, namely, ‘‘virions’’
and bacteria, forming bacterio-viruses. Yet another
approach is simply to characterize a bacteriophage’s parent
as its substance of origin.
Physico-Chemical-Biological Testing of Bacterio-
phages With respect to the characterization and
determination of the quality of a bacteriophage-based
product (Box 2), it could be argued that a combination of
physico-chemical-biological testing is required, together
with testing of the production process and its control, as
described in the Directive (Box 2). However, the exact
meaning of physico-chemical-biological testing in view of
bacteriophage therapy needs to be clarified, particularly in
relation to the required documentation package for bacte-
riophage therapy.
To generate a qualitative effect of therapeutic bacterio-
phages, the first requirement is to assess the underlying
therapeutic problem of the patient, namely to identify the
problematic bacterial strain so that the right corresponding
(most effective) therapeutic bacteriophage can be selected.
Once selected, the bacteriophage-bacterium interaction
(the efficacy) needs to be evaluated in vitro. Electron
microscopy can be helpful in documenting the interaction
bacteriophage-bacterium.
Bacteriophages need to be characterized in view of the
specific morphotype. Maximal molecular characterization
of the bacteriophage genome is mandatory to confirm the
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absence of known toxic genes or to confirm the absence of
known antibiotic-resistant genes, but not for each batch
produced (only for the master stock). In view of the genetic
testing of bacteriophages, it could be useful to have a
microchip formulation that could be used to test any
cocktail to ensure that it is not carrying a pathogenicity
island. Full genetic sequencing can, however, lead to false
safety statements since, even when a bacteriophage is fully
sequenced, half of its genome (and/or related functions)
remains unknown. The presence of lysogenic bacterio-
phages must be maximally excluded. In any case, it is also
important to point out that a bacteriophage that lacks any
lysogenic component can acquire one from a lysogenic
bacteriophage that is already present in the body. Bacte-
riophages arising from host bacteria with the lowest level
of emerging mutations must be chosen for the production
of bacteriophage preparations. When possible, bacterio-
phages should be produced in a non-pathogenic bacterial
host, and that host must be sequenced as well. This issue is
less (or not) relevant when bacteriophages are grown on the
patient’s own bacteria. In order to avoid genetic alterations,
it would be wise not to scale up the production of bacte-
riophages indefinitely. Although bacteriophages are natural
products, producing them in high quantities is not natural.
Unexpected changes could be introduced. In the case of
industrial bacteriophage preparations, permanent monitor-
ing of the production process is seen as mandatory and
must be reproducible.
Final bacteriophage preparations must be pure (absent
of residual contaminating bacteriophages, absent of (other)
hosts), sterile, endotoxin purified and pH neutral. (Endo)
toxin testing and/or pyrogenicity testing of the final pro-
ducts is/are considered necessary. The final bacteriophage
titre must be tested, as well as the (storage) stability (and
conditions).
Assessing pharmaco-kinetics of the bacteriophage
preparations (in relation to the application format, under
relevant conditions) is also beneficial. Also the (adverse)
immune response of the human body should be studied. In
vitro modeling is important to understanding the action of
the bacteriophages.
When bacteriophages are stored in a ‘‘therapeutic phage
bank’’, it would be interesting to compare the quality
management applied in such master bacteriophage banks
with that applied in human cell banks.
In contrast to this rationale, counterarguments state that
no elaborated bacteriophage quality and safety documen-
tation is necessary since the safety of bacteriophages has
been proven through their long-standing historical use.
Bacteriophages are the most abundant form of ‘‘life’’ on
earth and are even older than bacteria. If bacteriophages
were pathogenic to humans, so goes the argument, it would
be publicly known by now. According to this way of
thinking, efficacy is all that must be tested and human
clinical trials should be conducted. Historical data related
to bacteriophage therapy were not, in most cases, generated
in accordance with western research standards. Most of
these data were collected through ‘‘open’’ clinical trials in
eastern countries and lack any written decent reports or
data audits. Therefore, in order to be useful, these historical
data must be validated. In view of this, it has been sug-
gested to (partially) fall back on these historical data for
documenting bacteriophage safety. Efficacy must be pro-
ven through standardized clinical trials.
In any case, the documentation of therapeutic bacterio-
phages is something to take seriously. Data obtained
through scientifically sound clinical trials must live up to
western standards. It is important to explain (especially to
regulators) what is known about bacteriophages and their
therapeutic use and to define acceptable risks of bacterio-
phage therapy.
In the future, basic sequencing research should be per-
formed to see whether lytic bacteriophages could ever turn
into a lysogenic state. In addition, the question of how
bacteriophages can adapt to existing natural beneficial
bacteria—and what the consequences of such an adaptation
could be—should also be addressed. It remains uncertain
whether and how bacteriophages can infect eukaryotic
cells. Basic studies in vitro have to be validated in vivo.
The performance of bacteriophages in vivo can vary from
their in vitro activity. In addition, blood–brain barrier
crossings must be studied in humans as well as in mice.
Evolutionary models have also proven to be important to
the study of specific interactions between bacteria and
bacteriophages.
Natural Bacteriophages Comparable to Vaccines or Tox-
ins? From a regulatory point of view, bacteriophages are
most similar to a particular type of biological medicinal
products, namely vaccines. More in particular, bacterio-
phage cocktails used in humans need to be updated over
time, especially when bacterial resistance develops (as is
the case with the flu vaccine). For that reason, some bac-
teriophage companies are now liaising with the vaccine
unit of the European Medicines Agency (EMA).
However, bacteriophages are not ‘‘regular’’ vaccines that
are mostly used preventive to produce active immunity and
therapeutic only in particular cases. Bacteriophages on the
contrary are antimicrobials, with a secondary competence
of boosting the immune system, be it in a non-specific
manner. Since bacteriophages (or their lysates) can boost
the immune system (in different ways), they can effectively
be seen as ‘‘therapeutic vaccines’’. Using bacteriophages in
this way implies the concept of ‘‘auto-vaccination’’ via
bacteriophages, meaning vaccinating patients with their
own bacteriophages. Parallels exist in this sense between
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bacteriophage therapy and tumor vaccination. In the latter,
the patients’ own tumor tissue is taken for preparation of the
vaccine and the patient’s own immune response towards its
own tumor is modified. This immune response should be
self-limiting since the reaction has to stop when the tumor is
gone.
Triggering the immune system is not necessarily posi-
tive for the bacteriophage itself since it can be eliminated
by the immune system of the patient before destroying the
bacteria. On the other hand, bacteriophages can be used to
test the state of immunity of the patient in general.
With respect to the category of toxins, bacteriophages
are not toxic and hence they are not to be considered toxins
as described in the Directive 2001/83/EC.
Views on Bacteriophages and the Definition
of an ATMP (Box 3)
ATMPs are defined in Directive 2001/83/EC as complex
therapeutic products. Natural bacteriophages can be con-
sidered as complex products. Once administered to the
patient, control over the stability of the bacteriophage
products is lost. When bacteriophages are applied in the
wound-bed of the patient, bacteriophages can replicate in
bacteria and bacteriophage-variations and mutations can
develop. Pharmacokinetics of administered bacteriophages
(absorption process) is very complex. Sequencing and
determining the exact function (e.g., proteomics) is also
complex, as is determining the way bacteriophages realize
their therapeutic effect.
However, the actual categories within the ATMP
framework (products for gene therapy, somatic cell ther-
apy or tissue engineering) are not suitable to natural
therapeutic bacteriophages. For instance, natural bacterio-
phages are not gene therapy medicinal products since they
are not genetically modified. For obvious reasons, bacte-
riophages are not considered somatic cells therapy
medicinal products nor tissue engineered medicinal
products.
For most complex therapeutic products, a precise legal
definition is required. Since natural bacteriophages are
already present in nature and in our body, it is questionable
whether such a definition is necessary for bacteriophages.
The complexity is of a technically different nature than
gene or somatic cell therapy. Bacteriophages could be
compared to more widely used strategies for improving
microbial ecology such as probiotics.
Differences and/or Similarities of Bacteriophage Ther-
apy Versus Antibiotic Therapy.
At the product level, antibiotics are (mostly) syntheti-
cally prepared chemical products, although antibiotic
compounds isolated from nature exist as well. Natural
bacteriophages are (by definition) natural ‘‘products’’.
In terms of function, both antibiotics and bacterio-
phages modify (indirectly) human physiological functions
by destroying pathogenic bacteria. Some antibiotics act at
the genetic level while others block specific metabolic
pathways. Therapeutically relevant bacteriophages, which
are lytic natural bacteriophages, kill bacteria by other
mechanisms. Such bacteriophages destroy the bacterium
‘‘from the outside’’ by massively perforating the cell
membrane, or ‘‘from within’’ by multiplying within the
bacterium and eventually being released from that bacte-
rium. Some modern antibiotics cause lyses of the bacteria
as well. Endotoxins are released within the patient
through lyses or bacterial cell death in general. In the case
of antibiotics, this release almost never causes a major
problem for a patient confronted with major (resistant)
infections, which is what can be expected for bacterio-
phage therapy as well.
An important difference between bacteriophages and
antibiotics is that bacteriophages have a much more spe-
cific, targeted action. The broadest-spectrum bacteriophage
will never execute as wide an action as the most targeted
antibiotic product does. Therefore, bacteriophages do not
disturb the natural flora as much as antibiotics do. How-
ever, bacteriophages’ high specificity can also be
considered a negative factor for clinical application.
Another important difference is that bacteriophages are
able to diffuse in small numbers to the site of bacterial
infection and then multiply only when needed. Antibiotics,
on the other hand, must be administered in high doses right
at the site of treatment, which may cause collateral damage
to the patient.
In contrast to antibiotics, bacteriophages can cross the
blood–brain barrier (in small quantities) and perform their
action (massively) once the target bacteria are reached.
Another advantage of bacteriophages over antibiotics is the
reduced risk for development of resistance. The amount of
bacteriophages does not decrease when approaching the
bacterial target. Distinct from antibiotics, bacteriophages
have an additional capacity to act on biofilms since their
lysins can destroy the biofilm.
In view of those differences and similarities, most
experts agree that bacteriophages and antibiotics should be
used complementarily/synergistically.
Views with Respect to (Marketing) Authorization
for Bacteriophage Therapy
Two Regulatory Pathways According to the interviewees,
two (complementary) regulatory pathways should be
defined for bacteriophage therapy.
The first is a regulatory path for a uniform product
market placement of natural bacteriophage-based products.
Since bacteriophages are regarded as human medicinal
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products, the actual legal framework for human medicinal
products in Europe is applicable, implying submitting a full
product dossier (complying with Directive 2001/83/EG)
and conducting large-scale expensive clinical trials. This
path imposes several hurdles: (1) The high financial
threshold cannot easily be overcome by public stakeholders
such as hospitals without financial support from other
(government) sources. (2) The current Directive 2001/83/
EG provides insufficient technical guidance and legal cer-
tainty for the development of products for natural
bacteriophage therapy. (3) The primary aim of public
stakeholders is in fact not a real ‘‘market placement’’ or
‘‘marketing authorization’’ of a bacteriophage-based (or
any other) product. (4) One major risk of such market
placement of bacteriophage based products is the devel-
opment of large-scale resistance, at least when use is
widespread and uncontrolled. One suggestion could be to
update a standard bacteriophage cocktail preparation on a
yearly basis once it is on the market and resistance begins
to develop, as is done with the flu vaccine.
The second regulatory path should imply an approach
applicable to tailored, patient-specific treatments.
The question arises as to whether hospitals applying a
tailored bacteriophage therapy approach in close collabo-
ration with microbiological labs should be excluded from
the conventional marketing authorization requirement as
described in Directive 2001/83/EG and national laws.
Certain non-profit-driven hospitals often possess clinical
expertise to provide bacteriophage therapy but lack the
financial capacity and interest to engage themselves in
large-scale market placements of authorized bacteriophage
products. In addition, the bacteriophage itself is not a
‘‘product to be brought to the market’’ (citing the wordings
of Directive 2001/83/EC) and the tailored hospital-based
bacteriophage therapy approach is the only approach that in
reality fully exploits the clinical potential of a therapeutic
bacteriophage. Bacteriophage therapy is in fact a thera-
peutic concept.
If patient-specific use of bacteriophage therapy in hos-
pitals is made exempt from the regulatory framework
designed to receive marketing authorization (similar to the
hospital exemption rule within the regulatory framework of
advanced cell and tissues, ATMPs), quality and patient
safety must be guaranteed. It is also argued that not only
hospitals but also industry, with specific approval from
regulators, should in theory be able to deliver ‘‘out-of-
frame’’ and ‘‘tailored’’ bacteriophage preparations to
patients and hospitals on a per-request basis. However, the
difficulty and expense of applying the ‘‘one product for one
patient’’ model is not cost-efficient.
In view of this, it may be more prudent to regulate
bacteriophage therapy via a simplified marketing authori-
zation framework, feasible for hospitals as well, by strictly
defining the (often rare) indications for bacteriophages
uses. For industries interesting in market approval for
bacteriophage cocktails, endeavors to work under the
orphan drug legal frameworks should be explored.
Over-the-Counter Distribution In view of distribution,
there are arguments for a very ‘‘liberal’’ distribution
model for natural bacteriophages intended for therapeutic
use. Some argue that ‘‘over-the-counter’’ distribution of
bacteriophages will increase resistance development,
while others argue that ‘‘over-the-counter’’ distribution
should be possible on the grounds that solely hospital-
based use cannot preclude the development of resistance.
Next, others claim that limiting distribution to those who
are tested is unrealistic, since testing all patients before
allowing them to take bacteriophages would be expensive
and economically infeasible. Such pre-testing is not
readily available for other conventional drug therapies
either.
A consensus solution could be to organize over-the-
counter distribution of standard bacteriophage-based
cocktail products specifically selected for non-life-threat-
ening infections while leaving treatment in life-
threatening situations to tailored bacteriophage-based
products in a hospital environment. Most ideal would be
hospital-based (lab-linked) and accessible (cheap) use of
natural bacteriophage-based products. National ‘‘bacte-
riophage therapy centers’’ (scientific boards included) as
are now being set up in Brussels, could be of great value,
in preference when linked to a ‘‘therapeutic bacteriophage
bank’’ (e.g., DSMZ—http://www.dsmz.de) where specific
bacteriophages could be stored and produced as needed.
For any treatment, patients must be tested for the best
strain match. Individualized approaches and flexibility for
physicians to treat patients via personalized schemes
should be central.
Views on an Adapted or New Legal Framework
for Bacteriophage Therapy
Stakeholders are convinced of a need for a dedicated (new)
regulatory framework for bacteriophage therapy that
acknowledges the specific properties of bacteriophages and
their bacterial interaction as well as the role of hospitals as
providers of bacteriophage therapy. As explained above,
bacteriophages are uniquely different from conventional
human medicinal products (such as chemical substances,
somatic cell therapy products and gene therapy medicinal
products, among others) currently regulated under existing
frameworks. In view of the fact that even products for
homeopathy have a dedicated legal framework, some
question why bacteriophage therapy is not regulated in a
specified, dedicated way.
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An adapted regulatory framework could, for instance, be
inspired by the existing legislation governing ‘‘advanced
cellular and genetic therapy’’ (ATMPs), where regulators
took a binary approach towards industrial as well as hos-
pital-based use of cell and gene products and therapies.
Next to the two-way regulatory paths, a new or adapted
framework for bacteriophage therapy must in addition take
into account the different trajectories for storing and
making available therapeutic bacteriophages. (1) A first
possibility would be to use the patient’s own bacterio-
phages in a tailored approach for that individual patient. No
long-term storage of bacteriophages would be necessary,
but on-site testing facilities would have to be present
wherever this kind of tailored therapy is offered (‘‘bacte-
riophage therapy centers’’). (2) A second approach
comprises the isolation and storage of well-defined (GMP-
produced) therapeutic bacteriophages in a bacteriophage
bank, which would then be distributed as needed. Such
bacteriophages can represent starting materials for the
preparation of a cocktail that could be used for combating
broad-scale bacterial infections, e.g., in refugee camps
confronted with dysentery. At best, different bacterio-
phages targeting the same bacterium would be collected
and, if necessary, provided for therapeutic use, minimizing
resistance issues. (3) Such therapeutic bacteriophages
stored in a bank could be ordered as well by a physician for
tailored-use within a hospital.
An adapted or new regulatory framework for bacterio-
phage therapy must guarantee safety and quality.
Regulatory conditions that govern the production of human
medicinal products (e.g., Good Manufacturing Practices)
impose high costs and are perhaps not necessary to increase
the safety of bacteriophage-based products. Instead, spe-
cific guidelines solely directed at quality and safety of
bacteriophage preparations should be developed, harmo-
nized and controlled.
If regulators and legislators are to adapt existing legis-
lation (and its interpretation), public as well as private
stakeholders must agree on what type of pathways and
approaches need to be developed. All partners in these dis-
cussions will eventually come to a consensus understanding
on the use of therapeutic bacteriophages and that this
understanding will serve as a basis for moving forward in a
constructive way.
While regulatory frameworks are (and should be) the
product of negotiations with regulators and legislators, the
negotiation process takes time; time that is precious given
the acuteness of the problems faced. In view of the fact that
EMA recognized the regulatory framework of biological
medicinal products as applicable to bacteriophages, this
regulatory pathway might just be the best place to start for
further elaboration. Since the regulatory frameworks rele-
vant to the development of bacteriophage therapy are
actually more reasonable in, e.g., Australia, Canada, it is
time for Europe and individual European countries to take
action. At the same time, an international platform should
ensure that international harmonization develops.
Patenting Bacteriophage-Related Applications
Isolated, therapeutic bacteriophages can in theory be pat-
ented when a complete, well-defined documentation
package is available for the specific bacteriophage(s). This
package comprises data related to the genome sequence,
pre-clinical information, specific functionality, and specific
application, among other features. Inventive steps can be
defined on the basis of molecular characteristics, applica-
tion methodology and eventually production procedures. In
practice, patents on bacteriophage products are important
tools for attracting investors to new companies keen on
developing therapeutic bacteriophages.
Similar to most vaccine patents, a patent for a regularly
updated bacteriophage cocktail can also be sought.
Companies interested in placing therapeutic bacterio-
phages on the market take care of IP: they first choose their
most appropriate market niche, gain experience from a reg-
ulatory point of view and acquire a first return on investment.
In a next step, after building more experience on the subject,
expansion to other markets can proceed. IP protection is
important in order to be able to develop this pathway.
Discussion
Directive 2001/83/EC defines a human medicinal product,
the types of action, its sources and its starting materials.
This definition is formulated rather broadly, encompassing
natural bacteriophages. For instance, for the products cov-
ered by its scope, the Directive does not differentiate
between ‘‘direct’’ or ‘‘indirect’’ therapeutic actions. Bacte-
riophages generate their action on the patient in an indirect
way, similar to antibiotics. Bacteriophages destroy the
bacterial pathogen and consequently eradicate or decrease
the pathogenic bacterial load in the patient (Payne and
Jansen 2003).
It is clear from our analysis that natural bacteriophages
fit into the definition of a ‘‘biological medicinal product’’
(Box 2). However, different biological sources for the
production of a therapeutically active bacteriophage are
possible. Since the definition of a biological medicinal
product does not limit the types of potential biological
sources, therapeutic bacteriophages also comply with the
definition of a biological medicinal product. However,
therapeutic bacteriophages do not fit into the Special
Frames (indicated in the Directive 2001/83/EG) applicable
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to biological medicinal products, such as vaccines, toxins
and serum-derived products.
In view of the applicability of the ATMP definition (in
Regulation 1394/2007) to bacteriophages, it is not clear
whether bacteriophages are ‘‘complex therapeutic products
with technical specificities requiring precise legal definitions’’
(as is true for ATMPs). In a sense, the regulatory pathways
developed for ‘‘natural’’ ATMPs might provide a historical
reference point. Products used in somatic cell therapy, when
substantially manipulated or used in a non-homologous way,
are classified as ATMPs. The human medicinal product
Directive 2001/83/EC defines ‘‘cultivation’’, for instance, as a
substantial manipulation. Consequently, natural bacterio-
phages, when cultivated, could also be seen as fitting within
the ATMP framework since they would, according to this
definition, be substantially manipulated.
Impact of Classifying Natural Bacteriophages
as Human Medicinal Products
The development of a human medicinal product, either as a
biological medicinal product (Dir 2001/83/EG) or as an
ATMP (Dir 2001/83/EG and Regulation 1394/2007)
requires huge investments of time and money. The non-
profit sector and the diverse interested small and medium
enterprises can hardly afford this pathway without external
investments. Therefore, there is a need for products like
natural bacteriophages to be exempted from the scope of
the regulatory framework applicable to human medicinal
products, more specific Directive 2001/83/EG and Regu-
lation 1394/2007, depending on whether bacteriophages
are seen as biologics or ATMPs.
One way would be not to formulate the therapeutic
action of the bacteriophage as a primary mode of action,
arguing that such a product is not a human medicinal
product. However, this is not the most optimal scenario
when the ultimate goal of the exercise is ‘‘to bring thera-
peutic bacteriophages to the patient’’ (Mie˛dzybrodzki et al.
2012; Soothill 2013; Wittebole et al. 2013). In addition, by
reviewing the definitions, all reviewers acknowledged that
a bacteriophage may fit into the definition of a human
medicinal product.
Another way is to use exemptions within the existing
regulatory framework for human medicinal products. If
natural bacteriophages are considered ATMPs, the ATMP
Regulation 1394/2007 is applicable. This framework only
specifies certain categories, human somatic cell therapy,
gene therapy and tissue engineering. A specific category
‘‘viral therapy’’ could theoretically be introduced under this
ATMP framework. In any case, the ATMP Regulation
1394/2007 provides a possibility for hospitals to be
exempted from a stringent centralized marketing
authorization, referred to as the ‘‘hospital exemption’’ (Art.
28 of Regulation (EC) No. 1394/2007). National rules
apply to hospital exempted-ATMPs. However, if present,
such rules are in any case specifically designed for cell and
tissue based therapies, not bacteriophage therapy. In addi-
tion, often such national rules require similar GMP as
requested for fully centralized marketing authorization
dossiers. Therefore, a specific Directive covering natural
bacteriophage therapy (to be implemented in national laws
specific for bacteriophage therapy) is desirable.
If natural bacteriophages are considered biological human
medicinal products, Directive 2001/83/EG applies. Unfor-
tunately, the Directive 2001/83/EG (currently) does not
provide for a hospital exemption (as in the ATMP Regula-
tion). But Article 3 (Paragraph 1) of Title II of the Directive
states that it ‘‘shall not apply to any medicinal product pre-
pared in a pharmacy in accordance with a medical
prescription for an individual patient (commonly known as
the magisterial formula).’’ However, a (hospital) pharmacist
is not supposed to use non- (EU) licensed products as com-
ponents for magisterial preparations. Since natural
bacteriophages are not licensed products at the moment, this
potential pathway could be difficult to implement.
Another way to escape the marketing authorization
requirement is to consider the scope of that Directive.
Article 2, Par. 1 (Title II) of the Human Medicinal Product
Directive states that it ‘‘shall apply to medicinal products
for human use intended to be placed on the market in
Member States and either prepared industrially or manu-
factured by a method involving an industrial process’’. As
highlighted by the interviewees, a tailored (natural) bac-
teriophage production (Merabishvili et al. 2009),
performed within a hospital for use on particularly defined
patients can hardly be seen as an ‘‘industrial production’’.
In addition, the therapeutic, in-house use of these produced
bacteriophages is not ‘‘market placement’’. Hospitals are
not interested in producing human medicinal products for
the purpose of obtaining a ‘‘marketing authorization’’ for
further distribution. For these reasons, and analogous to the
logic developed in the field of the cellular ATMPs, the
tailored production and therapeutic use of natural bacte-
riophages on humans would appear not to be covered by
the scope of the Human Medicinal Product Directive. The
industrial productions of uniform bacteriophage products
intended for European market placement, on the other
hand, are covered by the scope of this Directive.
If natural bacteriophages would be covered by the scope
of the Directive 2001/83/EG, a new hospital exemption
needs to be designed for biological human medicinal pro-
ducts, accompanied by a specific Directive for bacteriophage
therapy (to be implemented in national laws).
It is clear from the above that there is a regulatory gap
for natural bacteriophage therapy. While regulators are
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responsible for applying a regulation, the regulation itself
can only be changed through legislative action, which is in
this case highly needed to guarantee a timely, flexible and
sustainable way of introducing bacteriophage therapy in
Europe.
The appropriate legal action we suggest is a European
wide Directive for Natural Bacteriophage Therapy. Such
Directive should regulate documentation requirements of
safety, potency, purity and toxicity, specific in the context
of hospital based patient-tailored (natural) bacteriophage
therapy. (Industrial) stakeholders aiming to bring pharma-
ceutical products based on natural bacteriophages to the
market could be exempted from the scope of the new
Directive and follow the classical medicinal product
approach instead (see Fig. 2).
The creation of a bacteriophage-specific Directive could
find inspiration on the evolution of what has transpired the
last several decennia in the field of human cell and tissue
engineered products. As early as the seventies, hospitals
were using processed human cells and tissue in treatments for
their patients, in accordance with the respective national
legislation, until the European Human Cell and Tissue
Directive was published in 2004 (Directive 2004/23/EC of
the European Parliament and the Council of 31 March 2004).
This Directive still applies to all work with human body
material today and focuses mainly on the hospital-based
development and use of cellular products. A few years later,
in 2007, the ATMP Regulation (EC) No. 1394/2007 came
into force. This ATMP regulation focused (and still does)
mainly on industrial work with human bodily material. At the
same time, it allows for a ‘‘hospital exemption’’. The hospital
exemption applies to non-industrial, tailored and hospital-
based clinical use of cell and gene based ATMPs. Industrial
ATMPs meant for market placement are regulated at the
European level while hospital-based (non-industrial) pro-
ductions are regulated at the national level.
In a similar way, the bacteriophage-specific regulatory
framework with its specific Directive should (1) distinguish
between hospital-based (tailor-made) use of natural thera-
peutic bacteriophages in patients on the one hand and
Fig. 2 Proposal for a new European directive for bacteriophage therapy
Arch. Immunol. Ther. Exp.
123
PhD Dissertation - Gilbert Verbeken - Page 207
industrial production and distribution of uniform bacterio-
phage products on the other, (2) define specific quality and
safety criteria relevant to the use of natural bacteriophages
on patients (Merabishvili et al. 2009; Wright et al. 2009),
(3) define a specific efficacy documentation package rele-
vant to (natural) bacteriophages, (4) make it possible to
give patients in need instant access to natural bacteriophage
therapy (Caplin 2009), (5) only define requirements rele-
vant to natural bacteriophages, and (6) fully exploit the co-
evolutionary aspects of natural bacteriophages (Krylov
2011; Levin and Bull 2004; Scanlan and Buckling 2012).
Close dialogue, open discussions and information exchange
with the EMA and national authorities is crucial. It is thus of
high importance that regulators and legislators (Members of
Parliament) be persuaded of the prudence of a dedicated Bac-
teriophage Therapy legal framework for Europe.
Conclusions
A dedicated European Bacteriophage Therapy Legal
Framework is a prerequisite for paving the way to the
smooth introduction of natural bacteriophage therapy into
western medicine. If Europe refuses to support the short-
term (safe) implementation of ‘‘hands-on’’ bacteriophage
therapy in its member states, the national authorities of the
member states should step into assert their responsibility in
this respect. Antibiotic resistance is an acute problem, both
in public health terms and socio-ethical terms. 25 000
Europeans die each year as a direct consequence of un-
treatable bacterial infections (Ackermann 2012). There is
an urgent need for national bacteriophage therapy centers.
Industry can play an important role in this. When bacte-
riophage therapy centers are unable to (financially) launch
themselves, national governments should provide sufficient
support and/or stimulate the creation of new pharmaco-
economic environments.
Box 1. Definition of a Human Medicinal Product
within the Directive 2001/83/EC of the European
Parliament and the Council of 6 November 2001
on the Community code relating to medicinal products
for humans use. Consolidated | 2001L0083-EN-
21.07.2011-010.002-1. Words written in Italic are
subject to interpretation, as discussed
in the manuscript.
According Art. 1(2) of the Medicinal Product Directive
2001/83/EC, a Human Medicinal Product is a substance
or a combination of substances presented as having
properties for treating or preventing disease in human
beings. According the same Directive, a Medicinal
Product can also be a substance or a combination of
substances which may be used in or administered to
human beings either with a view to restoring, correcting
or modifying physiological functions by exerting a
pharmacological, immunological or metabolic action, or
to making a medical diagnosis. The substance referred to
in the Directive is any matter irrespective of origin
which may be: human, e.g., human blood and human
blood products; animal, e.g., microorganisms, whole
animals, parts of organs, animal secretions, toxins,
extracts, blood products; vegetable, e.g., microorganisms,
plants, parts of plants, vegetable secretions, extracts;
chemical, e.g., elements, naturally occurring chemical
materials and chemical products obtained by chemical
change or synthesis.
Box 2. Definition of a Biological Medicinal Product.
Words written in Italic are subject to interpretation,
as discussed in the manuscript
According to Part I Module 3 (3.2.1.1) of the Medicinal
Product Directive 2001/83/EC, a Biological Medicinal
Product is a Medicinal Product of which the active
substance is a biological substance. A biological sub-
stance is a substance that is produced by or extracted
from a biological source and that requires for its char-
acterization and the quality determination a combination
of physico-chemical-biological testing, together with the
production process and its control. The Directive pro-
vides specific requirements for particular biological
medicinal products such as vaccines, toxins and sera, in
particular, for agents used to produce active immunity,
such as cholera vaccine, BCG, polio vaccines, smallpox
vaccine; agents used to diagnose the state of immunity,
including in particular tuberculin and tuberculin PPD,
toxins for the Schick and Dick Tests, brucellin; and
agents used to produce passive immunity, such as
diphtheria antitoxin, anti-smallpox globulin, antilympho-
cytic globulin. According the Directive (Part I Module 3
(3.2.1.1), the starting materials of a Biological Medicinal
Product shall mean any substance of biological origin
such as microorganisms, organs and tissues of either
plant or animal origin, cells or fluids (including blood or
plasma) of human or animal origin, and biotechnological
cell constructs (cell substrates, whether they are recom-
binant or not, including primary cells).
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Box 3. Definition of Advanced Therapy Medicinal
Product (ATMP) from Regulation (EC) No 1394/2007
of the European Parliament and the Council of 13
November 2007 on advanced therapy medicinal
products and amending Directive 2001/83/EC
and Regulation (EC) No 726/2004 | Official Journal
of the European Union | 10.12.2007 | L324:121-137.
Words written in Italic are subject to interpretation,
as discussed in the manuscript.
The Regulation 1394/2007 on ATMPs (Recital 3) describes
ATMPs as complex therapeutic products with technical
specificities requiring precise legal definitions. Under the
ATMP Regulation, Products for Somatic Cell Therapy,
Tissue Engineered Products as well as Gene Therapy
Medicinal Products (GTMPs) are classified as ATMPs.
According to Part IV of Annex I to Directive 2001/83/EC,
a Gene Therapy Medicinal Product is a biological medic-
inal product that has the following characteristics: (a) It
contains an active substance which contains or consists of a
recombinant nucleic acid used in or administered to human
beings with a view to regulating, repairing, replacing,
adding or deleting a genetic sequence; (b) Its therapeutic,
prophylactic or diagnostic effect relates directly to the
recombinant nucleic acid sequence it contains, or to the
product of genetic expression of this sequence. Gene
therapy medicinal products shall not include vaccines
against infectious diseases.
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ABSTRACT The worldwide antibiotic crisis has led to a renewed
interest in phage therapy. Since time immemorial phages control
bacterial populations on Earth. Potent lytic phages against bacterial
pathogens can be isolated from the environment or selected from a
collection in a matter of days. In addition, phages have the capacity to
rapidly overcome bacterial resistances, which will inevitably emerge.
To maximally exploit these advantage phages have over conventional
drugs such as antibiotics, it is important that sustainable phage prod-
ucts are not submitted to the conventional long medicinal product
development and licensing pathway. There is a need for an adapted
framework, including realistic production and quality and safety re-
quirements, that allowsa timely supplying of phage therapy products
for ‘personalized therapy’ or for public health or medical emergen-
cies. This paper enumerates all phage therapy product related quality
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and safety risks known to the authors, as well as the tests that can be
performed to minimize these risks, only to the extent needed to
protect the patients and to allow and advance responsible phage
therapy and research.
KEY WORDS antibiotic resistance . medicinal product . phage
therapy . production . quality and safety
Antimicrobial resistance in bacteria is an increasingly serious
threat in every part of the world [1].Without action, the world
could be heading towards a post-antibiotic era in which com-
mon infections become fatal and currently routine surgeries
become impossible. New initiatives to tackle the problem of
antibiotic resistance are urgently needed.
One promising solution is the therapeutic use of bacterio-
phages – the viruses of bacteria, also known as phages – to
treat bacterial infections. When discovered in the early twen-
tieth century, phages were immediately applied in medicine
(phage therapy) with variable success. After World War II,
Western industry and policymakers preferred antibiotics,
which at the time had obvious advantages in terms of breadth
of coverage and ease of production and patentability, and
phage therapy was pushed into the background. Today,
phage therapy is again put forward as a potential way to
address the current antibiotic crisis [2, 3].
Since time immemorial, phages have controlled bacterial
populations on our planet, locked in an evolutionary arms race
with their hosts (consisting of the repeated emergence of new
phage infectivity and bacterial defense mutations). The capacity
of bacteriophages to rapidly overcome bacterial resistancemakes
them suitable for flexible therapeutic applications. Tomaximally
exploit this key advantage of phages over conventional ‘static’
drugs such as traditional small molecule-type antibiotics, it is
important that sustainable phage products are not submitted to
the conventional long medicinal product development and li-
censing pathway [4]. A key goal for the modern phage therapy
community must be the development and validation of an
expedited product development and licensing pathway in con-
sultation with policymakers and competent authorities.
Georgian and Polish phage therapy centers maintain ex-
tensive therapeutic phage collections, which are regularly
enriched with new phages, thus widening the total host range
of the collection and adapting the collection to changing
bacterial populations (with regard to host range and antibiotic
resistance as well as phage resistance). Moreover, the effec-
tiveness of phages can be readily improved by in vitro selection
of (natural) phage mutants that exhibit an increased infectivity
range. For example, it is possible to obtain potent lytic phages
against problematic enteroaggregative Escherichia coli strains by
isolation of new phages from the environment or by selection
and adaptation of phages from an existing collection, and this
often in a matter of days [5]. As such, phages could probably
have been used to help control the O104:H4 (hybrid EAggEC
STEC/VTEC pathotype) E. coli outbreak that caused the
death of more than 50 patients in Germany in 2011. Unfor-
tunately, authorized use of phages would not have been
possible in this otherwise feasible context because under the
existing medicinal product legislation such an anti-O104:H4
phage preparation would have taken years to develop, pro-
duce and register. Since phages are species and often even
strain-specific, it is very likely that current O104:H4 specific
phage preparations will not be effective against future epi-
demic enteroaggregative E. coli strains. ‘Broad spectrum’
phage cocktails active against bacteria that are likely to cause
problems in the future could be developed in advance and
used as a first line treatment for acute healthcare problems
(e.g., foodborne disease outbreaks and bacterial bioweapon
threats). However, we need to keep in mind that some of these
cocktails will not always work due to the greater biodiversity
outside of the laboratory and the existing resistance to specific
phages. The cocktails that initially work will need to be regu-
larly updated (e.g., supplemented with new phages in response
to the evolution of phage resistance and the involvement of
new circulating bacterial strains). There are indications that
bacterial resistance to phages, even to cocktails containing
multiple potent phages, will inevitably occur [6].
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Table I Expert Consensus Quality and Safety Requirements for Sustainable Phage Therapy Products
A. Production environment
When production activities include the processing of intermediate, bulk or finished phage products exposed to the environment, this must take place in an
environment with specified air quality and cleanliness in order to minimize the risk of contamination. The effectiveness of these measures must be validated and
monitored. Where intermediate, bulk or finished products are exposed to the environment during processing, without a subsequent microbial inactivation
process, an air quality with particle counts and microbial colony counts equivalent to those of Grade A as defined in the current European Guide to Good
Manufacturing Practice (GMP), Annex 1 and Directive 2003/94/EC is required with a background environment at least equivalent to GMP Grade D in terms of
particles and microbial counts. The biosafety level (BSL) is determined by the host bacteria used in the production processes (e.g., BSL-2 for Pseudomonas
aeruginosa).
B. Production processes, equipment and materials
All equipment and material must be designed and maintained to suit its intended purpose and must minimize any hazard to recipients and staff. All critical
equipment and technical devices must be identified and validated, regularly inspected and preventively maintained in accordance with the manufacturers’
instructions. Where equipment or materials affect critical processing or storage parameters (e.g., temperature, pressure, particle counts, microbial
contamination levels), they must be identified and must be the subject of appropriate monitoring, alerts, alarms and corrective action, as required, to detect
malfunctions and defects and to ensure that the critical parameters are maintained within acceptable limits at all times. All equipment with a critical measuring
function must be calibrated against a traceable standard if available. Maintenance, servicing, cleaning, disinfection and sanitation of all critical equipment must be
performed regularly and recorded accordingly.
Production processes must be described in detail (equipment, materials, culture media, additives, culture conditions, purification steps,..) in standard operating
procedures (SOPs) and must be validated (procedures published in relevant peer-reviewed journals could be considered ‘validated’).
SOPs must detail the specifications for all critical materials and reagents. In particular, specifications for culture media, additives (e.g., solutions) and packaging
materials must be defined. Critical reagents and materials must meet documented requirements and specifications and when applicable the requirements of
Council Directive 93/42/EEC of 14 June 1993 concerning medical devices and Directive 98/79/EC of the European Parliament and of the Council of 27
October 1998 on in vitro diagnostic medical devices. If possible, animal component free culture media and additives should be used (the Note for Guidance on
Minimizing the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products (EMEA/410/01) in its current
version is to be applied). If animal–product free media are not used, Transmitting Animal Spongiform Encephalopathy (TSE)-free certification should be obtained
for all components containing products of animal origin.
Analytical methods can be validated according to: a) EMEA/CHMP/EWP/192217/2009 “Guideline on bioanalytical method validation” or b) CPMP/ICH /381/95
“ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology”.
Bacteria and phage bank systems need to be set up. These bank systems typically consist of Master seed lots and Working seed lots. The generation and
characterization of the banks should be performed in accordance with principles of CPMP/ICH guideline Q5D. The banked phages and bacteria should be
characterized for relevant phenotypic and genotypic markers so that the identity, viability (activity for phages), and purity of organisms used for the production
are ensured. Biological Resource Centers [10] could function as repositories for bacteriophage Master Seeds and host bacteria.
C. Quality Assurance and Quality Control (QA/QC) specifications
Products/characteristics Control test Limits of acceptance Recommended test procedures
C.1. Host bacteria used in production (stock suspensions)
The bacterial hosts used in the production process – with the exception of selection, adaptation and efficiency of plating (EOP) and host range determination –
should be as safe (or least pathogenic) as feasible.
Origin Document pedigree/
history/pathogenicity
level
Known origin Screening of scientific literature, lab
books, consignment letters,..
Identification Identification at the species
and strain levels
Matching species and strain identification • State of the art clinical microbiology
techniques
• Highly discriminating (molecular/
genomic) typing techniques (e.g.,
MLST, AFLP, PFGE, Rep-PCR,..)
Most often it will not be possible to find or
quickly generate a suitable host
bacterium that is free of prophages or
phage-like elements, but one should
nevertheless strive to use non-lysogenic
strains, containing as few phages or other
phage-like elements of genetic exchange
[11, 12] as possible
• Induction of phages As few spontaneously produced (or by
induction) temperate phages, complete
prophage sequences or phage-like ele-
ments as possiblea
• In vitro induction methods
(Mitomycine C [13] or UV
induction)
• Host genome screening
for phage or phage-like
elements
• State of the art DNA sequencing and
analysis (bioinformatics) procedures
Avoid mutator strains as host bacteria Screen for mutator strains in
case of doubt
No mutator strain State of the art tests (e.g., fosfomycin
and rifampicin Disk Diffusion Tests)
[14]
Validated preservation/storage (cryopreser-
vation, freeze-drying,..)
Monitor storage conditions
(e.g., temperature)
Variable, depending on the preservation
method
Variable (e.g., temperature probes,
temperature indicator labels,..)
C.2. Bacteriophages (Master Seed lots)
Origin • Known origin
Phage Product Quality and Safety Requirements
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Table I (continued)
Document bacteriophage
pedigree/history (e.g.,
isolation source)
Screening of scientific literature, lab
books, consignment letters,…
• Natural or naturally evolved
bacteriophages
Identification • Identification at the family
(subfamily), genus and
species and strain level
Matching identification, morphology and
biology
• State of the art DNA or RNA
sequencing and analysis procedures
• Morphology and biology • Highly discriminating genotyping
techniques (e.g., AFLP, fRFLP [15])b
• State of the art classification according
to the International Committee on
Taxonomy of Viruses (ICTV)
• State of the art electron microscopy
(optional)c
• One step growth curve [16]
Not containing potentially damaging genetic
determinants (e.g., conferring toxicity,
virulence, lysogeny or antibiotic
resistance)
Genome analysis for known
potentially damaging
genetic determinants
Absence of potentially damaging genetic
determinantsd
• State of the art DNA or RNA
sequencing and genome analysis
(bioinformatics) procedures
Non-transducing (optional) [17] Screen for ‘general
transduction’
Does not pack random host DNA in a
portion of progeny phage particlese
Transduction assay [18]
In vitro efficacy Determination of host range
on a panel of target
species (reference) strains
Broad host range (if possible) • Titration of bacteriophages against
target bacteria according to the soft-
agar overlay method [19]
Variable threshold according to species (e.g.,
>75% for Staphylococcus aureus) • Spot test [16]
Stability of lysis (optional)f Stable lysis in broth culture for 24–48 h Appelmans method [20]
Efficiency of plating (EOP)
under conditions similar
to eventual clinical appli-
cation (optional)
Threshold EOP value EOP determination [19]
Determination of frequency
of emergence of phage-
resistant bacteria
Low frequency of emergence of resistance Method described by Adams [19]
Improvement / adaptation / ‘training’ (if
warranted)
Optimization of host range Broadened and stable host range • Titration of bacteriophages against
target bacteria according to the soft-
agar overlay method [16]
• Spot test [16]
Validated preservation/storage (cryopreser-
vation, freeze-drying,..)
Monitor storage conditions
(e.g., temperature)
Variable, depending on the preservation
method
Variable (e.g., temperature probes,
temperature indicator labels,..)
C.3. Bacteriophages (Working Seed lots/Active Substances)
Quantitative determination of active
substance (bacteriophages)
Bacteriophage titration Variable. Typically log(8) – log(10) plaque
forming units (pfu)/ml
Soft-agar overlay method [19]
Identification of active substance Genomic fingerprinting Matching genomic fingerprint (max.
deviation depends on method)
State of the art genotyping techniques
(e.g., AFLP, fRFLP [15])
Microbial contamination Sterility (when there is no
sense of urgency)g
Sterile (absence of micro-organisms) Membrane filtration method based on
the European Pharmacopoeia (EP)
Absence of pathogens
(when there is a sense of
urgency)
Aseptic (absence of pathogens) State of the art clinical microbiology
methods
Toxicity Bacterial endotoxin or
lipopolysaccharides (LPS)
quantification [21]
Depends on posology and method and
route of administration. The maximum
level for intravenous applications for
pharmaceutical and biological products is
set to 5 endotoxin units per kg of body
weight per hour (EP).
Limulus Amebocyte Lysate (LAL) assay
according to the EP (e.g., kinetic-
QCL method)
Bacterial DNA contaminationh Screen for (potentially
damaging) host bacterial
DNA
Absence of potentially damaging genetic
determinants that are known to be
present in the host bacterium
Methods for the quantification of
bacterial DNA in general (e.g.,
PicoGreen) or for the quantification
Pirnay et al.
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Table I (continued)
of known DNA sequences (e.g.,
qPCR)i
Acidity or basicity of aqueous solution pH measurement Variable (typically 6,5–7,5) pH test (EP method)
Purity Clarity of phage solution Absence of visible particles EP method, CPMP-ICH guideline
Validated preservation/storage (cooling,
cryopreservation, freeze-drying,..)
Monitor/record/
demonstrate storage
conditions
(temperature,..)
Variable (e.g., 2–8°C) Variable (e.g., temperature probes,
temperature indicator labels,..)
C.4. Finished products
Bulk products may be diluted (typically to log(5)–log(7) pfu/ml), combined or added to a carrier (hydrogel, ointment, cream, bandage,..) prior to clinical use.
Dilution solutions, carriers and packaging materials must meet documented requirements and specifications and when applicable the requirements of Council
Directive 93/42/EEC of 14 June 1993 concerning medical devices. Carriers must be chosen that allow the required phage activity during the intended
application period (stability).
The following information must be provided either on the label or in accompanying documentation: (a) description (definition) and, if relevant, dimensions of the
bacteriophage product; (b) date of production of the bacteriophage product (c) storage recommendations; (d) instructions for opening the container, package,
and any required manipulation/reconstitution; (e) expiration dates (incl. after opening/manipulation); (f) instructions for reporting serious adverse reactions and/
or events; (g) presence of potentially harmful residues (e.g., antibiotics, ethylene oxide); (h) contraindications; (e) how to dispose of unused (expired)
bacteriophage products.
Validated storage (cold storage,..) Monitor/record/
demonstrate storage
conditions
(temperature,..)
Variable (e.g., 2–8°C) Variable (e.g., temperature probes,
temperature indicator labels,..)
D. Shelf life of phage stock suspensions, working solutions and finished products (at recommended storage conditions)
Stability • Periodic quantitative
determination of the
active substances
(bacteriophages) or
breakdown products
The shelf life is the time period during which
the product remains sterile and the
activity and pH remain within specified
limit thresholds
• Soft-agar overlay method [15]
• Periodic determination of
sterility
• CPMP-ICH guideline, Q5C, Q1A
• Periodic pH
measurements
• Membrane filtration method (EP
method)
• pH test (EP method)
E. Surveillance
The clinical use of phage therapy products must be surveyed and reported, including possible adverse events and reactions associated with the use of phage
therapy products. A centralized (publicly available) reporting system is warranted.
a Today it may be impossible to successfully cure some host strains that are indispensable for the production of some therapeutically interesting phages. In addition,
in some cases it might be necessary to use phages that were isolated from the patient’s bacteria and that are not able to replicate in known host strains devoid of
prophages. However, since that sort of phage preparations are only designed to be used in that given patient, any remaining traces of DNA from that host
bacterium would be orders of magnitude less than the amount already present in the patient from whom that bacterium was isolated for this purpose
b This genetic fingerprint can be used to timely identify bacteriophages and confirm their presence inWorking Seed lots and in finished products, without having to
re-perform full genome sequencing. It is however expected that fast, low-cost and accurate full genome sequencing and analysis (of bacteriophages) will replace
routine microbial genotyping techniques in the near future
c In some cases (e.g., novel bacteriophages with no homology in databases), electron microscopy could provide important information and could thus be
warranted
d In general, it is recommended to only use lytic phages (and no temperate phages) in phage therapy. Lytic phages are more potent killers of host bacteria, making
them more effective in therapy than temperate phages. Following lysogenic induction, temperate phages may transfer fragments of host bacterial DNA into non-
targeted bacteria (possibly belonging to other species). This phenomenon is called transduction or phage-mediated horizontal gene transfer (HGT). If these DNA
fragments contain toxin-encoding or antibiotic resistance-mediating genes, temperate phages could thus produce new pathogenic strains. However, in the future,
the dogma that the use, in treatment, of temperate phages is impossible or undesirable because of the danger of HGT might be abandoned in certain
circumstances (science- and risk-based decision, taking into consideration the patients’ needs). In certain bacterial species, the number of strictly virulent phages is
small and it might not be possible to isolate adequate new virulent phages in due time. Phage mediated HGT is abundant and virtually ubiquitous in bacterial
populations and the additional and immediate danger to the patient related to the use of temperate phages in the course of phage therapy (days) is bound to be
limited. Moreover, if a temperate phage acts as a lytic phage in relation to a particular pathogen, the probability of HGT might not be higher than for inherent
genetic virulent phages [22]. In the future, temperate phages might specifically be used in therapy, e.g., to introduce, by lysogenization, genes conferring sensitivity
to antimicrobials [23] or to inhibit virulence traits [24]. Finally, antibiotic stress was also shown to induce genetic transformability in human pathogens [25]
e Today, it is not feasible to exclude the possibility of low levels of generalized transduction by therapeutic phages into any of the infecting and commensal bacteria
present in or on the patient. The use in phage therapy of phages that mediate some random general transduction might be considered in certain circumstances
(science- and risk-based decision, taking into consideration the patients’ needs)
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Notwithstanding the Intellectual Property (IP) and regulatory
hurdles, as well as the empirical evidence suggesting that stable
and widely distributed phage preparations (prêt-à-porter) will need
to be constantly updated, a few companies have picked up the
gauntlet and are slowly moving along the elaborate and expen-
sive conventional medicinal product licensing pathway. The
development and marketing of phage medicinal products in
the EU – including Good Manufacturing Practice (GMP) pro-
duction, preclinical and Phase I, II and III clinical trials and
centralized marketing authorization – is in fact technically possi-
ble (and indeed advisable for some products), providing some
minor modifications and logical exemptions are made.
However, multiple discussions between experts, com-
petent authorities and policymakers have led to an
increasing awareness that sustainable (sur-mesure) phage
therapy is not compatible with the conventional ap-
proaches to the development and application of medic-
inal products [4]. Next to the classical medicinal prod-
uct pathway, which should be adjusted to support the
industrial production of (first line) broad-spectrum phage
cocktails or phage-derived products (e.g., phage
endolysins), there is a need for a specific framework
(including realistic production and quality and safety
requirements) that allows a timely (rapid) supplying of
adapted productions of natural bacteriophages for ‘per-
sonalized therapy’. This regulatory framework could be
based on the Quality by Design (QbD) concept, which
is increasingly applied to the development and produc-
tion of biopharmaceutical molecules [7]. The QbD ap-
proach entails designing quality into the process and the
product, and this in a science- and risk-based manner.
Understanding patients’ needs and determining the spe-
cific science and quality characteristics of the product
that are linked to safety and efficacy are crucial com-
ponents of QbD. More research is urgently needed to
gather the required data with regard to the efficacy of
phage therapy and to broaden our understanding of
bacteria-phage coevolution in nature and in the context
of human disease [8, 9]. To avoid the mistakes of the
past (which lead to the current antibiotic resistance
crisis), phage therapy products should not exclusively
be developed and marketed as antibiotics, i.e., applying
current pharmacoeconomic principles. Ideally, phage
therapy should be coordinated and standardized (in a
first instance) by national phage therapy centers, which
operate under the supervision of relevant public health
authorities and in interaction with private stakeholders.
There are precedents for such a dedicated ‘non-me-
dicinal product’ approach. In the European Union
(EU), human tissues and cells that are not considered
as ‘Advanced Therapy Medicinal Products (ATMPs)’ are
procured, processed, tested and allocated by (or under
the responsibility of) dedicated tissue establishments and
are exclusively regulated by the EU Tissue and Cell
Directives (EUTCDs). The EUTCDs consist of three
Directives, the parent Directive (2004/23/EC), which
provides the framework legislation, and two technical
Directives (2006/17/EC and 2006/86/EC), which pro-
vide the detailed requirements of the EUTCD. The
purpose of these Directives was to facilitate a safer
and easier exchange of human tissues and cells between
member states and to improve safety standards for Eu-
ropean citizens. They set a benchmark for the standards
that must be met when carrying out any activity involv-
ing tissues and cells for human application.
In view of further meetings with phage experts and
representatives of the competent authorities and
policymakers – coordinated by the European Commis-
sion Joint Research Centre, which acts in an advisory
capacity to the Commission and its policy making di-
rectorates general –, a group of ‘phage experts’ (the
authors of this paper) were asked through the interme-
diary of a not-for-profit organization (www.p-h-a-g-e.
org) to set realistic quality and safety requirements for
sustainable phage therapy products (Table I). These
requirements are intended to apply to the production
of phage therapy products (finished products), starting
from banked characterized natural therapeutic bacterio-
phages (Master Seed lots), and possibly using intermedi-
ate bacteriophage products (Working Seed lots or Active
Substances). They were roughly based on the EUTCD
quality and safety standards for human cells and were
f In some cases, phages that produce stable lysis will not be found in a timely fashion. Phages that induce relatively fast in vitro bacterial resistance might then be
considered
g In some cases, sterility may not be required (e.g., ‘non-sterile for topical application’)
hWorking Seed lots can be contaminated with low levels of DNA derived from the host bacteria used in production. Potentially damaging genetic determinants
(e.g., conferring toxicity, virulence or antibiotic resistance) might then be transferred (through transformation) to bacteria present in or on the patient, which could
potentially make them (more) pathogenic. While this would be expected to occur at a level well below exchanges already going on within the patient’s body
involving their own pathogenic bacteria and phages already resident it makes sense to select hosts that are as devoid of pathogenicity factors as reasonably possible
for growing therapeutic phage and treating the phage with DNase in the course of their purification to destroy such contaminants. If no non-pathogenic bacterial
strain is available for growing the phage, constructing a ‘defanged’ host strain, with all pathogenicity determinants deleted, could be envisaged as the best main step
in avoiding this issue. Note that the use of non-pathogenic host bacterial strains also reduces the potential hazard to the personnel involved in the production of
therapeutic phages
i A threshold level should be determined. Note that some DNA quantification methods might also pick up phage DNA
Pirnay et al.
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defined by consensus among 32 phage experts (biolo-
gists, geneticists, bioengineers, quality managers, phar-
macists and MDs) from 12 countries. This document
enumerates all possible phage product related quality
and safety risks known to the experts, as well as the
tests that can be performed to minimize these risks, only
to the extent needed to protect the patients and to
allow and advance responsible phage therapy and re-
search. The exact tests used and limits applied will
depend on the route of administration (e.g., topical or
systemic) and the regulatory path the product is being
used under. These requirements do not address efficacy
aspects of phage therapy products.
Should bacteriophages be used for a public health or
medical emergency and no adequate finished products,
Master Seed lots or Working Seed lots are available,
then less stringent requirements could be considered,
pending compliance (as quick as possible) to the quality
and safety requirements.
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Key issues in phage therapy: a report of a dedicated workshop at the viruses
of microbes II meeting1. Summary
A workshop addressing key issues in phage therapy was
organized by the non-profit organization P.H.A.G.E. during the
Viruses of Microbes II meeting, held in July 2012 in the Royal
Military Academy, Brussels, Belgium. This report summarizes
the major points that were addressed by the panel of experts
from the academic, public, private and legal domains.2. The experts
During the Viruses of Microbes II meeting, held in July 2012
at the Royal Military Academy in Brussels, Belgium, a work-
shop was dedicated to the clinical and regulatory barriers and
opportunities of the development of phage therapy in Europe. A
panel, chaired by Isabelle Huys (Univ. Leuven, Belgium) and
Martin Zizi (Free Univ. Brussels, Belgium, and president of
P.H.A.G.E.), included experts from diverse domains: Jacques
Scheres, board member of the European Centers for Disease
Control (ECDC, Stockholm, Sweden), a leading European
authority on the surveillance of bacterial resistance problems
and new antibacterial strategies. Je´roˆme Larche´, head of the
intensive care unit in Narbonne Hospital (France) and president
of the non-profit organization, PHAGESPOIR, who represented
the public sector. Harald Bru¨ssow from the Nestle´ Research
Center, Vers-Chez-Les-Blancs, Switzerland andDavid Harper
from BioControl, AmpliPhiBiosciences (Colworth Science
Park, London, UK)whowere delegates from private companies.
H. Bru¨ssow is involved since years in directing phage research
and safety trials (e.g. Bru¨ttin and Bru¨ssow, 2005) for a large
multinational company (Nestle´). D. Harper is the founder and
scientific officer of the startup which carried out the first phage
trials using modern, rigorous, clinical trials standards (Wright
et al., 2009). Andrzej Go´rski from the Hirszfeld Institute of
Immunology and Experimental Therapy (Wroclaw, Poland)
represented the long-standing ‘Eastern Bacteriophage therapy
tradition’ and is leading translational and fundamental research
on phages (Go´rski et al., 2009, 2012).Angus Buckling from the
University of Exeter (UK) has published extensively on the
interaction of phages and bacteria to better understand and deal
with the problems of emerging bacterial resistance to phages
when they are used therapeutically as antibacterial agents (Hall0923-2508/$ - see front matter  2013 Institut Pasteur. Published by Elsevier Ma
http://dx.doi.org/10.1016/j.resmic.2013.03.020
PhD Dissertation - Gilbeet al., 2012). Gilbert Verbeken (Laboratory of Molecular and
Cellular Technology, Burn Wound Center, Queen Astrid Mili-
tary Hospital, Brussels, Belgium) is a specialist concerned with
the numerous regulatory hurdles confronting clinical trials of
phage therapy (Verbeken et al., 2007). IsabelleHuys’s expertise
is in intellectual property (IP) affairs particularly focused in
phage therapy.
3. The need for phage therapy
The discussion started with what is, without a doubt, con-
sidered as one of the most serious problems confronting public
health authorities: the emergence of bacterial pathogens that
are resistant to the existing antibiotics and the failure to
develop new types of antibiotics. There was unanimity that the
overuse of antibiotics has to be reduced in order to slow down
the emergence of pan-resistant bacterial pathogens and in
addition, physicians as well as medical students need to be
educated accordingly. However, other antibacterial solutions
are urgently needed since some patients are nowadays con-
fronted with the difficulty if not yet impossibility to treat their
bacterial infections.
Phage therapy, initiated early in the previous century by
Fe´lix D’Herelle at the Institut Pasteur (Paris, France), and
almost exclusively expanded post World War II to several
Eastern European countries, represents a sustainable solution,
as demonstrated by its clinical use especially in Poland and
Georgia. In Western Europe, phage therapy does not picture
the conventional therapeutic schemes for infectious diseases.
Nevertheless, would it be unreasonable to consider uncon-
ventional solutions when dealing with therapeutic impasses
involving the life and well-being of patients? A reasonable,
responsible and appropriate response to that question, pro-
posed along this workshop, was: ‘Surely not, if done with
moderation and reason, and keeping in consideration that the
only objective is the improvement of the patient’s condition.’
4. The eastern legacy
Phage therapy has been implemented for decennia under
the umbrella of the Declaration of Helsinki, a non-binding
legal instrument providing for some ethical principlessson SAS. All rights reserved.
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phage therapy has via this way partially been published pre-
viously (Go´rski et al., 2009; Weber-Dabrowska et al., 2000).
In addition, under the auspices of the UK Global Threat
Reduction Program, a literature review and an English trans-
lation of some of the past Georgian clinical trials have been
published as well (Chanishvili, 2009, 2012).
The question is now whether it would be useful to preserve
and exploit such valuable experimental data from the past and
how such data could be implemented to serve the community.
There was general agreement that preservation of this abun-
dance of data from the East is of real importance and requires
for example the creation of a centralized bank, or an online
inventory of the various Phage Collections. When possible,
associated useful scientific and clinical information should be
collected. Such a central facility would enable the community
to classify, organize and study those phages and most impor-
tantly would increase their availability to be employed for
therapeutic use. This would also prevent isolation of related
phages again and again.5. Assessing phage efficacy
The ability of phages to act as anti-infectious agents (effi-
cacy) is most probably due to their direct killing action on
bacteria. This is most prominent in treatments of acute
infections resulting from massive clonal bacterial invasion, as
is the case for Escherichia coli enteritis in cattle, while Sal-
monella and Campylobacter infections, being more dispersed,
would be less prone to phage treatments. Complete elimi-
nation of the pathogen is however not required, as the reduc-
tion of the bacterial load appears sufficient to decrease
symptoms, allowing the immune defense to take over. For
human treatments, what really matters is the clinical outcome,
the favorable clinical progression, not the complete erad-
ication of the harmful bacteria. This was observed in the
chronic otitis clinical trials conducted by BioControl, where
the symptoms were relieved for several patients despite the
persistence of some Pseudomonas aeruginosa (Wright et al.,
2009).
Although counterintuitive, there might be good scientific
reasons for such observations. Besides a favorable initial
strong reduction in bacteria following phage application, the
resistant bacterial mutants against the phages that eventually
emerge may be less virulent and then less prone to elimination
by the immune system. Indeed, this loss of virulence is fre-
quently due to mutations affecting ligands involved in bacte-
rial invasion (adhesins, invasins) or subversion of the immune
system (PAMPs). Such ligands exposed to the cell surface are
also used by phages as receptors for adsorption and the sub-
sequent infection of their bacterial hosts. In a classical
example described 30 years ago, E. coli K1, a virulent
encapsulated strain, acquired resistance during an exper-
imental treatment with phages in animals by becoming K1-
negative as a consequence of mutations and lost its virulence
(Smith and Huggins, 1982).PhD Dissertation - Gilbert VAnother possible explanation of the ability of phages to act
as anti-infectious agents, that is not related to their anti-
bacterial activity, might be their immunomodulatory and anti-
inflammatory properties, which thus far have remained
understudied (Go´rski et al., 2012).
6. The problem of resistance
Although bacterial resistance to phage could cause a
simultaneous decrease in bacterial virulence (see above),
much caution needs to be exerted to avoid the same problems
that we now experience with antibiotics. Widespread use of
phages for human therapy, extensive prescriptions of phage
products and the treatment of livestock could inevitably lead to
substantial shedding of these phage strains in the environment
and thus could result in increased bacterial resistance to these
phages. It will be therefore important, at least during some-
time, to keep phage applications on a limited scale, for clear-
prescribed indications. Education of future medical doctors
toward responsible prescription of phages should also be
included in the development of phage therapy. Resistance is
however from a different kind as with antibiotics. There is the
continuously ongoing arms race/competition between bacteria
and phages, and specific phages that are able to infect the
formerly resistant bacterial strains can be expected to quickly
emerge (Pirnay et al., 2012). More experimental evolution
studies are however necessary to determine the potential
negative evolutionary consequences of unlimited phage ther-
apy. Ideally, environmental microbiology studies could help to
address this potential problem before it became a serious
concern. Last but certainly not the least aspect of the devel-
opment of phage therapy comes from the use of phages in
combination with conventional antibiotic treatments, as sup-
ported by a synergy observed in vitro between some phages
and some antibiotics (Comeau et al., 2007). Most likely, some
clinical data from Eastern Europe dataset should exist and be
used to guide this strategy that has been so far under looked
in vivo.
7. Regulatory hurdles
Accepting phage therapy as new cure in Western Europe
involves crucial legal issues which seem very phage-specific.
Therefore, some propose to regulate phage therapy via a
separate, eventually new regulatory category that would
account for the intrinsic ability of phages to evolve over time,
as opposed to traditional antibiotics (Verbeken et al., 2007;
Pirnay et al., 2011). The existence of such a specific regulatory
category could significantly facilitate clinical studies. There
are various examples of existing discrepancies in the ways
regulatory authorities treat different classes of products. For
example, a separate category has been created to allow the
toleration of homeopathic products, because the authorities
were confronted with a fait accompli of an enormous variety
of products already established in the market. Hence, they
were forced to create a separate category to assure at least a
bare minimum control of these products. On the other hand,erbeken - Page 228
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in the same subcategory than vaccines. This subcategory is
clearly defined, in part, as ‘aimed at curing diseases with
living viruses’, a definition which fits phages perfectly well.
Moreover, the vaccine subcategory tolerates some modest
level of naturally occurring changes of the vaccine products e
without the necessity of initiating an entirely new regulatory
procedure. For example, when protection from a newly arisen
variant pathogen is urgently required (as in a flu vaccine), the
appropriate modification of the vaccine can be easily and
rapidly accommodated by the flexibility of the regulations.
Such flexibility would be invaluable for therapeutic phage
cocktails, since they will need to be regularly updated because
of the emergence of phage resistant bacterial mutants. How-
ever, phage cocktails and phage-based products in general may
actually require greater compositional flexibility than the
once-in-a-year updates that suffices for vaccines. Then the
question remains whether regulators would accept to increase
further the current flexibility.
An additional difficulty to consider is the standardization of
the therapeutic phage-based products. Even a productmade from
a complete clonal phage population can change within the
patient.While this can be seen as the ultimate advantage of phage
therapy over treatment with antibiotics, as the phage can co-
adapt to an evolving pathogen, this intrinsic genetic variability
poses serious problems with respect to current policies advo-
cated by the regulatory authorities that place major emphasis on
the compositional uniformity of a therapeutic product.
Phage therapy requires the selection and application of
phages specifically targeting a particular patient’s bacterial
strain. In such a setting, it is important to distinguish between
two regulatory definitions, namely ‘product quality’ and
‘production quality’. For companies that want to market a
well-defined product, regulatory instances require ‘product
quality’. However, for custom-made products such as, for
example, the different combinations of phages that may be
required to deal with an emerging bacterial pathogen, it might
be better to opt for ‘production quality’ rather than ‘product
quality’. Thus, although the product may change slightly, the
production procedure would be standardized to ensure uniform
high quality of each individual batch.
Another way out of this regulatory conundrum is to get a
‘hospital exemption’ from the regulatory restrictions in case
phage therapy is applied within a hospital under supervision of
a medical doctor in a patient-specific setting. This would allow
the therapeutic application of phages, in cases of urgent and
serious health problems, like the German Shiga-toxin pro-
ducing EHEC strains that caused 54 deaths in June 2011, and
which could not be successfully treated with antibiotics. Such
tolerance would be necessary also today to offer a solution for
some chronically infected patients for which antibiotics are
not sufficient any more.
In addition to regulatory hurdles, issues with respect to IP
have withheld companies and other investors from investing
into phage therapy thus far. There are several patents (pri-
marily originating from the US) claiming protection for vari-
ous aspects of phage therapy, ranging from natural phages, toPhD Dissertation - Gilbephage cocktails and to various phage methods of treating
infectious diseases of bacterial origin. However, the validity
and enforceability of these patents are dubious since many of
them are overly broad and/or are imprecisely defined. As a
consequence, there is a widespread issue of legal uncertainty
for companies, hospitals and public institutions involved in the
applications of phage therapy.
8. And then, there is safety
Despite the sometimes kafkaesque regulations and exorbi-
tant safety concerns about phage therapy, the fact remains that
it has been generally proven to be very safe. However, there
simply is no way to avoid some safety regulations for phage
therapy. Indeed, however strong the claims regarding general
safety of phage preparations employed in the Eastern European
experience are, from the rigid point of view of the regulatory
authorities, they absolutely need to be convinced of the safety
of the precise product that will be employed in any future
therapy trials. For example, they must be convinced of the
absence of any possible harmful contamination or any possible
risk coming from the phage itself or its solute. Previous safety
data records, no matter how convincing and numerous they
may be, do not constitute a credible assurance of the safety of a
related new product (or even of a different batch of exactly the
same product) used in clinical trials. This is not a specific
problem related to phage therapy, even for well-established
products in clinical trials (for example, magisterial prepara-
tions that have been long employed in a hospital), the regu-
latory authorities require that investigational medical products
documents be filed and that certification be provided that these
products are produced under Good Manufacturing Procedures
conditions. Although phages seem safe and can cause spec-
tacular improvements in patients in some situations, this
therapy still needs to be applied with some caution. In spite of
the substantial empirical use in Eastern Europe, the numerous
experimental animal studies, the encouraging preclinical
studies on ex vivo samples, rigorous scientific evaluation will
still be necessary for general clinical use of phage therapy.
9. High costs, an inescapable major hindrance in the
pursuit of clinical trials
The best way to rigorously evaluate phage therapy is through
clinical trials in order to establish proof of principle and to
stimulate additional funding. But, in the first place, funding itself
is the primary bottleneck for setting up expensive clinical trials.
Hence, the current lack of clinical trials on phage therapy indi-
cates a general hesitancy of industry to invest the large sums
necessary to confirm phage safety and efficacy. Presumably, and
in view of the regulatory and IP hindrances indicated above, the
current evaluation of the industry is that it is not worth the large
risks for them to do it by themselves. Perhaps with the help of
public support they may get involved.
It is actually quite striking that public scientific institutions
have begun to promote ‘translational’ and ‘personalized’
medicines as a widespread concepts, but that many of thert Verbeken - Page 229
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potentially useful therapeutic agents and therapy strategies are
too often put aside when facing regulatory requirements. The
huge development cost of such long-term research projects
and the inevitable uncertainties presented by the strict regu-
latory requirements cannot be carried alone by academic
institutions, neither industrial startups. In consequence, the
notion that the development of phage therapy will be com-
paratively cheap in comparison to new antibiotic development
is probably too simplistic and fundamentally flawed. Consid-
ering the cost of production, both strategies are relatively
inexpensive but they are also equivalently expensive to be
developed for use in clinical trials and to eventually bring into
the market, because the costs of overcoming the regulatory
restrictions (e.g. number of trials, patients to be included, .)
are essentially the same for both and, indeed, very expensive.
Moreover, since a phage preparation may have only a narrow
spectrum of sensitive bacterial targets, the return-on-
investment for each preparation often may be too low for
any company to justify the risk. As clinical trial costs for
phages are at least as high as they are for antibiotics and since
the market for each phage product could be intrinsically rather
limited in their narrow therapeutic range, the profitability for
private phage-producing companies may simply be too modest
to provide economic sustainability.10. The European authorities
The lack of implementation of phage therapy presents a real
concern and triggers interest at the highest levels in Europe,
such as the ECDC which is responsible for the surveillance of
infectious diseases. This interest might forecast a significant
evolution in Europe’s attitude toward phage therapy, which in
the past can be fairly described as highly skeptical. The time
has now come in Europe, to take phage therapy seriously.
Patient groups and medical doctors should be encouraged to
exert pressure on the both European institutions and elected
political bodies because policy changes are only rarely ini-
tiated from above. More often these structures only respond
positively and rapidly to initiatives that originate from extra-
mural sources that have wide public support. Since regulators
only apply rules, they do not change them, political pressure
must be exerted from the bottom to influence the top. This
strategy is essentially what is being applied in France by
PHAGESPOIR, by actively implicating the patients who
would be the potential beneficiaries for phage therapy in the
appeals to the regulatory authorities and politicians. The
responsibility to move forward and not tolerate the status quo
rests not just with the public health authorities and health
professionals, but also squarely on the patients. There is also
an urgent need for research funding to explore and improve the
efficacy of phage therapy and importantly to unambiguously
demonstrate its safety.
One could then see explicitly with a video presentation
made by His Excellency Mr. Pieter De Crem, Belgian Min-
ister of Defense (http://player.vimeo.com/video/43203048) aPhD Dissertation - Gilbert Vglimpse of the involvement of public authorities as a sign that
the status quo may not stand any longer.
In conclusion, this workshop was perceived by both the
audience and the panel members as a milestone in the devel-
opment of phage therapy (Bru¨ssow, 2012). The road will
certainly not be short, as normal with development of new
medical treatments. But it is a road that must be explored and
that hopefully can get to its end before an inevitable outbreak
of a lethal infectious disease caused by an emergent bacterium,
resistant to our existing arsenal of antibiotics, emerges.
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The excessive and improper use of antibiotics has led to an increasing incidence of bacterial resistance. In Europe the yearly number
of infections caused bymultidrug resistant bacteria is more than 400.000, each year resulting in 25.000 attributable deaths. Few new
antibiotics are in the pipeline of the pharmaceutical industry. Early in the 20th century, bacteriophages were described as entities
that can control bacterial populations. Although bacteriophage therapy was developed and practiced in Europe and the former
Soviet republics, the use of bacteriophages in clinical setting was neglected inWestern Europe since the introduction of traditional
antibiotics. Given the worldwide antibiotic crisis there is now a growing interest in making bacteriophage therapy available for
use in modern western medicine. Despite the growing interest, access to bacteriophage therapy remains highly problematic. In
this paper, we argue that the current state of affairs is morally unacceptable and that all stakeholders (pharmaceutical industry,
competent authorities, lawmakers, regulators, and politicians) have the moral duty and the shared responsibility towards making
bacteriophage therapy urgently available for all patients in need.
1. Introduction
1.1. Factual (Nonnormative)Observations concerning Bacterio-
phageTherapy. The excessive and improper use of antibiotics
has led to an increasing incidence of bacterial resistance
and a significant threat to human health [1, 2]. Yearly, more
than 400.000 people are infected by multidrug resistant
bacterial strains, often called “superbugs” [3]. Superbugs
have a considerable economic impact: extra hospital costs
and related productivity losses amount to more than 1.5
billion Euros per year within the European Union (EU).
In the United States (US), infections with multidrug resistant
bacteria cause 20 billion US$ in additional health care costs
and 35 billion US$ societal costs annually [4].
At the same time, it is becoming more and more difficult
and expensive to develop new antibiotics as an adequate
response to the phenomenon of multidrug resistance. Actu-
ally, very few new antibiotics are in the pipeline of the
pharmaceutical industry at the moment [5].
Early in the 20th century, bacteriophages were described
as entities that can control bacterial populations. Bacterio-
phages (or “phages”) are viruses that infect and replicate
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within specific bacteria without harming others. Although
bacteriophage therapy (hereafter BPT) was developed and
practiced in Europe and the former Soviet republics, the
western world abandoned the use. This was mainly because
at that time (1930s) there was a lack of knowledge of what a
bacteriophage really was (a virus) as well as the discovery of
antibiotics. These molecules are well-characterized chemical
substances, relatively easy to produce in a well-controlled
fashion, initiating the golden age of antibiotics, the so called
“miracle drugs” [6].
Given the worldwide antibiotic crisis, the existing and
continued experiences build up in Eastern Europe and the
former Soviet Republics combined with recent encouraging
animal and human study results; there is a growing interest
for BPT in modern medicine and the agrobioindustry, a
recognized potential reservoir for antibiotic resistant germs
[1, 3, 7–10].
Despite this growing interest, introducing BPT in the
western medical world remains highly problematic as a con-
sequence of four main obstacles. First, historical clinical data
about the safety and effectiveness of BPT are not considered
proven and validated by European regulators. Second, given
the substantial costs and investment in the development
and marketing of conventional medicinal products by the
pharmaceutical industry, there is in our actual pharmacoeco-
nomic model an imperative demand for a strong intellectual
property (IP) protection. For now, such protection is rather
fragile for natural lytic phages.Third, an efficient and effective
BPT-concept needs to be flexible and tailored to the patient
[11, 12]. That requirement is not compatible with the usual
timeframes (years) for the development and the marketing
of conventional medicinal products [11, 12]. Rather, the
regulatory framework for medicinal product development,
as present in most countries, calls for drugs to have a
fixed chemical composition. Bacteriophages challenge this
definition by being mutable. Last (fourth obstacle), uncer-
tainty exists about the potential negative coevolutionary
consequences of unlimited use of BPT [13]. In view of these
obstacles, access to BPT for patients in need remains highly
problematic as discussed earlier [12, 14].
Recently, Henein emphasized that so far no bioethical
bacteriophage therapy debate has been published. He gave
the most recent E. coli 0104 outbreak as an example [15].
Indeed in 2011, an emerging strain ofO104:H4Escherichia coli
caused a serious outbreak of food borne haemolytic uremic
syndrome and bloody diarrhoea in Germany. Antibiotics
were of questionable use and 54 deaths occurred, beside
tens of clinical cases with lasting sequels [16, 17]. Several
bacteriophage research groups had in their collection isolated
candidate therapeutic bacteriophages that efficiently lyse the
E. coli O104:H4 outbreak strain [18–20]. The public health
sector never asked for these phages during the outbreak and
none of the scientific papers published during the outbreak
mentioned BPT as a potential treatment. Nestle´ Research
Centre even offered their phage isolate to the German public
health sector during the epidemic, but the proposal was
apparently not addressed [20].
Międzybrodzki et al. [21] addressed briefly the ethical
aspects of bacterial drug resistance and phage therapy.
The authors also highlighted the appeals for decisive changes
in the policies governing the development of antimicrobials.
Bacteriophages should be considered as a public good and the
government should be responsible for their development and
production. Thus, the development and introduction of new
antimicrobials should not only be regulated by market forces
[21].
The main purpose of this paper is not so much to fleece
out these four main obstacles, nor to determine how an
adequate regulatory framework for BPTmight look like.This
has already been done in other publications [11, 12, 14, 22].
We here argue why there exists a moral need or duty to
develop such a regulatory framework. The different actors
in the field, mainly the industrial partners, politicians and
regulators as well as consumers, urgently need to take up
their responsibility in order to guarantee BPT accessibility
for patients in need. What is more, when the costs of phage
therapy and antibiotic therapy were compared, phages were
approximately 50% cheaper than antibiotics. This means that
a wider application of phage therapy could lead to substantial
savings in healthcare costs and make antibacterial therapy
accessible to those who otherwise cannot afford treatment
[23].
1.2. Normative-Ethical Considerations concerning BPT. Given
the above nonnormative specifications of BPT, the basic
moral problem associated with BPT can be formulated as
follows. BPT, when used in a flexible (tailor-made, locally
developed) and sustainable manner, has the potential of
saving thousands of lives every year [11, 24]. However, due
to the above-mentioned obstacles, access to that therapy
remains highly problematic in thewesternworld.How canwe
argue from a moral point of view that this situation is simply
unacceptable?
Central to this moral problem are the preservation and
restoration of the health and well-being of the patient. Two
basic underlying moral principles are relevant in this patient-
centred approach and will be further investigated in this
paper. The first is the principle of nonmaleficence, which
implies the obligation not to inflict harm on another. This
principle is designed to protect the patient. The second
principle is the principle of beneficence, which implies the
obligation to prevent or to remove harm or the obligation to
promote good [25].
2. Bacteriophage Therapy: An Ethically
Justified Medical Therapy?
The fact that efficacy of BPT has not yet been proven accord-
ing to European regulatory standards is one of the obstacles
that clearly suggests the moral relevance to investigate the
principle of nonmaleficence in the context of BPT. Indeed, a
patient has a right not to be subjected to a medical treatment
or therapy that has not yet been rigorously tested for its
effectiveness and possible health risks (as is BPT). The moral
duty, however, not to subject a patient to a not yet approved
therapy is not an absolute, but a prima facie duty. This means
that under well-defined, specific circumstances this duty not
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Table 1: Six criteria for a therapy to be labelled as an EJMT.
It is morally permissible to set aside the prima facie duty not to impose a risk of harm if and only if
(i) there is a just cause;
(ii) those who want to put aside the duty not to impose a risk of harm have good intentions;
(iii) there is a reasonable chance that the just cause will be realized;
(iv) the harm prevented will outweigh the risk of harm imposed;
(v) the just cause cannot be obtained with at least the same probability of success but without imposing a risk of harm;
(vi) those who decide on putting aside the duty not to impose a risk of harm constitute a legitimate authority.
to subject someone to a not yet approved therapy can be set
aside [26]. At this point in the argument, it is appropriate
to introduce the notion of an “Ethically Justified Medical
Therapy” (EJMT). This is a medical therapy that has not yet
obtained an official approval for its health effectiveness (at
least not according to western standards), and/or for which
some doubts remain concerning possible health risks, but the
use of which seems to bemorally acceptable given the specific
circumstances of the case at hand. For such a therapy to be
labelled as an EJMT, six criteria need to be met (Table 1) [27].
First of all, there has to be a just cause or a very good
reason for subjecting a patient to a possibly hazardous
medical therapy and/or a therapy the effectiveness of which
has not yet been demonstrated in a rigorous manner. The
moral weight of whatever it is we want to achieve with this
therapy has to be sufficiently important. In the case of BPT-
therapy we might think of a patient whose life or limb is
threatened by a serious bacteriological infection. Saving that
patient’s limb or threatened life, for instance, constitutes such
a good reason beyond any doubt.
Secondly, we need to make sure that all the moral agents
involved are motivated by ethically proper intentions. In a
clinician-patient relationship, the medical practitioner ought
to have the intention to help the patient in need, although
other interests (e.g., hospital-related) may play a certain
role as well. Therefore, if indeed a patient’s health is at
stake (a good reason), then our intention for using the yet
unapproved therapy has to be about improving the patient’s
health condition and not about commercial, research, or cost-
reducing benefits.
Next, there needs to be a reasonable chance that the use of
the therapy in a particular case will have the desired result. In
case of BPT, based on preliminary examinations and testing
by experienced specialists, multiple case studies reporting
success were published [28–30].
Efficacy of bacteriophage therapy has not yet been proven
according to European regulators, but anyway the concept
of reasonable chance does not imply real proof of such
efficacy.What is more, there must be a good prospect that the
probable health benefits will outweigh the risks of subjecting
the patient to the therapy (proportionality). It is important in
this respect to try to avoid as much as possible undesired side
effects related to BPT [31–33].
Another criterion is that the unapproved therapy needs
to be a last resort. All existing treatments must have been
tried with little or no success. BPT might for instance be
considered as such a last resort when marketed antibiotics
are no longer effective. In reality, in particular circumstances
of multidrug resistance, BPT offers today a reasonable and
feasible alternative or complimentary treatment approach to
save such patients. Indeed it has been shown that BPT and
traditional antibiotic therapy can create a synergic beneficial
effect [34, 35].
Medical practitioners’ assessment in these circumstances
is crucial. It needs to be stressed that in clear cases of
antibiotic resistance, BPT most likely constitutes the first
and not just the last resort. Indeed, the last resort principle
only demands that we consider reasonable alternatives, since
hopeless situations due to lack of adequate alternatives need
to be avoided as much as possible according to international
and national legislations and declarations. In Belgium, the
compassionate use regime provides such a “last resort”
mechanism, whereby a medical practitioner may apply an
unapproved product provided marketing authorization is
applied for or clinical trials are ongoing. At the international
level, Article 37 of the Declaration of Helsinki states the
following: “In the treatment of an individual patient, where
proven interventions do not exist or other known interventions
have been ineffective, the physician, after seeking expert advice,
with informed consent from the patient or a legally authorized
representative, may use an unproven intervention if in the
physician’s judgement it offers hope of saving life, re-establishing
health or alleviating suffering. This intervention should subse-
quently be made the object of research, designed to evaluate
its safety and efficacy. In all cases, new information must
be recorded and, where appropriate, made publicly available”
[36].Note however, that theDeclaration ofHelsinki, although
at the international medical community level is well accepted
as a basic document, is not a national binding law, meaning
that it has no national juridical value and as such could put
the practitioner in a position of juridical vulnerability as
experienced in France (personal communications, M.D. A.
Dublanchet and Court Lawyer B. Papin).
Finally, a decision to subject a patient to a not yet
approved therapy needs to be made in respect with the
patient’s right to autonomy (legitimate authority) [26]. How-
ever, it should be noted that a patient’s consent to be
subjected to a not yet approved treatment is not a sufficient
condition to go ahead with the therapy. The other above-
mentioned criteria need to be respected as well. Within this
context, we need to determine whether a patient’s (or its legal
representative) consent constitutes a necessary condition.
Although these six criteria were originally developed
within another context, namely, that of the just war theory
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(JWT), it seems that these criteria can also be of valuable
use in the ethical discussion on BPT [37]. This is because
the underlying ethical argument is very similar. The JWT
starts from the supposition that war is a moral evil, and
that because of this we have an obligation to avoid war as
much as possible. Notice here again that the obligation not
to wage war is not an absolute, but a prima facie duty. In
specific circumstances (determined by the above criteria)
war can be a morally acceptable option (for instance in
case of self-defense or humanitarian intervention). A very
similar moral mechanism is at work in our discussion about
BPT. Subjecting a patient to a not yet approved therapy
is morally wrong, but sometimes, in specific (exceptional)
circumstances (determined by the six criteria), it can be
a morally acceptable option to subject a patient to such
unapproved therapy, and not just amorally excusable option.
Whether or not BPT is an EJMT needs to be checked on
a case-by-case basis. Numerous types of bacterial infections
exist. Any manner to combat such infection needs to be
considered separately. In fact, medical ethical committees
provide also case-by-case reasoning while evaluating propos-
als for treatment.
We would like to conclude the first part of our argument
by saying that the six criteria we used to evaluate BPT’s moral
permissibility form the ethical basis for some kind of pre-
cautionary regulatory framework. Until it can be adequately
shown that BPT can live up to western health care standards,
there will be a constant need to justify the use of BPT on a
case-by-case basis.Moreover, given the specific nature of BPT
(its interactive and ever-evolving character) and the need
to focus on tailor-made solutions, it will be difficult, if not
impossible, to claim once and for all (as it is probably the case
for traditional “static” chemicalmedicinal products) that BPT
is effective and safe.This would also imply that any regulatory
framework designed to assure the safety and effectiveness of
flexible and sustainable BPT will never completely lose its
precautionary character.
3. Towards a Moral Duty to Invest in
the Development of Bacteriophage Therapy
3.1. Do Pharmaceutical Companies Have a Duty to Care?
Demonstrating that BPT constitutes an EJMT in a sufficient
number of cases is of course but a first part of our moral
argument. Showing that in a specific case BPT is an EJMT
makes its use morally permissible in that specific case. But
showing moral permissibility for BPT is only a necessary
condition for our purpose, which is demonstrating that it is
simply morally unacceptable to obstruct (or, at least, to not
sufficiently facilitate) the accessibility to BPT. We also need
to show that somehow there exists a moral duty to take the
necessary steps in order to make flexible and sustainable BPT
available in a more organized fashion.
Pharmaceutical companies are the primary actors in
the business of developing new and improved medicinal
products and therapies. Hospitals do not have the financial
capacity and resources to fully develop bacteriophage-based
products according to the current pharmaceutical medicinal
product guidelines. Although our initial focus will be on
pharmaceutical companies, this does not mean that other
actors (like public authorities) are absolutely absolved of all
responsibility in this respect. We will come back to this
specific issue later on in this paper.
In our patient-centred approach, we perceived that the
principle of nonmaleficence provides a so-called prima facie
moral protection for the patient against therapies and treat-
ments that have not yet proven their health effectiveness
and/or for which some doubts remain concerning their
possible health risks. In trying to establish a moral duty to
contribute to the development of lifesaving therapies, such as
BPT [28, 30, 38], it is suitable to turn to the other basic moral
principle in bioethics, that of beneficence.
Despite the fact that it is not in the interest of the
classic pharmaceutical industry, organized in accordance
with the actual pharmacoeconomic environment, to invest
in sustainable BPT (see the above mentioned obstacles), the
beneficence-principle seems to provide a sufficient moral
basis for arguing that the pharmaceutical industry has a duty
to do so anyway.
In the 1970s, most supporters of market economy
embraced Friedman’s view that the social responsibility of
business is to increase its profits, not to relax the conditions of
profit-maximization on behalf of thewider interests of society
[39]. But, is this acceptable when it comes to healthcare?
Surely, companies involved in the healthcare industry should
live up to their responsibilities towards the public interest,
not only towards their shareholders. To quote Blasszauer:
“medicine is a moral enterprise whether it is practiced in
the system of slavery or market economy” [40]. Defenders of
Friedman’s thesis claim that for executives to use company
resources to advance social goals, it would be for them to
usurp the political function. In this context it might thus be
up to the political world to demand healthcare companies to
defy the laws of economics and fulfil social duties [12, 41].
One of the reasons why the above conclusion is not that
straightforward has to do with the specific nature of the
beneficence-principle. Indeed this basic principle is especially
morally relevant within the relation between the health care
professional and his patient. Because of his specific role, it
can be said that the health care professional has the moral
obligation to undertake all the necessary and reasonable
measures to improve his patient’s health condition (or to
prevent his patient’s health fromdeteriorating).The relational
context between a patient and the pharmaceutical industry
is of course very different from the one between the health
care professional and his patient. It is no longer a relation
of care, compassion, and beneficence, but a relation of an
economic or a commercial kind. The industry’s role is to
develop, produce, and sell medicinal products, whereas the
role of the patient is that of a consumer. This does not
mean that the pharmaceutical industry has absolutely no
obligations whatsoever towards its patient-consumers. The
industry has the obligation to take all the necessary and
reasonablemeasures to ensure the effectiveness and the safety
of the medicinal products it decides to develop, produce, and
sell [42]. Within that same commercial relation (“patient-
consumer/pharmaceutical industry”) it is very hard, as far
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as we can tell, to justify the imposition of an additional
requirement on the pharmaceutical industry to invest in the
development and production of medicinal products that are
of a lifesaving importance to some patients, but that are rather
uninteresting from a pure commercial point of view as is the
case for flexible and sustainable BPT that has been shown
lifesaving in specific individual cases [28, 30, 38]. Here we
need to look for another way to morally justify an obligation
to make available for as many patients as possible medicinal
products or therapies for which there does not seem to exist
a sufficient commercial incentive to start a development and
production process.
3.2. Do Pharmaceutical Companies Have a Social Responsibil-
ity to Invest in BPT inOrder to PromoteOverall SocialWelfare?
Perhaps a more promising line of argument is of a utilitarian
kind. One might quite convincingly argue that economic
actors in our society, like private businesses and companies,
do not only have specific client-related obligations, but also
a somewhat broader social responsibility to promote overall
well-being in society. If we agree that this is the case (that
there exists such a utilitarian-based responsibility), then it
still remains to be seen of course whether the moral require-
ment to promote novel antimicrobial approaches like BPT
can indeed be based on such a notion of social responsibility.
To verify this, we need to explore two separate questions.
The first question goes as follows: to what extent may we
assume that the promotion of BPT (eventually in combina-
tion with existing therapies) constitutes indeed the course of
action that, compared to other possible alternatives, will lead
to better results in confronting the health challenges related
to an increasing antibiotic resistance problem in bacteria
(hereafter the resistance problem)? Proving that BPT is the
best option in tackling this specific health problem from a
utilitarian point of view is essentially a technical matter that
requires further thorough knowledge in microbiology and
in health care economics. In other publications it has been
shown that this may be the case [7, 43, 44].
Establishing with a reasonable degree of certainty that
BPT is indeed a good option in confronting the resistance
problem from a utilitarian point of view constitutes, however,
a necessary, but not a sufficient condition for our purpose to
demonstrate that there is such a thing as a moral requirement
to promote BPT. A part of our common-sense morality
clearly states that promoting the best overall result does not
automatically generate a moral requirement to do so. We
can illustrate this with an example. Suppose that ten people
are on the verge of losing their lives (that they are about
to drown). Suppose also that person A could save all of
them if he wanted to. The only trouble is that person A can
only do so with a considerable risk to himself. Although,
saving the ten lives (even with the risk of losing his own
life in the process) is the best option from a utilitarian
point of view; there is a general agreement within common-
sense morality that person A is under no moral obligation
to do so. In this specific example person A is allowed to
favour his own life, even if sacrificing it in order to save the
ten others would be preferable from a utilitarian viewpoint.
In the theory of normative ethics, common-sense moral-
ity contains so-called agent-favouring options (or agent-
favouring prerogatives) [45]. These are moral principles that
protect an agent from the obligation to always promote the
overall good. The key word here is “always”.
Indeed, in some cases the promotion of the overall good
does create a moral requirement to do so. For instance:
if person A could save the lives of those ten people with
practically no risk for himself, he can no longer avoid the
obligation to do so. In order to understand the mechanism
of the agent-favouring options better, it is essential to take
into account two factors: the (probable) cost to the agent, and
the (probable) amount of overall good or well-being that is at
stake. If the amount of good at stake outweighs the cost to the
agent (who has no risk to lose his life), then the requirement
to promote the overall good can no longer be blocked by
the agent-favouring option. This seems to suggest that the
option protecting amoral agent’s self-interest is characterized
by some kind of threshold, the level of which is determined
by the cost the moral agent will have to pay when he decides
to serve the overall good. Once the amount of good or well-
being at stake crosses that threshold, the creation of a moral
requirement to bring about this amount of good canno longer
be blocked by the agent-favouring option. A general rule
seems to be then: the higher the cost to the agent, the higher
the threshold, the stronger the agent-favouring option, and
the lesser the probability that the agent will be subjected to
the obligation to promote the overall good. It should be clear,
however, that whenever the interests of an agent are protected
by such an agent-favouring option, he or she is still at liberty
to promote the overall good. If, for instance, person A is a
heroic kind of a person and he will not hesitate to save those
ten people, even if this means sacrificing his own life. It is
obvious that such an act will not be morally condemned. Far
from it: such an act will typically be praised and admired. But
again, it is not an obligatory act, but rather a supererogatory
act inspired by idealism [46].
Let us assume for the sake of argument that such agent-
favouring options are indeed a part of our common-sense
morality. This being the case, it might very well be that the
economic and commercial interests of the pharmaceutical
industry are going to be protected by such options. Even
if it would appear that promoting BPT is indeed the best
choice in tackling the resistance problem, pharmaceutical
enterprises cannot be morally obligated to sacrifice their
own commercial interests in order to give priority to the
development of BPT. It is possible, however, that some
pharmaceutical companies could decide to go ahead anyway
with the development of BPT. But, again, such a decision
would constitute a supererogatory act, not a mandatory act.
We now come to our second question: is it reasonable to
assume that there exists such an agent-favouring option that
protects the private interests of the pharmaceutical industry
and thereby blocks the creation of a moral requirement
to promote BPT? Answering this question requires a more
profound cost/benefit analysis. In case of pharmaceutical
companies’ investments in bacteriophage product develop-
ment, costs are considerable since all regulatory processes
need to be conducted [20]. Assuming that (a) cost-based
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option(s) protecting the interests of a moral agent is (are)
indeed a part or our common-sense morality and (b) the
development of BPT will definitely entail a commercial costs
to a pharmaceutical company (resources that will be invested
in this kind of research and development can no longer be
used to develop more lucrative products); it is also fair to
assume that pharmaceutical companies will try to protect
their private interests by appealing to such agent-favouring
option and pretend that there is no such thing as a duty to
promote BPT. Whether or not the pharmaceutical industry
is justified in hiding behind such agent-favouring option will
depend on two factors: what is the moral force of that option
and will it be strong enough to block a moral requirement
to promote BPT? At this point in the argument we will need
to evaluate the importance of the cost to the pharmaceutical
industry. This will indeed give us some idea of the moral
force of the agent-favouring option (the higher the cost, the
stronger the option). Today, any organization, pharmaceuti-
cal company, or any nonprofit actor like a hospital, willing to
implement BPT, is expected to follow the classical marketing
authorization and market placement procedures. The costs
for developing BPT following these frameworks can be as
much as 400–800 million USD [15] and not realistic for
nonprofit actors.
In addition, intellectual property rights (IPRs) that in
general provide owners exclusivities to recoup investment
costs are hardly unavailable (or weak) in the context of BPT
[15]. The reason is that IPRs do not protect natural products
(e.g., natural bacteriophages) or processes covering natural
phenomena (e.g., mechanism of action of BPT based on
the inherent coevolution of bacteria and bacteriophages).
However, given the widespread availability of bacteriophages
and the fact that natural bacteriophages are from a structural
point of view less complex than other biological (protein-
based) products or advanced therapies medicinal products,
the costs to develop BPT could eventually be lower compared
with these latter medicinal products.
Will the overall health benefits of saving thousands
of lives, generated by the introduction of BPT, cross the
option’s threshold (the height of which is determined by the
option’s moral force)? To verify this, we need to compare the
costs of investment in BPT development by pharmaceutical
companies with the unproven potential BPT of, for example,
savings of the lives of 25.000 Europeans each year [28, 30,
38], with the cost associated with bacterial outbreaks caused
by bacterial infections [47], costs to the social security for
hospitalized patients [3], and emotional costs associated with
the disease itself. According to the authors of this paper,
these costs to society by not developing BPT clearly indicate
that the option’s threshold protecting the pharmaceutical
industry’s private interests will be crossed. In our opinion,
pharmaceutical companies hence do have a moral duty to
contribute in one or another way to the development of
BPT.Thinking of phage therapy as a sustainable antibacterial
approach should have the potential of cost reduction for
society that should be considered as a major incentive
for companies to invest in BPT. However, in the current
regulatory climate, the pharmaceutical companies are unable
to do it without adequate incentives or support. Clearly other
stakeholders like the public authorities need to provide the
right incentives by creating feasible regulatory frameworks.
4. Closing the Moral Gap
4.1. Reconciling Private Interests and Social Responsibilities.
According to the authors, previous analysis demonstrates that
arguments can be found to support a moral requirement for
the pharmaceutical industry to promote BPT. It remains to be
seen what specific form this moral requirement will take.The
pharmaceutical industry, due to its specific knowledge and
know-how, will certainly have some role to play in the valida-
tion process of the clinical data relating to BPT (obstacle (1))
and/or in furthering the research concerning the potential
negative coevolutionary consequences of unlimited use of
BFT (obstacle (4)). In addition, it is important to consider
how in the future industrial companies will maintain (keep
on respecting) this moral duty and how these companies can
bemade aware of the importance of creating andmaintaining
high moral standards in the long run. History portrays
similar developments, more specific in the domain of cell
and gene therapy. Several regulatory incentives, specific types
of subsidies and models for public-private partnerships have
contributed to stimulate the industry for investments into
these therapies [48]. More in particular, a specific European
framework covering advanced therapy medicinal product
(Regulation 1394/2007) was created, offering legal incentives
(e.g., scientific advice at reduced costs) to developers of
cell and gene based therapies. Specific calls for research
funding were launched via the FP7 programs of the European
Commission, and large-scale collaborative efforts are in place
between industry and academia, under the umbrella of, for
example, Europe’s Innovative Medicines Initiative (IMI).
4.2. Other Stakeholders’ Responsibilities. Until now we have
solely focused on the pharmaceutical industry as the prin-
cipal bearer of this potential moral requirement to promote
BPT. Obviously, political authorities, much more so than
private companies, have a social responsibility to promote
public health in themost efficient way they can.What ismore,
due to their public nature, public authorities cannot hide
behind cost-based options to protect their “private” interests
as private companies can. As such, since we have shown
that according to the evidence available, the promotion of
flexible (characterized by its locally produced and tailor-
made nature) and sustainable BPT is, compared to other
alternatives, for different particular disease situations, the
best solution to promote overall health benefits, then there is a
publicmoral duty to do so.This particular public requirement
to promote this specific kind of BPT can perhaps best man-
ifest itself by providing an adapted regulatory framework, so
that the full potential of BPT as a locally prepared and tailor-
made therapy can finally be realized.
5. Conclusion
In this paper, we have argued that the current state of affairs
as described in the introduction is morally unacceptable.
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We succeeded in underpinning the desirability for developing
a flexible and sustainable BPT-adapted regulatory framework
with the necessary moral force. The authors are aware that
moral arguments in favour of BPT may equally be identified
(via a similar moral analysis) and apply to other areas of
drug development (e.g., orphan diseases). We argued that the
pharmaceutical industry has a moral duty to invest in BPT
in view of the social responsibility they need to take. But
of equally crucial importance is the role of the competent
public authorities to create the appropriate regulatory and
legal framework to stimulate companies to invest in BPT.
Political representatives and lawmakers have an inevitable,
logical responsibility to support health care and welfare.That
is what they are for. We identified a shared responsibility
making BPT accessible for patients in need. The develop-
ment and production of BPT products in a pharmaceutical
context (clinical trials, production requirements, marketing
authorization procedures...) requires time. Patients in need
have no time. Therefore, lawmakers and regulators need to
design appropriate solutions on a short term to buffer for the
years needed for companies to develop BPT-based medicinal
products. Much more urgent and optimal, regulatory solu-
tions need to be created to allow hospitals to adopt patient-
oriented and tailored BPT in a legal way for treating those
patients that are waiting to be cured.
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7 Concluding discussion 
 
7.1 Legislative frameworks 
 
7.1.1 Options inside the Medicinal Products Directive 2001/83/EC: under or alongside the 
Biological Medicinal Products 
 
Bacteriophages are not straightforward inanimate and stable substances [Chapter 2.1.2 / Chapter 
2.3.2]. They are evolvable and natural biological entities. A sustainable bacteriophage therapy 
concept should fully acknowledge the potential of the co-evolutionary aspect of the bacteriophage/ 
bacterium couplet. Only then, it should be possible to put the inherent potential of bacteriophages as 
natural biological bacterium controllers to use [Chapter 3.1.2]. Indeed, bacteria will inevitably become 
resistant to bacteriophages, but due to the continuously ongoing evolutionary arms race between the 
two protagonists, specific bacteriophages that are able to infect the formerly resistant bacterial strains 
can be expected to quickly emerge.  
The existing pharmaceutical regulatory framework and business models are not compatible with such 
a dynamic and at the long term sustainable bacteriophage therapy concept. Therefore, a suitable 
legislative environment for bacteriophage therapy should be developed [Chapter 5.3.1]. Fundamental 
changes in the medical and pharmaco-economic environment are essential for a successful re-
introduction of bacteriophage therapy into modern medicine. Bacteriophage therapy fits well in the 
new emerging field of Darwinian/evolutionary medicine where the insights of evolution are fully taken 
into account. Viruses, among which are bacteriophages, were involved in the origin of life itself and 
play a major role in biological evolution [Villarreal 2005, Forterre 2006, Koonin 2006]. Hopefully, they 
will play a more important role in the future control of bacterial diseases. We must learn from the 
errors that contributed to the rise of antibiotic resistance. This vision has to be fostered in 
collaboration with the competent authorities and responsible political and economic actors, as only a 
common effort will make bacteriophage therapy a (direly needed) reality. The setting up of credible 
studies to gather the required data with regard to the modern evidence based efficacy paradigm and 
the evolutionary consequences of bacteriophage therapy needs to be stimulated. The development of 
a specific legislative framework with realistic production and documentation requirements that allow a 
timely supply of safe, tailored natural bacteriophages has to be promoted. Products for bacteriophage 
therapy deserve their specific (European) regulatory frame. Various pharmaceutical products different 
from the classical chemical molecules such as vaccines and cell therapy products already have their 
proper frames [Chapter 4.1.1].  
Natural bacteriophages are by definition “products” in the pharmaco-legal jargon. They are natural 
lifelike biological entities. They proved, although mostly empirically, to have a real value in medical 
practice in the former Soviet Republics. Bacteriophages are still a therapeutic tool in daily medicine in 
countries like Georgia and Poland. Bacteriophages could be considered a type of Particular medicinal 
products, to be defined under Annex 1 Part III of Human Medicinal Products Directive 2001/83/EC 
[Table 1]. Bacteriophages could be categorized at potentially two classification places. A first 
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possibility is the creation of a new and specific “Biological medicinal products” categorical ranking 
place under the name “Bacteriophage medicinal products” at the same rank level as “Plasma-derived 
medicinal products” and “Vaccines”. The second possibility could be the creation of a dedicated new 
category of the Part III Particular medicinal products division, also named “Bacteriophage medicinal 
products”. Both proposed new legal frame options are visualized in Table 1 (Italic/bold) and concern 
as “products” only the natural exclusively lytic natural bacteriophages, in contrast to potential useful 
“genetically engineered” or “bacteriophage derived” products which are not in the scope of this 
dissertation.  
 
Table 1:   Annex 1 Part III of Human Medicinal Products Directive 2001/83/EC in which the bacteriophage therapy concept 
could be integrated or classified (Italic/bold). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part I: Standardized marketing authorisation dossier 
 
Part II: Specific marketing authorisation dossier 
 
• Well-established medicinal use    
• Essentially similar medicinal products 
• Additional data required in specific situations 
• Similar biological medicinal products 
• Fixed combination medicinal products 
• Documentation for applications in exceptional circumstances 
• Mixed marketing authorisation  applications 
 
Part III: Particular medicinal products 
 
• Biological medicinal products 
o Plasma-derived medicinal products   
o Vaccines 
o Bacteriophage medicinal products   
  
• Radio-pharmaceuticals and precursors 
o Radio-pharmaceuticals 
o Radio-pharmaceutical precursors for radio-labelling purposes 
• Homeopathic medicinal products 
• Herbal medicinal products 
• Orphan medicinal products 
• Bacteriophage medicinal products 
 
Part IV: Advanced Therapy Medicinal Products 
 
• Gene therapy medicinal products    
• Somatic cell therapy medicinal products 
• Tissue engineered products 
• Combined advanced therapy medicinal products 
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7.1.2 Options outside the Medicinal Products Directive 2001/83/EC: European (centralized) or 
national (de-centralized) procedure 
 
An alternative pathway could be the creation of a new and dedicated Bacteriophage Therapy 
Directive, outside the existing Human Medicinal Products Directive 2001/83/EC [Chapter 5.1.1 Fig. 2].  
 
Chapter 5.1.1 Fig. 2: Proposal for a new European directive for bacteriophage therapy. 
 
 
 
In both pathways followed (inside or outside the Human Medicinal Products Directive 2001/83/EC) the 
frames tailored to bacteriophage therapy should allow an adapted developmental timeframe.  The 
development of a ‘‘new’’ natural bacteriophage “product” can in practice happen in a matter of days to 
weeks [Merabishvili 2012], in contrast to the timeframes applicable to the developing of classical 
chemical antibiotics. This development is in line with the so called Quality by Design (QbD) drug 
development principle [Chapter 3.1.1 Fig. 1, Chapter 4.1.1], in use for example in the field of 
therapeutic human cell culture and vaccine production. The new or adapted frameworks should also 
make the tailored use of bacteriophage therapy in hospitals or recognized bacteriophage therapy 
centres possible. 
Regulatory authorities have the responsibility to survey the application of the existing regulations. 
Actually a specific regulation is lacking for bacteriophage therapy. Hence there is a need for a 
legislative action at the political level. We suggest a regulatory framework, inspired by the existing 
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legislation governing the Advanced Therapy Medicinal Products (ATMPs), which includes a “Hospital-
Exemption” (HE) for the hospital-based use of cell and gene-based products and therapies. The 
European Medicines Agency (EMA) recently classified natural therapeutic bacteriophages as 
Biological Medicinal Products (BMPs). Actually however, a defined HE does not exist under the 
Biological Medicinal Products legislative frame [Chapter 4.2.1, Chapter 5.2.1]. 
An optimized regulatory framework would distinguish between the hospital-based (tailor-made) “Sur-
Mesure” use of natural bacteriophages in patients and the industrial production and distribution of 
uniform “Prêt-a-Porter” bacteriophage products. This would allow treating physicians to fully exploit 
the co-evolutionary aspects of natural bacteriophages to their patients’ benefit [Chapter 2.3.1, Chapter 
3.1.1 Fig. 1, Chapter 3.1.3].  
 
Chapter 3.1.1 Fig. 1: Two bacteriophage therapy concepts: “Prêt-a-Porter” and “Sur-Mesure” 
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In case the European Union would not actively support, in the near future, the re-introduction of 
tailored bacteriophage therapy into its Member States, national authorities of these Member States 
could also regulate bacteriophage therapy at their level.  There is an urgent need for bacteriophage 
therapy centres seen the increasing antibiotic resistances and its negative consequences. If in the 
actual pharmaco-economic environment the launch of hospital-based (non-profit) bacteriophage 
therapy centres should be financially impossible, national governments should support those 
initiatives and eventually help to develop new pharmaco-economic models. 
 
7.2 Complementary actions for re-introducing bacteriophage therapy into the European 
Union: a bottom-up approach 
 
Since several years there is an increasing amount of actions undertaken in order to bring the 
therapeutic potentialities of bacteriophage therapy also under the consciousness of a broader public, 
consisting of the patients, the first line medical community, the politicians as decision makers and 
society as a whole. Therefore several societies organise information sessions or new associations are 
specifically created. As well at the national as at the international level, dedicated bacteriophage 
therapy symposia and workshops are organised. Examples are the “Viruses of Microbes” conference 
[Switzerland 2014], the “Bacteriophage 2015 & Bacteriophage 2016” conferences [Oxford 2015, 
London 2016] and the “Phages in Interacation” symposium [Leuven 2015]. Actually, a big change is 
observed among the attitude of the competent authorities now also organizing meetings about the 
subject. A situation that was almost unthinkable a few years ago. The European Medicines Agency 
(EMA) recently organized a workshop concerning the therapeutic use of bacteriophages [EMA 2015] 
while the Joint Research Centre (JRC) of the European Commission organized a meeting where also 
bacteriophage therapy was put on the agenda [JRC 2013]. These initiatives are important at the 
scientific and technical industrial level, as well as for the creation of a positive public opinion and 
political awareness at the decision making level. Some initiatives led by non-profit organizations like 
GEEPhage [GEEPhage], P.H.A.G.E. [P.H.A.G.E.] and PHAG ESPOIRS [PHAGESPOIRS] play an 
active and primary role for change, particularly due to a co-involvement of patient organizations. 
Another positive evolution is that organizations like the World Alliance Against Antibiotic Resistance 
include bacteriophages as a potential help in the fight against antibiotic resistance [WAAAR 2015]. 
 
7.3 The moral issue 
 
There are moral arguments for taking the re-introduction of bacteriophage therapy into (Western) 
medicine seriously [Chapter 3.1.2, Chapter 6.1.1]. All stakeholders (pharmaceutical industry, 
competent authorities, lawmakers, regulators, and politicians) have the moral duty and the shared 
responsibility towards making bacteriophage therapy urgently available for all patients in need 
[Chapter 6.1.1]. The pharmaceutical industry has a moral duty to invest in bacteriophage therapy in 
view of the social responsibility they need to take. Of equally crucial importance is the role of the 
competent public authorities to create the appropriate legislative framework to stimulate companies to 
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invest in bacteriophage therapy. Political representatives and lawmakers have an inevitable, logical 
responsibility to support health care and welfare. The development and production of bacteriophage 
products in a classical pharmaceutical context (clinical trials, production requirements, marketing 
authorization procedures...) requires much time. Patients in need have no time. Therefore, lawmakers 
and regulators need to design appropriate solutions, on a short term, to buffer for the years needed 
for companies to develop bacteriophage-based medicinal products. Much more urgent and optimal, 
legislative solutions need to be created to allow hospitals to adopt patient-oriented and tailored 
bacteriophage therapy in a legal way for treating those patients that are waiting to be cured today. For 
these patients in need, bacteriophage therapy as it stands today can be labelled as an Ethically 
Justified Medical Therapy (EJMT) [Kagan 1998, Miller 1996]. This means that, although it has not yet 
been officially approved, the use of bacteriophage therapy is morally justifiable if and only if the 
EJMT-related criteria are satisfied (Table 2) [Chapter 6.1.1]. 
 
Table 2: Six criteria for a therapy to be labelled as Ethically Justified Medical Therapy. 
 
 
 
 
 
 
 
 
7.4 Bacteriophage therapy concepts 
 
Ninety years of bacteriophage therapy have shown that after a while bacteriophage preparations 
become less effective and need to be updated [Chanishvili 2012]. The ineffective bacteriophages can 
either be “trained,” a term used in the Georgian Eliava Institute of Bacteriophage Microbiology and 
Virology (EIBMV), to indicate the selection of bacteriophage mutants more active against the 
bacteriophage-resistant bacteria, or replaced by new active bacteriophages. New bacteriophages are 
generally selected from the environment (e.g. hospital sewage water), but in some cases they can be 
isolated from clinical samples containing the problematic bacterium. In bacteriophage therapy centres 
in Georgia and Poland, therapeutic bacteriophage banks containing many different bacteriophages 
are kept and regularly updated. Sometimes custom bacteriophage preparations are developed for a 
patient’s infection, a procedure that usually takes a few days to weeks. This “Sur-Mesure” approach is 
not compatible with the current (medicinal product) licensing processes [Chapter 3.1.1].  
EMA recently classified natural therapeutic bacteriophages under the (classical) Medicinal Product 
Legislation. Also, in the US, the amount of research and testing required by the FDA is seriously 
hampering the resurgence of bacteriophage therapy. Notwithstanding these regulatory hurdles and 
the empirical evidence suggesting that stable and widely distributed bacteriophage preparations 
(“Prêt-à-Porter”) will only be of (time-)limited use, a few companies have picked up the gauntlet and 
are moving along the elaborate and expensive licensing pathways. If nothing else, these efforts will 
put bacteriophage therapy back on the map in the “Western World” and, once commonly accepted, 
It is morally permissible to set aside the prima facie duty not to impose a risk of harm if and only if 
 
(i)  there is a just cause; 
(ii)  those who want to put aside the duty not to impose a risk of harm have good intentions; 
(iii)  there is a reasonable chance that the just cause will be realized; 
(iv)  the harm prevented will outweigh the risk of harm imposed; 
(v)  the just cause cannot be obtained with at least the same probability of success but without imposing a risk of harm; 
(vi)  those who decide on putting aside the duty not to impose a risk of harm constitute a legitimate authority. 
PhD Dissertation - Gilbert Verbeken - Page 256
EMA and FDA might revise their rules the way they did for influenza vaccines which also require a 
rapid updating and licensing procedure [Wood 2003].  
However, are pharmaceutical companies willing to commit to rapidly and regularly adapting their 
bacteriophage preparations to very specific or newly emerging demands? E.g. for a hospital unit 
confronted with a multi-drug resistant bacterial strain that causes untreatable infections in only one or 
two of its patients? For all these reasons, as well the “Prêt-à-Porter” or the “Sur-Mesure” approaches 
should be developed. Operational, they even could be complementary [Chapter 3.1.2]  
The specificity of bacteriophages, resistance and intellectual property (IP) issues may hamstring 
pharmaceutical companies in the worldwide marketing of tailored bacteriophage preparations. Indeed, 
the lack of strong IP protection is a discouraging factor for pharmaceutical companies [Chapter 2.1.1]. 
The principle of bacteriophage therapy has been common knowledge since the 1920s and many 
aspects might thus be un-patentable. In addition, there are indications that in the future 
bacteriophages, which are natural entities composed of genetic material and proteins, will only be 
patentable if they have been engineered into something distinctly different in character. Engineered 
bacteriophages could be patented but, considering the current concerns about potential risks for 
public health and the environment which may arise from genetic engineering in genetically modified 
organisms (GMOs), they are not likely to be given licensing approval as a medicinal product in the 
near future.  
The long and expensive regulatory pathways form insurmountable obstacles for bonafide non-profit 
bacteriophage therapy centres or hospitals which opt for a “Sur-Mesure” concept, as well as for 
institutions that would like to use bacteriophages for commercially unattractive applications, in e.g. 
emerging countries. Also this “Sur-Mesure” conceptual approach should adhere to relevant standards 
of safety, quality and efficacy [Chapter 2.2.1, Chapter 5.2.1]. 
Bacteriophage therapy (in general) has great potential but, as with antibiotic treatment, there are likely 
to be important evolutionary consequences [Levin 2004] if bacteriophage therapy is implemented 
widely and without sufficient oversight. Some aspects of the bacteriophage/bacterium evolution 
ecology (e.g. emergence of resistance) should be analysed in the light of bacteriophage therapy. 
Real-time experimental evolution studies could help determine these evolutionary consequences and 
generate the analytical knowledge in support of the empirical knowledge and clinical experience that 
was accumulated in the “Eastern World”. More importantly, they will hopefully enable the creation of a 
rational bacteriophage therapy concept, avoiding the historical mistakes that occurred in the course of 
antibiotic therapy development and which lead to the current massive and widespread occurrence of 
antibiotic resistance in the patient population as well as in the natural environment. 
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7.5 Re-thinking the European Medicinal Products Directive 2001/83/EC and evaluating its 
scope 
 
European Human Medicinal Product legislation needs to be reworked in relation to the re-introduction 
of bacteriophage therapy into the European Union. The creation of a HE (comparable to the HE 
already defined for the ATMPs) could make tailored in-hospital use of bacteriophages possible. 
Products falling under the HE definition will no longer be covered by the scope of the European 
Medicinal Product Directive 2001/83/EC (Art. 3.7)
1
 [EMPD 2001, Cuende2014, Belgian SHC Advice 
9218].  
It could be contended that the tailored production and the in-hospital use of natural therapeutic 
bacteriophages do not constitute a market placement of that product. This places these products and 
their use again outside the scope of European Medicinal Product Directive 2001/83/EC (Art. 2.1)
2
 
[Chapter 4.2.1, Bredin 2012]. Both arguments motivate for the creation of a totally new and specific 
European bacteriophage therapy directive.  
Last but not least the European Medicinal Product Directive 2001/83/EC itself foresees that Member 
States could declare the European Medicinal Product Directive not being applicable in relation to their 
special national needs (Art.5.1)
3
. As such, e.g. in Belgium, it is possible that a recognized physician 
orders the production of a specific bacteriophage therapeutic product, based on his own 
specifications, for use on his own patients, under his sole responsibility [Belgian SHC Advice 9218].  
 
7.6 Final reflexions 
 
We have to conclude that a continuous talk and interaction with all the actors in the field is of prime 
necessity. Doing nothing to address the growing bacterial resistance to antibiotics is not an option 
considering that 25.000 European citizens die annually from untreatable bacterial infections [Chapter 
5.1.1, Ackermann 2012]. Europe and its Member States should take their responsibility to financially, 
technically and legally support the re-introduction of bacteriophage therapies into the European 
Union. A collective action at the European political level can be an option for securing a vote of the 
European Parliament to adapt the actual European Medicinal Product legislative frame in view of 
these statements.  
                                                          
1
Art. 3.7 >This Directive shall not apply to:  Any advanced therapy medicinal product, as defined in Regulation 
(EC) No 1394/2007, which is prepared on a non- routine basis according to specific quality standards, and used 
within the same Member State in a hospital under the exclusive professional responsibility of a medical 
practitioner, in order to comply with an individual medical prescription for a custom-made product for an 
individual patient. 
 
2
Art. 2.1 > Scope: This Directive shall apply to medicinal products for human use intended to be placed on the 
market in Member States and either prepared industrially or manufactured by a method involving an industrial 
process. 
 
3
   Art. 5.1 > A Member State may, in accordance with legislation in force and to fulfil special needs, exclude 
from the provisions of this Directive medicinal products supplied in response to a bona fide unsolicited order, 
formulated in accordance with the specifications of an authorised health-care professional and for use by an 
individual patient under his direct personal responsibility. 
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7.8 Remarque 
 
During all thesis-related discussions and contacts, I have never encountered real opposition to the 
idea of a smooth and qualitative re-introduction of bacteriophage therapy into the European Union. On 
the other hand, what I regularly came across, were “believers” and “non-believers” when discussing 
the potential of natural lytic bacteriophages to solve the (in-vivo) problem of antimicrobial resistance to 
antibiotics. Therefore and again, “state-of-the-art” clinical trials (control-groups included) are a pre-
requisite to go fast-forward in this promising and lifesaving therapeutic field.  
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8. Summary 
 
The worldwide emergence of antibiotic resistant bacteria and constraints to investment in potential 
solutions may eventually lead to a return to the pre-antibiotic era. As industries’ antibiotic pipeline is 
virtually dry and infectious diseases are steadily on the increase, the use of bacteriophages 
(bacteriophages are bacterio-specific viruses) to kill bacteria can be considered as a valuable option. 
Bacteriophages (meaning “bacteria-eaters”) are the bacteria’s natural enemies. In combination with or 
as substitute for antibiotics, bacteriophage therapy could be a therapeutic option in the eradication or 
control of bacterial colonization/infections. Bacteriophages can be considered as self-amplifying 
therapeutic products. By setting up a screening system for the circulating noxious bacteria and their 
respective bacteriophages it will be possible to obtain the right bacteriophage against any emerging 
pathogen. 
 
Bacteriophages were discovered independently during World War I by the French-Canadian biologist 
Felix d’Herelle and by the English microbiologist Frederick Twort. d’Herelle developed a commercial 
laboratory in Paris that produced and distributed bacteriophage preparations against various bacterial 
infections. In the 1930s, therapeutic bacteriophages were also marketed in the United States by major 
pharmaceutical companies. The advent of antibiotics relegated bacteriophage therapy to complete 
obscurity in most of the Western world.  
 
This PhD project aims at contributing to the creation of a dedicated European regulatory framework 
that makes the smooth re-introduction of bacteriophage therapy in the European Union possible. The 
research hypothesis is that final reflections and proposals, specifically designed in relation to 
bacteriophage therapy, will offer new and usable insights to all stakeholders involved. This research 
(11 studies) resulted in 14 international scientific publications that form the core of this thesis 
manuscript.  
 
Chapter 1 of this manuscript is written as a general introduction and describes the natural 
bacteriophage, the problem of bacterial resistance development to antibiotics, the potential of natural 
bacteriophages in tackling this problem, the history of bacteriophage therapy and the actual European 
medicinal product regulatory setting relevant to the therapeutic use of bacteriophages. This chapter 
also contains an overview of the PhD project, including the research objectives.  
 
Chapter 2 investigates the actual European regulatory and intellectual property hurdles relevant to the 
re-introduction of bacteriophage therapy into the European Union. This chapter also describes what a 
small-scale production of a qualitative bacteriophage cocktail, meant for use in e.g. a clinical trial, 
could look like. These investigations (and their results) intrigued regulators, politicians and medical 
ethical committees. The regulatory discussion on the subject of “bacteriophage therapy” was opened.  
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Chapter 3 explains what an optimal regulatory pathway, tailored to bacteriophage therapy, could look 
like. It explains why bacteriophage therapy is probably best served by a tailor-made and sustainable 
bacteriophage therapy concept.  
 
Chapter 4 compares the bacteriophage therapy concept (explained in Chapter 3) with other medicinal 
products and assesses the compatibility of this bacteriophage therapy concept with current attitudes 
of national and European regulatory agencies towards bacteriophage products. Chapter 4 also 
analyses if the European Advanced Therapy Medicinal Products (ATMPs) Regulation, an example of 
an existing adapted medicinal product legislative framework, could be tailored to also cater for flexible 
bacteriophage therapy concepts. 
 
Chapter 5 proposes a dedicated European regulatory frame for bacteriophage therapy, including 
quality and safety requirements for sustainable bacteriophage therapy products. These requirements 
are consensus-requirements defined by 33 bacteriophage experts from 11 different countries. The 
proposed regulatory framework was validated during an international workshop that took place at the 
Belgian Royal Military Academy (Viruses of Microbes II, Brussels, Belgium).  
  
Chapter 6 investigates all stakeholders’ moral responsibility in relation to the large-scale re-
introduction of bacteriophage therapy into the European Union. Moral principles are investigated and 
moral arguments are formulated in an effort to motivate all stakeholders to take bacteriophage 
therapy seriously. Although the efficacy of bacteriophage therapy has not been proven according to 
the actual standards of the European Union, bacteriophage therapy can be considered to be an 
Ethically Justified Medical Therapy (EJMT) within the European Union. 
 
Chapter 7 is written in the format of a concluding discussion summarizing legislative proposals that 
could work for the conceptual re-introduction of natural bacteriophage therapy into the European 
Union. 
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9. Samenvatting 
 
De wereldwijde opkomst van antibiotica resistente bacteriën en het gebrek aan investeringen 
teneinde dit probleem grondig aan te pakken zou kunnen leiden tot een terugkeer naar het pre-
antibiotica tijdperk. Aangezien de industriële antibiotica pijplijn virtueel droog is en de infectieuze 
ziekten aan een permanente opmars bezig zijn, zou het gebruik van bacteriofagen (bacteriofagen zijn 
bacterie-specifieke virussen) als een waardevolle optie kunnen worden beschouwd. Bacteriofagen 
(wat “bacteriën-eters” betekent) zijn de natuurlijke vijanden van bacteriën. In combinatie met of als 
vervanging van antibiotica zou bacteriofaag therapie een therapeutische optie kunnen zijn voor wat 
het uitroeien of controleren van bacteriële kolonisaties/infecties betreft. Bacteriofagen kunnen gezien 
worden als zelf-vermenigvuldigende therapeutische producten. Door een screening systeem op te 
zetten voor de circulerende ziekteverwekkende bacteriën en hun overeenkomstige bacteriofagen 
wordt het mogelijk de juiste bacteriofaag tegenover om het even welke opkomende 
ziekteverwekkende bacterie te vinden.  
 
Bacteriofagen werden gedurende Wereld Oorlog I, onafhankelijk van elkaar, ontdekt door de Frans-
Canadese bioloog Felix d’Herelle en de Engelse microbioloog Frederick Twort. d’Herelle ontwikkelde 
in Parijs een commercieel laboratorium dat bacteriofaagpreparaten tegen verschillende bacteriële 
infecties produceerde en distribueerde. In de jaren ‘30 werden therapeutische bacteriofagen ook in de 
Verenigde Staten gecommercialiseerd en dat door grote farmaceutische bedrijven. De opkomst van 
antibiotica verdrong bacteriofaag therapie in het grootste deel van de Westerse wereld. 
 
Dit PhD project heeft tot doel bij te dragen tot de vormgeving van een specifiek Europees 
regelgevend kader dat de vlotte (re-) introductie van bacteriofaag therapie in de Europese Unie moet 
mogelijk maken. De onderzoekshypothese is dat finale reflecties en voorstellen, specifiek ontwikkeld 
in relatie tot bacteriofaag therapie, nieuwe en bruikbare inzichten kunnen bieden aan alle betrokken 
stakeholders. Het gevoerde onderzoek (11 studies) resulteerde in 14 internationale 
wetenschappelijke publicaties. Zij maken samen de kern uit van dit thesis-manuscript.  
 
Hoofdstuk 1 van dit manuscript is geschreven als een algemene inleiding en beschrijft de natuurlijke 
bacteriofaag, het probleem van de ontwikkeling van bacteriële resistentie aan antibiotica, het 
potentieel van natuurlijke bacteriofagen ter oplossing van dit probleem, de geschiedenis van 
bacteriofaag therapie en het actuele Europese medicinale producten regelgevende kader relevant 
voor het therapeutisch gebruik van bacteriofagen. Dit hoofdstuk bevat tevens een overzicht van het 
PhD project, de onderzoek objectieven inbegrepen.  
 
Hoofdstuk 2 onderzoekt de actuele Europese regelgevende en intellectuele eigendom obstakels 
relevant voor wat de (re-) introductie van bacteriofaag therapie in de Europese Unie betreft. Dit 
hoofdstuk beschrijft eveneens hoe een kleinschalige en kwalitatieve productie van een 
bacteriofaagcocktail, bedoeld voor gebruik in bv een klinisch studie, er uit zou kunnen zien. Deze 
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onderzoeken (en de resultaten er van) intrigeerden regulators, politici en medisch ethische comités. 
De regelgevende discussie m.b.t. “bacteriofaag therapie” werd hierbij geopend.  
 
Hoofdstuk 3 beschrijft een mogelijk optimaal regelgevend kader, specifiek voor bacteriofaag therapie. 
Het legt uit waarom bacteriofaag therapie waarschijnlijk beter af is met een op maat gemaakt en 
duurzaam bacteriofaag therapie concept. 
 
Hoofdstuk 4 vergelijkt het bacteriofaag therapie concept (uitgelegd in Hoofdstuk 3) met andere 
medicinale producten en beoordeelt de verenigbaarheid van dit bacteriofaag therapie concept met 
actuele houdingen van nationale en Europese regelgevende autoriteiten tegenover bacteriofaag 
producten. Hoofdstuk 4 analyseert eveneens of de Europese regelgeving m.b.t. “geavanceerde 
therapie” medicinale producten (ATMPs), een voorbeeld van een bestaand aangepast regulerend 
kader voor medicinale producten, zou kunnen worden aangepast zodat het ook toepasbaar wordt op 
flexibele bacteriofaag therapie concepten.  
 
Hoofdstuk 5 stelt een specifiek “bacteriofaag therapie” Europees regelgevend kader voor, inclusief 
kwaliteit- en veiligheidsvereisten voor duurzame bacteriofaag therapie producten. Deze vereisten zijn 
consensus-vereisten gedefinieerd door 33 bacteriofaag-experten uit 11 verschillende landen. Het 
voorgestelde regelgevende kader werd gevalideerd gedurende een internationale workshop die 
plaats vond aan de Belgische Koninklijke Militaire School (Viruses of Microbes II, Brussels, Belgium). 
 
Hoofdstuk 6 onderzoekt de morele verantwoordelijkheid van alle stakeholders in relatie tot de 
grootschalige (re-) introductie van bacteriofaag therapie in de Europese Unie. Morele principes 
worden onderzocht en morele argumenten worden geformuleerd met als doel alle stakeholders te 
motiveren bacteriofaag therapie ernstig te nemen. Ondanks het feit dat de werkzaamheid van 
bacteriofaag therapie nog niet bewezen is in overeenstemming met de standaarden actueel 
gehanteerd door de Europese Unie, kan bacteriofaag therapie toch gezien worden als een Ethisch 
Gerechtvaardigde Medische Therapie (EJMT) binnen de Europese Unie.  
 
Hoofdstuk 7 is geschreven in het formaat van een afsluitende discussie die een samenvatting geeft 
van de regelgevende voorstellen die geschikt kunnen zijn voor de conceptuele (re-) introductie van 
natuurlijke bacteriofaag therapie in de Europese Unie.  
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Cica-démie, 19 Oct. 2013, UC Louvain, Louvain-la-Neuve, Belgium 
 
G. Verbeken, A. Vanderkelen, T. Rose, S. Jennes, D. De Vos, J.-P. Draye, J.-P. Pirnay 
HUMAN BODY MATERIAL ™ 
15th European Burns Association Congress, 28-31 Aug. 2013, Vienna, Austria 
 
J.-P. Draye, M. Boone, G. Verween, A. Aiti, J.-P. Pirnay, G. Verbeken, T. Rose, S. Jennes, G. Jemec, V. del Marmol 
ASSESSMENT OF DECELLULARIZED AND RECELLULARIZED HUMAN DERMAL MATRICES USING INVASIVE REAL-
TIME HIGH DEFINITION OPTICAL COHERENCE TOMOGRAPHY AND REFLECTANCE CONFOCAL MICROSCOPY 
15th European Burns Association Congress, 28-31 Aug. 2013, Vienna, Austria 
 
G. Verbeken 
WHAT DOES THE HISTORY OF KERATINOCYTES TEACH US FOR ATMPS? 
ATMP-Day, 17 May 2013, KU Leuven, Leuven, Belgium 
 
G. Verbeken 
BACTERIOPHAGE THERAPY AND GMP 
The Rebirth of Phage Therapy: Why? How? , 31 JAN 2013, Institut Mutualiste Montsouris, Paris, France 
 
G. Verbeken 
HOW TO ADAPT THE REQUIREMENTS IN DIRECTIVE 86 TO IMPROVE FEASIBILITY FOR TISSUE BANKS AND STILL 
GUARANTEE THE SAFETY AND QUALITY OF THE TISSUE PRODUCTS 
21
st
 Annual Congress of the EATB, 21-23 NOV 2012, Vienna, Austria  
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G. Verbeken 
DONOR SKIN PROCUREMENT 
Annual Congress, SIZ Nursing Association, 13th Oct. 2012, La Marlagne, Wepion, Belgium 
 
G. Verbeken, J.P. Pirnay, R. Lavigne, S. Jennes, D. De Vos, I. Huys 
EXPERTS’ VIEWS ON THE CURRENT REGULATORY MEDICINAL PRODUCT FRAMEWORK: CALL FOR A DEDICATED 
EUROPEAN BACTERIOPHAGE THERAPY DIRECTIVE 
EuroPhages2012, Bacteriophage in Medicine, Food and Biotechnology, 24-26 SEPT 2012, St Hilda’s College, Oxford, UK 
 
G. Verbeken, J.P. Pirnay, S. Jennes, C. Ceulemans, D. De Vos, R. Lavigne, M. Casteels, M. Zizi, I. Huys 
BATERIOPHAGE THERAPY: ANALYSES OF SPECIFIC LEGAL HURDLES IN CURRENT REGULATORY FRAMES 
Viruses of Microbes (VoM2012), 16-20 July 2012, Royal Military Academy, Brussels, Belgium 
 
I. Huys, G. Verbeken, J.P. Pirnay, D. De Vos, R. Lavigne 
INTELLECTUAL PROPERTY RIGHTS IN THE REALM OF PHAGE-BASED PRODUCTS 
Viruses of Microbes (VoM2012), 16-20 July 2012, Royal Military Academy, Brussels, Belgium 
 
I. Huys, G. Verbeken, J.P. Pirnay, S. Jennes, D. De Vos., R. Lavigne 
PERSPECTIVES IN ANTIMICROBIL AGENTS: PHAGE THERAPY 
ESCP International Workshop, 30 May - 1 JUN 2012, Leuven, Belgium 
 
G. Verbeken 
CULTIVATION OF NEWBORN FORESKIN KERATINOCYTES: “EPIDERMAL STEM CELLS”? 
Cica-démie, 24 March 2012, FUNDP, Namur, Belgium 
 
G. Verbeken  
EUROPEAN GOOD TISSUE PRACTICES 
Annual Symposium Donation of Organs and Tissues, 8 February 2012, UZ Gasthuisberg, Leuven, Belgium 
 
J. Klykens, J.-P. Pirnay, G. Verbeken, O. Giet, E. Baudoux, R. Jashari, A. Vanderkelen, N. Ectors 
CLEAN ROOMS AND TISSUE BANKING: HOW HAPPY I COULD BE WITH EITHER GMP OR GTP 
European Association of Tissue Banks, 9-11 November 2011, Barcelona, Spain 
 
G. Verbeken 
ALLOGENEIC DONOR SKIN / AN INDISPENSIBLE BIOLOGICAL DRESSING 
Organ Donation and Transplantation, 4
th
 Annual Meeting, October 13
th
 2011, Biopôle, Gosselies, Belgium 
 
G. Verbeken, J.-P. Pirnay, S. Jennes, C. Ceulemans, I. Huys, D. De Vos 
BACTERIOPHAGE THERAPY: THE ACTUAL STATUS, A REGULATORY PERSPECTIVE  
1
st
 International Oxford Bacteriophage (Phage) Applications Conference, Phages2011, 19-21 September 2011, St Hilda’s 
College, Oxford, U.K. 
 
D. De Vos, M. Merabishvili, G. Verbeken, T. Rose, M. Vaneechoutte, P. Cornelis, R. Lavigne, V. Krylov, A. Dublanchet, I. Huys, 
S. Jennes, M. Zizi, G. Laire, J.-P. Pirnay 
BACTERIOPHAGES AS ANTIMICROBIAL AGAINST MULTIDRUG RESITANT PSEUDOMONAS AERUGINOSA  
13
th
 International Conference on Pseudomonas, 4-7 September 2011, Sydney, Australia 
 
H. Stevens, G. Verbeken, M. Verlinden, I. Huys 
LEGAL CHALLENGES FOR ATMP DEVELOPMENT 
Termis-EU 2011 Annual Meeting, 7-10 June 2011, Granada, Spain 
 
D. De Vos, G. Verbeken, T. Rose, S. Jennes, J.-P. Pirnay 
BACTERIOPHAGES FOR THE TREATMENT OF SEVERE INFECTIONS: A ‘NEW’ WAY FOR THE FUTURE? 
EWMA 2011, 25-27 MAY 2011, Brussels, Belgium 
 
G. Verbeken  
BACTERIOPHAGE THERAPY: EUROPEAN REGULATORY FRAMEWORK 
BACTERIOPHAGE THERAPY: EXPERIMENTS ON HUMANS 
GEEPhage, Phagothérapie, Atelier de Travail: « La Phagothérapie en 2011 », 30 March 2011, HIA du Val-de-Grâce, Paris, 
France 
 
G. Verbeken 
DERMAL SUBSITUTES – AN OVERVIEW 
Teaching Day Collegium Chirurgicum Plasticum, 26 February 2011, Gent, Belgium 
 
Jean-Paul Pirnay, Gilbert Verbeken 
HUMAN CELLS AND TISSUES: THE NEED FOR A GLOBAL ETHICAL FRAMEWORK 
Ethical Review in FP7  > “Ethical Issues in Human Cells and Tissues Research”, Kick-off Meeting, 14 December 2010, 
European Commission, Brussels, Belgium 
 
Rob Lavigne, Pieter-Jan Ceyssens, Anneleen Cornelissen, Yves Briers, Maarten Walmagh, Elke Lecoutere, Maia Merabishvili, 
Gilbert Verbeken, Jean-Paul Pirnay, Daniel De Vos, Mario Vaneechoutte, Stefan Miller, Guido Volckaert 
BACTERIOPHAGE-BASED STRATEGIES TO COMBAT PSEUDOMONAS INFECTIONS 
Workshop “Current Trends in Biomedicine”, 8-10 November 2010, Universidad Internacional de Andalucia, Baeza, Spain 
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G. Verbeken, D. De Vos, T. Rose, S. Jennes, J.P. Pirnay 
SKIN EQUIVALENTS” IN (BURN) WOUND TREATMENT: “REVIEW AND CHALLENGES” 
Scientific Meeting, Dutch Society for Burn Wound Care, Friday 5 November 2010, Queen Astrid Military Hospital, Brussels, 
Belgium 
 
G. Verbeken, D. De Vos, T. Rose, A. Vanderkelen, E. Kets, S. Jennes, J.P. Pirnay 
SKIN EQUIVALENTS” IN (BURN) WOUND TREATMENT: “REVIEW AND CHALLENGES” 
20
th
 European Tissue Repair Society Congress, 15-17 Sept. 2010, Ghent, Belgium 
 
Daniel De Vos, Maia Merabishvili, Gilbert Verbeken, Thomas Rose, Mario Vaneechoutte, Rob Lavigne, Victor Krylov, Pierre 
Neirinckx, Serge Jennes, Martin Zizi and Jean-Paul Pirnay 
BACTERIOPHAGE THERAPY: THE ROAD TO ACCEPTANCE 
“Viruses of Microbes”, 21-25 June 2010, Paris, France  
 
D. De Vos, M. Merabishvili, G. Verbeken, T. Rose, M. Vaneechoutte, R. Lavigne, V. Krylov, P. Neirinckx, S. Jennes, M. Zizi, J.-
P. Pirnay 
BACTERIOPHAGE THERAPY: THE ROAD TO ACCEPTANCE  
5
th
 International Conference of the Royal Medical Services, Dead Sea, 3-6 May 2010, Jordan  
 
G. Verbeken, T. Rose, S. Jennes, J. P. Pirnay
 
NEW EUROPEAN DIRECTIVES ON HUMAN CELL- AND TISSUE BANKING: ETHICAL ASPECTS AND THEIR ECONOMIC 
IMPACT
 
European Association of Tissue Banks, 4-6 November 2009, Cracow, Poland, 
 
D. De Vos, T. Rose, S. Jennes, G. Verbeken, J.P. Pirnay 
PHAGE THERAPY: FACTS OR FICTION? 
European Tissue Repair Society, 2-5 Sept. 2009, Paris, France 
 
G. Verbeken, T. Rose, S. Jennes, J. P. Pirnay
 
NEW EUROPEAN DIRECTIVES ON HUMAN CELL- AND TISSUE BANKING: ETHICAL ASPECTS AND THEIR ECONOMIC 
IMPACT 
European Burns Association, Lausanne, Switzerland 2-5 September 2009 
 
G. Verbeken, G. Verween, A. De Coninck, T. Rose, D. Roseeuw, S. Jennes, J. P. Pirnay 
GLYCEROL TREATMENT AS A BACTERIOLOGICAL DECONTAMINATION PROCEDURE FOR CONTAMINATED ALREADY 
CRYO PRESERVED DONOR SKIN: METHODOLOGY AND EVALUATION   
European Burns Association, Lausanne, Switzerland, 2-5 September 2009 
 
G. Verbeken,  
EUROPEAN CLINICAL TRIAL DIRECTIVES / CLINICAL SCIENTIFIC RESEARCH IN BELGIUM / EXPERIMENTS ON 
HUMANS IN BELGIUM / CLINICAL TRIALS IN BELGIUM 
Staff-Training Queen Astrid Military Hospital (QAMH), 24-25-29-30
th
 June 2009, Brussels, Belgium 
 
G. Verbeken, J.P. Pirnay 
THE NEW BELGIAN LAW ON CELL- AND TISSUE BANKING: ETHICAL ASPECTS AND THEIR ECONOMIC IMPACT 
13
th
 Day of Clinical Biology, Saint-Luc University Hospital (UCL), 9
th
 May 2009, Brussels, Belgium 
 
G. Verbeken
1 
, D. De Vos, M. Zizi, M. Vaneechoutte, M. Merabishvili, T. Rose, S. Jennes, J.P. Pirnay 
THE CLINICAL USE OF BACTERIOPHAGES: (EUROPEAN) REGULATORY & PSYCHOLOGICAL HURDLES 
Phages in Interaction II, Leuven, Belgium, December 19
th
, 2008 
 
G. Verbeken  
SYMPOSIUM “BURN WOUNDS, SKIN DISEASES, CHRONIC WOUNDS AND NOSOCOMIAL INFECTIONS” 
Burn Wound Center, Queen Astrid Military Hospital, 25
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T. Roelandt, C. Heugheubaert, G. Verween, G. Verbeken, J.-P. Pirnay, D. De Vos, D. Crumrine, D. Roseeuw, P. M. Elias and 
J.-P. Hachem.  
ACTIN / PLASMA MEMBRANE DYNAMICS REGULATE PAR-2-DEPENDENT PERMEABILITY BARRIER RESPONSES TO 
ACUTE STRESS 
International Investigative Dermatology, May 14-17, 2008, Kyoto, Japan  
 
G. Verbeken, M. Vaneechoutte, M. Zizi, T. Rose, S. Jennes, J.P. Pirnay 
BACTERIOPHAGES: PHAGE CLINICAL TRIAL VS THERAPY 
Phage Biology, Ecology and Therapy Meeting, Eliava 2008, Tbilisi, Georgia 
 
G. Verbeken, T. Rose, S. Jennes, J.P.Pirnay 
THE ROLE OF CULTURED HUMAN KERATINOCYTE SHEETS IN THE TREATMENT OF CHRONIC SKIN WOUNDS 
Symposium “Chronic Skin Wound Treatment”, 2008, Queen Astrid Military Hospital, Brussels 
 
G. Verbeken MSc, P. De Corte BSc, G. Verween BSc, T. Rose MD, S. Jennes MD, J.P. Pirnay 
HUMAN CULTURED EPITHELIAL ALLOGRAFTS: INTRODUCING MORE EFFICIENT PRODUCTION SCHEMES AND 
EXTRA PATIENT SAFETY 
TERMIS-EU, June 2008, Porto, Portugal and E.A.T.B., Nov. 2008, Edinburgh, Scotland , U.K. 
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Thomas Rose, Daniel De Vos, Gilbert Verbeken, Jean-Paul-Pirnay. 
NEW BELGIAN GUIDELINES FOR MICROBIOLOGICAL SAFETY SCREENING OF DONOR TISSUE: OPTIMIZED DONOR 
SKIN SPECIFIC SCREENING PROCEDURE 
5
th
 World Congress on Tissue Banking, Kuala Lumpur 2008, Malaysia & E.A.T.B., Nov.2008, Edinburgh, Scotland, U.K. 
 
M. Zizi, G. Verbeken, D. De Vos, M. Merabishvili, N. Chanishvili, T. Rose, S. Jennes, M. Vaneechoutte, J.P. Pirnay 
EVALUATION OF A PHAGE COCKTAIL IN THE TREATMENT OF BURN WOUNDS INFECTED WITH MULTI-RESISTANT 
PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS STRAINS  
Symposium “Bacterial Infectiology”, Pasteur Institute, 20 Nov. 2007, Paris, France 
 
Verbeken G. , Rose T. , Ortiz S. , Verween G. , De Corte P.,  Pirson J. , Jennes S.  
QUALITY MANAGEMENT SYSTEMS AND TISSUE BANKING 
Congress European Burns Association, Budapest, Hungary, Sept. 2007 
 
Verbeken G. , Rose T. , Ortiz S. , Verween G. , De Corte P.,  Pirson J. , Jennes S.  
QUALITY MANAGEMENT SYSTEMS AND TISSUE BANKING “A PRACTICAL APPROACH LEADING TO THE 
IMPLEMENTATION OF ISO 9001:2000 FOR TISSUE BANKS”: UPDATED EXPERIENCE OF THE QUEEN ASTRID MILITARY 
HOSPITAL  
Congress European Association of Tissue banks, Budapest, Hungary, Oct 2007 
 
Verbeken G. 
NEW REGULATORY ENVIRONMENT, QUALITY MANAGEMENT SYSTEMS AND TISSUE BANKS: “A PRACTICAL 
APPROACH” 
“Belgian Association of Tissue Banks”, Brussels (HCB-KA), April 2007 
 
Ortiz S., Coenye K., Rose T., Verbeken G., De Vos D., Pirnay J.P., Pirson J. 
ORGANIZATION OF THE SKIN BANK OF THE BURN WOUND CENTER OF THE QUEEN ASTRID MILITARY HOSPITAL 
15
th
 Brussels International Symposium on Vascularised and Non-Vascularised Allografts in Hand/Upper Extremity Surgery, 
2007, Brussels, Belgium 
 
Coenye K.E., Verween G., Verbeken G., De Corte P., De Vos D., Vanderkelen A., Pirnay J.P., Pirson J. 
CRYOPRESERVED UNDIFFERENTIATED ALLOGENIC KERATINOCYTES AS ADJUVANS TO LARGELY MESHED 
AUTOLOGOUS SKIN GRAFTS: A FIRST EXPERIENCE 
Congress European Association Tissue Banks,Varna, Bulgaria, Oct. 2006 
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Verween G., Draye J.-P., A. Aiti, G. Verbeken, D. De Vos, T. Rose, S. Jennes, J-P Pirnay CULTURING AND STORING 
DIFFERENT HUMAN SKIN CELL TYPES TO REPOPULATE DECELLULARISED HUMAN DERMAL MATRICES 
Annual Congress European Association of Tissue Banks, 20-22 NOV 2013, Brussels, Belgium 
 
Pirnay J.-P., A. Vanderkelen, D. De Vos, J.-P. Draye, T. Rose, G. Verbeken, N. Ectors, I. Huys, S. Jennes, C. Ceulemans 
THE EU HUMAN CELL AND TISSUE LEGISLATION SHOULD OVERCOME ETHICAL ISSUES 
Annual Congress European Association of Tissue Banks, 20-22 NOV 2013, Brussels, Belgium 
 
J.-P. Pirnay, A. Vanderkelen, D. De Vos, J.-P. Draye, T. Rose, C. Ceulemans, N. Ectors, I. Huys, S. Jennes, G. Verbeken 
BUSINESS ORIENTED EU HUMAN CELL AND TISSUE PRODUCT LEGISLATION WILL ADVERSELY IMPACT MEMBER 
STATES’ HEALTH CARE SYSTEMS 
Annual Congress European Association of Tissue Banks, 20-22 NOV 2013, Brussels, Belgium 
 
M. Merabishvili, D. De Vos, G. Verbeken, T. Rose, V. Druez, S. De Roock, P. Soentjens, S. Jennes, J.-P. Pirnay 
PHAGE THERAPY RESEARCH AT THE BURN WOUND CENTER OF THE QUEEN ASTRID MILITARY HOSPITAL 
15th European Burns Association Congress, 28-31 Aug. 2013, Vienna, Austria 
 
J.-P. Pirnay, A. Vanderkelen, T. Rose, J.-P. Draye, D. De Vos, S. Jennes, G. Verbeken 
BUSINESS ORIENTED EU HUMAN CELL AND TISSUE PRODUCT LEGISLATION WILL ADVERSELY IMPACT BURN 
WOUND TREATMENT 
 
15th European Burns Association Congress, 28-31 Aug. 2013, Vienna, Austria 
T. Rose, G. Verween, M. van Brussel, P. Massage, V. Druez, A. Neuprez, E. Keersebilck, G. Verbeken, J.-P. Pirnay, S. Jennes 
THE CHALLENGE OF TREATING A 93% TBSA BURNED CHILD 
15th European Burns Association Congress, 28-31 Aug. 2013, Vienna, Austria 
 
G. Verween, J.-P. Draye, M.A.L.M. Boone, A. Aiti, G. Verbeken, D. De Vos, T. Rose, S. Jennes, V. del Marmol, G. Jemec, J.-P. 
Pirnay 
CULTIVATION AND STORAGE OF SEVERAL HUMAN SKIN CELL TYPES TO REPOPULATE ACELLULAR HUMAN 
DERMAL MATRICES  
Congress European Tissue Repair Society, 23-25 Oct. 2013, Reims, France 
 
J.-P. Draye, M.A.L.M. Boone, G. Verween, A.-L. Aiti, G. Verbeken, D. De Vos, T. Rose, S. Jennes, J.-P. Pirnay, G. Jemec, V. 
del Marmol 
CELLULAR AND ACELLULAR HUMAN DERMAL MATRICES ASSESSED BY HIGH-DEFINITION OPTICAL COHERENCE 
TOMOGRAPHY AND REFLECTANCE CONFOCAL MICROSCOPY  
Congress European Tissue Repair Society, 23-25 Oct. 2013, Reims, France 
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Draye J.-P., M. Boone, G. Verween, J.-P Pirnay, G. Verbeken, D. De Vos, T. Rose, S. Jennes, G. Jemec; V. Del Marmol 
NONINVASIVE ASSESSMENT OF ACELLULAR DERMAL MATRICES PREPARED BY TWO DIFFERENT METHODS USING 
NONINVASIVE OPTICAL TECHNOLOGY. HISTOPATHOLOGICAL CORRELATION.  
International Investigative Dermatology 2013, May 8th-11th 2013, Edinburgh, Scotland 
 
J.P. Pirnay, G. Verbeken, D. De Vos, J.P. Draye, T. Rose, A. Vanderkelen 
BUSINESS ORIENTED EU SAFETY AND HEALTH LEGISLATION UNDERMINES MEMBER STATES’ SOCIAL HEALTH 
SYSTEMS: THE EXAMPLE OF HUMAN CELLS AND TISSUES 
21st Annual Congress of the EATB, 21-23 NOV 2012, Vienna, Austria 
 
J.P. Draye, G. Verween, A. vander Straeten, E. Vanderlinden, A. De Coninck, G. Verbeken, D. De Vos, T. Rose, S. Jennes, J.P. 
Pirnay 
PREPARATION OF HUMAN ACELLULAR MATRICES FOR THE DEVELOPMENT OF A LIVING SKIN EQUIVALENT 
22
nd
 ETRS Annual Meeting, 4 - 5 OKT 2012, Athens, Greece 
 
G. Verween, J.P. Draye, H. Vroninks, G. Verbeken, T. Rose, S. Jennes, J.P. Pirnay 
CULTURING GROWTH RATE IMPROVEMENT OF NEONATAL FORESKIN KERATINOCYTES WITH A NEW DEFINED 
ANIMAL ORIGIN-FREE CELL CULTURE MEDIUM SUPPELEMENT 
22
nd
 ETRS Annual Meeting, 4 - 5 OKT 2012, Athens, Greece 
 
J.P. Pirnay, G. Verbeken, T. Rose, S. Jennes, M. Zizi, I. Huys, R. Lavigne, M. Merabishvili, M. Vaneechoutte, A. Buckling, et al. 
INTRODUCING YESTERDAY’S PHAGE THERAPY IN TODAY’S MEDICINE 
Viruses of Microbes (VoM2012), 16-20 July 2012, Royal Military Academy, Brussels, Belgium 
+ “Bacteriophages and Probiotics – Alternatives to Antibiotics”, 1 - 4 JUL 2012, Eliava Institute, Tbilisi, Georgia 
 
M. Merabishvili, D. De Vos, A. Kropinski, R. Lavigne, D. Vandenheuvel, G. Verbeken, M. Vaneechoutte, J.P. Pirnay 
CHARACTERIZATION OF NEWLY ISOLATED LYTIC BACTERIIOPHAGES ACTIVE AGAINST ACINETOBACTER 
BAUMANNII 
Viruses of Microbes (VoM2012), 16-20 July 2012, Royal Military Academy, Brussels, Belgium 
+ “Bacteriophages and Probiotics – Alternatives to Antibiotics”, 1 - 4 JUL 2012, Eliava Institute, Tbilisi, Georgia 
 
M. Merabishvili, P. Wattiau, J. mast, C. ragimbeau, J. Mossong, A. Kropinski, D. Vandenheuvel, R. Lavigne, G. Verbeken, D. De 
Vos, N. Chanishvili, M. Vaneechoutte, J.P. Pirnay 
ISOLATION AND SELECTION OF BACTERIOPHAGES ACTIVE AGAINST ENTEROAGGREGATIVE, SHIGA 
TOXIN/VEROTOXIN-PRODUCING ESCHERICHIA COLI (EAggEC STEC/VTEC) STRAIN O104:H4 
Viruses of Microbes (VoM2012), 16-20 July 2012, Royal Military Academy, Brussels, Belgium 
+ “Bacteriophages and Probiotics – Alternatives to Antibiotics”, 1 - 4 JUL 2012, Eliava Institute, Tbilisi, Georgia 
 
Verbeken G., Verween G., Pascual B., De Corte P., Rose T., Jennes S., Vanderkelen A., Marichal M., Heuninckx W., De Vos 
D., Pirnay J.-P.  
EVALUATION OF A MICROBIOLOGICAL SCREENING AND ACCEPTANCE PROCEDURE FOR CRYOPRESERVED SKIN 
ALLOGRAFTS BASED ON 14 DAY CULTURES  
European Burns Association, 14-17 September 2011, The Hague, The Netherlands 
 
D. De Vos, M. Merabishvili, G. Verbeken, T. Rose, M. Vaneechoutte, P. Cornelis, R. Lavigne, V. Krylov, A. Dublanchet, I. Huys, 
S. Jennes, M. Zizi, G. Laire, J.P. Pirnay 
BACTERIOPHAGES AS ANTIMICROBIAL AGAINST MULTIDRUG RESISTENANT PSEUDOMONAS AERUGINOSA 
13
th
 International Conference on Pseudomonas, 4 – 7 Sept 2011, Sydney, NSW, Australia 
 
Verlinden M., Verbeken G., Huys I. 
STUDY OF MODELS FOR ‘BIOBANK’ PARTNERSHIPS 
3
rd
 Annual World Biobanking Summit, 30
 
June-1
 
July 2011, Hamburg, Germany 
 
Maia Merabishvili, Gilbert Verbeken, Daniel De Vos, Serge Jennes, Mario Vaneechoutte and Jean-Paul Pirnay 
ISOLATION OF BACTERIOPHAGES ACTIVE AGAINST MULTIDRUG-RESISTANT CLINICAL ISOLATES OF 
ACINETOBACTER BAUMANNII 
“Acinetobacter 2010”, 1-3 Sept 2010, Rome, Italy  
 
Maia Merabishvili, Jean-Paul Pirnay, Gilbert Verbeken, Daniel De Vos, Nina Chanishvili and Mario Vaneechoutte 
STABILITY OF THERAPEUTICALLY APPLICABLE STAPHYLOCOCCUS AUREUS PHAGE ISP IN COMMON 
ANTIMICROBIALS AND NEUTRAL CARRIERS, “Viruses of Microbes”, 21-25 June 2010, Paris, France 
 
Maia Merabishvili, Gilbert Verbeken, Daniel De Vos, Serge Jennes, Mario Vaneechoutte and Jean-Paul Pirnay 
ISOLATION OF BACTERIOPHAGES ACTIVE AGAINST MULTIDRUG-RESISTANT CLINICAL ISOLATES OF 
ACINETOBACTER BAUMANNII 
“Viruses of Microbes”, 21-25 June 2010, Paris, France (Poster) 
 
G. Verbeken, G. Verween, D. Schoeters, K. Geukens, A. De Coninck, D. Roseeuw, T. Rose, S. Jennes, J. P. Pirnay 
POTENTIAL RELEASE OF HEAVY METALS BY FOOD GRADE ALUMINUM FOILS USED FOR SKIN ALLOGRAFT CRYO 
PRESERVATION 
European Burns Association, Lausanne, Switzerland, September 2009 
European Association of Tissue Banks, 4-6 Nov 2009, Cracow, Poland 
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A. Pierlot, S. Ortiz, G. Verbeken, D. De Vos, S. Jennes
 
DEEP SECOND DEGREE BURNED HAND PALMS OF CHILDREN YOUNGER THAN 2 YEARS NEED CONSERVATIVE 
SURGERY AND INTENSIVE STRETCHING   
European Burns Association, Lausanne, Switzerland, 2-5 September 2009 
 
D. De Vos, T. Rose, S. Jennes, M. Zizi, M. Merabishvili, M. Vaneechoutte, G. Verbeken, J.P. Pirnay 
PHAGE THERAPY: FACT OR FICTION? 
European Burns Association, Lausanne, Switzerland, 2-5 September 2009 
 
Jean-Paul Pirnay, Thomas Rose, Daniel De Vos, Serge Jennes, Alain Vanderkelen, Nadine Ectors, Gilbert Verbeken 
HUMAN DONOR SKIN: NEED FOR EUROPEAN ALLOCATION RULES 
European Burns Association, Lausanne, Switzerland, 2-5 September 2009 
 
Maya Merabishvili, Jean-Paul Pirnay, Gilbert Verbeken, Nina Chanishvili, Marina Tediashvili, Nino Lashkhi, Thea Glonti, Victor 
Krylov, Jan Mast , Luc Van Parijs, Rob Lavigne, Guido Volckaert, Wesly Mattheus, Gunther Verween, Peter de Corte, Thomas 
Rose, Serge Jennes, Martin Zizi, Mario Vaneechoutte 
EVALUATION OF SAFETY ASPECTS OF BACTERIOPHAGE COCKTAIL USED IN THE TREATMENT OF INFECTED BURN 
WOUNDS IN HUMAN CLINICAL TRIAL 
“18
th
 Biennial Evergreen International Phage Biology Meeting”, 9-13 August 2009, Washington, U.S. 
 
Pirnay J.-P.
 
, Verbeken G., Rose T., De Vos D., Jennes S., Lismont D., Vanderkelen A. and Ectors N. 
HUMAN DONOR SKIN: NEED FOR EUROPEAN ALLOCATION RULES  
European Association of Tissue Banks (E.A.T.B.), 12-14 Nov. 2008, Edinburgh, Scotland, U.K. 
 
Pirnay J.-P., Verbeken G., De Vos D., Rose T., Jennes S., Jashari R.,  Zizi M., Ectors N., Vanderkelen A. 
HUMAN CELL AND TISSUE BANKING: NEED FOR A EUROPEAN ETHICAL FRAMEWORK  
European Association of Tissue Banks (E.A.T.B.), 12-14 Nov. 2008, Edinburgh, Scotland , U.K. 
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